text,title,id,project_number,terms,administration,organization,mechanism,year,award_amount,cong_dist,score
"Methods for high-resolution analysis of genetic effects on gene expression    DESCRIPTION (provided by applicant):    Summary Gene expression is a fundamental function of any cell. It is the main mechanism by which information is transmitted from the nucleus to the rest of the cell and eventually to other cells and the body of the organism. Genetic variation in components of the transcriptional machinery and signals that regulate gene function generates variation in transcriptional response and consequently variation in phenotypes. It has become apparent that many of the common genetic signals associated with disease are found away from the DNA sequence that encodes for protein sequence and is likely to be functioning in regulating gene expression. In this project we propose to develop methodologies that will explore the consequences of genetic variation in gene expression. There are three main goals of this project. First we will explore and develop methodologies to mine information from experiments that perform deep sequencing of the human transcriptome. The new sequencing technologies are providing us with unprecedented resolution into the transcriptome but are also raising challenges in the computational and biological models to use to interpret such large amounts of data. Secondly, we will use high-resolution genetic data to develop and use methodologies to dissect the fine structure of genetic variants that affect regulation of gene expression. Finally, we will implement and test models to infer the higher-order interactions of genome function so as to dig deeply into the biological consequences of genetic variants and how the signal is transmitted from the DNA sequence to higher levels of cell and body function. Our goals is to develop methodologies that will significantly improve our insight to the variability in human populations and assist in interpreting predisposition to genetic diseases.      PUBLIC HEALTH RELEVANCE:    Project narrative The proposed project aims at the development of statistical methods for the interpretation and study of the impact of genetic variants in cell function. Understanding the cellular effects of genetic variants provides a fundamental framework for the deep understanding of human genetic disease and increases the potential for the development of relevant treatments and drugs. It is the understanding of the basic molecular functions in health and disease that will provide the utmost resolution of information for the improvement of human health.           Project narrative The proposed project aims at the development of statistical methods for the interpretation and study of the impact of genetic variants in cell function. Understanding the cellular effects of genetic variants provides a fundamental framework for the deep understanding of human genetic disease and increases the potential for the development of relevant treatments and drugs. It is the understanding of the basic molecular functions in health and disease that will provide the utmost resolution of information for the improvement of human health.",Methods for high-resolution analysis of genetic effects on gene expression,7934780,R01MH090941,"['Disease ', ' disease/disorder ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Data Set ', ' Dataset ', ' DNA Resequencing ', ' Resequencing ', ' Data ', ' Detection ', ' Interphase Cell ', ' Resting Cell ', ' Non-dividing Cell ', ' Resolution ', ' Transcript ', ' Molecular ', ' Development ', ' developmental ', ' DNA Sequence ', ' RNA Sequences ', ' Affect ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genes ', ' Genome ', ' Genotype ', ' base ', ' density ', ' Goals ', ' improved ', ' Health ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Gene Expression Profile ', ' transcriptome ', ' gene expression signature ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Human Genetics ', ' Variant ', ' Variation ', ' Biological ', ' Biochemical ', ' Alleles ', ' Allelomorphs ', ' Training ', ' insight ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Linkage Disequilibrium ', ' Maps ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Methods ', ' Methodology ', ' Method LOINC Axis 6 ', ' Mining ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Simulate ', ' Nucleotides ', ' Organism ', ' living system ', ' Phenotype ', ' Genetic ', ' gene function ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Proteins ', ' gene product ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Technology ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Work ', ' Complex ', ' cell type ', ' Pattern ', ' Techniques ', ' Location ', ' cell body (neuron) ', ' soma ', ' neuronal cell body ', ' neural cell body ', ' Cell Body ', ' trait ', ' Structure ', ' simulation ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' Cell Nucleus ', ' Nucleus ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cells ', ' genetic analysis ', ' Genetic analyses ', ' Relative (related person) ', ' Relative ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' Property ', ' LOINC Axis 2 Property ', ' response ', ' protein protein interaction ', ' Genomics ', ' Accounting ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' reconstruction ', ' genetic variant ', ' Population ', ' human disease ', ' network models ', ' public health relevance ', ' ']",NIMH,UNIVERSITY OF GENEVA,R01,2010,332535,,0.12043845719054862
"Novel Statistical Methods for Human Gene Mapping    DESCRIPTION (provided by applicant): Many common human diseases originate in part from the complicated effects of multiple genetic variants found throughout the genome. Given the enormous impact of such diseases on public health, it is imperative to map relevant genetic variants to improve our understanding of the molecular basis of such diseases, as well as improve screening techniques for disease prevention. To this end, successful human gene mapping of complex diseases requires the development and application of powerful statistical methods that fully utilize the resources of the Human Genome Project. This grant proposes a set of such statistical methods that either address novel problems or improve existing solutions to problems in human gene mapping studies. These proposed methods are applicable to a variety of genetic studies as they address topics in linkage, linkage disequilibrium, and high-dimensional genetic analyses of complex diseases and disease-related quantitative traits. The methods can be partitioned into the two general groups: mixed-modeling procedures and case-control likelihood procedures. The mixed-modeling procedures considered include a general variance-component (VC) mapping framework for continuous and discrete trait data and a modified VC mapping framework that allows for haplotypes. Also considered is a novel linear-mixed-model framework that identifies a large combination of genetic variants that influence a quantitative trait using support-vector- machine regression. The case-control likelihood procedures considered are extensions of the approach of Epstein and Satten (2003) for haplotype inference on disease. Extensions considered include allowing for covariates and haplotype-covariate interactions, and also categorical disease outcomes. The proposed statistical methods in this grant have the potential to increase the power to identify genetic variants that influence complex diseases and disease-related quantitative traits. This project will evaluate the performance of these methods using simulations based on the study design and data from an existing gene mapping study of type 2 diabetes. Also, this grant will implement the proposed statistical methods in user- friendly, efficient software for public distribution. Finally, this project will be opportunistic in identifying and addressing unforseen statistical problems arising in human gene mapping studies.           ",Novel Statistical Methods for Human Gene Mapping,7930715,R01HG003618,"['Non-Insulin-Dependent Diabetes Mellitus ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' MODY ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Environment ', ' Address ', ' Biochemical Reaction ', ' Enzymatic Reaction ', ' Data ', ' International ', ' Human Gene Mapping ', ' Human genetic mapping ', ' Human Gene Mapping DNA Sequencing ', ' Other Genetics ', ' Molecular ', ' Development ', ' developmental ', ' Finland ', ' Pathway interactions ', ' pathway ', ' Genome ', ' base ', ' Grant ', ' improved ', ' Procedures ', ' Haplotypes ', ' Human Genome Project ', ' Variant ', ' Variation ', ' Series ', ' Screening procedure ', ' screenings ', ' screening ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Linkage Disequilibrium ', ' Biochemical Pathway ', ' Metabolic Networks ', ' Maps ', ' Methods ', ' Methodology ', ' Method LOINC Axis 6 ', ' Normal Statistical Distribution ', ' Normal Distribution ', ' Gaussian Distribution ', ' Paper ', ' Genetic ', ' public health medicine (field) ', ' Public Health ', ' Nature ', ' Research Design ', ' study design ', ' Study Type ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Computer software ', ' computer program/software ', ' Software ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Solutions ', ' programs ', ' Testing ', ' United States ', ' Investigation ', ' Complex ', ' Techniques ', ' Severity of illness ', ' disease severity ', ' interest ', ' Performance ', ' trait ', ' simulation ', ' Disease Outcome ', ' novel ', ' disorder prevention ', ' disease prevention ', ' Categories ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Case-Control Studies ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' genetic analysis ', ' Genetic analyses ', ' Relative (related person) ', ' Relative ', ' Statistical Methods ', ' Chromosome Mapping ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosomes ', ' Modeling ', ' case control ', ' genetic variant ', ' Outcome ', ' user-friendly ', ' human disease ', ' non-genetic ', ' nongenetic ', ' flexibility ', ' flexible ', ' ']",NHGRI,EMORY UNIVERSITY,R01,2010,288566,GA-05,0.07676431027644787
"Methods for high-resolution analysis of genetic effects on gene expression    DESCRIPTION (provided by applicant):    Summary Gene expression is a fundamental function of any cell. It is the main mechanism by which information is transmitted from the nucleus to the rest of the cell and eventually to other cells and the body of the organism. Genetic variation in components of the transcriptional machinery and signals that regulate gene function generates variation in transcriptional response and consequently variation in phenotypes. It has become apparent that many of the common genetic signals associated with disease are found away from the DNA sequence that encodes for protein sequence and is likely to be functioning in regulating gene expression. In this project we propose to develop methodologies that will explore the consequences of genetic variation in gene expression. There are three main goals of this project. First we will explore and develop methodologies to mine information from experiments that perform deep sequencing of the human transcriptome. The new sequencing technologies are providing us with unprecedented resolution into the transcriptome but are also raising challenges in the computational and biological models to use to interpret such large amounts of data. Secondly, we will use high-resolution genetic data to develop and use methodologies to dissect the fine structure of genetic variants that affect regulation of gene expression. Finally, we will implement and test models to infer the higher-order interactions of genome function so as to dig deeply into the biological consequences of genetic variants and how the signal is transmitted from the DNA sequence to higher levels of cell and body function. Our goals is to develop methodologies that will significantly improve our insight to the variability in human populations and assist in interpreting predisposition to genetic diseases.      PUBLIC HEALTH RELEVANCE:    Project narrative The proposed project aims at the development of statistical methods for the interpretation and study of the impact of genetic variants in cell function. Understanding the cellular effects of genetic variants provides a fundamental framework for the deep understanding of human genetic disease and increases the potential for the development of relevant treatments and drugs. It is the understanding of the basic molecular functions in health and disease that will provide the utmost resolution of information for the improvement of human health.           Project narrative The proposed project aims at the development of statistical methods for the interpretation and study of the impact of genetic variants in cell function. Understanding the cellular effects of genetic variants provides a fundamental framework for the deep understanding of human genetic disease and increases the potential for the development of relevant treatments and drugs. It is the understanding of the basic molecular functions in health and disease that will provide the utmost resolution of information for the improvement of human health.",Methods for high-resolution analysis of genetic effects on gene expression,8144831,R01MH090941,"['Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Linkage Disequilibrium ', ' Cell Nucleus ', ' Nucleus ', ' Alleles ', ' Allelomorphs ', ' genetic analysis ', ' Genetic analyses ', ' Organism ', ' living system ', ' Genotype ', ' Mining ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Transcript ', ' reconstruction ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' Human Genetics ', ' RNA Sequences ', ' density ', ' Nucleotides ', ' genetic variant ', ' DNA Resequencing ', ' Resequencing ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' cell body (neuron) ', ' soma ', ' neuronal cell body ', ' neural cell body ', ' Cell Body ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Statistical Methods ', ' protein protein interaction ', ' DNA Sequence ', ' Gene Expression Profile ', ' transcriptome ', ' gene expression signature ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' gene function ', ' Pattern ', ' Biochemical ', ' Genomics ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Structure ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Variant ', ' Variation ', ' Health ', ' Genome ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Tissues ', ' Body Tissues ', ' Development ', ' developmental ', ' Simulate ', ' Affect ', ' Resolution ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Population ', ' Relative (related person) ', ' Relative ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' human disease ', ' base ', ' public health relevance ', ' response ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Gene Expression ', ' insight ', ' Methods ', ' simulation ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Data ', ' Cells ', ' Goals ', ' Accounting ', ' Genetic ', ' Genes ', ' Complex ', ' DNA ', ' Deoxyribonucleic Acid ', ' Training ', ' Sampling ', ' programs ', ' Detection ', ' Technology ', ' Biological ', ' Work ', ' trait ', ' network models ', ' Molecular ', ' Modeling ', ' Testing ', ' Phenotype ', ' Property ', ' LOINC Axis 2 Property ', ' Data Set ', ' Dataset ', ' Techniques ', ' improved ', ' Maps ', ' Location ', ' cell type ', ' Methodology ', ' Method LOINC Axis 6 ', ' Interphase Cell ', ' Resting Cell ', ' Non-dividing Cell ', ' ']",NIMH,UNIVERSITY OF GENEVA,R01,2011,315416,,0.12043845719054862
"Functional genetic variations in splicing regulation     DESCRIPTION (provided by applicant): Recently, tremendous success has been achieved in constructing a catalog of genetic variants in disease genomes or across population. The next great challenge is to elucidate the potential function of various genetic variants in biological an disease processes. An important type of functional variants consists of those that affect gene expression in cis. Indeed, cis-regulatory variants are involved in a broad range of diseases and they showed a consistently stronger influence on gene expression than trans-acting determinants. Alternative splicing is an essential mechanism via which cis-regulatory changes may occur. Previous studies estimated that 15- 60% of point mutations that result in human genetic diseases disrupt splicing, highlighting the importance of this regulatory step. In addition to the well-known splice site signals, splicing is closely regulated by many exonic or intronic cis elements, associated with trans-acting proteins. Disruption of these cis-regulatory elements can cause aberrant splicing. Yet this crucial regulatory aspect remains largely unexplored. We propose to combine computational, genomic and molecular approaches to study splicing changes due to genetic variations. The specific aims are: (1) To globally identify exons and genes that are under differential splicing regulation by the alternative alleles of genetic variant, via bioinformatic analysis of high-throughput sequencing of transcriptome profiles (RNA-Seq). (2) To identify causal genetic variants in splicing alteration using minigene-based experiments. (3) To develop an integrative model to predict causal genetic variants in splicing alteration, using machine learning approaches, RNA- Seq data and molecular validations. This project will elucidate functional cis-regulatory genetic variants in splicing and provide significant insight ino the involvement of genetic variations in human diseases. In addition, this work will generate valuable bioinformatic tools to make full use of the increasingly available RNA-Seq data in a wide variety of cell types for identification and prediction of disease-related genetic variants.        PUBLIC HEALTH RELEVANCE: Aberrant splicing can significantly alter gene expression and contribute to human diseases. The proposed research aims to gain a systematic understanding of the functional roles of genetic variations (e.g., mutations or polymorphisms) in the regulation of splicing. This work will provide mechanistic basis for how genetic variations may contribute to diseases, such that future interventions can target specific splicing events therapeutically.                      Aberrant splicing can significantly alter gene expression and contribute to human diseases. The proposed research aims to gain a systematic understanding of the functional roles of genetic variations (e.g., mutations or polymorphisms) in the regulation of splicing. This work will provide mechanistic basis for how genetic variations may contribute to diseases, such that future interventions can target specific splicing events therapeutically.                    ",Functional genetic variations in splicing regulation,8295524,R01HG006264,"['Cells ', ' Cataloging ', ' Affect ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Alternative Splicing ', ' Allelomorphs ', ' Alleles ', ' Goals ', ' Future ', ' Exons ', ' Elements ', ' Gene Expression ', ' Genome ', ' Environment ', ' Genes ', ' Complement Proteins ', ' Complement ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Methods ', ' Nucleotides ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Intervening Sequences ', ' Introns ', ' Human Genetics ', ' Housing ', ' social role ', ' Role ', ' Splicing ', ' RNA Splicing ', ' gene product ', ' Proteins ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' mRNA ', ' Messenger RNA ', ' Research ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' Variation ', ' Variant ', ' Measures ', ' Point Mutation ', ' base ', ' Dataset ', ' Data Set ', ' improved ', ' Biological ', ' Body Tissues ', ' Tissues ', ' trans acting factor (genetic) ', ' Transactivators ', ' Trans-Acting Factors ', ' Trans-Activators ', ' Work ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Testing ', ' Event ', ' Knowledge ', ' Catalogs ', ' Reporter ', ' Pattern ', ' Techniques ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' tool ', ' cell type ', ' Training ', ' Site ', ' insight ', ' high throughput analysis ', ' RNA analysis ', ' novel technologies ', ' new technology ', ' Genomics ', ' Modeling ', ' Regulation ', ' Coding System ', ' Code ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' novel ', ' success ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' designing ', ' design ', ' Process ', ' developmental ', ' Development ', ' Tissue-Specific Splicing ', ' genetic variant ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' Characteristics ', ' Validation ', ' Molecular ', ' Transcript ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Bio-Informatics ', ' Bioinformatics ', ' Resolution ', ' Data ', ' Regulatory Element ', ' Outcome ', ' human disease ', ' Population ', ' ']",NHGRI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2012,308000,CA-33,0.08928996060586614
"Methods for high-resolution analysis of genetic effects on gene expression    DESCRIPTION (provided by applicant):    Summary Gene expression is a fundamental function of any cell. It is the main mechanism by which information is transmitted from the nucleus to the rest of the cell and eventually to other cells and the body of the organism. Genetic variation in components of the transcriptional machinery and signals that regulate gene function generates variation in transcriptional response and consequently variation in phenotypes. It has become apparent that many of the common genetic signals associated with disease are found away from the DNA sequence that encodes for protein sequence and is likely to be functioning in regulating gene expression. In this project we propose to develop methodologies that will explore the consequences of genetic variation in gene expression. There are three main goals of this project. First we will explore and develop methodologies to mine information from experiments that perform deep sequencing of the human transcriptome. The new sequencing technologies are providing us with unprecedented resolution into the transcriptome but are also raising challenges in the computational and biological models to use to interpret such large amounts of data. Secondly, we will use high-resolution genetic data to develop and use methodologies to dissect the fine structure of genetic variants that affect regulation of gene expression. Finally, we will implement and test models to infer the higher-order interactions of genome function so as to dig deeply into the biological consequences of genetic variants and how the signal is transmitted from the DNA sequence to higher levels of cell and body function. Our goals is to develop methodologies that will significantly improve our insight to the variability in human populations and assist in interpreting predisposition to genetic diseases.      PUBLIC HEALTH RELEVANCE:    Project narrative The proposed project aims at the development of statistical methods for the interpretation and study of the impact of genetic variants in cell function. Understanding the cellular effects of genetic variants provides a fundamental framework for the deep understanding of human genetic disease and increases the potential for the development of relevant treatments and drugs. It is the understanding of the basic molecular functions in health and disease that will provide the utmost resolution of information for the improvement of human health.           Project narrative The proposed project aims at the development of statistical methods for the interpretation and study of the impact of genetic variants in cell function. Understanding the cellular effects of genetic variants provides a fundamental framework for the deep understanding of human genetic disease and increases the potential for the development of relevant treatments and drugs. It is the understanding of the basic molecular functions in health and disease that will provide the utmost resolution of information for the improvement of human health.",Methods for high-resolution analysis of genetic effects on gene expression,8509240,R01MH090941,"['virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Linkage Disequilibrium ', ' Maps ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Mining ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' Nucleotides ', ' living system ', ' Organism ', ' Phenotype ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Technology ', ' Testing ', ' Body Tissues ', ' Tissues ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Work ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' RNA Sequences ', ' base ', ' density ', ' improved ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Training ', ' insight ', ' Simulate ', ' Genetic ', ' gene function ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Predisposition to Disease ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Complex ', ' cell type ', ' Pattern ', ' Techniques ', ' Location ', ' soma ', ' neuronal cell body ', ' neural cell body ', ' Cell Body ', ' cell body (neuron) ', ' trait ', ' Structure ', ' simulation ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' Peptide Sequence Determination ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' Genetic analyses ', ' genetic analysis ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' LOINC Axis 2 Property ', ' Property ', ' response ', ' protein protein interaction ', ' Genomics ', ' Resequencing ', ' DNA Resequencing ', ' Data ', ' Detection ', ' Resting Cell ', ' Non-dividing Cell ', ' Interphase Cell ', ' Resolution ', ' Transcript ', ' Molecular ', ' developmental ', ' Development ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' reconstruction ', ' genetic variant ', ' Population ', ' human disease ', ' network models ', ' public health relevance ', ' Accounting ', ' Affect ', ' Allelomorphs ', ' Alleles ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Alternative Splicing ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' Nucleus ', ' Cell Nucleus ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cells ', ' ']",NIMH,UNIVERSITY OF GENEVA,R01,2012,215355,,0.12043845719054862
"Clinically Relevant Genome Variation Database We propose to create the world's premier database of genetic variants relevant to clinical care (Clinically Relevant Genetic Variants Resource or CRVR). We will provide transparent data synthesis and consensus opinion on the clinical utility of a given genetic variant across a spectrum of genetic lesions including single nucleotide changes, small indels and structural variants. We will integrate with ClinVar, PharmGKB, and OMIM and draw upon NHGRI initiatives including the Genome Sequencing and Analysis and Mendelian Disorders Sequencing Centers, and the Clinical Sequencing Exploratory Research Centers. We will work closely with other CRVR sites and NHGRI funded initiatives to improve deposition of data from clinical laboratories. Our database will be built through three Aims. Aim 1 will engage and energize the clinical genomics community around CRVR efforts. We will partner with the other CRVR and U41 investigators in this activity as they will focus on engagement of professional societies, clinical testing laboratories, and the broader clinical genomics community to ensure creation of a CRVR resource that meets anticipated community needs including assembly of Disease-Specific and Mutation Type Working Groups (DSWGs and MTWGs) comprised of expert clinical geneticists and molecular diagnosticians to establish metrics for the initial classification of variants and integration of guidelines from professional organizations. Aim 2 will involve creation of a CRVR CoreDB resource through expert review of the existing literature, locus databases, and NHGRI initiatives. We will disseminate consensus findings on clinically relevant genetic variants and the clinical implications of these variants, with supporting evidence and documentation of the consensus process. Information will be aggregated using standard ontologies and advanced methodologies for handling heterogeneous data to create a Core Database (CoreDB). The consensus of expert review will be disseminated through a user-friendly web Portal (vetted by Genetic Counseling WG), web services for data mining, and consensus clinical guidelines to the appropriate clinical and research communities. The results will be organized by gene, variant, disease, pathway, and literature. Supporting evidence will also be curated and disseminated, and the resource will be updated continuously as new information accumulates. Aim 3 will involve deployment of machine-learning algorithms for semi- automatic identification of putative Clinically Relevant Variants (CRVs). We will undertake data mining of the clinical and epidemiological genetics literature and existing databases to identify putative clinically important variants. This will involve mining data from ClinVar, OMIM, CSER, and the Mendelian centers aggregated in Aim 2. The Working Groups formed in Aim 1 will establish criteria and oversee curators vetting variants. We will develop and optimize disease- and gene-specific machine learning algorithms to facilitate rapid classification of variants based on data provided by genetic testing services via ClinVar. We will integrate population-genetic data inferred from at least 25 reference populations from the 1000 Genomes Project and other large endeavors into our machine learning approaches so as to infer the global relevance of CRVs discovered here. PUBLIC HEALTH RELEVANCE: We propose to create a unified, public, and freely available database of genetic alterations relevant to clinical care. Our ultimate goal is to empower clinicians, genetic counselors, and patients to make informed decisions based on DNA testing. Because much of the information required for such decisions is scattered among public and private databases, we propose combining the medical literature, expert summary of millions of de- identified genetic tests, and results from current and past NIH-funded genetic studies into a single unified database.",Clinically Relevant Genome Variation Database,8574128,U01HG007436,"['Professional Organizations ', ' Genes ', ' Genetic Counseling ', ' Medical Genetics ', ' Population Genetics ', ' Genome ', ' Goals ', ' Health ', ' Algorithms ', ' Research ', ' Research Personnel ', ' Resources ', ' Human Genetics ', ' medical schools ', ' Societies ', ' Biological Assay ', ' Laboratories ', ' Disease ', ' DNA ', ' North Carolina ', ' Nucleotides ', ' Mutation ', ' Literature ', ' Variation (Genetics) ', ' Classification ', ' Clinical Research ', ' Medicine ', ' Data Sources ', ' Cataloging ', ' Patients ', ' Methodology ', ' United States National Institutes of Health ', ' Translating ', ' Work ', ' Universities ', ' Communities ', ' Testing ', ' Professional counselor ', ' Epidemiology ', ' Ensure ', ' response ', ' Clinical ', ' Phase ', ' Variant ', ' Machine Learning ', ' Consensus ', ' Online Mendelian Inheritance In Man ', ' meetings ', ' Medical ', ' college ', ' Services ', ' empowered ', ' Genetic ', ' gene function ', ' Lesion ', ' Catalogs ', ' base ', ' Deposition ', ' Guidelines ', ' Internet ', ' Documentation ', ' Collaborations ', ' Letters ', ' Clinical Practice Guideline ', ' Knowledge ', ' American ', ' Genomics ', ' improved ', ' knowledge base ', ' Site ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Databases ', ' Metric ', ' Bioinformatics ', ' Test Result ', ' Funding ', ' Genetic screening method ', ' novel ', ' Population ', ' clinically relevant ', ' Counselor ', ' Molecular ', ' Process ', ' Genetic Population Study ', ' user-friendly ', ' disease/disorder ', ' Development ', ' clinical care ', ' Deoxyribonucleic Acid ', ' Systematics ', ' Clinical Study ', ' Update ', ' genome analysis ', ' Ontology ', ' data exchange ', ' Disorder ', ' data mining ', ' genome sequencing ', ' Clinical Data ', ' research clinical testing ', ' Disease Association ', ' Disease Pathway ', ' genetic variant ', ' design ', ' web services ', ' working group ', ' National Human Genome Research Institute ', ' genome mutation ', ' epidemiologic ', ' epidemiological ', ' NIH ', ' Genetic Alteration ', ' National Institutes of Health ', ' Genetic Change ', ' Genetic defect ', ' Data ', ' Gene variant ', ' Genetic Diversity ', ' Genetic Variation ', ' allelic variant ', ' genetic testing ', ' Method LOINC Axis 6 ', ' Variation ', ' kernel methods ', ' statistical learning ', ' support vector machine ', ' medical college ', ' school of medicine ', ' Investigators ', ' Researchers ', ' Research Resources ', ' knowledgebase ', ' Data Banks ', ' Data Bases ', ' Databanks ', ' collegiate ', ' Electronic Databank ', ' Electronic Database ', ' clinical data repository ', ' OMIM ', ' data repository ', ' WWW ', ' web ', ' world wide web ', ' Deposit ', ' Bio-Informatics ', ' data transmission ', ' developmental ', ' Clinical Evaluation ', ' designing ', ' Clinical Testing ', ' clinical test ', ' clinical relevance ', ' NHGRI ', ' National Center for Human Genome Research ', ' datamining ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2013,1400000,CA-18,0.19693482019914982
"NHGRI PAGE Coordinating Center     DESCRIPTION (provided by applicant): NHGRI developed the Population Architecture Using Genomics and Epidemiology (PAGE) research program to identify and characterize genomic variants in non-European populations. To support the complexities of such an ambitious effort, we have convened a strong team of statistical, population, and molecular geneticists, computer and information scientists, biostatisticians, and project management staff with many years of related experience to serve as a Coordinating Center (CC). Specifically, the CC will serve as a centralized resource to facilitate and support the activities of the program and Study Investigators focused on characterization of causal variants by: (1) coordinating phenotype harmonization efforts, including mapping phenotype variables across studies and to the PhenX measures; (2) synthesizing individual-level data into centralized datasets to facilitate sharing of data within and outside of PAGE; (3) utilizing state-of-the-art computer and information science support and scientific workflows that will facilitate analyses, ancestry deconvolution, genotype calling and imputation, SNP annotation, and data synthesis; (4) rapidly disseminating all study data via dbGaP and/or the PAGE website or other applicable databases; and (5) serving as a centralized resource to facilitate, support, and manage program activities and logistics as requested by the Steering Committee or Project Office and as needed for successful coordination of the program. Coordination of the program will be done in a spirit of collaboration using creative and flexible approaches, while providing leadership in statistical genetic methodologies and approaches to project management. The ultimate goal of our CC is to facilitate the identification and characterization of genotype-phenotype associations, especially as relevant to non-European populations, thereby accelerating our understanding of ancestral differences in the genetic and environmental causes of common diseases. Critical to achieving this mission is the deployment of powerful methods for ancestry deconvolution, multi- and trans-ethnic mapping, and imputation. Building upon our success as the PAGE I CC, we have added additional investigators with expertise in these areas and consortium experience with next-generation sequence analysis of both whole-genome and exome data. Our collaborative team is ideally staffed to meet the challenges of the new round of PAGE.         PUBLIC HEALTH RELEVANCE: The PAGE study focuses on analysis of existing large samples of primarily non- European ancestry to broaden our understanding of the ethnic differences in the genetic basis of complex disease. The PAGE coordinating center supports the functions of this study.                ",NHGRI PAGE Coordinating Center,8573120,U01HG007419,"['epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Engineering / Architecture ', ' Architecture ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Communication ', ' Computers ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Protocol Screening ', ' Eligibility ', ' Eligibility Determination ', ' Methods Epidemiology ', ' Epidemiological Techniques ', ' Epidemiological Methods ', ' Epidemiologic Methods ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Future ', ' Genome ', ' Genotype ', ' Goals ', ' Group Meetings ', ' Information Sciences ', ' Informed Consent ', ' Leadership ', ' Maps ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Mining ', ' Mission ', ' Phenotype ', ' Productivity ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Running ', ' Technology ', ' Time ', ' Voice ', ' Work ', "" formycin A 5'-triphosphate "", "" formycin 5'-triphosphate "", ' FTP ', ' formycin triphosphate ', ' Measures ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' conference ', ' symposium ', ' hispanic community ', ' Spanish Origin ', ' Latino Population ', ' Hispanic Populations ', ' Hispanics ', ' Latino ', ' Dataset ', ' Data Set ', ' Custom ', ' Sequence Analyses ', ' SEQ-AN ', ' Sequence Analysis ', ' base ', ' improved ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Individual ', ' European ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Logistics ', ' Data Quality ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Deposit ', ' Deposition ', ' tool ', ' instrument ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Scientist ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Source ', ' meetings ', ' experience ', ' success ', ' computer science ', ' Population Study ', ' ethnic difference ', ' Metric ', ' epidemiology study ', ' Reporting ', ' Genetic analyses ', ' genetic analysis ', ' Sampling ', ' genetic epidemiology ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' Documentation ', ' Data ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Update ', ' Monitor ', ' Molecular ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' website ', ' web site ', ' disease phenotype ', ' cost ', ' designing ', ' design ', ' next generation ', ' Population ', ' wiki ', ' public health relevance ', ' dbGaP ', ' database of Genotypes and Phenotypes ', ' exomes ', ' exome ', ' sharing data ', ' flexible ', ' flexibility ', ' next generation sequencing ', ' exome sequencing ', ' ']",NHGRI,"RUTGERS, THE STATE UNIV OF N.J.",U01,2013,720000,NJ-06,0.07844014580334506
"Functional genetic variations in splicing regulation     DESCRIPTION (provided by applicant): Recently, tremendous success has been achieved in constructing a catalog of genetic variants in disease genomes or across population. The next great challenge is to elucidate the potential function of various genetic variants in biological an disease processes. An important type of functional variants consists of those that affect gene expression in cis. Indeed, cis-regulatory variants are involved in a broad range of diseases and they showed a consistently stronger influence on gene expression than trans-acting determinants. Alternative splicing is an essential mechanism via which cis-regulatory changes may occur. Previous studies estimated that 15- 60% of point mutations that result in human genetic diseases disrupt splicing, highlighting the importance of this regulatory step. In addition to the well-known splice site signals, splicing is closely regulated by many exonic or intronic cis elements, associated with trans-acting proteins. Disruption of these cis-regulatory elements can cause aberrant splicing. Yet this crucial regulatory aspect remains largely unexplored. We propose to combine computational, genomic and molecular approaches to study splicing changes due to genetic variations. The specific aims are: (1) To globally identify exons and genes that are under differential splicing regulation by the alternative alleles of genetic variant, via bioinformatic analysis of high-throughput sequencing of transcriptome profiles (RNA-Seq). (2) To identify causal genetic variants in splicing alteration using minigene-based experiments. (3) To develop an integrative model to predict causal genetic variants in splicing alteration, using machine learning approaches, RNA- Seq data and molecular validations. This project will elucidate functional cis-regulatory genetic variants in splicing and provide significant insight ino the involvement of genetic variations in human diseases. In addition, this work will generate valuable bioinformatic tools to make full use of the increasingly available RNA-Seq data in a wide variety of cell types for identification and prediction of disease-related genetic variants.          Aberrant splicing can significantly alter gene expression and contribute to human diseases. The proposed research aims to gain a systematic understanding of the functional roles of genetic variations (e.g., mutations or polymorphisms) in the regulation of splicing. This work will provide mechanistic basis for how genetic variations may contribute to diseases, such that future interventions can target specific splicing events therapeutically.                    ",Functional genetic variations in splicing regulation,8452075,R01HG006264,"['Affect ', ' Allelomorphs ', ' Alleles ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Alternative Splicing ', ' Cataloging ', ' Cells ', ' Complement Proteins ', ' Complement ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Elements ', ' Environment ', ' Exons ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Housing ', ' Human Genetics ', ' Intervening Sequences ', ' Introns ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Research ', ' Splicing ', ' RNA Splicing ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Body Tissues ', ' Tissues ', ' trans acting factor (genetic) ', ' Transactivators ', ' Trans-Acting Factors ', ' Trans-Activators ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Work ', ' Measures ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' insight ', ' Reporter ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Catalogs ', ' Event ', ' cell type ', ' Pattern ', ' Techniques ', ' success ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' novel technologies ', ' new technology ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' high throughput analysis ', ' RNA analysis ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' Data ', ' Regulatory Element ', ' Resolution ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Tissue-Specific Splicing ', ' Transcript ', ' Validation ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' Population ', ' human disease ', ' RNA-seq ', ' transcriptome sequencing ', ' ']",NHGRI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2013,294140,CA-33,0.10493672460502469
"Discovery and analysis of structural variation in whole genome sequences     DESCRIPTION (provided by applicant):     The whole genome sequencing of large cohorts of individuals is quickly becoming a common tool for researchers to investigate the genetic basis of many disease phenotypes. The primary goals are to discover the underlying genetic variation that cause or contribute to these diseases as well as to correctly identify these variants in a diagnostic setting. These differences typicall consist of single base changes (SNPs), but can also encompass larger, more complex chromosomal rearrangements in the form of structural variation (SV) which are much more difficult to detect even with modern sequencing technologies. A number of approaches have been published that have studied this problem, but even the largest scale endeavors have only focused on deletion events and reported a sensitivity of <70%. Complex chromosomal rearrangements are even less well studied. Thus, it is paramount that accurate methods are developed which can detect all types of SVs at high specificity from sequence data. This proposal aims to improve the overall ability of researchers to identify and analyze genetic variation from whole genome sequences. An important, and often overlooked, aspect of SV discovery is the fact that typical paired-end, read depth, and split read approaches will identify different sets of non-overlapping variants at varying degrees of accuracy. In Aim 1, we will develop a unified SV discovery algorithm that can incorporate all of these different sources of information in a probabilistic fashion. Such a method would be useful for research, in particular with the identification of rare variants, as well as clinical applications which require a great del of accuracy and have thus far been limited to older karyotyping and microarray approaches. This would identify the majority of structural variants, however there are many regions in genomic sequences which are complex in nature, defined as consisting of multiple neighboring or overlapping chromosomal rearrangements that are challenging to resolve with typical SV detection approaches. In Aim 2, we propose methods to resolve these complex regions and assess their frequency and impact. Furthermore, a crucial step in medical genetics is the comparison of identified genetic mutations to databases of known pathogenic and benign variants. This is currently problematic with SVs, as they have often been originally reported with varying degrees of breakpoint resolution that can hamper the correct assignment of the variant. This issue is compounded further in more complex regions with multiple breakpoints, for which simplistic comparison methods do not work well. In Aim 3, we will develop and implement a system that describes and utilizes variant profiles to identify whether an individual's sequence data contains a variant of interest. Overall, this project will advance our understanding of the human genome as well as provide tools for use in the general research and clinical communities.         PUBLIC HEALTH RELEVANCE:     The rearrangement of chromosomal material in the form of structural variation is directly responsible for many disease phenotypes, however our ability to detect and resolve these events from whole genome sequence data is currently limited. We propose a number of strategies for improving the detection and analysis of structural genomic variation between individuals and resolving their underlying structure and function. These approaches will have direct application to the clinical diagnosis of such events and the future of personalized genomics.            ",Discovery and analysis of structural variation in whole genome sequences,8528145,R01HG007068,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Future ', ' Medical Genetics ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Karyotyping Genetics ', ' Karyotyping ', ' Karyotype determination procedure ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Probabilistic Models ', ' Statistical Models ', ' living system ', ' Organism ', ' Publishing ', ' Reading ', ' Records ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' seed ', ' Plant Zygotes ', ' Plant Embryos ', ' Seeds ', ' Specificity ', ' Technology ', ' Testing ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Work ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Area ', ' Benign ', ' Clinical ', ' Variation ', ' Variant ', ' Medical ', ' Training ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Genetic ', ' clinical Diagnosis ', ' tool ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequency ', ' Frequencies (time pattern) ', ' Hereditary ', ' Inherited ', ' Complex ', ' Event ', ' Scanning ', ' Source ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' interest ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' cohort ', ' Structure ', ' Reporting ', ' Modeling ', ' Genomics ', ' Pathogenicity ', ' structural genomics ', ' genome sequencing ', ' Address ', ' Length ', ' Rearrangement ', ' DNA Sequence Rearrangement ', ' Data ', ' Detection ', ' Resolution ', ' Chromosomal Rearrangement ', ' disease phenotype ', ' genetic variant ', ' virtual ', ' markov model ', ' Population ', ' direct application ', ' clinical applicability ', ' clinical application ', ' public health relevance ', ' ']",NHGRI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2013,382699,MI-12,0.16686769703965587
"Mechanisms underlying complex trait human disease     DESCRIPTION (provided by applicant): There is now an explosion of new genome scale data relating genetic variation within the human population to phenotype, and particularly to common disease. Microarray technology has identified 100s of loci where the presence of particular variants is associated with altered risk of many common diseases; complete sequencing of individual exomes in cancer samples has discovered many somatic mutations in a variety of genes; and sequencing of 1000 human genomes has provided an almost complete inventory of common population variants. Further, these data are only the first in an ever-increasing flood, as even faster and cheaper sequencing technologies come on line. The results hold promise for major advances in treatment and diagnosis of common human diseases. Extracting the expected benefits is not straightforward, and will necessitate acquiring detailed knowledge of the mechanisms linking genetic variation to disease. This project focuses on one aspect of this challenge - using the new genomic data to identify new therapeutic opportunities. We will investigate those principles underlying complex trait disease that are particularly relevant to tha goal. We introduce a three stage mechanistic framework, relating genomic variation to the function of impacted gene products, the impact of these altered functions on pathways, processes and subsystems; and finally the consequences for complex trait disease phenotypes. We will develop computational methods to address key questions concerning three major aspects of the framework (1) How large are the changes in protein function brought about by the genomic variants underlying complex trait disease? What role do different classes of genomic and protein level mechanism, such as expression, non-synonymous changes and splicing, play in these variants? (2) How complete is the set genes with strong influence on the disease phenotypes discovered by current technologies, and how can missing genes be imputed from the genomic and network data? (3) What is the distribution of coupling between the activity of genes involved in disease mechanism and disease phenotypes? The results will deepen understanding of these aspects of complex disease, and provide a basis for identifying potential new drug targets from GWAS and other genomic studies.         PUBLIC HEALTH RELEVANCE: New technologies are now providing extensive information on human genetic variation associated with increased risk of a wide range of common human disease, such as Alzheimer's, diabetes, heart disease, and many cancers. These data hold the promise for the development of new therapies, and realizing those benefits requires the acquisition of complementary knowledge of the mechanisms that link genetic variation to disease risk. This project is focused on analysis of the relationship between genetic variation and common disease with the goal of identifying new therapeutic opportunities.                ",Mechanisms underlying complex trait human disease,8431505,R01GM104436,"['Affect ', ' Algorithms ', ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Explosion ', ' Flooding ', ' Floods ', ' Future ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Information Networks ', ' Inventory ', ' Equipment and supply inventories ', ' Methods ', ' Minor ', ' Phenotype ', ' Play ', ' gene product ', ' Proteins ', ' Risk ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Technology ', ' Translations ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Work ', ' Relative ', ' Relative (related person) ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Therapeutic ', ' gene function ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Frequency ', ' Frequencies (time pattern) ', ' Complex ', ' Somatic Mutation ', ' trait ', ' disease risk ', ' disorder risk ', ' novel technologies ', ' new technology ', ' Network Analysis ', ' Pathway Analysis ', ' Modeling ', ' Sampling ', ' Genomics ', ' genome sequencing ', ' Address ', ' microarray technology ', ' Microarray-Based Analysis ', ' Microarray Analysis ', ' Data ', ' Other Genetics ', ' Molecular ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' genetic variant ', ' Population ', ' Coupled ', ' Coupling ', ' Heritability ', ' human disease ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' therapeutic target ', ' public health relevance ', ' exomes ', ' exome ', ' exome sequencing ', ' risk variant ', ' Drug Targeting ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2013,278213,MD-05,0.09578463956340716
"An Integrative Analysis of Structural Variation for the 1000 Genomes Project DESCRIPTION (provided by applicant): Structural variation (SV), involving deletions, duplications, insertions and inversions of DNA segments, accounts for a large proportion of human genetic diversity. Comprehensive identification and analysis of these genetic variants will help us more fully elucidate the biology of their functional effects on human health and demography. Despite recent advances, the tools and data needed to comprehensively identify all types of SVs, genotype each variant, integrate and phase these variants remain lacking. Indeed, the data released from the early phases of the 1000 Genomes Project (1000GP) (1000 Genomes Project Consortium, 2010; 1000 Genomes Project Consortium, 2012) are biased primarily towards the detection of deletions within relatively unique regions of the genome. As a consortium, we propose to pool expertise from various research groups to provide an integrative analysis of SVs by combining rigorous computational algorithmic development with extensive experimental validation. The new algorithms we develop and the high confidence lists of SVs obtained will be rapidly made available as a public resource. ",An Integrative Analysis of Structural Variation for the 1000 Genomes Project,8589933,U41HG007497,"['Accounting ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Biology ', ' Chromosomes ', ' Complement Proteins ', ' Complement ', ' Population Studies / Demography ', ' Demography ', ' Deoxyribonucleic Acid ', ' DNA ', ' Future ', ' Gene Conversion ', ' Genome ', ' Genotype ', ' Goals ', ' Au element ', ' Gold ', ' Haplotypes ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Maps ', ' Methods ', ' Probabilistic Models ', ' Statistical Models ', ' Nucleotides ', ' Reading ', ' Research ', ' Research Resources ', ' Resources ', ' Technology ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Repetitive Regions ', ' Repetitive Element ', ' Repetitive Sequence ', ' base ', ' method development ', ' improved ', ' Site ', ' Phase ', ' Variation ', ' Variant ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Complex ', ' Best Practice Analysis ', ' Benchmarking ', ' insertion sequence ', ' insertion element ', ' DNA Insertion Elements ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Modeling ', ' Sampling ', ' genome sequencing ', ' Data ', ' Detection ', ' Resolution ', ' Validation ', ' Process ', ' developmental ', ' Development ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' ']",NHGRI,JACKSON LABORATORY,U41,2013,2766009,ME-02,0.11924110504807471
"Decrypting Variants of Uncertain Significance in Long-QT Syndrome     DESCRIPTION (provided by applicant): Clinical genetic testing has become standard-of-care for many diseases including hundreds of inherited conditions. However, interpreting genetic test results is often confounded by the discovery of 'variants of unknown significance' (VUS) for which there is insufficient data or inadequate predictive tools to establish whether or not a particular variant predisposes to a disease. This problem is particularly vexing for genetic disorders with strong allelic heterogeneity and a preponderance of 'private' mutations such as the congenital long-QT syndrome (LQTS), which predisposes young adults and children to sudden death from cardiac arrhythmias. With the anticipated incorporation of personal exome or genome data into routine clinical care, interpreting VUS will become an even greater challenge especially when variants in genes associated with human disorders are incidentally discovered. Unfortunately, there are no reliable methods to predict a priori whether a given variant predisposes an individual to a particular disorder or whether the change is merely a benign rare variant. We propose to develop a novel paradigm for distinguishing disease-causing mutations from benign variants in LQTS as a model for other inherited arrhythmia syndromes and channelopathies. We will focus on variants in KCNQ1, the most commonly mutated gene in LQTS. The central hypothesis of this proposal is that a holistic predictive model that relates experimentally determined protein structure and dynamics to function and disease is highly accurate even for novel variants. Our ultimate objectives are to develop a data-trained, web-accessible algorithm that classifies VUS discovered in KCNQ1 based on reliable predictions of the structure and dynamics of the affected protein, and to achieve prediction accuracy to levels needed to inform medical decisions. The medical importance of correctly classifying KCNQ1 variants provides strong justification for having a dedicated and highly-tailored gene-specific prediction model. The ability to distinguish deleterious from neutral variants would help avoid unnecessary and potentially harmful interventions in carriers of benign alleles, and save the lives of those with true mutations. We propose to collect extensive electrophysiological, biochemical and structural data on a large set of KCNQ1 variants discovered in LQTS subjects as well as several suspected benign or neutral variants (Aims 1-2), then use these data to iteratively train and validate a machine learning based algorithm that can differentiate benign from deleterious KCNQ1 alleles among a set of new VUS (Aim 3). Our proposal is innovative in the use of a multidisciplinary approach to functionally and structurally annotate genomic variant data for a medically important gene at an unprecedented scale, and then to use these experimental findings to train/test a novel computational system to achieve clinical-grade predictions. Targeting KCNQ1 will also validate an approach for parallel work that can be utilized to predict the medical significance of variants in closely related potassium channels associated with heritable epilepsy (KCNQ2, KCNQ3) or deafness (KCNQ4).          PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a method to reliably predict the consequences of genetic variants of unknown significance discovered in the course of genetic testing in the congenital long-QT syndrome (LQTS), a cause of sudden cardiac death in children and young adults. We propose a multidisciplinary experimental approach including electrophysiology, biochemistry and structural biology deployed on a large scale to generate information on at least 110 genetic variants in the main gene responsible for LQTS (KCNQ1), which encodes a potassium channel required for normal electrical activity in the heart. Our final product will be a data-trained computational strategy that will outperform existing methods for accurately predicting the functional consequences of novel KCNQ1 genetic variants, enhance the value of genetic testing in LQTS and provide for more informed medical decisions.                ",Decrypting Variants of Uncertain Significance in Long-QT Syndrome,8786636,R01HL122010,"['Affect ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' arrhythmic agent ', ' antiarrhythmic agent ', ' Antiarrhythmic Drugs ', ' Antiarrhythmia Drugs ', ' Antiarrhythmia Agents ', ' Anti-Arrhythmics ', ' Anti-Arrhythmia Drugs ', ' Anti-Arrhythmia Agents ', ' Heart Arrhythmias ', ' Cardiac Arrhythmia ', ' Arrhythmia ', ' Biological Chemistry ', ' Biochemistry ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' Child Human ', ' 0-11 years old ', ' Child ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Deafness ', ' Sudden Death ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Neurophysiology / Electrophysiology ', ' Electrophysiology ', ' Electrophysiology (science) ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Patient Care Delivery ', ' Patient Care ', ' Genes ', ' Genome ', ' Goals ', ' Heart ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Heterogeneity ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Membrane Channels ', ' Ionic Channels ', ' Ion Channel ', ' Long QT Syndrome ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Patients ', ' Physicians ', ' Potassium Ion Channels ', ' K channel ', ' Potassium Channel ', ' gene product ', ' Proteins ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Syndrome ', ' Testing ', ' Work ', ' Death, Sudden, Cardiac ', ' Dataset ', ' Data Set ', ' Caring ', ' base ', ' Stimulators, Electrical, Cardiac, Shock ', ' Electric Shock Cardiac Stimulators ', ' Defibrillators ', ' Benign ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Medical ', ' Link ', ' Susceptibility ', ' Predisposition ', ' Training ', ' cardiac rhythm ', ' heart rhythm ', ' Individual ', ' young adulthood ', ' adult youth ', ' young adult ', ' Therapeutic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Hereditary ', ' Inherited ', ' LOINC Axis 4 System ', ' System ', ' Test Result ', ' structural biology ', ' knowledgebase ', ' knowledge base ', ' Protein Trafficking ', ' protein transport ', ' trafficking ', ' Structure ', ' genetic testing ', ' Genetic screening method ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Cell surface ', ' proband ', ' Modeling ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' Genomics ', ' genome sequencing ', ' protein structure ', ' Data ', ' Mutate ', ' Protein Dynamics ', ' First Degree Relative ', ' Other Genetics ', ' Molecular ', ' Cardiac ', ' protein function ', ' developmental ', ' Development ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' innovative ', ' innovate ', ' innovation ', ' multidisciplinary ', ' Implant ', ' web-accessible ', ' disease-causing mutation ', ' multidisciplinary approach ', ' interdisciplinary approach ', ' public health relevance ', ' clinical care ', ' exomes ', ' exome ', ' rare allele ', ' rare variant ', ' ']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2014,1308724,IL-07,0.1801325412341593
"Functional genetic variations in splicing regulation     DESCRIPTION (provided by applicant): Recently, tremendous success has been achieved in constructing a catalog of genetic variants in disease genomes or across population. The next great challenge is to elucidate the potential function of various genetic variants in biological an disease processes. An important type of functional variants consists of those that affect gene expression in cis. Indeed, cis-regulatory variants are involved in a broad range of diseases and they showed a consistently stronger influence on gene expression than trans-acting determinants. Alternative splicing is an essential mechanism via which cis-regulatory changes may occur. Previous studies estimated that 15- 60% of point mutations that result in human genetic diseases disrupt splicing, highlighting the importance of this regulatory step. In addition to the well-known splice site signals, splicing is closely regulated by many exonic or intronic cis elements, associated with trans-acting proteins. Disruption of these cis-regulatory elements can cause aberrant splicing. Yet this crucial regulatory aspect remains largely unexplored. We propose to combine computational, genomic and molecular approaches to study splicing changes due to genetic variations. The specific aims are: (1) To globally identify exons and genes that are under differential splicing regulation by the alternative alleles of genetic variant, via bioinformatic analysis of high-throughput sequencing of transcriptome profiles (RNA-Seq). (2) To identify causal genetic variants in splicing alteration using minigene-based experiments. (3) To develop an integrative model to predict causal genetic variants in splicing alteration, using machine learning approaches, RNA- Seq data and molecular validations. This project will elucidate functional cis-regulatory genetic variants in splicing and provide significant insight ino the involvement of genetic variations in human diseases. In addition, this work will generate valuable bioinformatic tools to make full use of the increasingly available RNA-Seq data in a wide variety of cell types for identification and prediction of disease-related genetic variants.          Aberrant splicing can significantly alter gene expression and contribute to human diseases. The proposed research aims to gain a systematic understanding of the functional roles of genetic variations (e.g., mutations or polymorphisms) in the regulation of splicing. This work will provide mechanistic basis for how genetic variations may contribute to diseases, such that future interventions can target specific splicing events therapeutically.                    ",Functional genetic variations in splicing regulation,8662290,R01HG006264,"['Affect ', ' Allelomorphs ', ' Alleles ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Alternative Splicing ', ' Cataloging ', ' Cells ', ' Complement Proteins ', ' Complement ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Elements ', ' Environment ', ' Exons ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Housing ', ' Human Genetics ', ' Intervening Sequences ', ' Introns ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Research ', ' Splicing ', ' RNA Splicing ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Body Tissues ', ' Tissues ', ' trans acting factor (genetic) ', ' Transactivators ', ' Trans-Acting Factors ', ' Trans-Activators ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' Measures ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' insight ', ' Reporter ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Catalogs ', ' Event ', ' cell type ', ' Pattern ', ' Techniques ', ' success ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' novel technologies ', ' new technology ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' RNA analysis ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' Data ', ' Regulatory Element ', ' Resolution ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Tissue-Specific Splicing ', ' Transcript ', ' Validation ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' Population ', ' human disease ', ' RNA-seq ', ' transcriptome sequencing ', ' High-Throughput Sequencing ', ' High-Throughput Nucleotide Sequencing ', ' ']",NHGRI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2014,301840,CA-33,0.10493672460502469
"GWAS TO GENE FUNCTION: NOS1AP AND OTHER QT INTERVAL GENES     DESCRIPTION (provided by applicant): Genome-wide association studies (GWAS) of the electrographic QT-interval, an intermediate trait that impacts the risks of long QT syndrome and sudden cardiac death, have identified 68 independent variants at 35 loci, explaining 8% of the phenotypic (20% of the additive) variance. Nevertheless, the identity, function and mechanisms of action of the underlying DNA sequence variants and genes remain unknown, and are major impediments for understanding the molecular structure and functional architecture of this complex phenotype. We hypothesize that the majority of functional trait variants are polymorphic, non-coding and perturb transcription of a specific gene by altering the functions of their cis-regulatory elements. We propose a research paradigm for systematically identifying these non-coding trait variants, the regulatory functions they disrupt and the specific genes whose functions are altered at each quantitative trait locus. We will utilize integrative statisticl genetic, computational, molecular genetics and cellular approaches for elucidating the underlying mechanisms, using QT interval as a model 'system'. Our specific aims are: (1) to perform high- resolution mapping of GWAS signals to identify all polymorphic (>1%) and rare variants at loci that modulate the QT-interval; (2) to conduct in silico and in vitro analysis to predict and prioritize all cardiac regulatory (enhancer, silencer, insulator) elements and their cognate DNA-binding proteins; and, (3) to identify trait variants, genes and their mechanisms of genetic action. The overall goals are to improve the molecular genetic and mechanistic understanding of multifactorial traits for applications to other complex phenotypes.         PUBLIC HEALTH RELEVANCE: The electrocardiographic QT-interval, an intermediate trait for arrhythmias and sudden cardiac death, has 68 predominantly non-coding variants at 35 loci explaining 8% of the phenotypic (20% of the additive) variance upon meta-analyses in >76,000 individuals of European and >11,000 individuals of African ancestry: nevertheless, the molecular details remain unknown. We propose a program of research for systematically identifying the functional non-coding quantitative trait variants, the regulatory function they disrupt and the specific gene whose functions are altered, at each locus. We utilize integrative statistical genetic, computational, molecular genetics and cellular approaches for understanding the underlying genetic mechanisms in this model trait with the overall goal to improve the molecular understanding of all complex phenotypes.                ",GWAS TO GENE FUNCTION: NOS1AP AND OTHER QT INTERVAL GENES,8625164,R01GM104469,"['Action Potentials ', ' adulthood ', ' adult human (21+) ', ' Adult Human ', ' 21+ years old ', ' Adult ', ' Allelomorphs ', ' Alleles ', ' Engineering / Architecture ', ' Architecture ', ' Heart Arrhythmias ', ' Cardiac Arrhythmia ', ' Arrhythmia ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Base Sequence ', ' Beer ', ' Reactive Site ', ' Combining Site ', ' Binding Sites ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' cell culture ', ' Cell Culture Techniques ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' disease/disorder ', ' Disorder ', ' Disease ', ' DNA-Binding Proteins ', ' Future ', ' Genes ', ' Goals ', ' Heart ', ' Heterogeneity ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Allergy ', ' Hypersensitivity ', ' In Vitro ', ' Infection ', ' Laboratories ', ' Long QT Syndrome ', ' Maps ', ' Methods ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' Macromolecular Structure ', ' Molecular Structure ', ' Oligo ', ' Oligonucleotides ', ' Phenotype ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Rats Mammals ', ' Rat ', ' Common Rat Strains ', ' Rattus ', ' Research ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrum Analysis ', ' Body Tissues ', ' Tissues ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Weight ', ' Death, Sudden, Cardiac ', ' Enhancers ', ' Molecular Genetics ', ' Promotor ', ' Promoters (Genetics) ', ' Promoter ', ' Promotor (Genetics) ', ' DNA Sequence ', ' base ', ' Label ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Evaluation ', ' Individual ', ' African ', ' European ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Gene Targeting ', ' Collaborations ', ' Genetic ', ' gene function ', ' Reporter ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Complex ', ' Myocytes ', ' Mature Muscle Cells ', ' Muscle Cells ', ' QTL ', ' Quantitative Trait Loci ', ' trait ', ' novel ', ' Position ', ' Positioning Attribute ', ' Modeling ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' gel shift assay ', ' Mobility Shift Assay ', ' Bandshift Mobility Assay ', ' Band Shift Mobility Assay ', ' Electrophoretic Mobility Shift Assay ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Insulator Elements ', ' Protein Microarray ', ' Protein Chips ', ' Protein Biochips ', ' Protein Microchips ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' ChIP (chromatin immunoprecipitation) ', ' CHIP assay ', ' chromatin immunoprecipitation ', ' p300 ', ' EP300 ', ' EP300 gene ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Affinity ', ' Data ', ' Regulatory Element ', ' Resolution ', ' in vivo ', ' Nuclear Extract ', ' Transcript ', ' Validation ', ' Molecular ', ' Ventricular ', ' Cardiac ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' epigenomics ', ' knock-down ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' Neonatal ', ' computer algorithm ', ' Computational algorithm ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' exomes ', ' exome ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' High-Throughput Sequencing ', ' High-Throughput Nucleotide Sequencing ', ' ']",NIGMS,JOHNS HOPKINS UNIVERSITY,R01,2014,621641,MD-07,0.0976757613835259
"Clinically Relevant Genome Variation Database We propose to create the world's premier database of genetic variants relevant to clinical care (Clinically Relevant Genetic Variants Resource or CRVR). We will provide transparent data synthesis and consensus opinion on the clinical utility of a given genetic variant across a spectrum of genetic lesions including single nucleotide changes, small indels and structural variants. We will integrate with ClinVar, PharmGKB, and OMIM and draw upon NHGRI initiatives including the Genome Sequencing and Analysis and Mendelian Disorders Sequencing Centers, and the Clinical Sequencing Exploratory Research Centers. We will work closely with other CRVR sites and NHGRI funded initiatives to improve deposition of data from clinical laboratories. Our database will be built through three Aims. Aim 1 will engage and energize the clinical genomics community around CRVR efforts. We will partner with the other CRVR and U41 investigators in this activity as they will focus on engagement of professional societies, clinical testing laboratories, and the broader clinical genomics community to ensure creation of a CRVR resource that meets anticipated community needs including assembly of Disease-Specific and Mutation Type Working Groups (DSWGs and MTWGs) comprised of expert clinical geneticists and molecular diagnosticians to establish metrics for the initial classification of variants and integration of guidelines from professional organizations. Aim 2 will involve creation of a CRVR CoreDB resource through expert review of the existing literature, locus databases, and NHGRI initiatives. We will disseminate consensus findings on clinically relevant genetic variants and the clinical implications of these variants, with supporting evidence and documentation of the consensus process. Information will be aggregated using standard ontologies and advanced methodologies for handling heterogeneous data to create a Core Database (CoreDB). The consensus of expert review will be disseminated through a user-friendly web Portal (vetted by Genetic Counseling WG), web services for data mining, and consensus clinical guidelines to the appropriate clinical and research communities. The results will be organized by gene, variant, disease, pathway, and literature. Supporting evidence will also be curated and disseminated, and the resource will be updated continuously as new information accumulates. Aim 3 will involve deployment of machine-learning algorithms for semi- automatic identification of putative Clinically Relevant Variants (CRVs). We will undertake data mining of the clinical and epidemiological genetics literature and existing databases to identify putative clinically important variants. This will involve mining data from ClinVar, OMIM, CSER, and the Mendelian centers aggregated in Aim 2. The Working Groups formed in Aim 1 will establish criteria and oversee curators vetting variants. We will develop and optimize disease- and gene-specific machine learning algorithms to facilitate rapid classification of variants based on data provided by genetic testing services via ClinVar. We will integrate population-genetic data inferred from at least 25 reference populations from the 1000 Genomes Project and other large endeavors into our machine learning approaches so as to infer the global relevance of CRVs discovered here. PUBLIC HEALTH RELEVANCE: We propose to create a unified, public, and freely available database of genetic alterations relevant to clinical care. Our ultimate goal is to empower clinicians, genetic counselors, and patients to make informed decisions based on DNA testing. Because much of the information required for such decisions is scattered among public and private databases, we propose combining the medical literature, expert summary of millions of de- identified genetic tests, and results from current and past NIH-funded genetic studies into a single unified database.",Clinically Relevant Genome Variation Database,8738706,U01HG007436,"['Algorithms ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Counselor ', ' Professional counselor ', ' Data Sources ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Genes ', ' Genetic Counseling ', ' Medical Genetics ', ' Population Genetics ', ' Genome ', ' Goals ', ' Health ', ' Human Genetics ', ' Laboratories ', ' Literature ', ' Medicine ', ' Method LOINC Axis 6 ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North Carolina ', ' Nucleotides ', ' Patients ', ' Professional Organizations ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Societies ', ' Testing ', ' Translating ', ' Universities ', ' Work ', ' Guidelines ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Lesion ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Clinical Practice Guideline ', ' Genetic ', ' gene function ', ' Deposit ', ' Deposition ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' Catalogs ', ' Test Result ', ' meetings ', ' collegiate ', ' college ', ' Services ', ' empowered ', ' American ', ' knowledgebase ', ' knowledge base ', ' genetic testing ', ' Genetic screening method ', ' novel ', ' Metric ', ' response ', ' Genomics ', ' Documentation ', ' OMIM ', ' Online Mendelian Inheritance In Man ', ' Bio-Informatics ', ' Bioinformatics ', ' datamining ', ' data mining ', ' genome sequencing ', ' Data ', ' Disease Association ', ' Disease Pathway ', ' Clinical Data ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' Genetic Population Study ', ' Ontology ', ' Update ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' web services ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' clinical relevance ', ' clinically relevant ', ' user-friendly ', ' clinical care ', ' data transmission ', ' data exchange ', ' genome analysis ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2014,2351999,CA-18,0.19693482019914982
"Mechanisms underlying complex trait human disease     DESCRIPTION (provided by applicant): There is now an explosion of new genome scale data relating genetic variation within the human population to phenotype, and particularly to common disease. Microarray technology has identified 100s of loci where the presence of particular variants is associated with altered risk of many common diseases; complete sequencing of individual exomes in cancer samples has discovered many somatic mutations in a variety of genes; and sequencing of 1000 human genomes has provided an almost complete inventory of common population variants. Further, these data are only the first in an ever-increasing flood, as even faster and cheaper sequencing technologies come on line. The results hold promise for major advances in treatment and diagnosis of common human diseases. Extracting the expected benefits is not straightforward, and will necessitate acquiring detailed knowledge of the mechanisms linking genetic variation to disease. This project focuses on one aspect of this challenge - using the new genomic data to identify new therapeutic opportunities. We will investigate those principles underlying complex trait disease that are particularly relevant to tha goal. We introduce a three stage mechanistic framework, relating genomic variation to the function of impacted gene products, the impact of these altered functions on pathways, processes and subsystems; and finally the consequences for complex trait disease phenotypes. We will develop computational methods to address key questions concerning three major aspects of the framework (1) How large are the changes in protein function brought about by the genomic variants underlying complex trait disease? What role do different classes of genomic and protein level mechanism, such as expression, non-synonymous changes and splicing, play in these variants? (2) How complete is the set genes with strong influence on the disease phenotypes discovered by current technologies, and how can missing genes be imputed from the genomic and network data? (3) What is the distribution of coupling between the activity of genes involved in disease mechanism and disease phenotypes? The results will deepen understanding of these aspects of complex disease, and provide a basis for identifying potential new drug targets from GWAS and other genomic studies.         PUBLIC HEALTH RELEVANCE: New technologies are now providing extensive information on human genetic variation associated with increased risk of a wide range of common human disease, such as Alzheimer's, diabetes, heart disease, and many cancers. These data hold the promise for the development of new therapies, and realizing those benefits requires the acquisition of complementary knowledge of the mechanisms that link genetic variation to disease risk. This project is focused on analysis of the relationship between genetic variation and common disease with the goal of identifying new therapeutic opportunities.                ",Mechanisms underlying complex trait human disease,8738688,R01GM104436,"['Affect ', ' Algorithms ', ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Explosion ', ' Flooding ', ' Floods ', ' Future ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Information Networks ', ' Inventory ', ' Equipment and supply inventories ', ' Methods ', ' Minor ', ' Phenotype ', ' Play ', ' gene product ', ' Proteins ', ' Risk ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Technology ', ' Translations ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' Relative ', ' Relative (related person) ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Therapeutic ', ' gene function ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Frequency ', ' Frequencies (time pattern) ', ' Complex ', ' Somatic Mutation ', ' trait ', ' disease risk ', ' disorder risk ', ' novel technologies ', ' new technology ', ' Network Analysis ', ' Pathway Analysis ', ' Modeling ', ' Sampling ', ' Genomics ', ' genome sequencing ', ' Address ', ' microarray technology ', ' Microarray-Based Analysis ', ' Microarray Analysis ', ' Data ', ' Other Genetics ', ' Molecular ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Coupled ', ' Coupling ', ' Heritability ', ' human disease ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' therapeutic target ', ' public health relevance ', ' exomes ', ' exome ', ' exome sequencing ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' risk variant ', ' Drug Targeting ', ' rare allele ', ' rare variant ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2014,288080,MD-05,0.09578463956340716
"Discovery and analysis of structural variation in whole genome sequences     DESCRIPTION (provided by applicant):     The whole genome sequencing of large cohorts of individuals is quickly becoming a common tool for researchers to investigate the genetic basis of many disease phenotypes. The primary goals are to discover the underlying genetic variation that cause or contribute to these diseases as well as to correctly identify these variants in a diagnostic setting. These differences typicall consist of single base changes (SNPs), but can also encompass larger, more complex chromosomal rearrangements in the form of structural variation (SV) which are much more difficult to detect even with modern sequencing technologies. A number of approaches have been published that have studied this problem, but even the largest scale endeavors have only focused on deletion events and reported a sensitivity of <70%. Complex chromosomal rearrangements are even less well studied. Thus, it is paramount that accurate methods are developed which can detect all types of SVs at high specificity from sequence data. This proposal aims to improve the overall ability of researchers to identify and analyze genetic variation from whole genome sequences. An important, and often overlooked, aspect of SV discovery is the fact that typical paired-end, read depth, and split read approaches will identify different sets of non-overlapping variants at varying degrees of accuracy. In Aim 1, we will develop a unified SV discovery algorithm that can incorporate all of these different sources of information in a probabilistic fashion. Such a method would be useful for research, in particular with the identification of rare variants, as well as clinical applications which require a great del of accuracy and have thus far been limited to older karyotyping and microarray approaches. This would identify the majority of structural variants, however there are many regions in genomic sequences which are complex in nature, defined as consisting of multiple neighboring or overlapping chromosomal rearrangements that are challenging to resolve with typical SV detection approaches. In Aim 2, we propose methods to resolve these complex regions and assess their frequency and impact. Furthermore, a crucial step in medical genetics is the comparison of identified genetic mutations to databases of known pathogenic and benign variants. This is currently problematic with SVs, as they have often been originally reported with varying degrees of breakpoint resolution that can hamper the correct assignment of the variant. This issue is compounded further in more complex regions with multiple breakpoints, for which simplistic comparison methods do not work well. In Aim 3, we will develop and implement a system that describes and utilizes variant profiles to identify whether an individual's sequence data contains a variant of interest. Overall, this project will advance our understanding of the human genome as well as provide tools for use in the general research and clinical communities.         PUBLIC HEALTH RELEVANCE:     The rearrangement of chromosomal material in the form of structural variation is directly responsible for many disease phenotypes, however our ability to detect and resolve these events from whole genome sequence data is currently limited. We propose a number of strategies for improving the detection and analysis of structural genomic variation between individuals and resolving their underlying structure and function. These approaches will have direct application to the clinical diagnosis of such events and the future of personalized genomics.            ",Discovery and analysis of structural variation in whole genome sequences,8733748,R01HG007068,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Future ', ' Medical Genetics ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Karyotyping Genetics ', ' Karyotyping ', ' Karyotype determination procedure ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' living system ', ' Organism ', ' Publishing ', ' Reading ', ' Records ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' seed ', ' Plant Zygotes ', ' Plant Embryos ', ' Seeds ', ' Specificity ', ' Technology ', ' Testing ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Area ', ' Benign ', ' Clinical ', ' Variation ', ' Variant ', ' Medical ', ' Training ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Genetic ', ' clinical Diagnosis ', ' tool ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequency ', ' Frequencies (time pattern) ', ' Hereditary ', ' Inherited ', ' Complex ', ' Event ', ' Scanning ', ' Source ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' interest ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' cohort ', ' Structure ', ' Reporting ', ' Modeling ', ' Genomics ', ' Pathogenicity ', ' structural genomics ', ' genome sequencing ', ' Address ', ' Length ', ' Rearrangement ', ' DNA Sequence Rearrangement ', ' Data ', ' Detection ', ' Resolution ', ' Chromosomal Rearrangement ', ' disease phenotype ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' virtual ', ' markov model ', ' Population ', ' direct application ', ' clinical applicability ', ' clinical application ', ' public health relevance ', ' rare allele ', ' rare variant ', ' ']",NHGRI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2014,374673,MI-12,0.16686769703965587
"NHGRI PAGE Coordinating Center     DESCRIPTION (provided by applicant): NHGRI developed the Population Architecture Using Genomics and Epidemiology (PAGE) research program to identify and characterize genomic variants in non-European populations. To support the complexities of such an ambitious effort, we have convened a strong team of statistical, population, and molecular geneticists, computer and information scientists, biostatisticians, and project management staff with many years of related experience to serve as a Coordinating Center (CC). Specifically, the CC will serve as a centralized resource to facilitate and support the activities of the program and Study Investigators focused on characterization of causal variants by: (1) coordinating phenotype harmonization efforts, including mapping phenotype variables across studies and to the PhenX measures; (2) synthesizing individual-level data into centralized datasets to facilitate sharing of data within and outside of PAGE; (3) utilizing state-of-the-art computer and information science support and scientific workflows that will facilitate analyses, ancestry deconvolution, genotype calling and imputation, SNP annotation, and data synthesis; (4) rapidly disseminating all study data via dbGaP and/or the PAGE website or other applicable databases; and (5) serving as a centralized resource to facilitate, support, and manage program activities and logistics as requested by the Steering Committee or Project Office and as needed for successful coordination of the program. Coordination of the program will be done in a spirit of collaboration using creative and flexible approaches, while providing leadership in statistical genetic methodologies and approaches to project management. The ultimate goal of our CC is to facilitate the identification and characterization of genotype-phenotype associations, especially as relevant to non-European populations, thereby accelerating our understanding of ancestral differences in the genetic and environmental causes of common diseases. Critical to achieving this mission is the deployment of powerful methods for ancestry deconvolution, multi- and trans-ethnic mapping, and imputation. Building upon our success as the PAGE I CC, we have added additional investigators with expertise in these areas and consortium experience with next-generation sequence analysis of both whole-genome and exome data. Our collaborative team is ideally staffed to meet the challenges of the new round of PAGE.         PUBLIC HEALTH RELEVANCE: The PAGE study focuses on analysis of existing large samples of primarily non- European ancestry to broaden our understanding of the ethnic differences in the genetic basis of complex disease. The PAGE coordinating center supports the functions of this study.                ",NHGRI PAGE Coordinating Center,8728994,U01HG007419,"['epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Engineering / Architecture ', ' Architecture ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Communication ', ' Computers ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Protocol Screening ', ' Eligibility ', ' Eligibility Determination ', ' Methods Epidemiology ', ' Epidemiological Techniques ', ' Epidemiological Methods ', ' Epidemiologic Methods ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Future ', ' Genome ', ' Genotype ', ' Goals ', ' Group Meetings ', ' Information Sciences ', ' Informed Consent ', ' Leadership ', ' Maps ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Mining ', ' Mission ', ' Phenotype ', ' Productivity ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Running ', ' Technology ', ' Time ', ' Voice ', ' Work ', "" formycin A 5'-triphosphate "", "" formycin 5'-triphosphate "", ' FTP ', ' formycin triphosphate ', ' Measures ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' conference ', ' symposium ', ' hispanic community ', ' Spanish Origin ', ' Latino Population ', ' Hispanic Populations ', ' Hispanics ', ' Latino ', ' Dataset ', ' Data Set ', ' Custom ', ' Sequence Analyses ', ' SEQ-AN ', ' Sequence Analysis ', ' base ', ' improved ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Individual ', ' European ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Logistics ', ' Data Quality ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Deposit ', ' Deposition ', ' tool ', ' instrument ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Scientist ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Source ', ' meetings ', ' experience ', ' success ', ' computer science ', ' Population Study ', ' ethnic difference ', ' Metric ', ' epidemiology study ', ' Reporting ', ' Genetic analyses ', ' genetic analysis ', ' Sampling ', ' genetic epidemiology ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' Documentation ', ' Data ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Update ', ' Monitor ', ' Molecular ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' website ', ' web site ', ' disease phenotype ', ' cost ', ' designing ', ' design ', ' next generation ', ' Population ', ' wiki ', ' public health relevance ', ' dbGaP ', ' database of Genotypes and Phenotypes ', ' exomes ', ' exome ', ' sharing data ', ' flexible ', ' flexibility ', ' next generation sequencing ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' ']",NHGRI,"RUTGERS, THE STATE UNIV OF N.J.",U01,2014,690507,NJ-06,0.07844014580334506
"An Integrative Analysis of Structural Variation for the 1000 Genomes Project DESCRIPTION (provided by applicant): Structural variation (SV), involving deletions, duplications, insertions and inversions of DNA segments, accounts for a large proportion of human genetic diversity. Comprehensive identification and analysis of these genetic variants will help us more fully elucidate the biology of their functional effects on human health and demography. Despite recent advances, the tools and data needed to comprehensively identify all types of SVs, genotype each variant, integrate and phase these variants remain lacking. Indeed, the data released from the early phases of the 1000 Genomes Project (1000GP) (1000 Genomes Project Consortium, 2010; 1000 Genomes Project Consortium, 2012) are biased primarily towards the detection of deletions within relatively unique regions of the genome. As a consortium, we propose to pool expertise from various research groups to provide an integrative analysis of SVs by combining rigorous computational algorithmic development with extensive experimental validation. The new algorithms we develop and the high confidence lists of SVs obtained will be rapidly made available as a public resource. ",An Integrative Analysis of Structural Variation for the 1000 Genomes Project,8737934,U41HG007497,"['Accounting ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Biology ', ' Chromosomes ', ' Complement Proteins ', ' Complement ', ' Population Studies / Demography ', ' Demography ', ' Deoxyribonucleic Acid ', ' DNA ', ' Future ', ' Gene Conversion ', ' Genome ', ' Genotype ', ' Goals ', ' Au element ', ' Gold ', ' Haplotypes ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Maps ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Nucleotides ', ' Reading ', ' Research ', ' Research Resources ', ' Resources ', ' Technology ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Repetitive Regions ', ' Repetitive Element ', ' Repetitive Sequence ', ' base ', ' method development ', ' improved ', ' Site ', ' Phase ', ' Variation ', ' Variant ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Complex ', ' Best Practice Analysis ', ' Benchmarking ', ' insertion sequence ', ' insertion element ', ' DNA Insertion Elements ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Modeling ', ' Sampling ', ' genome sequencing ', ' Data ', ' Detection ', ' Resolution ', ' Validation ', ' Process ', ' developmental ', ' Development ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' ']",NHGRI,JACKSON LABORATORY,U41,2014,2684060,ME-02,0.11924110504807471
"Statistical and computational analysis in whole genome sequencing studies.     DESCRIPTION (provided by applicant): This project will investigate several issues arising from the statistical and computational analysis of whole genome sequencing (WGS) based genomics studies. In the area of data management in WGS studies, we address the rapidly increasing cost associated with the transfer and storage of the massive files for the sequence reads and their associated quality scores. We will develop data compression methods to achieve a further compression of several folds beyond current standards, with minimal incurred errors. In the area of secondary analysis, we will develop new statistical learning methods to improve variant quality score recalibration and to filter out unreliable calls. This will improve te reliability of the key information provided by the WGS data, which are the variants calls indicating the locations where the genome differs from the reference and the nature of the differences. We will study methods for case-control studies based on WGS. In particular, we will develop statistical models to enable the integrating of information from multiple types of variants to obtain more powerful tests of association. We will apply the methods developed in this aim to the analysis of WGS data from a study on abdominal aortic aneurysm. Finally, we will address selected new questions associated with population scale WGS projects. Several national programs have recently been initiated to generate WGS data for hundreds of thousands of individuals with longitudinal medical records. The availability of this comprehensive data on a population scale will open up a rich frontier for genome medicine and will pose many new challenges for statistical analysis. We will formulate some of these new challenges and develop the statistical methods needed to meet these challenges.         PUBLIC HEALTH RELEVANCE: The research in this project concerns the design and implementation of statistical and computational methods for the analysis of data from whole genome sequencing studies. Methods will be developed for sequence quality score compression, variant call filtering, and methods for case-control association analysis and mega-cohort analysis based on whole genome sequencing.                ",Statistical and computational analysis in whole genome sequencing studies.,8750827,R01HG007834,"['Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Data Analysis ', ' Data Analyses ', ' Genome ', ' Goals ', ' Medical Records ', ' Medicine ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Reading ', ' Research ', ' Testing ', ' Cohort Analyses ', ' Cohort Analysis ', ' Abdominal Aortic Aneurysm ', ' base ', ' improved ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Location ', ' meetings ', ' data management ', ' Statistical Methods ', ' case control ', ' Genomics ', ' data processing ', ' computerized data processing ', ' compression algorithm ', ' Data Compression ', ' genome sequencing ', ' Address ', ' Data ', ' computational analysis ', ' Computer Analysis ', ' cost ', ' designing ', ' design ', ' Population ', ' frontier ', ' public health relevance ', ' population based ', ' ']",NHGRI,STANFORD UNIVERSITY,R01,2014,300000,CA-18,0.12716769703704645
"Clinically Relevant Genome Variation Database We propose to create the world's premier database of genetic variants relevant to clinical care (Clinically Relevant Genetic Variants Resource or CRVR). We will provide transparent data synthesis and consensus opinion on the clinical utility of a given genetic variant across a spectrum of genetic lesions including single nucleotide changes, small indels and structural variants. We will integrate with ClinVar, PharmGKB, and OMIM and draw upon NHGRI initiatives including the Genome Sequencing and Analysis and Mendelian Disorders Sequencing Centers, and the Clinical Sequencing Exploratory Research Centers. We will work closely with other CRVR sites and NHGRI funded initiatives to improve deposition of data from clinical laboratories. Our database will be built through three Aims. Aim 1 will engage and energize the clinical genomics community around CRVR efforts. We will partner with the other CRVR and U41 investigators in this activity as they will focus on engagement of professional societies, clinical testing laboratories, and the broader clinical genomics community to ensure creation of a CRVR resource that meets anticipated community needs including assembly of Disease-Specific and Mutation Type Working Groups (DSWGs and MTWGs) comprised of expert clinical geneticists and molecular diagnosticians to establish metrics for the initial classification of variants and integration of guidelines from professional organizations. Aim 2 will involve creation of a CRVR CoreDB resource through expert review of the existing literature, locus databases, and NHGRI initiatives. We will disseminate consensus findings on clinically relevant genetic variants and the clinical implications of these variants, with supporting evidence and documentation of the consensus process. Information will be aggregated using standard ontologies and advanced methodologies for handling heterogeneous data to create a Core Database (CoreDB). The consensus of expert review will be disseminated through a user-friendly web Portal (vetted by Genetic Counseling WG), web services for data mining, and consensus clinical guidelines to the appropriate clinical and research communities. The results will be organized by gene, variant, disease, pathway, and literature. Supporting evidence will also be curated and disseminated, and the resource will be updated continuously as new information accumulates. Aim 3 will involve deployment of machine-learning algorithms for semi- automatic identification of putative Clinically Relevant Variants (CRVs). We will undertake data mining of the clinical and epidemiological genetics literature and existing databases to identify putative clinically important variants. This will involve mining data from ClinVar, OMIM, CSER, and the Mendelian centers aggregated in Aim 2. The Working Groups formed in Aim 1 will establish criteria and oversee curators vetting variants. We will develop and optimize disease- and gene-specific machine learning algorithms to facilitate rapid classification of variants based on data provided by genetic testing services via ClinVar. We will integrate population-genetic data inferred from at least 25 reference populations from the 1000 Genomes Project and other large endeavors into our machine learning approaches so as to infer the global relevance of CRVs discovered here. PUBLIC HEALTH RELEVANCE: We propose to create a unified, public, and freely available database of genetic alterations relevant to clinical care. Our ultimate goal is to empower clinicians, genetic counselors, and patients to make informed decisions based on DNA testing. Because much of the information required for such decisions is scattered among public and private databases, we propose combining the medical literature, expert summary of millions of de- identified genetic tests, and results from current and past NIH-funded genetic studies into a single unified database.",Clinically Relevant Genome Variation Database,9120986,U01HG007436,"['Algorithms ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Data Sources ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Genes ', ' Genetic Counseling ', ' Medical Genetics ', ' Population Genetics ', ' Genome ', ' Goals ', ' Health ', ' Human Genetics ', ' Laboratories ', ' Literature ', ' Medicine ', ' Method LOINC Axis 6 ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North Carolina ', ' Nucleotides ', ' Patients ', ' Professional Organizations ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Societies ', ' Testing ', ' Translating ', ' Universities ', ' Work ', ' Guidelines ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Lesion ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Clinical Practice Guideline ', ' Genetic ', ' gene function ', ' Deposit ', ' Deposition ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' Catalogs ', ' Test Result ', ' meetings ', ' collegiate ', ' college ', ' Services ', ' empowered ', ' American ', ' knowledgebase ', ' knowledge base ', ' genetic testing ', ' Genetic screening method ', ' novel ', ' response ', ' Genomics ', ' Documentation ', ' OMIM ', ' Online Mendelian Inheritance In Man ', ' Bio-Informatics ', ' Bioinformatics ', ' datamining ', ' data mining ', ' genome sequencing ', ' Data ', ' Disease Pathway ', ' Clinical Data ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' Genetic Population Study ', ' Ontology ', ' Update ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' web services ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' clinical relevance ', ' clinically relevant ', ' user-friendly ', ' clinical care ', ' genomewide ', ' genome-wide ', ' data transmission ', ' data exchange ', ' genome analysis ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2015,68720,CA-18,0.19693482019914982
"An Integrative Analysis of Structural Variation for the 1000 Genomes Project DESCRIPTION (provided by applicant): Structural variation (SV), involving deletions, duplications, insertions and inversions of DNA segments, accounts for a large proportion of human genetic diversity. Comprehensive identification and analysis of these genetic variants will help us more fully elucidate the biology of their functional effects on human health and demography. Despite recent advances, the tools and data needed to comprehensively identify all types of SVs, genotype each variant, integrate and phase these variants remain lacking. Indeed, the data released from the early phases of the 1000 Genomes Project (1000GP) (1000 Genomes Project Consortium, 2010; 1000 Genomes Project Consortium, 2012) are biased primarily towards the detection of deletions within relatively unique regions of the genome. As a consortium, we propose to pool expertise from various research groups to provide an integrative analysis of SVs by combining rigorous computational algorithmic development with extensive experimental validation. The new algorithms we develop and the high confidence lists of SVs obtained will be rapidly made available as a public resource. ",An Integrative Analysis of Structural Variation for the 1000 Genomes Project,8920443,U41HG007497,"['Accounting ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Biology ', ' Chromosomes ', ' Complement Proteins ', ' Complement ', ' Population Studies / Demography ', ' Demography ', ' Deoxyribonucleic Acid ', ' DNA ', ' Future ', ' Gene Conversion ', ' Genome ', ' Genotype ', ' Goals ', ' Au element ', ' Gold ', ' Haplotypes ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Maps ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Nucleotides ', ' Reading ', ' Research ', ' Research Resources ', ' Resources ', ' Technology ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Repetitive Regions ', ' Repetitive Element ', ' Repetitive Sequence ', ' base ', ' method development ', ' improved ', ' Phase ', ' Variation ', ' Variant ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Complex ', ' Best Practice Analysis ', ' Benchmarking ', ' insertion sequence ', ' insertion element ', ' DNA Insertion Elements ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Modeling ', ' Sampling ', ' genome sequencing ', ' Data ', ' Resolution ', ' Validation ', ' Process ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' ']",NHGRI,JACKSON LABORATORY,U41,2015,2663757,ME-02,0.11924110504807471
"Mechanisms underlying complex trait human disease DESCRIPTION (provided by applicant): There is now an explosion of new genome scale data relating genetic variation within the human population to phenotype, and particularly to common disease. Microarray technology has identified 100s of loci where the presence of particular variants is associated with altered risk of many common diseases; complete sequencing of individual exomes in cancer samples has discovered many somatic mutations in a variety of genes; and sequencing of 1000 human genomes has provided an almost complete inventory of common population variants. Further, these data are only the first in an ever-increasing flood, as even faster and cheaper sequencing technologies come on line. The results hold promise for major advances in treatment and diagnosis of common human diseases. Extracting the expected benefits is not straightforward, and will necessitate acquiring detailed knowledge of the mechanisms linking genetic variation to disease. This project focuses on one aspect of this challenge - using the new genomic data to identify new therapeutic opportunities. We will investigate those principles underlying complex trait disease that are particularly relevant to tha goal. We introduce a three stage mechanistic framework, relating genomic variation to the function of impacted gene products, the impact of these altered functions on pathways, processes and subsystems; and finally the consequences for complex trait disease phenotypes. We will develop computational methods to address key questions concerning three major aspects of the framework (1) How large are the changes in protein function brought about by the genomic variants underlying complex trait disease? What role do different classes of genomic and protein level mechanism, such as expression, non-synonymous changes and splicing, play in these variants? (2) How complete is the set genes with strong influence on the disease phenotypes discovered by current technologies, and how can missing genes be imputed from the genomic and network data? (3) What is the distribution of coupling between the activity of genes involved in disease mechanism and disease phenotypes? The results will deepen understanding of these aspects of complex disease, and provide a basis for identifying potential new drug targets from GWAS and other genomic studies. PUBLIC HEALTH RELEVANCE: New technologies are now providing extensive information on human genetic variation associated with increased risk of a wide range of common human disease, such as Alzheimer's, diabetes, heart disease, and many cancers. These data hold the promise for the development of new therapies, and realizing those benefits requires the acquisition of complementary knowledge of the mechanisms that link genetic variation to disease risk. This project is focused on analysis of the relationship between genetic variation and common disease with the goal of identifying new therapeutic opportunities.",Mechanisms underlying complex trait human disease,8854112,R01GM104436,"['Affect ', ' Algorithms ', ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Explosion ', ' Flooding ', ' Floods ', ' Future ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Information Networks ', ' Inventory ', ' Equipment and supply inventories ', ' Methods ', ' Minor ', ' Phenotype ', ' Play ', ' gene product ', ' Proteins ', ' Risk ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Technology ', ' Translations ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' Relative ', ' Relative (related person) ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Therapeutic ', ' gene function ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Frequency ', ' Frequencies (time pattern) ', ' Complex ', ' Somatic Mutation ', ' trait ', ' disease risk ', ' disorder risk ', ' novel technologies ', ' new technology ', ' Network Analysis ', ' Pathway Analysis ', ' Modeling ', ' Sampling ', ' Genomics ', ' genome sequencing ', ' Address ', ' microarray technology ', ' Microarray-Based Analysis ', ' Microarray Analysis ', ' Data ', ' Other Genetics ', ' Molecular ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Coupled ', ' Coupling ', ' Heritability ', ' human disease ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' therapeutic target ', ' genomewide ', ' genome-wide ', ' exomes ', ' exome ', ' exome sequencing ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' Drug Targeting ', ' rare allele ', ' rare variant ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2015,288058,MD-05,0.09578463956340716
"GWAS TO GENE FUNCTION: NOS1AP AND OTHER QT INTERVAL GENES DESCRIPTION (provided by applicant): Genome-wide association studies (GWAS) of the electrographic QT-interval, an intermediate trait that impacts the risks of long QT syndrome and sudden cardiac death, have identified 68 independent variants at 35 loci, explaining 8% of the phenotypic (20% of the additive) variance. Nevertheless, the identity, function and mechanisms of action of the underlying DNA sequence variants and genes remain unknown, and are major impediments for understanding the molecular structure and functional architecture of this complex phenotype. We hypothesize that the majority of functional trait variants are polymorphic, non-coding and perturb transcription of a specific gene by altering the functions of their cis-regulatory elements. We propose a research paradigm for systematically identifying these non-coding trait variants, the regulatory functions they disrupt and the specific genes whose functions are altered at each quantitative trait locus. We will utilize integrative statisticl genetic, computational, molecular genetics and cellular approaches for elucidating the underlying mechanisms, using QT interval as a model 'system'. Our specific aims are: (1) to perform high- resolution mapping of GWAS signals to identify all polymorphic (>1%) and rare variants at loci that modulate the QT-interval; (2) to conduct in silico and in vitro analysis to predict and prioritize all cardiac regulatory (enhancer, silencer, insulator) elements and their cognate DNA-binding proteins; and, (3) to identify trait variants, genes and their mechanisms of genetic action. The overall goals are to improve the molecular genetic and mechanistic understanding of multifactorial traits for applications to other complex phenotypes. PUBLIC HEALTH RELEVANCE: The electrocardiographic QT-interval, an intermediate trait for arrhythmias and sudden cardiac death, has 68 predominantly non-coding variants at 35 loci explaining 8% of the phenotypic (20% of the additive) variance upon meta-analyses in >76,000 individuals of European and >11,000 individuals of African ancestry: nevertheless, the molecular details remain unknown. We propose a program of research for systematically identifying the functional non-coding quantitative trait variants, the regulatory function they disrupt and the specific gene whose functions are altered, at each locus. We utilize integrative statistical genetic, computational, molecular genetics and cellular approaches for understanding the underlying genetic mechanisms in this model trait with the overall goal to improve the molecular understanding of all complex phenotypes.",GWAS TO GENE FUNCTION: NOS1AP AND OTHER QT INTERVAL GENES,8904675,R01GM104469,"['Action Potentials ', ' adulthood ', ' adult human (21+) ', ' Adult Human ', ' 21+ years old ', ' Adult ', ' Allelomorphs ', ' Alleles ', ' Engineering / Architecture ', ' Architecture ', ' Heart Arrhythmias ', ' Cardiac Arrhythmia ', ' Arrhythmia ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Base Sequence ', ' Beer ', ' Reactive Site ', ' Combining Site ', ' Binding Sites ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' cell culture ', ' Cell Culture Techniques ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' disease/disorder ', ' Disorder ', ' Disease ', ' DNA-Binding Proteins ', ' Future ', ' Genes ', ' Goals ', ' Health ', ' Heart ', ' Heterogeneity ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Allergy ', ' Hypersensitivity ', ' In Vitro ', ' Infection ', ' Laboratories ', ' Long QT Syndrome ', ' Maps ', ' Methods ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' Macromolecular Structure ', ' Molecular Structure ', ' Oligo ', ' Oligonucleotides ', ' Phenotype ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Rats Mammals ', ' Rat ', ' Common Rat Strains ', ' Rattus ', ' Research ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrum Analysis ', ' Body Tissues ', ' Tissues ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Weight ', ' Death, Sudden, Cardiac ', ' Enhancers ', ' Molecular Genetics ', ' Promotor ', ' Promoters (Genetics) ', ' Promoter ', ' Promotor (Genetics) ', ' DNA Sequence ', ' base ', ' Label ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Evaluation ', ' Individual ', ' African ', ' European ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Gene Targeting ', ' Collaborations ', ' Genetic ', ' gene function ', ' Reporter ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Complex ', ' Myocytes ', ' Mature Muscle Cells ', ' Muscle Cells ', ' QTL ', ' Quantitative Trait Loci ', ' trait ', ' novel ', ' Position ', ' Positioning Attribute ', ' Modeling ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Untranslated RNA ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' gel shift assay ', ' Mobility Shift Assay ', ' Bandshift Mobility Assay ', ' Band Shift Mobility Assay ', ' Electrophoretic Mobility Shift Assay ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Insulator Elements ', ' Protein Microarray ', ' Protein Chips ', ' Protein Biochips ', ' Protein Microchips ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' ChIP assay ', ' ChIP (chromatin immunoprecipitation) ', ' chromatin immunoprecipitation ', ' p300 ', ' EP300 ', ' EP300 gene ', ' Affinity ', ' Data ', ' Regulatory Element ', ' Resolution ', ' in vivo ', ' Nuclear Extract ', ' Transcript ', ' Validation ', ' Molecular ', ' Ventricular ', ' Cardiac ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' epigenomics ', ' knock-down ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' Neonatal ', ' computer algorithm ', ' Computational algorithm ', ' genomewide ', ' genome-wide ', ' exomes ', ' exome ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' High-Throughput Sequencing ', ' High-Throughput Nucleotide Sequencing ', ' ']",NIGMS,JOHNS HOPKINS UNIVERSITY,R01,2015,606539,MD-07,0.0976757613835259
"Clinically Relevant Genome Variation Database We propose to create the world's premier database of genetic variants relevant to clinical care (Clinically Relevant Genetic Variants Resource or CRVR). We will provide transparent data synthesis and consensus opinion on the clinical utility of a given genetic variant across a spectrum of genetic lesions including single nucleotide changes, small indels and structural variants. We will integrate with ClinVar, PharmGKB, and OMIM and draw upon NHGRI initiatives including the Genome Sequencing and Analysis and Mendelian Disorders Sequencing Centers, and the Clinical Sequencing Exploratory Research Centers. We will work closely with other CRVR sites and NHGRI funded initiatives to improve deposition of data from clinical laboratories. Our database will be built through three Aims. Aim 1 will engage and energize the clinical genomics community around CRVR efforts. We will partner with the other CRVR and U41 investigators in this activity as they will focus on engagement of professional societies, clinical testing laboratories, and the broader clinical genomics community to ensure creation of a CRVR resource that meets anticipated community needs including assembly of Disease-Specific and Mutation Type Working Groups (DSWGs and MTWGs) comprised of expert clinical geneticists and molecular diagnosticians to establish metrics for the initial classification of variants and integration of guidelines from professional organizations. Aim 2 will involve creation of a CRVR CoreDB resource through expert review of the existing literature, locus databases, and NHGRI initiatives. We will disseminate consensus findings on clinically relevant genetic variants and the clinical implications of these variants, with supporting evidence and documentation of the consensus process. Information will be aggregated using standard ontologies and advanced methodologies for handling heterogeneous data to create a Core Database (CoreDB). The consensus of expert review will be disseminated through a user-friendly web Portal (vetted by Genetic Counseling WG), web services for data mining, and consensus clinical guidelines to the appropriate clinical and research communities. The results will be organized by gene, variant, disease, pathway, and literature. Supporting evidence will also be curated and disseminated, and the resource will be updated continuously as new information accumulates. Aim 3 will involve deployment of machine-learning algorithms for semi- automatic identification of putative Clinically Relevant Variants (CRVs). We will undertake data mining of the clinical and epidemiological genetics literature and existing databases to identify putative clinically important variants. This will involve mining data from ClinVar, OMIM, CSER, and the Mendelian centers aggregated in Aim 2. The Working Groups formed in Aim 1 will establish criteria and oversee curators vetting variants. We will develop and optimize disease- and gene-specific machine learning algorithms to facilitate rapid classification of variants based on data provided by genetic testing services via ClinVar. We will integrate population-genetic data inferred from at least 25 reference populations from the 1000 Genomes Project and other large endeavors into our machine learning approaches so as to infer the global relevance of CRVs discovered here. PUBLIC HEALTH RELEVANCE: We propose to create a unified, public, and freely available database of genetic alterations relevant to clinical care. Our ultimate goal is to empower clinicians, genetic counselors, and patients to make informed decisions based on DNA testing. Because much of the information required for such decisions is scattered among public and private databases, we propose combining the medical literature, expert summary of millions of de- identified genetic tests, and results from current and past NIH-funded genetic studies into a single unified database.",Clinically Relevant Genome Variation Database,8919725,U01HG007436,"['Algorithms ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Data Sources ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Genes ', ' Genetic Counseling ', ' Medical Genetics ', ' Population Genetics ', ' Genome ', ' Goals ', ' Health ', ' Human Genetics ', ' Laboratories ', ' Literature ', ' Medicine ', ' Method LOINC Axis 6 ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North Carolina ', ' Nucleotides ', ' Patients ', ' Professional Organizations ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Societies ', ' Testing ', ' Translating ', ' Universities ', ' Work ', ' Guidelines ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Lesion ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Clinical Practice Guideline ', ' Genetic ', ' gene function ', ' Deposit ', ' Deposition ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' Catalogs ', ' Test Result ', ' meetings ', ' collegiate ', ' college ', ' Services ', ' empowered ', ' American ', ' knowledgebase ', ' knowledge base ', ' genetic testing ', ' Genetic screening method ', ' novel ', ' response ', ' Genomics ', ' Documentation ', ' OMIM ', ' Online Mendelian Inheritance In Man ', ' Bio-Informatics ', ' Bioinformatics ', ' datamining ', ' data mining ', ' genome sequencing ', ' Data ', ' Disease Pathway ', ' Clinical Data ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' Genetic Population Study ', ' Ontology ', ' Update ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' web services ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' clinical relevance ', ' clinically relevant ', ' user-friendly ', ' clinical care ', ' genomewide ', ' genome-wide ', ' data transmission ', ' data exchange ', ' genome analysis ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2015,3090000,CA-18,0.19693482019914982
"Decrypting Variants of Uncertain Significance in Long-QT Syndrome DESCRIPTION (provided by applicant): Clinical genetic testing has become standard-of-care for many diseases including hundreds of inherited conditions. However, interpreting genetic test results is often confounded by the discovery of 'variants of unknown significance' (VUS) for which there is insufficient data or inadequate predictive tools to establish whether or not a particular variant predisposes to a disease. This problem is particularly vexing for genetic disorders with strong allelic heterogeneity and a preponderance of 'private' mutations such as the congenital long-QT syndrome (LQTS), which predisposes young adults and children to sudden death from cardiac arrhythmias. With the anticipated incorporation of personal exome or genome data into routine clinical care, interpreting VUS will become an even greater challenge especially when variants in genes associated with human disorders are incidentally discovered. Unfortunately, there are no reliable methods to predict a priori whether a given variant predisposes an individual to a particular disorder or whether the change is merely a benign rare variant. We propose to develop a novel paradigm for distinguishing disease-causing mutations from benign variants in LQTS as a model for other inherited arrhythmia syndromes and channelopathies. We will focus on variants in KCNQ1, the most commonly mutated gene in LQTS. The central hypothesis of this proposal is that a holistic predictive model that relates experimentally determined protein structure and dynamics to function and disease is highly accurate even for novel variants. Our ultimate objectives are to develop a data-trained, web-accessible algorithm that classifies VUS discovered in KCNQ1 based on reliable predictions of the structure and dynamics of the affected protein, and to achieve prediction accuracy to levels needed to inform medical decisions. The medical importance of correctly classifying KCNQ1 variants provides strong justification for having a dedicated and highly-tailored gene-specific prediction model. The ability to distinguish deleterious from neutral variants would help avoid unnecessary and potentially harmful interventions in carriers of benign alleles, and save the lives of those with true mutations. We propose to collect extensive electrophysiological, biochemical and structural data on a large set of KCNQ1 variants discovered in LQTS subjects as well as several suspected benign or neutral variants (Aims 1-2), then use these data to iteratively train and validate a machine learning based algorithm that can differentiate benign from deleterious KCNQ1 alleles among a set of new VUS (Aim 3). Our proposal is innovative in the use of a multidisciplinary approach to functionally and structurally annotate genomic variant data for a medically important gene at an unprecedented scale, and then to use these experimental findings to train/test a novel computational system to achieve clinical-grade predictions. Targeting KCNQ1 will also validate an approach for parallel work that can be utilized to predict the medical significance of variants in closely related potassium channels associated with heritable epilepsy (KCNQ2, KCNQ3) or deafness (KCNQ4). PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a method to reliably predict the consequences of genetic variants of unknown significance discovered in the course of genetic testing in the congenital long-QT syndrome (LQTS), a cause of sudden cardiac death in children and young adults. We propose a multidisciplinary experimental approach including electrophysiology, biochemistry and structural biology deployed on a large scale to generate information on at least 110 genetic variants in the main gene responsible for LQTS (KCNQ1), which encodes a potassium channel required for normal electrical activity in the heart. Our final product will be a data-trained computational strategy that will outperform existing methods for accurately predicting the functional consequences of novel KCNQ1 genetic variants, enhance the value of genetic testing in LQTS and provide for more informed medical decisions.",Decrypting Variants of Uncertain Significance in Long-QT Syndrome,8892240,R01HL122010,"['Affect ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' arrhythmic agent ', ' antiarrhythmic agent ', ' Antiarrhythmic Drugs ', ' Antiarrhythmia Drugs ', ' Antiarrhythmia Agents ', ' Anti-Arrhythmics ', ' Anti-Arrhythmia Drugs ', ' Anti-Arrhythmia Agents ', ' Heart Arrhythmias ', ' Cardiac Arrhythmia ', ' Arrhythmia ', ' Biological Chemistry ', ' Biochemistry ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' Child Human ', ' 0-11 years old ', ' Child ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Deafness ', ' Sudden Death ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Neurophysiology / Electrophysiology ', ' Electrophysiology ', ' Electrophysiology (science) ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Patient Care ', ' Patient Care Delivery ', ' Genes ', ' Medical Genetics ', ' Genome ', ' Goals ', ' Heart ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Heterogeneity ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Membrane Channels ', ' Ionic Channels ', ' Ion Channel ', ' Long QT Syndrome ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Patients ', ' Physicians ', ' Potassium Ion Channels ', ' K channel ', ' Potassium Channel ', ' gene product ', ' Proteins ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Syndrome ', ' Testing ', ' Work ', ' Death, Sudden, Cardiac ', ' Dataset ', ' Data Set ', ' Caring ', ' base ', ' Stimulators, Electrical, Cardiac, Shock ', ' Electric Shock Cardiac Stimulators ', ' Defibrillators ', ' Benign ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Medical ', ' Link ', ' Susceptibility ', ' Predisposition ', ' Training ', ' cardiac rhythm ', ' heart rhythm ', ' Individual ', ' young adulthood ', ' adult youth ', ' young adult ', ' Therapeutic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Hereditary ', ' Inherited ', ' LOINC Axis 4 System ', ' System ', ' Test Result ', ' structural biology ', ' knowledgebase ', ' knowledge base ', ' Protein Trafficking ', ' protein transport ', ' trafficking ', ' Structure ', ' genetic testing ', ' Genetic screening method ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Cell surface ', ' proband ', ' Modeling ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' genome sequencing ', ' protein structure ', ' Data ', ' Mutate ', ' Protein Dynamics ', ' First Degree Relative ', ' Other Genetics ', ' Molecular ', ' Cardiac ', ' protein function ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' innovative ', ' innovate ', ' innovation ', ' multidisciplinary ', ' Implant ', ' web-accessible ', ' disease-causing mutation ', ' multidisciplinary approach ', ' interdisciplinary approach ', ' public health relevance ', ' clinical care ', ' exomes ', ' exome ', ' rare allele ', ' rare variant ', ' ']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2015,1254784,IL-07,0.1801325412341593
"NHGRI PAGE Coordinating Center DESCRIPTION (provided by applicant): NHGRI developed the Population Architecture Using Genomics and Epidemiology (PAGE) research program to identify and characterize genomic variants in non-European populations. To support the complexities of such an ambitious effort, we have convened a strong team of statistical, population, and molecular geneticists, computer and information scientists, biostatisticians, and project management staff with many years of related experience to serve as a Coordinating Center (CC). Specifically, the CC will serve as a centralized resource to facilitate and support the activities of the program and Study Investigators focused on characterization of causal variants by: (1) coordinating phenotype harmonization efforts, including mapping phenotype variables across studies and to the PhenX measures; (2) synthesizing individual-level data into centralized datasets to facilitate sharing of data within and outside of PAGE; (3) utilizing state-of-the-art computer and information science support and scientific workflows that will facilitate analyses, ancestry deconvolution, genotype calling and imputation, SNP annotation, and data synthesis; (4) rapidly disseminating all study data via dbGaP and/or the PAGE website or other applicable databases; and (5) serving as a centralized resource to facilitate, support, and manage program activities and logistics as requested by the Steering Committee or Project Office and as needed for successful coordination of the program. Coordination of the program will be done in a spirit of collaboration using creative and flexible approaches, while providing leadership in statistical genetic methodologies and approaches to project management. The ultimate goal of our CC is to facilitate the identification and characterization of genotype-phenotype associations, especially as relevant to non-European populations, thereby accelerating our understanding of ancestral differences in the genetic and environmental causes of common diseases. Critical to achieving this mission is the deployment of powerful methods for ancestry deconvolution, multi- and trans-ethnic mapping, and imputation. Building upon our success as the PAGE I CC, we have added additional investigators with expertise in these areas and consortium experience with next-generation sequence analysis of both whole-genome and exome data. Our collaborative team is ideally staffed to meet the challenges of the new round of PAGE. PUBLIC HEALTH RELEVANCE: The PAGE study focuses on analysis of existing large samples of primarily non- European ancestry to broaden our understanding of the ethnic differences in the genetic basis of complex disease. The PAGE coordinating center supports the functions of this study.",NHGRI PAGE Coordinating Center,9121301,U01HG007419,"['epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Engineering / Architecture ', ' Architecture ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Communication ', ' Computers ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Protocol Screening ', ' Eligibility ', ' Eligibility Determination ', ' Methods Epidemiology ', ' Epidemiological Techniques ', ' Epidemiological Methods ', ' Epidemiologic Methods ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Future ', ' Genome ', ' Genotype ', ' Goals ', ' Group Meetings ', ' Information Sciences ', ' Informed Consent ', ' Leadership ', ' Maps ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Mining ', ' Mission ', ' Phenotype ', ' Productivity ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Running ', ' Technology ', ' Time ', ' Voice ', ' Work ', "" formycin A 5'-triphosphate "", "" formycin 5'-triphosphate "", ' FTP ', ' formycin triphosphate ', ' Measures ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' conference ', ' symposium ', ' hispanic community ', ' Spanish Origin ', ' Latino Population ', ' Hispanic Populations ', ' Hispanics ', ' Latino ', ' Dataset ', ' Data Set ', ' Custom ', ' Sequence Analyses ', ' SEQ-AN ', ' Sequence Analysis ', ' base ', ' improved ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Individual ', ' European ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Logistics ', ' Data Quality ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Deposit ', ' Deposition ', ' tool ', ' instrument ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Scientist ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Source ', ' meetings ', ' experience ', ' success ', ' computer science ', ' Population Study ', ' ethnic difference ', ' epidemiology study ', ' Reporting ', ' Genetic analyses ', ' genetic analysis ', ' Sampling ', ' genetic epidemiology ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' Documentation ', ' Data ', ' Genomic Segment ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Update ', ' Monitor ', ' Molecular ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' website ', ' web site ', ' disease phenotype ', ' cost ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' next generation ', ' Population ', ' wiki ', ' public health relevance ', ' dbGaP ', ' database of Genotypes and Phenotypes ', ' exomes ', ' exome ', ' sharing data ', ' flexible ', ' flexibility ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' ']",NHGRI,"RUTGERS, THE STATE UNIV OF N.J.",U01,2015,124339,NJ-06,0.07844014580334506
"Super-enhancer structure defines a signature of inflammatory bowel disease (IBD)     DESCRIPTION (provided by applicant): The goal of this proposal is to decipher the genetic basis of inflammatory bowel disease (IBD) by integrating genome-wide association studies (GWAS) with the chromatin modification information in human immune system. Accumulating evidence suggests that IBD results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host. Among complex diseases, GWAS methods have been successful in IBD, identifying hundreds of non-overlapping genetic risk loci. However, the majority of these disease-associated DNA variants fall into the gene-desert part of the genome, complicating their functional evaluation. There is now overwhelming evidence that the noncoding disease-associated DNA variants disrupt the action of key regulatory elements in relevant cell types. Since genomic coordinates of active regulatory elements can be charted using unique chromatin features, genome-wide profiling of chromatin modifications in relevant cell types can be used to pinpoint to DNA variants disrupting active regulatory elements.  Two recent studies discovered a novel kind of enhancers that occurs within exceptionally large genomic domains. These regions were initially dubbed as 'super-enhancers'. Super-enhancer domains occur at key identity genes in a variety of cell types. Strikingly, these enhancer domains are more sensitive to perturbation such as loss of transcription factors than typical shorter enhancers.  Because of the fragility of super-enhancers to perturbation, I postulate that super-enhancer domains of relevant immune cells harbor IBD-associated DNA variants. To test this hypothesis, in Aim 1 of this proposal, I will characterize super-enhancer structures of the human immune system. I will first develop an unsupervised machine learning technique to chart super-enhancer structures from histone acetylation (H3K27Ac) data in diverse immune cells. Using this technique, I will next delineate cell type- specific enhancer domains in the immune cells and investigate the relationship among cells types with respect to their super-enhancer structures. In Aim 2 of this proposal, I will investigate the enrichment of IBD-associated DNA variants within the super-enhancers of the most relevant immune cells. I then link these variants to genes and pathways that they regulate and are affected in disease utilizing gene expression and long-range chromatin interaction datasets. Completion of these aims, along with training opportunities associated with this proposal will establish the necessary foundation for my career as an independent investigator.         PUBLIC HEALTH RELEVANCE:  Crohn's disease and ulcerative colitis, the two common forms of (IBD), affect over 2.5 million people in North America and Europe. GWAS methods have identified hundreds of non-overlapping genetic risk loci in IBD. Yet, the functional effects of mos IBD-implicated variants remain largely unexplained. The finding that nearly 90% of these sites occur outside of protein-coding sequences suggests that many associated variants may instead have a role in gene regulation. Cell context is a key determinant of gene regulation but where IBD genetic variants are functional is largely unknown. This proposal seeks to utilize the chromatin structure of human immune cells to discover the cell context for IBD-associated variants. The identification of the pathogenic cell types as well as the molecular pathways that contribute to the disease will contribute greatly to our ability to treat patients.              ",Super-enhancer structure defines a signature of inflammatory bowel disease (IBD),8749475,K22AI112570,"['Affect ', ' Inflammatory Arthritis ', ' Atrophic Arthritis ', ' Rheumatoid Arthritis ', ' Bursa-Equivalent Lymphocyte ', ' Bursa-Dependent Lymphocytes ', ' B-Cells ', ' B blood cells ', ' B-Lymphocytes ', ' Reactive Site ', ' Combining Site ', ' Binding Sites ', ' Peripheral Blood Cell ', ' Blood Cells ', ' Cataloging ', ' Cells ', ' Chromatin ', ' Ulcerated Colitis ', ' Ulcerative Colitis ', ' regional enteritis ', ' eleocolitis ', ' Granulomatous Enteritis ', "" Crohn's disorder "", ' Crohn disease ', "" Crohn's disease "", ' disease/disorder ', ' Disorder ', ' Disease ', ' liability to disease ', ' disease/disorder proneness/risk ', ' Diathesis ', ' Disease susceptibility ', ' Deoxyribonucleic Acid ', ' DNA ', ' genetic enhancer element ', ' Enhancer Elements ', ' Enhancer Elements (Genetics) ', ' Europe ', ' Foundations ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' allergic/immunologic organ system ', ' allergic/immunologic body system ', ' Immune system ', ' Non-Specific Immunity ', ' Native Immunity ', ' Innate Immunity ', ' Natural Immunity ', ' Inflammatory Intestinal Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Bowel Disorder ', ' Inflammatory Bowel Diseases ', ' bowel ', ' Intestinal ', ' Intestines ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Maps ', ' Methods ', ' Marrow monocyte ', ' Blood monocyte ', ' monocyte ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North America ', ' Patients ', ' Play ', ' gene product ', ' Proteins ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Risk ', ' social role ', ' Role ', ' thymus derived lymphocyte ', ' Thymus-Dependent Lymphocytes ', ' T-Cells ', ' T-Lymphocyte ', ' helper T cell ', ' T4 Lymphocytes ', ' T4 Cells ', ' CD4-Positive Lymphocytes ', ' CD4+ T-Lymphocyte ', ' CD4+ T cell ', ' CD4 lymphocyte ', ' CD4 T cells ', ' CD4 Cells ', ' CD4 Positive T Lymphocytes ', ' Testing ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Work ', ' Measures ', ' falls ', ' Enhancers ', ' T3 molecule ', ' T3 Complex ', ' T3 Antigens ', ' OKT3 antigen ', ' CD3 molecule ', ' CD3 Complex ', ' CD3 ', ' CD3 Antigens ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' Site ', ' Variation ', ' Variant ', ' Link ', ' Evaluation ', ' Training ', ' Epithelial ', ' Individual ', ' Collaborations ', ' Genetic ', ' Inflammatory ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Catalogs ', ' Immune ', ' Complex ', ' cell type ', ' Techniques ', ' interest ', ' cohort ', ' gene desert ', ' Junk DNA ', ' Structure ', ' novel ', ' Pathogenesis ', ' Coding System ', ' Code ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Untranslated RNA ', ' Genomics ', ' Inflammatory Response ', ' chromatin modification ', ' Histone Acetylation ', ' NCAM1 ', ' NCAM ', ' CD56 ', ' NCAM1 gene ', ' LYT3 ', ' CD8B1 ', ' CD8B ', ' CD8 ', ' CD8B1 gene ', ' CD14 ', ' CD14 gene ', ' CD19 ', ' CD19 gene ', ' Address ', ' Data ', ' Regulatory Element ', ' Chromatin Structure ', ' Genetic Risk ', ' Molecular ', ' pathway ', ' Pathway interactions ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' epigenomics ', ' commensal bacteria ', ' commensal microbes ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' markov model ', ' predisposing gene ', ' Predisposition gene ', ' Susceptibility Gene ', ' Microbe ', ' human disease ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' adaptive immunity ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' ']",NIAID,UNIVERSITY OF PENNSYLVANIA,K22,2015,161200,PA-03,0.03328268953540488
"Statistical and computational analysis in whole genome sequencing studies. DESCRIPTION (provided by applicant): This project will investigate several issues arising from the statistical and computational analysis of whole genome sequencing (WGS) based genomics studies. In the area of data management in WGS studies, we address the rapidly increasing cost associated with the transfer and storage of the massive files for the sequence reads and their associated quality scores. We will develop data compression methods to achieve a further compression of several folds beyond current standards, with minimal incurred errors. In the area of secondary analysis, we will develop new statistical learning methods to improve variant quality score recalibration and to filter out unreliable calls. This will improve te reliability of the key information provided by the WGS data, which are the variants calls indicating the locations where the genome differs from the reference and the nature of the differences. We will study methods for case-control studies based on WGS. In particular, we will develop statistical models to enable the integrating of information from multiple types of variants to obtain more powerful tests of association. We will apply the methods developed in this aim to the analysis of WGS data from a study on abdominal aortic aneurysm. Finally, we will address selected new questions associated with population scale WGS projects. Several national programs have recently been initiated to generate WGS data for hundreds of thousands of individuals with longitudinal medical records. The availability of this comprehensive data on a population scale will open up a rich frontier for genome medicine and will pose many new challenges for statistical analysis. We will formulate some of these new challenges and develop the statistical methods needed to meet these challenges. PUBLIC HEALTH RELEVANCE: The research in this project concerns the design and implementation of statistical and computational methods for the analysis of data from whole genome sequencing studies. Methods will be developed for sequence quality score compression, variant call filtering, and methods for case-control association analysis and mega-cohort analysis based on whole genome sequencing.",Statistical and computational analysis in whole genome sequencing studies.,8930750,R01HG007834,"['Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Data Analysis ', ' Data Analyses ', ' Genome ', ' Goals ', ' Health ', ' Medical Records ', ' Medicine ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Reading ', ' Research ', ' Testing ', ' Cohort Analyses ', ' Cohort Analysis ', ' Abdominal Aortic Aneurysm ', ' base ', ' improved ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Location ', ' meetings ', ' data management ', ' Statistical Methods ', ' case control ', ' Genomics ', ' data processing ', ' computerized data processing ', ' compression algorithm ', ' Data Compression ', ' genome sequencing ', ' Address ', ' Data ', ' computational analysis ', ' Computer Analysis ', ' cost ', ' designing ', ' design ', ' Population ', ' frontier ', ' population based ', ' ']",NHGRI,STANFORD UNIVERSITY,R01,2015,292499,CA-18,0.12716769703704645
"Inferring the effects of genetic variants on gene expression and splicing     DESCRIPTION (provided by applicant): The objective of this project is to facilitate the interpretation of genetic variants identified in clinical whole- genome and whole-exome sequencing studies through the development of computational methods to predict functional effects of individual variants. Genome-scale sequencing technologies are increasingly enabling studies of genetic variation in large numbers of individuals; however, interpreting the clinical significance of the hundreds of thousands of genetic variants identified in these studies remains a critical challenge. Gene expression regulation is one mechanism by which variants can result in disease or other clinically-significant phenotypes. This mechanism is likely to be particularly important for disease-causing variants that do not directly affect protein structure by altering an amino acid sequence. The methods developed here will enable researchers to predict whether genetic variants are likely to have a regulatory effect on gene expression. The first stage of the project is to build computational models to predict such regulatory effects using a random forest machine learning approach. These models will be trained to recognize regulatory variation using a set of variants that have been shown to be involved in expression regulation in a recent study of gene expression across hundreds of individuals. Separate algorithms will be developed to predict two different types of regulatory effects: changes in the total amount of RNA produced from a particular gene (expression level variation) and changes in the specific form of RNA produced from a particular gene (splicing or isoform ratio variation). The second stage of the project is to evaluate the performance of these models on gene expression datasets from a separate human population and from different tissues within the human body, to explore their generalizability and to determine to what extent the characteristics of regulatory variants are conserved across tissues and populations. The final stage of the project is to use genetic variants in publicly-available databases that are known to be pathogenic to characterize how well these models perform at predicting clinical significance. This stage will test the hypothesis that variants that regulate gene expression are more likely to be clinically significant than variants that do not regulate expression. This project will impact public health by providing useful tools to improve prediction of the clinical significance of genetic variants identified in genome- scale sequencing studies. In addition, the project will provide biological insight into the tissue-specificity and population-specificity of genomic features that characterize regulatory genetic variants.         PUBLIC HEALTH RELEVANCE: Genome-scale sequencing technologies are increasingly enabling studies of genetic variation in large numbers of patients and other individuals. However, interpreting the clinical significance of the hundreds of thousands of genetic variants identified in these studies remains a critical challenge. This project will provide useful tools to improve automated prediction of the clinical significance of such genetic variants as well as their regulatory effects on gene expression.            ",Inferring the effects of genetic variants on gene expression and splicing,8835598,F32HG008330,"['Affect ', ' Algorithms ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Elements ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Exons ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genes ', ' Spliced Genes ', ' Gene Splicing ', ' Genome ', ' Genotype ', ' Goals ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Articulation ', ' Joints ', ' Mentorship ', ' Methods ', ' Patients ', ' Phenotype ', ' Probability ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Public Health ', ' public health medicine (field) ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' Splicing ', ' RNA Splicing ', ' Specificity ', ' Technology ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Universities ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Relative ', ' Relative (related person) ', ' forest ', ' Dataset ', ' Data Set ', ' Proteins [By Structure] ', ' Organized by Structure Protein ', ' base ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' insight ', ' Individual ', ' European ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Human Figure ', ' Human body ', ' Genetic ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Performance ', ' Isoforms ', ' Protein Isoforms ', ' QTL ', ' Quantitative Trait Loci ', ' professor ', ' novel ', ' lymphoblastoid cell line ', ' Categories ', ' Reporting ', ' Position ', ' Positioning Attribute ', ' Regulation ', ' Modeling ', ' Genomics ', ' Transcription Start Site ', ' Transcription Initiation Site ', ' genome sequencing ', ' Address ', ' protein structure ', ' Transcript ', ' Characteristics ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Population ', ' clinical significance ', ' clinically significant ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' exome sequencing ', ' ']",NHGRI,STANFORD UNIVERSITY,F32,2015,52306,CA-18,0.15773554392890257
"NHGRI PAGE Coordinating Center DESCRIPTION (provided by applicant): NHGRI developed the Population Architecture Using Genomics and Epidemiology (PAGE) research program to identify and characterize genomic variants in non-European populations. To support the complexities of such an ambitious effort, we have convened a strong team of statistical, population, and molecular geneticists, computer and information scientists, biostatisticians, and project management staff with many years of related experience to serve as a Coordinating Center (CC). Specifically, the CC will serve as a centralized resource to facilitate and support the activities of the program and Study Investigators focused on characterization of causal variants by: (1) coordinating phenotype harmonization efforts, including mapping phenotype variables across studies and to the PhenX measures; (2) synthesizing individual-level data into centralized datasets to facilitate sharing of data within and outside of PAGE; (3) utilizing state-of-the-art computer and information science support and scientific workflows that will facilitate analyses, ancestry deconvolution, genotype calling and imputation, SNP annotation, and data synthesis; (4) rapidly disseminating all study data via dbGaP and/or the PAGE website or other applicable databases; and (5) serving as a centralized resource to facilitate, support, and manage program activities and logistics as requested by the Steering Committee or Project Office and as needed for successful coordination of the program. Coordination of the program will be done in a spirit of collaboration using creative and flexible approaches, while providing leadership in statistical genetic methodologies and approaches to project management. The ultimate goal of our CC is to facilitate the identification and characterization of genotype-phenotype associations, especially as relevant to non-European populations, thereby accelerating our understanding of ancestral differences in the genetic and environmental causes of common diseases. Critical to achieving this mission is the deployment of powerful methods for ancestry deconvolution, multi- and trans-ethnic mapping, and imputation. Building upon our success as the PAGE I CC, we have added additional investigators with expertise in these areas and consortium experience with next-generation sequence analysis of both whole-genome and exome data. Our collaborative team is ideally staffed to meet the challenges of the new round of PAGE. PUBLIC HEALTH RELEVANCE: The PAGE study focuses on analysis of existing large samples of primarily non- European ancestry to broaden our understanding of the ethnic differences in the genetic basis of complex disease. The PAGE coordinating center supports the functions of this study.",NHGRI PAGE Coordinating Center,8849936,U01HG007419,"['epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Engineering / Architecture ', ' Architecture ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Communication ', ' Computers ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Protocol Screening ', ' Eligibility ', ' Eligibility Determination ', ' Methods Epidemiology ', ' Epidemiological Techniques ', ' Epidemiological Methods ', ' Epidemiologic Methods ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Future ', ' Genome ', ' Genotype ', ' Goals ', ' Group Meetings ', ' Information Sciences ', ' Informed Consent ', ' Leadership ', ' Maps ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Mining ', ' Mission ', ' Phenotype ', ' Productivity ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Running ', ' Technology ', ' Time ', ' Voice ', ' Work ', "" formycin A 5'-triphosphate "", "" formycin 5'-triphosphate "", ' FTP ', ' formycin triphosphate ', ' Measures ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' conference ', ' symposium ', ' hispanic community ', ' Spanish Origin ', ' Latino Population ', ' Hispanic Populations ', ' Hispanics ', ' Latino ', ' Dataset ', ' Data Set ', ' Custom ', ' Sequence Analyses ', ' SEQ-AN ', ' Sequence Analysis ', ' base ', ' improved ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Individual ', ' European ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Logistics ', ' Data Quality ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Deposit ', ' Deposition ', ' tool ', ' instrument ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Scientist ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Source ', ' meetings ', ' experience ', ' success ', ' computer science ', ' Population Study ', ' ethnic difference ', ' epidemiology study ', ' Reporting ', ' Genetic analyses ', ' genetic analysis ', ' Sampling ', ' genetic epidemiology ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' Documentation ', ' Data ', ' Genomic Segment ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Update ', ' Monitor ', ' Molecular ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' website ', ' web site ', ' disease phenotype ', ' cost ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' next generation ', ' Population ', ' wiki ', ' public health relevance ', ' dbGaP ', ' database of Genotypes and Phenotypes ', ' exomes ', ' exome ', ' sharing data ', ' flexible ', ' flexibility ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' ']",NHGRI,"RUTGERS, THE STATE UNIV OF N.J.",U01,2015,681355,NJ-06,0.07844014580334506
"Clinically Relevant Genome Variation Database We propose to create the world's premier database of genetic variants relevant to clinical care (Clinically Relevant Genetic Variants Resource or CRVR). We will provide transparent data synthesis and consensus opinion on the clinical utility of a given genetic variant across a spectrum of genetic lesions including single nucleotide changes, small indels and structural variants. We will integrate with ClinVar, PharmGKB, and OMIM and draw upon NHGRI initiatives including the Genome Sequencing and Analysis and Mendelian Disorders Sequencing Centers, and the Clinical Sequencing Exploratory Research Centers. We will work closely with other CRVR sites and NHGRI funded initiatives to improve deposition of data from clinical laboratories. Our database will be built through three Aims. Aim 1 will engage and energize the clinical genomics community around CRVR efforts. We will partner with the other CRVR and U41 investigators in this activity as they will focus on engagement of professional societies, clinical testing laboratories, and the broader clinical genomics community to ensure creation of a CRVR resource that meets anticipated community needs including assembly of Disease-Specific and Mutation Type Working Groups (DSWGs and MTWGs) comprised of expert clinical geneticists and molecular diagnosticians to establish metrics for the initial classification of variants and integration of guidelines from professional organizations. Aim 2 will involve creation of a CRVR CoreDB resource through expert review of the existing literature, locus databases, and NHGRI initiatives. We will disseminate consensus findings on clinically relevant genetic variants and the clinical implications of these variants, with supporting evidence and documentation of the consensus process. Information will be aggregated using standard ontologies and advanced methodologies for handling heterogeneous data to create a Core Database (CoreDB). The consensus of expert review will be disseminated through a user-friendly web Portal (vetted by Genetic Counseling WG), web services for data mining, and consensus clinical guidelines to the appropriate clinical and research communities. The results will be organized by gene, variant, disease, pathway, and literature. Supporting evidence will also be curated and disseminated, and the resource will be updated continuously as new information accumulates. Aim 3 will involve deployment of machine-learning algorithms for semi- automatic identification of putative Clinically Relevant Variants (CRVs). We will undertake data mining of the clinical and epidemiological genetics literature and existing databases to identify putative clinically important variants. This will involve mining data from ClinVar, OMIM, CSER, and the Mendelian centers aggregated in Aim 2. The Working Groups formed in Aim 1 will establish criteria and oversee curators vetting variants. We will develop and optimize disease- and gene-specific machine learning algorithms to facilitate rapid classification of variants based on data provided by genetic testing services via ClinVar. We will integrate population-genetic data inferred from at least 25 reference populations from the 1000 Genomes Project and other large endeavors into our machine learning approaches so as to infer the global relevance of CRVs discovered here. PUBLIC HEALTH RELEVANCE: We propose to create a unified, public, and freely available database of genetic alterations relevant to clinical care. Our ultimate goal is to empower clinicians, genetic counselors, and patients to make informed decisions based on DNA testing. Because much of the information required for such decisions is scattered among public and private databases, we propose combining the medical literature, expert summary of millions of de- identified genetic tests, and results from current and past NIH-funded genetic studies into a single unified database.",Clinically Relevant Genome Variation Database,9047616,U01HG007436,"['Algorithms ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Data Sources ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Genes ', ' Genetic Counseling ', ' Medical Genetics ', ' Population Genetics ', ' Genome ', ' Goals ', ' Health ', ' Human Genetics ', ' Laboratories ', ' Literature ', ' Medicine ', ' Method LOINC Axis 6 ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North Carolina ', ' Nucleotides ', ' Patients ', ' Professional Organizations ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Societies ', ' Testing ', ' Translating ', ' Universities ', ' Work ', ' Guidelines ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Lesion ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Clinical Practice Guideline ', ' Genetic ', ' gene function ', ' Deposit ', ' Deposition ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' Catalogs ', ' Test Result ', ' meetings ', ' collegiate ', ' college ', ' Services ', ' empowered ', ' American ', ' knowledgebase ', ' knowledge base ', ' genetic testing ', ' Genetic screening method ', ' novel ', ' response ', ' Genomics ', ' Documentation ', ' OMIM ', ' Online Mendelian Inheritance In Man ', ' Bio-Informatics ', ' Bioinformatics ', ' datamining ', ' data mining ', ' genome sequencing ', ' Data ', ' Disease Pathway ', ' Clinical Data ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' Genetic Population Study ', ' Ontology ', ' Update ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' web services ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' clinical relevance ', ' clinically relevant ', ' user-friendly ', ' clinical care ', ' genomewide ', ' genome-wide ', ' data transmission ', ' data exchange ', ' genome analysis ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2015,249543,CA-18,0.19693482019914982
"An integrative approach to functionalize GWAS hits in MI and stroke     DESCRIPTION (provided by applicant): Coronary heart disease (CHD) and cerebrovascular disease result from platelet thrombus formation at the site of a ruptured atherosclerotic plaque. Numerous studies have shown enhanced platelet reactivity, and increased platelet count and volume are risk factors for CHD events and fatality, and a recent NHLBI Working Group concluded that variation in platelet reactivity is a major determinant of ischemic events, like MI or stroke. Genome wide association studies (GWASs) have identified numerous common genetic variants associated with the risk of CHD and platelet function parameters, but most of the positive ""hits"" are not causative of the phenotype. To understand the cellular mechanisms by which these variants affect platelet function it is imperative to know the repertoire of mRNAs, miRNAs and lncRNAs expressed in the cell of interest. Our team has been a leader in the field of platelet transcriptomics as well as functional assessment of variants in platelet genes. We have profiled mRNAs and miRNAs from 183 subjects using multiple platforms and have also performed platelet RNA-seq on 14 different subjects. This information provides a critical ability to filter, prioritize and obtain variant functional insights for evaluating GWAS SNPs associated with MI, stroke and platelet parameters. We have identified 142 mRNAs and 9 miRNAs that are expressed in platelets and linked to these GWAS hits. The goals of this proposal are to identify, assay, and validate functional variation previously tagged in GWASs of platelet-mediated ischemic arterial disease and of platelet phenotypes. Aim 1 will identify GWAS-linked mRNAs, miRNAs and lncRNAs that are functional in platelets. Candidate RNAs will be refined by association with platelet function, eQTLs and QTLs using our previously generated platelet RNA data. We will develop a supervised machine-learning, statistical pattern matching algorithm to prioritize likely platelet-functional genes. Gene-level assays in which we knock down mRNA, miRNA and lncRNA in our human megakaryocyte culture system, followed by assays for integrin activation and quantification of platelet number and volume will be used to confirm platelet functionality. Aim 2 will identify functionally divergent SNPs and haplotypes. We will impute missing SNPs and perform fine-mapping to the phenotypes of interest. Variants will be prioritized by association strength, annotation data, and predicted function using publically available resources and our own platelet eQTL data. Non-coding candidates will be tested by reporter gene assay and non-synonymous variants will be tested using functional assays in cell lines in which the endogenous gene has been silenced. We will validate our findings with a replication analysis in which we use an independent cohort dataset to quantify the association of the tested variants with the original GWAS phenotype.         PUBLIC HEALTH RELEVANCE:  Platelet-mediated arterial thrombosis in the coronary or cerebrovascular circulation is the major cause of mortality and morbidity in the U.S. Numerous DNA variations have been associated with these disorders, but the causal genes are unknown. This research will test whether genes near these DNA variations - and candidate variations themselves - alter platelet function or number to understand better the molecular mechanisms causing heart attacks and strokes.            ",An integrative approach to functionalize GWAS hits in MI and stroke,8985084,R01HL128234,"['Affect ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' aminoacid ', ' Amino Acids ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' platelet disorder ', ' platelet disease ', ' Thrombocytopathy ', ' Blood Platelet Disorders ', ' thrombocyte/platelet ', ' Thrombocytes ', ' Platelets Reticuloendothelial System ', ' Platelets ', ' Marrow platelet ', "" Hayem's elementary corpuscle "", "" Deetjeen's body "", "" Bizzozero's corpuscle/cell "", ' Blood Platelets ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cells ', ' cerebrocirculation ', ' cerebral vasculature ', ' cerebral circulation ', ' cerebral blood flow ', ' Cerebrovascular Circulation ', ' Intracranial Vascular Disorders ', ' Intracranial Vascular Diseases ', ' Cerebrovascular Disease ', ' Brain Vascular Disorders ', ' Cerebrovascular Disorders ', ' Coronary Circulation ', ' coronary disorder ', ' Coronary Disease ', ' Coronary heart disease ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' vulnerable plaque ', ' atherosclerotic plaque ', ' atherosclerotic lesions ', ' atherosclerosis plaque ', ' Atheromatous plaque ', ' Atheromatous degeneration ', ' Atheromatous ', ' Atheroma ', ' Arterial Fatty Streaks ', ' Arterial Fatty Streak ', ' Gene Expression ', ' Genes ', ' Genotype ', ' Goals ', ' Haplotypes ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Integrins Extracellular Matrix ', ' Integrins ', ' Intervening Sequences ', ' Introns ', ' Laboratories ', ' Maps ', ' Megalokaryocyte ', ' Blood megakaryocyte ', ' Megakaryocytes ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' Mortality ', ' Mortality Vital Statistics ', ' heart infarction ', ' heart infarct ', ' heart attack ', ' coronary infarction ', ' coronary infarct ', ' coronary attack ', ' cardiac infarct ', ' Myocardial Infarct ', ' Cardiac infarction ', ' Myocardial Infarction ', ' Phenotype ', ' Platelet Activation ', ' Platelet Number ', ' Platelet Count ', ' Blood Platelet Number ', ' Blood Platelet Count ', ' Platelet Count measurement ', ' Rad.-PET ', ' Positron Emission Tomography Scan ', ' Positron Emission Tomography Medical Imaging ', ' PETT ', ' PETSCAN ', ' PET imaging ', ' PET Scan ', ' PET ', ' Positron-Emission Tomography ', ' Production ', ' genetic regulatory element ', ' Regulatory Regions, Nucleic Acid (Genetics) ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Research Resources ', ' Resources ', ' Risk ', ' Risk Factors ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' stroke ', ' Testing ', ' Thrombosis ', ' transcription factor ', ' Measures ', ' falls ', ' Enhancers ', ' Mediating ', ' Promotor ', ' Promoters (Genetics) ', ' Promoter ', ' Promotor (Genetics) ', ' Thrombus ', ' Dataset ', ' Data Set ', ' base ', ' human subject ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Reporter Genes ', ' Link ', ' insight ', ' Individual ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Investigation ', ' Event ', ' Protocol ', ' Protocols documentation ', ' Pattern ', ' LOINC Axis 4 System ', ' System ', ' interest ', ' cohort ', ' UTRs ', ' Untranslated Regions ', ' Prevention ', ' Reporting ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Untranslated RNA ', ' Sentinel ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' HPCA1 ', ' CD34 ', ' CD34 gene ', ' Mediator of Activation ', ' Mediator ', ' Mediator of activation protein ', ' Data ', ' Pathologic ', ' Molecular ', ' protein function ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' clinical phenotype ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' knock-down ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' Rupture ', ' Coupled ', ' transcriptomics ', ' clinical relevance ', ' clinically relevant ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' ChIP Sequencing ', ' ChIP-seq ', ' RNAseq ', ' RNA-seq ', ' transcriptome sequencing ', ' screening ', ' ']",NHLBI,THOMAS JEFFERSON UNIVERSITY,R01,2015,406469,PA-03,0.04809103870656848
"Discovery and analysis of structural variation in whole genome sequences DESCRIPTION (provided by applicant):     The whole genome sequencing of large cohorts of individuals is quickly becoming a common tool for researchers to investigate the genetic basis of many disease phenotypes. The primary goals are to discover the underlying genetic variation that cause or contribute to these diseases as well as to correctly identify these variants in a diagnostic setting. These differences typicall consist of single base changes (SNPs), but can also encompass larger, more complex chromosomal rearrangements in the form of structural variation (SV) which are much more difficult to detect even with modern sequencing technologies. A number of approaches have been published that have studied this problem, but even the largest scale endeavors have only focused on deletion events and reported a sensitivity of <70%. Complex chromosomal rearrangements are even less well studied. Thus, it is paramount that accurate methods are developed which can detect all types of SVs at high specificity from sequence data. This proposal aims to improve the overall ability of researchers to identify and analyze genetic variation from whole genome sequences. An important, and often overlooked, aspect of SV discovery is the fact that typical paired-end, read depth, and split read approaches will identify different sets of non-overlapping variants at varying degrees of accuracy. In Aim 1, we will develop a unified SV discovery algorithm that can incorporate all of these different sources of information in a probabilistic fashion. Such a method would be useful for research, in particular with the identification of rare variants, as well as clinical applications which require a great del of accuracy and have thus far been limited to older karyotyping and microarray approaches. This would identify the majority of structural variants, however there are many regions in genomic sequences which are complex in nature, defined as consisting of multiple neighboring or overlapping chromosomal rearrangements that are challenging to resolve with typical SV detection approaches. In Aim 2, we propose methods to resolve these complex regions and assess their frequency and impact. Furthermore, a crucial step in medical genetics is the comparison of identified genetic mutations to databases of known pathogenic and benign variants. This is currently problematic with SVs, as they have often been originally reported with varying degrees of breakpoint resolution that can hamper the correct assignment of the variant. This issue is compounded further in more complex regions with multiple breakpoints, for which simplistic comparison methods do not work well. In Aim 3, we will develop and implement a system that describes and utilizes variant profiles to identify whether an individual's sequence data contains a variant of interest. Overall, this project will advance our understanding of the human genome as well as provide tools for use in the general research and clinical communities. PUBLIC HEALTH RELEVANCE:     The rearrangement of chromosomal material in the form of structural variation is directly responsible for many disease phenotypes, however our ability to detect and resolve these events from whole genome sequence data is currently limited. We propose a number of strategies for improving the detection and analysis of structural genomic variation between individuals and resolving their underlying structure and function. These approaches will have direct application to the clinical diagnosis of such events and the future of personalized genomics.",Discovery and analysis of structural variation in whole genome sequences,8906910,R01HG007068,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Future ', ' Medical Genetics ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Health ', ' Karyotyping Genetics ', ' Karyotyping ', ' Karyotype determination procedure ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' living system ', ' Organism ', ' Publishing ', ' Reading ', ' Records ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' seed ', ' Plant Zygotes ', ' Plant Embryos ', ' Seeds ', ' Specificity ', ' Technology ', ' Testing ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Area ', ' Benign ', ' Clinical ', ' Variation ', ' Variant ', ' Medical ', ' Training ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Genetic ', ' clinical Diagnosis ', ' tool ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequency ', ' Frequencies (time pattern) ', ' Hereditary ', ' Inherited ', ' Complex ', ' Event ', ' Scanning ', ' Source ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' interest ', ' cohort ', ' Structure ', ' Reporting ', ' Modeling ', ' Genomics ', ' Pathogenicity ', ' structural genomics ', ' genome sequencing ', ' Address ', ' Length ', ' DNA Sequence Alteration ', ' Rearrangement ', ' DNA Sequence Rearrangement ', ' Data ', ' Detection ', ' Resolution ', ' Chromosomal Rearrangement ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' virtual ', ' markov model ', ' Population ', ' direct application ', ' clinical applicability ', ' clinical application ', ' rare allele ', ' rare variant ', ' ']",NHGRI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2015,371408,MI-12,0.16686769703965587
"F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes     DESCRIPTION (provided by applicant): Patient-to-patient variability in response to drugs creates a significant challenge for the safe and effective treatment of many human diseases. Pharmacogenomics seeks to address this challenge by linking drug response to patient genotypes at important loci, termed pharmacogenes, in order to better customize patient treatments. Genetic variation in pharmacogenes is extensive. For example, amongst 12 CYP genes, 10% of people carry at least one rare, potentially deleterious variant. Unfortunately, only a small number of variants have been unambiguously linked to alterations in drug response. Clearly, new approaches are needed to annotate the consequences of the huge pool of variants of unknown significance, including those already identified by existing large-scale sequencing programs, and those that will be discovered as clinical sequencing becomes routine. In this proposal, we seek to address this problem directly and at a scale never before possible by taking advantage of new technologies in sequencing and functional analysis. Our resource, termed F-CAP (Functionalization of Variants in Clinically Actionable Pharmacogenes) will test all possible substitutions at all amino acid residues in some of the most clinically important pharmacogenes and disseminate these data to the medical and research communities. In order to accomplish this, we will use deep mutational scanning, a method we have developed that allows parallelized, and quantitative measurements to be performed on libraries of genetic variants. In Aim 1 we will create these libraries, starting with five of the most important CPIC level A or B priority genes (CYP2C9, CYP2C19, CYP2D6, TPMT and VKORC1), and test the stability and enzymatic activity of each variant en masse using a pooled selection strategy. In Aim 2, we will integrate these data to create an impact score. This impact score provides a numerical value for a variant's functional effects that is amenable to easy integration into prescribing guidelines being developed by the pharmacogenomics community. Aim 3 will validate this score for a subset of variants that span the impact score spectrum using therapeutically relevant substrates for each pharmacogene. Finally, Aim 4 describes a key component of this resource: the dissemination of our findings to the entire pharmacogenomics community through partnership with CPIC and PharmGKB. In addition, we will make available our raw and processed data via a custom web resource that will also be developed in Aim 4. This resource will provide a series of fully annotated datasets describing the functional consequences of every possible single mutation in a series of key pharmacogenes, thereby greatly advancing the field of personalized medicine.         PUBLIC HEALTH RELEVANCE: Pharmacogenomics seeks to identify genetic sources of inter-individual variability in drug response, with the goal of personalizing drug selection and dose to improve patient outcomes. A key barrier to using pharmacogenomic information is lack of clarity about the functional impact of variants, which hampers the provision of clear, unambiguous guidance to health care providers. We propose to connect pharmacogenomic variant discovery with novel high-throughput experimental approaches to deliver a resource to guide the use of individual pharmacogenomic information in personalizing drug treatment.            ",F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes,8933744,R24GM115277,"['Affect ', ' Algorithms ', ' aminoacid ', ' Amino Acids ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Systematics ', ' Classification ', ' Communities ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Elements ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' In Vitro ', ' Libraries ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Research Resources ', ' Resources ', ' Testing ', ' Translations ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Generations ', ' Measures ', ' Medical Research ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' Custom ', ' Guidelines ', ' improved ', ' Variation ', ' Variant ', ' Biochemical ', ' Medical ', ' Series ', ' Link ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Measurement ', ' root ', ' Plant Roots ', ' Funding ', ' R24 ', ' R-24 Monoclonal Antibody ', ' MoAb R24 ', ' Monoclonal Antibody R24 ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Scanning ', ' Source ', ' interest ', ' genetic disorder diagnosis ', ' novel ', ' novel technologies ', ' new technology ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' response ', ' Pharmacogenomics ', ' data processing ', ' computerized data processing ', ' P450IIC19 ', ' P450C2C ', ' CYP2C19 ', ' CPCJ ', ' CYP2C19 gene ', ' P450IIC9 ', ' P450 PB-1 ', ' P450 MP-4 ', ' CYP2C9 ', ' CYP2C10 ', ' CPC9 ', ' CYP2C9 gene ', ' P450C2D ', ' P450-DB1 ', ' CYP2DL1 ', ' CYP2D6 ', ' CYP2D ', ' CPD6 ', ' CYP2D6 gene ', ' TPMT ', ' TPMT gene ', ' Address ', ' Dose ', ' Data ', ' Grant Proposals ', ' Applications Grants ', ' Mutate ', ' Cellular Assay ', ' Large-Scale Sequencing ', ' Numerical value ', ' Output ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' user-friendly ', ' human disease ', ' public health relevance ', ' effective treatment ', ' effective therapy ', ' stability testing ', ' exomes ', ' exome ', ' High-Throughput DNA Sequencing ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NIGMS,UNIVERSITY OF WASHINGTON,R24,2015,751729,WA-07,0.1902170025038608
"Predicted Gene Expression: High Power, Mechanism, and Direction of Effect     DESCRIPTION (provided by applicant): Although investments in genomic studies of mental disorders enabled the discovery of thousands of robustly associated variants with these complex diseases, the translation of these discoveries into actionable targets has been hampered by the lack of a mechanistic understanding on how genome variation relates to phenotype. Moreover, it has been widely shown that a substantial portion of the genetic control of complex traits, including mental disorders, is exerted through the regulation of gene expression. However, effective methods to fully harness this mechanism are lagging. To address these challenges, we propose a novel gene-based test -PrediXcan- that directly tests this regulatory mechanism and substantially improves power relative to single variant tests and other gene-based tests. PrediXcan is inherently mechanistic and provides directionality, highlighting its potential utility in identifying novel targets for therapy. The method consists of predicting the whole genome effect on expression traits and correlating this effect with disease risk to identify novel disease genes. In addition, we propose novel approaches to investigate the context-specificity of expression traits (Orthogonal Tissue Decomposition) and to quantify the collective effect of the regulated transcriptome on phenotypes of interest (Regulability). Regulability is similar to the concept of chip heritability (total variability explained collectivey by genotyped variants). First, we will develop cross-tissue, tissue-specific (for over 30 different human tissue types), and brain-region specific expression traits. We will use statistical machine learning methods to develop whole genome prediction models for these traits and extend this work to other molecular phenotypes. All models will be stored in open access databases. Next, we will apply the PrediXcan method to 7 mental disorder phenotypes. More specifically, we will compute genetically predicted levels of gene expression traits and correlate them with disease risk to identify genes involved in disease pathways. We will also quantify the collective effect of the predicted transcriptome (regulability) on mental disorder risk across multiple tissues. Finally we will extend PrediXcan method and develop a method to infer the results of PrediXcan using summary statistics data as opposed to individual level data. This will extend the applicability of the approach to all summary results generated by meta-analysis consortia and increase the power to discover novel genes given the larger sample sizes. The research we propose is driven by an extensive set of preliminary studies, and promises substantial deliverables in both new methods of analysis and public access results databases.         PUBLIC HEALTH RELEVANCE: Large investments in genome studies have been made to understand the consequences of genetic variation on human traits. These have yielded many genetic variants reproducibly associated with disease but the underlying biology is still unclear. We propose a novel computational method that links mechanistically the genetic variability to disease risk and apply it to a range of mental disorder studies to provide more biological insights and enable discovery of potential targets for drug development.            ","Predicted Gene Expression: High Power, Mechanism, and Direction of Effect",8945859,R01MH107666,"['senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Anorexia Nervosa ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' psychological disorder ', ' mental illness ', ' Psychiatric Disorder ', ' Psychiatric Disease ', ' Mental health disorders ', ' Mental disorders ', ' Biology ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' depression ', ' Mental Depression ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Exons ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genes ', ' Genome ', ' Genotype ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Investments ', ' Learning ', ' Methods ', ' Protein Methylation ', ' Methylation ', ' National Institute of Mental Health ', ' NIMH ', ' National Institute of Mental Health (U.S.) ', ' Obsessive-Compulsive Neurosis ', ' Obsessive-Compulsive Disorder ', ' Phenotype ', ' Quality Control ', ' Research ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' computer program/software ', ' Software ', ' Computer software ', ' Specificity ', ' statistics ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Translations ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' Relative ', ' Relative (related person) ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Biological ', ' Link ', ' Training ', ' insight ', ' Individual ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Sample Size ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' gene function ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' human tissue ', ' Source ', ' interest ', ' Performance ', ' user friendly computer software ', ' user friendly software ', ' trait ', ' genetic testing ', ' Genetic screening method ', ' novel ', ' disease risk ', ' disorder risk ', ' Regulation ', ' Modeling ', ' drug development ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Attention deficit hyperactivity disorder ', ' Brain region ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Address ', ' Data ', ' Disease Pathway ', ' Tissue Model ', ' Molecular ', ' Process ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' Coupled ', ' Heritability ', ' public health relevance ', ' molecular phenotype ', ' dbGaP ', ' database of Genotypes and Phenotypes ', ' ']",NIMH,UNIVERSITY OF CHICAGO,R01,2015,487902,IL-01,0.04160953443502988
"Integrative interpretation of the organismal consequences of non-coding variation     DESCRIPTION (provided by applicant): Our capacity to sequence human genomes has exceeded our ability to interpret genetic variation, particularly in non-coding regions. To address this challenge, we recently developed a novel framework, Combined Annotation Dependent Depletion (CADD), for estimating the deleteriousness of any genetic variant. CADD defines an objective, data-rich, and quantitative integration of many genomic annotations into a single measure of variant effect at the organismal level. The goals of this R01 proposal are to further develop the CADD framework, to apply it in the context of ongoing genetic studies of both rare and common human diseases, and to experimentally evaluate its predictions. In Specific Aim 1, we will substantially modify CADD in both straightforward and creative ways, with the goal of dramatically improving CADD's ability to annotate non- coding variants, not only to estimate their organismal effects but also to provide insights into molecular mechanisms. In Specific Aim 2, we will apply CADD to a variety of ongoing whole genome sequencing studies of human disease, especially those in which non-coding variants are either known or suspected to be causal. As part of this effort, we will develop new statistical frameworks that directly incorporat CADD into traditional genome-wide discovery approaches. In Specific Aim 3, we will perform a combination of high-throughput (massively parallel reporter assays), medium-throughput (CRISPR/Cas9), and low-throughput (in vivo mouse transgenics) experimental assays for systematic and targeted assessment of CADD predictions. This proposal includes both computational and experimental innovations, and builds on established collaborative relationships between investigators with complementary strengths. The completion of our aims will yield novel methods, data, and resources with which to annotate whole genome sequences, broadly enabling the field to more effectively identify and mechanistically understand non-coding genetic variants that are causally relevant to human disease.         PUBLIC HEALTH RELEVANCE: As we enter an era of personalized medicine, a deep understanding of human genomes will be increasingly important to public health, contributing to the unraveling of the genetic basis of human disease, as well as serving an increasing role in clinical diagnostics. However, our limited understanding of the functional consequences of most genetic variants, especially those that do not alter protein sequence, represents a major obstacle. This proposal seeks to dramatically improve our ability to identify and interpret ""non-coding"" variants that causally contribute to human disease. A recently developed computational approach will be substantially improved and evaluated in a variety of genetic studies, and its predictions will be experimentally validated. This project will provide much needed methods and resources to address the looming analytical challenges associated with individual whole genome sequencing in both biomedical research and patient care.                ",Integrative interpretation of the organismal consequences of non-coding variation,8792292,R01CA197139,"['Algorithms ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biomedical Research ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Feedback ', ' Patient Care ', ' Patient Care Delivery ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Maps ', ' Methods ', ' Transgenic Mice ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' living system ', ' Organism ', ' pedigree structure ', ' Pedigree ', ' genetic pedigree ', ' Phenotype ', ' Public Health ', ' public health medicine (field) ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Testing ', ' Body Tissues ', ' Tissues ', ' transcription factor ', ' Translating ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Vocabulary Words ', ' Vocabulary ', ' Weight ', ' Measures ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Training ', ' insight ', ' Individual ', ' Genetic ', ' Reporter ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' LOINC Axis 4 System ', ' System ', ' QTL ', ' Quantitative Trait Loci ', ' trait ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' Human Biology ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' Peptide Sequence Determination ', ' Genetic analyses ', ' genetic analysis ', ' Coding System ', ' Code ', ' LOINC Axis 2 Property ', ' Property ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Untranslated RNA ', ' Genomics ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Pathogenicity ', ' RNA Binding ', ' Transcriptional Control ', ' Transcription Regulation ', ' Transcriptional Regulation ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' genome sequencing ', ' Address ', ' Data ', ' Regulatory Element ', ' in vivo ', ' Molecular ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' disease phenotype ', ' Complex Genetic Trait ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' insertion/deletion mutation ', ' innovative ', ' innovate ', ' innovation ', ' human disease ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' candidate identification ', ' exomes ', ' exome ', ' exome sequencing ', ' Cas nuclease technology ', ' CRISPR/Cas system ', ' CRISPR ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NCI,UNIVERSITY OF WASHINGTON,R01,2015,666593,WA-07,0.15195866583693662
"Predicting causal non-coding variants in a founder population Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. In order to characterize the molecular and cellular causes of human disease, it will be essential to unravel the functional impact of genetic variation. However, we are currently unable to predict the impact of the majority of genetic variants that lie in non-coding regions of the genome, where indeed most complex disease-associated variants are found. Additionally, recent evidence suggests that a significant fraction of the non-coding genome is likely to be functional, often playing a role in gene regulation. Therefore, our limited understanding of non- coding variation is a critical hurdle to characterizing the genetic basis of disease. The goal of this project is to develop methods for interpreting non-coding genetic variation: to provide a robust and extensible Bayesian method for predicting causal variants from full genomes, to identify and validate a large set of functional non- coding variants using CRISPR technology, and to predict disease-relevant traits likely to be affected by each variant. Our project will leverage the increasing availability of cohorts such as UK10K, GTEx, CARTaGENE and SardiNIA, with genome sequence and transcriptome data available from thousands of individuals, along with extensive phenotyping for hundreds of traits. We will combine advanced statistical modeling with experimental validation based on genome engineering to identify causal non-coding variants affecting biomedical traits in the cohort, along with predicting functional mechanisms through which these variants ultimately perturb the cell. In Aim 1, we develop computational methods for predicting causal non-coding variation from full genomes, incorporating multiple informative genomic features into a Bayesian approach. We will optimize and apply these methods on genome and transcriptome data available for well-studied and broadly-accessible cohorts to identify a large set of variants predicted to causally affect gene expression. Based on these predictions, in Aim 2, we connect putative causal variants with the diverse set of disease- relevant traits measured in the cohort, using network inference to capture the cascade from genetic variation to gene expression to disease. We will develop methods to integrate across variants, using the models in Aim 1, to identify the common causal mechanisms related to each trait. In Aim 3, we validate the causal impact of non-coding variants predicted to affect high-level traits. We will use genome editing through CRISPR to introduce individual genetic variants into cell lines and use qPCR to validate the predicted effects on gene expression. Finally, a major goal throughout this proposal will be to provide the research community with convenient computational tools for the prediction of causal non-coding variants from individual genomes, updated on an ongoing basis to integrate the most recent genomic annotations and public data in order to provide the best possible accuracy in predicting causal variants and the traits they are likely to affect. Our project will greatly advance our understanding of non-coding genetic variation, the specific mechanisms affected by causal variants, and the downstream consequences to the cell and individual health. 2. PUBLIC HEALTH RELEVANCE:  Understanding the impact of variation in the entire genome, beyond the well-studied protein-coding regions, is essential to understanding the relationship between genetics and human health. This proposal addresses the problem of identifying functional non-coding genetic variants and predicting the impact of each variant on hundreds of disease-relevant traits. Our approach will focus on integrative, transformative methods for understanding mechanisms underlying the function of the human genome.                ",Predicting causal non-coding variants in a founder population,8792751,R01HG008150,"['Affect ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Cataloging ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cells ', ' Cell Body ', ' Communities ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Disease ', ' Disorder ', ' Family ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Human Genetics ', ' Linkage Disequilibrium ', ' Maps ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Phenotype ', ' Play ', ' Research ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Sardinia ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Technology ', ' Testing ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Measures ', ' Protein Coding Region ', ' ORFs ', ' Open Reading Frames ', ' Data Set ', ' Dataset ', ' base ', ' density ', ' improved ', ' Variant ', ' Variation ', ' Link ', ' Individual ', ' Bayesian Method ', ' Bayesian posterior distribution ', ' Bayesian classification procedure ', ' Bayesian classification method ', ' Bayesian approaches ', ' Bayesian Statistical Method ', ' Bayesian Methodology ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Frequencies (time pattern) ', ' Frequency ', ' Inherited ', ' Hereditary ', ' Complex ', ' Techniques ', ' System ', ' human data ', ' cohort ', ' trait ', ' novel ', ' Categories ', ' disorder risk ', ' disease risk ', ' Pathogenesis ', ' genetic linkage analysis ', ' linkage analyses ', ' genetic linkage analyses ', ' family based linkage study ', ' Linkage Analysis ', ' Widespread Disease ', ' Generalized Disease ', ' Extensive Disease ', ' Modeling ', ' Sampling ', ' Property ', ' functional genomics ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' genome sequencing ', ' Address ', ' Data ', ' Resolution ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Founder Generation ', ' founder population ', ' Genomic Segment ', ' genomic region ', ' Transcript ', ' Update ', ' Validation ', ' Molecular ', ' Development ', ' developmental ', ' Gene Expression Profile ', ' gene expression signature ', ' gene expression pattern ', ' disease phenotype ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' data modeling ', ' computerized tools ', ' computational tools ', ' Genome engineering ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' transcriptomics ', ' human disease ', ' public health relevance ', ' molecular phenotype ', ' genome-wide ', ' genomewide ', ' genome scale ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' genome annotation ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' human genome sequencing ', ' genome editing ', ' genomic editing ', ' ']",NHGRI,STANFORD UNIVERSITY,R01,2015,477647,CA-18,0.19172731860914194
"EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE     DESCRIPTION (provided by applicant): The eMERGE III Clinical Center proposal from Partners HealthCare leverages a large biobank, clinical data in the electronic medical records (EMR) for >4 million participants from the largest integrated health care provider in New England, advanced bioinformatics expertise and state-of-the-art genetic analysis. We propose three aims. (1) Aim 1. Discovery. We will test the hypothesis that common and rare variants from a custom chip including 50,000 loss of function (LoF) alleles will be associated with cardiovascular, neuropsychiatric and immune-mediated phenotypes derived from the EMR. We are currently genotyping 25,000 Partners HealthCare Biobank subjects with a custom chip that includes LoF alleles from 63,000 exomes that we have analyzed. (2) Aim 2. Penetrance and Pleiotropy. We will test the hypothesis that sequencing a set of established genes or loci will allow us to discover additional variation, and define penetrance and pleiotropy using EMR phenotypes. Rare variants in genes selected by the eMERGE network will be studied for penetrance and pleiotropic outcomes by PheWAS and chart review. In addition, we are poised to perform recall-by-genotype studies because all Biobank participants have provided consent for such callback. (3) Aim 3. Implementation. We will test the hypothesis that physicians will alter their surveillance and treatment of patients based upon voluntary return of actionable variants to provide safe and cost-effective benefits to patients. We will screen our entire Biobank population of 25,000 individuals for pathogenic variants in the LDLR gene, the leading genetic cause of premature coronary artery disease, and conduct an exploratory trial in disclosing this information. Biobank participants with pathogenic variants in LDLR will be offered enrollment into a randomized trial, in which their finding will be CLIA-confirmed, and in one arm, this result will be communicated to their physicians through the EMR. Over one year, we will collect the following outcomes through participant surveys and EMR queries: physician visits, laboratory testing, changes in medication prescriptions, LDL levels, medical costs and the number of family members screened and treated as a result of the intervention. We will collaborate with the entire eMERGE III Network to incorporate what we learn from this pilot trial into large-scale implementation protocols for the genes selected by the Network for sequencing. Finally, we will participate in all Network activities to enhance the movement of genetics into clinical practice.         PUBLIC HEALTH RELEVANCE: The discovery and clinical use of genetic variants associated with both rare Mendelian and more common complex diseases promises to dramatically change the practice of medicine. Our eMERGE III project will leverage a large Biobank and a rich electronic medical record to define the phenotypic impact of mutations emerging from sequencing and then return results on selected variants to Biobank participants using a clinical trial.                ",EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE,8968123,U01HG008685,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' Inflammatory Arthritis ', ' Atrophic Arthritis ', ' Rheumatoid Arthritis ', ' Bronchial Asthma ', ' Asthma ', ' Biology ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular system (all sites) ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardiovascular system ', ' clinical investigation ', ' Clinical Trials ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary Arteriosclerosis ', ' coronary disorder ', ' Coronary Disease ', ' Coronary heart disease ', ' depression ', ' Mental Depression ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Genes ', ' Genotype ', ' Goals ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' Heart Decompensation ', ' Cardiac Failure Congestive ', ' Congestive Heart Failure ', ' Hypercholesteremia ', ' hypercholesterolemia ', ' newborn human (0-6 weeks) ', ' Newborns ', ' 0-6 weeks old ', ' Newborn Infant ', ' Inflammatory Intestinal Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Bowel Disorder ', ' Inflammatory Bowel Diseases ', ' Laboratories ', ' Learning ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' Low-Density Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' LDL Cholesterol Lipoproteins ', ' Medicine ', ' Mining ', ' body movement ', ' Movement ', ' insular sclerosis ', ' MS (Multiple Sclerosis) ', ' Disseminated Sclerosis ', ' Multiple Sclerosis ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Northeastern United States ', ' New England ', ' Patients ', ' Pharmacogenetics ', ' Phenotype ', ' Physicians ', ' Public Health ', ' public health medicine (field) ', ' Research ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' stroke ', ' Survey Instrument ', ' Surveys ', ' Testing ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' Family member ', ' health care ', ' Healthcare ', ' Mediating ', ' HLA-DRB1 antigen ', ' HLA-DRB1 ', ' Custom ', ' base ', ' Area ', ' Clinical ', ' prematurity ', ' premature ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Individual ', ' Funding ', ' Genetic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Immune ', ' Complex ', ' Stream ', ' Protocol ', ' Protocols documentation ', ' Source ', ' Penetrance ', ' Visit ', ' experience ', ' pleiotropy ', ' pleiotropism ', ' Informatics ', ' TYK2 ', ' novel ', ' Participant ', ' Genetic analyses ', ' genetic analysis ', ' neuropsychiatric ', ' neuropsychiatry ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Attention deficit hyperactivity disorder ', ' Cytotoxic T-Lymphocyte-Associated Serine Esterase-4 Gene ', ' Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene ', ' Cytotoxic T-Lymphocyte Protein 4 Gene ', ' CTLA4 ', ' CTLA-4 Gene ', ' CD152 Gene ', ' CD152 Antigen Gene ', ' CTLA4 gene ', ' Dopamine Receptor D2 Gene ', ' DRD2 ', ' D2R Gene ', ' D2R ', ' D2DR Gene ', ' D2DR ', ' D(2) Dopamine Receptor Gene ', ' DRD2 gene ', ' p55-R ', ' TNFRSF1A ', ' TNFR60 ', ' TNFR55 ', ' TNFR1 ', ' TNFAR ', ' TNF-R55 ', ' TNF-R-I ', ' TNF-R ', ' TBP1 ', ' MGC19588 ', ' CD120a ', ' TNFRSF1A gene ', ' LDLR gene ', ' TCF7L2 ', ' TCF4 ', ' TCF-4 ', ' TCF7L2 gene ', ' Consent ', ' cost-effectiveness analysis ', ' cost-effective analysis ', ' cost efficient analysis ', ' cost effective analysis ', ' Cost Effective Analyses ', ' Cost Effectiveness Analysis ', ' Data ', ' attributable fraction ', ' Population Attributable Risks ', ' Callback ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' pilot trial ', ' cost ', ' implementation research ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' cost-effective ', ' cost effective ', ' Population ', ' loss of function ', ' public health relevance ', ' clinical care ', ' clinical practice ', ' biorepository ', ' biobank ', ' exomes ', ' exome ', ' randomized trial ', ' arm ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' ']",NHGRI,BRIGHAM AND WOMEN'S HOSPITAL,U01,2015,972425,MA-07,0.12018567818483675
"Functional genetic variations in splicing regulation DESCRIPTION (provided by applicant): Recently, tremendous success has been achieved in constructing a catalog of genetic variants in disease genomes or across population. The next great challenge is to elucidate the potential function of various genetic variants in biological an disease processes. An important type of functional variants consists of those that affect gene expression in cis. Indeed, cis-regulatory variants are involved in a broad range of diseases and they showed a consistently stronger influence on gene expression than trans-acting determinants. Alternative splicing is an essential mechanism via which cis-regulatory changes may occur. Previous studies estimated that 15- 60% of point mutations that result in human genetic diseases disrupt splicing, highlighting the importance of this regulatory step. In addition to the well-known splice site signals, splicing is closely regulated by many exonic or intronic cis elements, associated with trans-acting proteins. Disruption of these cis-regulatory elements can cause aberrant splicing. Yet this crucial regulatory aspect remains largely unexplored. We propose to combine computational, genomic and molecular approaches to study splicing changes due to genetic variations. The specific aims are: (1) To globally identify exons and genes that are under differential splicing regulation by the alternative alleles of genetic variant, via bioinformatic analysis of high-throughput sequencing of transcriptome profiles (RNA-Seq). (2) To identify causal genetic variants in splicing alteration using minigene-based experiments. (3) To develop an integrative model to predict causal genetic variants in splicing alteration, using machine learning approaches, RNA- Seq data and molecular validations. This project will elucidate functional cis-regulatory genetic variants in splicing and provide significant insight ino the involvement of genetic variations in human diseases. In addition, this work will generate valuable bioinformatic tools to make full use of the increasingly available RNA-Seq data in a wide variety of cell types for identification and prediction of disease-related genetic variants. Aberrant splicing can significantly alter gene expression and contribute to human diseases. The proposed research aims to gain a systematic understanding of the functional roles of genetic variations (e.g., mutations or polymorphisms) in the regulation of splicing. This work will provide mechanistic basis for how genetic variations may contribute to diseases, such that future interventions can target specific splicing events therapeutically.",Functional genetic variations in splicing regulation,8822892,R01HG006264,"['Affect ', ' Allelomorphs ', ' Alleles ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Alternative Splicing ', ' Cataloging ', ' Cells ', ' Complement Proteins ', ' Complement ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Elements ', ' Environment ', ' Exons ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Housing ', ' Human Genetics ', ' Intervening Sequences ', ' Introns ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Research ', ' Splicing ', ' RNA Splicing ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Body Tissues ', ' Tissues ', ' trans acting factor (genetic) ', ' Transactivators ', ' Trans-Acting Factors ', ' Trans-Activators ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' Measures ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' insight ', ' Reporter ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Catalogs ', ' Event ', ' cell type ', ' Pattern ', ' Techniques ', ' success ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' novel technologies ', ' new technology ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' RNA analysis ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' Data ', ' Regulatory Element ', ' Resolution ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Tissue-Specific Splicing ', ' Transcript ', ' Validation ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' Population ', ' human disease ', ' RNAseq ', ' RNA-seq ', ' transcriptome sequencing ', ' High-Throughput Sequencing ', ' High-Throughput Nucleotide Sequencing ', ' ']",NHGRI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2015,300300,CA-33,0.10493672460502469
"Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases     DESCRIPTION (provided by applicant) Over the past 10 years human genetics studies made unprecedented numbers of discoveries relating genome variation to common diseases. While it is unquestionably true that we have learned substantially from the discoveries made to date, we must also acknowledge that with respect to the identification and characterization of the genome variation affecting risk of common human diseases - those accounting for the overwhelming majority of public health care expenditures - our discoveries have not generated nearly the knowledge of disease etiology that we would have expected given the sheer number of these discoveries. The combination of these observations coupled with the dramatic reduction in the cost of sequencing is driving the case for moving to whole genome sequencing studies for common disease. We have focused our application on three critical challenges for methods development and analysis of whole genome sequence data. While there has been substantial progress in methods development for analysis of exome sequencing, with gene-based tests that are relatively robust to the direction of effects of rare coding variants as well as the proportionof the gene's rare variants contributing to phenotype, it is clear that methods integrating the analysis of common and rare variation as well as functional genomics data will be essential for appropriate analysis of whole genome sequence data. Thus, we propose in Specific Aim 1 to develop novel methods, software and analysis pipelines for integrated analysis of common and rare variants for the analysis of whole genome sequence on 50,000- 100,000 individuals for any given common disease, and in Specific Aim 2 to develop and apply novel approaches for prioritizing results from these large-scale sequencing studies using BioVU, the 200,000 member biobank at Vanderbilt that is associated with 30 years of high quality electronic health records, and in Specific Aim 3 to develop queriable results databases and a comprehensive web portal to serve results of our studies on the sequence data for both the internal sequencing community and for the broader scientific community.         PUBLIC HEALTH RELEVANCE Large-scale whole genome sequencing studies are being carried out to understand the genetic architecture of human complex diseases. It remains challenging to decipher the genetic mechanisms of disease etiology. In this application we aim to develop a suite of statistical and computational methods to identify genes and variants associated with complex disease and use BioVU, a DNA BioBank linked to electronic health records, to validate and investigate genetic architecture of multiple complex diseases.            ","Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases",9132585,U01HG009086,"['Accounting ', ' Affect ', ' Engineering / Architecture ', ' Architecture ', ' driving ', ' Automobile Driving ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' health care expenditure ', ' Health Expenditures ', ' facial ', ' faces ', ' Face ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Learning ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Phenotype ', ' Public Health ', ' Research ', ' Research Resources ', ' Resources ', ' Risk ', ' Science ', ' Software ', ' Computer software ', ' Technology ', ' Time ', ' Body Tissues ', ' Tissues ', ' Generations ', ' Data Set ', ' Dataset ', ' base ', ' method development ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Policies ', ' Genetic ', ' genetically predisposed ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Predisposition to Disease ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Complex ', ' experience ', ' pleiotropy ', ' pleiotropic effect ', ' pleiotropism ', ' success ', ' expectation ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' member ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Reporting ', ' Coding System ', ' Code ', ' Statistical Methods ', ' functional genomics ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' genome sequencing ', ' Data ', ' Large-Scale Sequencing ', ' Validation ', ' Electronic Health Record ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' cost ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Coupled ', ' human disease ', ' public health relevance ', ' biobank ', ' biorepository ', ' exome ', ' exomes ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' Genetic study ', ' web portal ', ' internet portal ', ' human genomics ', ' whole genome ', ' entire genome ', ' genomic data ', ' ']",NHGRI,VANDERBILT UNIVERSITY,U01,2016,854333,TN-05,0.12227602667964475
"Discovery of pathogenic germline variants in pediatric cancers using genomics. Project Summary/Abstract Genomic alterations drive cancer development in pediatric and adult patients, but pediatric cancers display a relative scarcity of somatic variants. This observation coupled with the earlier age of onset in familial cancer syndromes suggests that germline variants contribute to the development of many pediatric cancers. Many known pathogenic germline variants exhibit biological features such as loss of heterozygosity and rarity within the general population; certain germline cancer-causing variants also cause cancer when acquired somatically. Identifying pathogenic germline variants from whole exome sequence (WES) data would clarify the pathogenesis of pediatric cancers, and might support improved treatments for cancer subtypes with poor prognosis such as relapsed acute lymphoblastic leukemia (ALL), high-grade glioma (glioma), and ependymoma. The long-term goal of this research is to understand the role of germline variants in pediatric cancer development using genomic data. The objective of this application is to develop a computational biology tool that identifies pathogenic germline variants from WES data, and to apply this tool to analyze germline variants in relapse ALL, glioma, and ependymoma. This application's central hypothesis is that pathogenic germline variants have biological and cohort-specific features that distinguish them from benign variants, such that a machine learning pipeline trained on these features can predict pathogenic germline variants. Aim 1 will call germline variants in WES data from 1) pediatric patients with known cancer-causing germline variants and 2) control patients without cancer; patients in data set 1) are randomly divided into a training and test set. A bioinformatics pipeline will call variants, add annotation, and filter out low quality variants. Aim 2 will use the training set to train and optimize a machine-learning algorithm to predict high confidence germline driver variants. Aim 3 will apply the final pipeline to validation sets of pediatric relapsed ALL, glioma, and ependymoma samples. These aims will generate a computational pipeline that predicts pathogenicity of germline variants using a pediatric cancer cohort, enabling improved understanding of the contribution of germline variants to multiple pediatric cancers. Project Narrative Improved understanding how certain germline DNA variants (those DNA changes that are inherited or occur early in development) promote cancer might lead to better treatments for pediatric cancers. However, identifying which germline variants cause cancer is challenging without genetic information from family members. To address this, this research proposal develops a computational tool that learns from germline variants known to cause cancer and then predicts cancer-causing variants from pediatric cancer patient DNA sequences in the absence of family information; these predicted variants will undergo computational and experimental testing, and may clarify how pediatric cancers like relapsed acute lymphoblastic leukemia, glioma, and ependymoma develop.",Discovery of pathogenic germline variants in pediatric cancers using genomics.,9195404,F31CA210607,"['abstracting ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Adult ', ' Affect ', ' Age ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Control Groups ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' WHO Grade II Ependymal Tumor ', ' WHO Grade II Ependymal Neoplasm ', ' Ependymoma ', ' Exhibits ', ' Family ', ' Genes ', ' neuroglia tumor ', ' neuroglia neoplasm ', ' glial-derived tumor ', ' Neuroglial Tumor ', ' Neuroglial Neoplasm ', ' Glial Tumor ', ' Glial Neoplasm ', ' Glial Cell Tumors ', ' Glioma ', ' Goals ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' acute lymphomatic leukemia ', ' acute lymphogenous leukemia ', ' acute lymphatic leukemia ', ' Precursor Lymphoblastic Leukemia ', ' Precursor Cell Lymphoblastic Leukemia ', ' Acute Lymphoid Leukemia ', ' Acute Lymphoblastic Leukemia ', ' ALL - Acute Lymphocytic Leukemia ', ' Acute Lymphocytic Leukemia ', ' infant ALL ', ' Pediatric Acute Lymphoid Leukemia ', ' Pediatric Acute Lymphogenous Leukemia ', ' Pediatric Acute Lymphocytic Leukemia ', ' Pediatric Acute Lymphoblastic Leukemia ', ' Pediatric ALL ', ' Lymphoblastic Leukemia, Acute, L1 ', ' L1 Lymphocytic Leukemia ', ' Childhood Acute Lymphoid Leukemia ', ' Childhood Acute Lymphogenous Leukemia ', ' Childhood Acute Lymphocytic Leukemia ', ' Childhood Acute Lymphoblastic Leukemia ', ' Childhood ALL ', ' Leukemia, Lymphocytic, Acute, L1 ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Prognosis ', ' outcome forecast ', ' Relapse ', ' Research ', ' Research Proposals ', ' social role ', ' Role ', ' Syndrome ', ' Testing ', ' Tumor Suppressor Genes ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' Family member ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Benign ', ' Variation ', ' Variant ', ' Biological ', ' Age of Onset ', ' Training ', ' pediatric ', ' Childhood ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' pediatric malignancy ', ' pediatric cancer ', ' children with cancer ', ' childhood malignancy ', ' child with cancer ', ' cancer in children ', ' cancer in a child ', ' Malignant childhood cancer ', ' Malignant Pediatric Tumor ', ' Malignant Pediatric Neoplasm ', ' Malignant Childhood Tumor ', ' Childhood Cancers ', ' Malignant Childhood Neoplasm ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' computer biology ', ' Computational Biology ', ' Hereditary ', ' Inherited ', ' Techniques ', ' Allelic Loss ', ' Loss of Heterozygosity ', ' Penetrance ', ' Somatic Mutation ', ' Tumor Cell ', ' neoplastic cell ', ' Performance ', ' cohort ', ' General Public ', ' General Population ', ' Pathogenesis ', ' Cancer Relapse ', ' Modeling ', ' Sampling ', ' Genomics ', ' Pathogenicity ', ' Bio-Informatics ', ' Bioinformatics ', ' Oncogenesis ', ' tumorigenesis ', ' familial cancer ', ' Hereditary Cancer ', ' Familiar Malignant Neoplasm ', ' Hereditary Malignant Neoplasm ', ' Pediatric Tumor ', ' Childhood Tumor ', ' Childhood Neoplasm ', ' Pediatric Neoplasm ', ' Address ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' DNA Sequence Alteration ', ' Data ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Validation ', ' Characteristics ', ' developmental ', ' Development ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' computational tools ', ' computerized tools ', ' Population ', ' Coupled ', ' Susceptibility Gene ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' Oncogenic ', ' functional loss ', ' tumor ', ' effective therapy ', ' effective treatment ', ' exome ', ' exomes ', ' exome sequencing ', ' Childhood Cancer Treatment ', ' Pediatric Cancer Treatment ', ' pediatric patients ', ' child patients ', ' genetic information ', ' tumor DNA ', ' tumor-specific DNA ', ' tumor cell DNA ', ' cancer subtypes ', ' cancer sub-types ', ' genomic data ', ' ']",NCI,COLUMBIA UNIVERSITY HEALTH SCIENCES,F31,2016,39638,NY-13,0.18637022043195645
"An integrative approach to functionalize GWAS hits in MI and stroke     DESCRIPTION (provided by applicant): Coronary heart disease (CHD) and cerebrovascular disease result from platelet thrombus formation at the site of a ruptured atherosclerotic plaque. Numerous studies have shown enhanced platelet reactivity, and increased platelet count and volume are risk factors for CHD events and fatality, and a recent NHLBI Working Group concluded that variation in platelet reactivity is a major determinant of ischemic events, like MI or stroke. Genome wide association studies (GWASs) have identified numerous common genetic variants associated with the risk of CHD and platelet function parameters, but most of the positive ""hits"" are not causative of the phenotype. To understand the cellular mechanisms by which these variants affect platelet function it is imperative to know the repertoire of mRNAs, miRNAs and lncRNAs expressed in the cell of interest. Our team has been a leader in the field of platelet transcriptomics as well as functional assessment of variants in platelet genes. We have profiled mRNAs and miRNAs from 183 subjects using multiple platforms and have also performed platelet RNA-seq on 14 different subjects. This information provides a critical ability to filter, prioritize and obtain variant functional insights for evaluating GWAS SNPs associated with MI, stroke and platelet parameters. We have identified 142 mRNAs and 9 miRNAs that are expressed in platelets and linked to these GWAS hits. The goals of this proposal are to identify, assay, and validate functional variation previously tagged in GWASs of platelet-mediated ischemic arterial disease and of platelet phenotypes. Aim 1 will identify GWAS-linked mRNAs, miRNAs and lncRNAs that are functional in platelets. Candidate RNAs will be refined by association with platelet function, eQTLs and QTLs using our previously generated platelet RNA data. We will develop a supervised machine-learning, statistical pattern matching algorithm to prioritize likely platelet-functional genes. Gene-level assays in which we knock down mRNA, miRNA and lncRNA in our human megakaryocyte culture system, followed by assays for integrin activation and quantification of platelet number and volume will be used to confirm platelet functionality. Aim 2 will identify functionally divergent SNPs and haplotypes. We will impute missing SNPs and perform fine-mapping to the phenotypes of interest. Variants will be prioritized by association strength, annotation data, and predicted function using publically available resources and our own platelet eQTL data. Non-coding candidates will be tested by reporter gene assay and non-synonymous variants will be tested using functional assays in cell lines in which the endogenous gene has been silenced. We will validate our findings with a replication analysis in which we use an independent cohort dataset to quantify the association of the tested variants with the original GWAS phenotype. PUBLIC HEALTH RELEVANCE:  Platelet-mediated arterial thrombosis in the coronary or cerebrovascular circulation is the major cause of mortality and morbidity in the U.S. Numerous DNA variations have been associated with these disorders, but the causal genes are unknown. This research will test whether genes near these DNA variations - and candidate variations themselves - alter platelet function or number to understand better the molecular mechanisms causing heart attacks and strokes.",An integrative approach to functionalize GWAS hits in MI and stroke,9115225,R01HL128234,"['cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' stroke ', ' Testing ', ' Thrombosis ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Measures ', ' falls ', ' Enhancers ', ' Mediating ', ' promoter ', ' promotor ', ' Thrombus ', ' Data Set ', ' Dataset ', ' base ', ' human subject ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Reporter Genes ', ' Link ', ' insight ', ' Individual ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Investigation ', ' Event ', ' Protocol ', ' Protocols documentation ', ' Pattern ', ' System ', ' interest ', ' cohort ', ' UTRs ', ' Untranslated Regions ', ' Prevention ', ' Reporting ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Untranslated RNA ', ' Sentinel ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' Molecular Interaction ', ' Binding ', ' HPCA1 ', ' CD34 ', ' CD34 gene ', ' Mediator of Activation ', ' Mediator ', ' Mediator of activation protein ', ' Data ', ' Pathologic ', ' Molecular ', ' protein function ', ' work group ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' clinical phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' knockdown ', ' knock-down ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Rupture ', ' Coupled ', ' transcriptomics ', ' clinically relevant ', ' clinical relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' ChIP-seq ', ' chromatin immunoprecipitation-sequencing ', ' ChIP Sequencing ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' screening ', ' transcriptome ', ' inter-individual variation ', ' interindividual variation ', ' Affect ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' aminoacid ', ' Amino Acids ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' platelet disorder ', ' platelet disease ', ' Thrombocytopathy ', ' Blood Platelet Disorders ', ' thrombocyte/platelet ', ' Thrombocytes ', ' Platelets Reticuloendothelial System ', ' Platelets ', ' Marrow platelet ', "" Hayem's elementary corpuscle "", "" Deetjeen's body "", "" Bizzozero's corpuscle/cell "", ' Blood Platelets ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cell Body ', ' Cells ', ' cerebrovascular blood flow ', ' cerebrocirculation ', ' cerebral circulation ', ' cerebral blood flow ', ' brain blood flow ', ' Cerebrovascular Circulation ', ' cerebral vascular disease ', ' brain vascular disease ', ' Intracranial Vascular Disorders ', ' Intracranial Vascular Diseases ', ' Cerebrovascular Disease ', ' Brain Vascular Disorders ', ' Cerebrovascular Disorders ', ' Coronary Circulation ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Coronary heart disease ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' vulnerable plaque ', ' atherosclerotic plaque ', ' atherosclerotic lesions ', ' atherosclerosis plaque ', ' Atheromatous plaque ', ' Atheromatous degeneration ', ' Atheromatous ', ' Atheroma ', ' Arterial Fatty Streaks ', ' Arterial Fatty Streak ', ' Gene Expression ', ' Genes ', ' Genotype ', ' Goals ', ' Haplotypes ', ' Health ', ' Modern Man ', ' Human ', ' Integrins Extracellular Matrix ', ' Integrins ', ' Intervening Sequences ', ' Introns ', ' Laboratories ', ' Maps ', ' Megalokaryocyte ', ' Blood megakaryocyte ', ' Megakaryocytes ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' heart infarction ', ' heart infarct ', ' heart attack ', ' coronary infarction ', ' coronary infarct ', ' coronary attack ', ' cardiac infarct ', ' Myocardial Infarct ', ' Cardiac infarction ', ' Myocardial Infarction ', ' Phenotype ', ' Platelet Activation ', ' Platelet Number ', ' Platelet Count ', ' Blood Platelet Number ', ' Blood Platelet Count ', ' Platelet Count measurement ', ' positron emitting tomography ', ' positron emission tomographic imaging ', ' positron emission tomographic (PET) imaging ', ' Rad.-PET ', ' Positron Emission Tomography Scan ', ' Positron Emission Tomography Medical Imaging ', ' PETT ', ' PETSCAN ', ' PET imaging ', ' PET Scan ', ' PET ', ' Positron-Emission Tomography ', ' Production ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Research Resources ', ' Resources ', ' Risk ', ' Risk Factors ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' ']",NHLBI,THOMAS JEFFERSON UNIVERSITY,R01,2016,392349,PA-03,0.04809103870656848
"Predicting causal non-coding variants in a founder population DESCRIPTION (provided by applicant): In order to characterize the molecular and cellular causes of human disease, it will be essential to unravel the functional impact of genetic variation. However, we are currently unable to predict the impact of the majority genetic variants that lie in non-coding regions of the genome, where indeed most complex disease-associated variants are found. Additionally, recent evidence suggests that a significant fraction of the non-coding genome is likely to be functional, often playing a role in gene regulation. Therefore, our limited understanding of non- coding variation is a critical hurdle to characterizing the genetic basis of disease. The goal of this project is to develop methods for interpreting non-coding genetic variation: to provide a robust and extensible Bayesian method for predicting causal variants from full genomes, to identify and validate a large set of functional non- coding variants using CRISPR technology, and to predict disease-relevant traits likely to be affected by each variant. Our project will leverage a unique cohort from a founder population in Sardinia, with genome sequence and/or transcriptome data available from 3000 individuals, along with extensive phenotyping for hundreds of traits. We will combine advanced statistical modeling with experimental validation based on genome engineering to identify causal non-coding variants affecting biomedical traits in the cohort, along with predicting functional mechanisms through which these variants ultimately perturb the cell. In Aim 1, we develop computational methods for predicting causal non-coding variation from full genomes, incorporating informative genomic features including epigenetic data, sequence motifs, and conservation information into a Bayesian approach jointly modeling multiple transcriptomic signals. We will optimize and apply these methods on genome and transcriptome data available for the Sardinia cohort to identify a large set of variants predicted to causally affect gene expression. Based on these predictions, in Aim 2, we connect putative causal variants with the diverse set of disease-relevant traits measured in the cohort, using network inference to capture the cascade from genetic variation to gene expression to disease. We will develop methods to integrate across variants, using the models in Aim 1, to identify the common causal mechanisms related to each trait. In Aim 3, we validate the causal impact of non-coding variants predicted to affect high-level traits. We will us genome editing through CRISPR to introduce individual genetic variants into cell lines and use qPCR to validate the predicted effects on gene expression. Finally, a major goal throughout this proposal will be to provide the research community with convenient computational tools for the prediction of causal non-coding variants from individual genomes, updated on an ongoing basis to integrate the most recent genomic annotations and public data in order to provide the best possible accuracy in predicting causal variants and the traits they are likely to affect. Our projet will greatly advance our understanding of non-coding genetic variation, the specific mechanisms affected by causal variants, and the downstream consequences to the cell and individual health. PUBLIC HEALTH RELEVANCE:  Understanding the impact of variation in the entire genome, beyond the well-studied protein-coding regions, is essential to understanding the relationship between genetics and human health. This proposal addresses the problem of identifying functional non-coding genetic variants and predicting the impact of each variant on hundreds of disease-relevant traits. Our approach will focus on integrative, transformative methods for understanding mechanisms underlying the function of the human genome.",Predicting causal non-coding variants in a founder population,9116910,R01HG008150,"['Affect ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biology ', ' Cataloging ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cell Body ', ' Cells ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Family ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Human Genetics ', ' Linkage Disequilibrium ', ' Maps ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Phenotype ', ' Play ', ' Research ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Sardinia ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' Open Reading Frames ', ' Protein Coding Region ', ' ORFs ', ' Data Set ', ' Dataset ', ' base ', ' density ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' Individual ', ' Bayesian posterior distribution ', ' Bayesian classification procedure ', ' Bayesian classification method ', ' Bayesian approaches ', ' Bayesian Statistical Method ', ' Bayesian Methodology ', ' Bayesian Method ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' Frequencies ', ' Hereditary ', ' Inherited ', ' Complex ', ' Techniques ', ' System ', ' human data ', ' cohort ', ' trait ', ' novel ', ' Categories ', ' disease risk ', ' disorder risk ', ' Pathogenesis ', ' linkage analyses ', ' genetic linkage analyses ', ' family based linkage study ', ' Linkage Analysis ', ' genetic linkage analysis ', ' Generalized Disease ', ' Extensive Disease ', ' Widespread Disease ', ' Modeling ', ' Sampling ', ' Property ', ' functional genomics ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Untranslated RNA ', ' Genomics ', ' genome sequencing ', ' Address ', ' Data ', ' Resolution ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' founder population ', ' Founder Generation ', ' genomic region ', ' Genomic Segment ', ' Transcript ', ' Update ', ' Validation ', ' Molecular ', ' developmental ', ' Development ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' data modeling ', ' computational tools ', ' computerized tools ', ' Genome engineering ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' transcriptomics ', ' human disease ', ' molecular phenotype ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' genome annotation ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' human genome sequencing ', ' genome editing ', ' genomic editing ', ' learning strategy ', ' learning method ', ' learning activity ', ' transcriptome ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR method ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' whole genome ', ' entire genome ', ' genomic data ', ' ']",NHGRI,STANFORD UNIVERSITY,R01,2016,454272,CA-18,0.19317893142270912
"Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea ABSTRACT  Obstructive sleep apnea (OSA) is recognized as an extremely common disorder that results in excessive daytime sleepiness and an increased risk of automobile crashes. It is also an independent risk factor for insulin resistance, hypertension, cardiovascular events, increased cancer rates and cancer mortality, and accelerates the progression of neurodegenerative disorders. OSA is a systemic disorder and the cyclical intermittent hypoxia that occurs during sleep affects every organ system. OSA is heritable, with first degree relatives of individuals with OSA having a two-fold increased risk of the disorder. Although this has been known for over two decades, there are very limited data on gene variants conferring risk or protection for OSA. This is likely the result of underpowered studies and GENETIC HETEROGENEITY. There are multiple pathways to OSA. Obesity is a major risk factor, as are craniofacial dimensions. The relative risk of these different risk factors varies by ethnic group. There are also neuronal mechanisms and other physiological risk factors. This proposal seeks to directly address the issue of genetic heterogeneity using a very large sample of patients and state-of- the-art analysis techniques. Towards this end, we have assembled by far the largest sample of well characterized and genotyped patients with OSA. This is the result of collaboration with key sites in the eMERGE Network [Geisinger, Vanderbilt, Mayo Clinic, Northwestern], Kaiser Permanente Southern California, and the University of Pennsylvania. We propose to carry out a robust genome-wide association studies (GWAS) using an electronic health record (EHR) derived case definition and quantitative trait analysis of OSA severity. We will use novel machine learning approaches to specifically address genetic heterogeneity. The GWAS approach will be complimented by a PheWAS strategy as another approach to identifying common variants and related clinical phenotypes. Specifically, we will look for variants that associate with OSA and other clinical diagnoses in the EHR. It is likely that gene variants for OSA will have pleiotropic effects. Gene variants identified from GWAS and/or PheWAS will be further assessed. First, we will use available whole exome sequencing data to see if there are relevant rare variants in these genes, as well as to perform exploratory discovery analyses to look for novel rare variation. The functional role of the genes identified will be studied by functional network analysis. Finally, we will assess associations with quantitative data on intermediate traits identified by high throughput craniofacial and intra-oral photography. These data are currently available within the Sleep Apnea Global Interdisciplinary Consortium (SAGIC). Future directions will assess the function of the genes identified in model systems and the clinical utility of utilizing variants as part of risk stratification for OSA. PROJECT NARRATIVE  Obstructive sleep apnea (OSA) is a common disorder with multiple adverse consequences. It is known that OSA has a genetic basis, but to date no convincing gene variants have been identified. This study uses state of the art approaches to identifying relevant genes based on a very large sample of patients with OSA obtained from multiple institutions in the United States. It is by far the largest study ever proposed for identifying genes for this common sleep disorder.",Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea,9177170,R01HL134015,"['Accounting ', ' Affect ', ' Algorithms ', ' Automobiles ', ' urinary bladder ', ' Bladder Urinary System ', ' Bladder ', ' California ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardio-vascular ', ' Cardiovascular system ', ' Diagnosis ', ' Disorder ', ' Disease ', ' ethnicity group ', ' Ethnic group ', ' Fats ', ' Fatty acid glycerol esters ', ' Foundations ', ' Future ', ' Genes ', ' Genotype ', ' Heterogeneity ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Hypertension ', ' insulin resistant ', ' Insulin Resistance ', ' Learning ', "" men's "", ' men ', ' Methodology ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' mortality ', ' neuronal ', ' Neurocyte ', ' Neural Cell ', ' Nerve Unit ', ' Nerve Cells ', ' Neurons ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' Patients ', ' Pennsylvania ', ' Phenotype ', ' Photography ', ' Play ', ' Public Health ', ' Research ', ' Research Resources ', ' Resources ', ' Risk ', ' Risk Factors ', ' social role ', ' Role ', ' Sleep ', ' sleep-related breathing disorder ', ' Sleep-Disordered Breathing ', ' Sleep Hypopnea ', ' Sleep Apnea ', ' Sleep Apnea Syndromes ', ' Body Tissues ', ' Tissues ', ' United States ', ' Universities ', ' Woman ', ' Measures ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' soft tissue ', ' Individual ', ' Oxygen Deficiency ', ' Hypoxic ', ' Hypoxia ', ' Relative Risks ', ' Genetic Heterogeneity ', ' Collaborations ', ' Genetic ', ' gene function ', ' clinical Diagnosis ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Dimensions ', ' Severities ', ' Complex ', ' Event ', ' Oral ', ' Clinic ', ' Techniques ', ' System ', ' Organ System ', ' body system ', ' Syndrome, Sleep Apnea, Obstructive ', ' Obstructive Sleep Apnea ', ' disease severity ', ' Severity of illness ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neuro-degenerative Disorders ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' Neurodegenerative Disorders ', ' craniofacies ', ' craniofacial ', ' pleiotropy ', ' pleiotropic effect ', ' pleiotropism ', ' cohort ', ' trait ', ' Structure ', ' novel ', ' Participant ', ' disease risk ', ' disorder risk ', ' Excessive daytime somnolence ', ' Excessive Daytime Sleepiness ', ' Coding System ', ' Code ', ' sleep problem ', ' Sleep Disorders ', ' Network Analysis ', ' Pathway Analysis ', ' Sampling ', ' case control ', ' Genomics ', ' Institution ', ' genetic association ', ' Address ', ' Data ', ' Stratification ', ' Collection ', ' 1st degree relative ', ' First Degree Relative ', ' Process ', ' Electronic Health Record ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Vehicle crash ', ' Vehicular crash ', ' Vehicular collision ', ' Motor vehicle crash ', ' Motor vehicle collision ', ' Car crash ', ' Car collision ', ' Automobile crash ', ' Automobile collision ', ' innovation ', ' innovative ', ' innovate ', ' gene discovery ', ' discover genes ', ' high risk ', ' genome-wide ', ' genomewide ', ' genome scale ', ' phenome ', ' adverse outcome ', ' adverse consequence ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' precision medicine ', ' learning strategy ', ' learning method ', ' learning activity ', ' genotyped patients ', ' genomic data ', ' ']",NHLBI,UNIVERSITY OF PENNSYLVANIA,R01,2016,740775,PA-03,-0.01804975114259039
"GWAS TO GENE FUNCTION: NOS1AP AND OTHER QT INTERVAL GENES DESCRIPTION (provided by applicant): Genome-wide association studies (GWAS) of the electrographic QT-interval, an intermediate trait that impacts the risks of long QT syndrome and sudden cardiac death, have identified 68 independent variants at 35 loci, explaining 8% of the phenotypic (20% of the additive) variance. Nevertheless, the identity, function and mechanisms of action of the underlying DNA sequence variants and genes remain unknown, and are major impediments for understanding the molecular structure and functional architecture of this complex phenotype. We hypothesize that the majority of functional trait variants are polymorphic, non-coding and perturb transcription of a specific gene by altering the functions of their cis-regulatory elements. We propose a research paradigm for systematically identifying these non-coding trait variants, the regulatory functions they disrupt and the specific genes whose functions are altered at each quantitative trait locus. We will utilize integrative statisticl genetic, computational, molecular genetics and cellular approaches for elucidating the underlying mechanisms, using QT interval as a model 'system'. Our specific aims are: (1) to perform high- resolution mapping of GWAS signals to identify all polymorphic (>1%) and rare variants at loci that modulate the QT-interval; (2) to conduct in silico and in vitro analysis to predict and prioritize all cardiac regulatory (enhancer, silencer, insulator) elements and their cognate DNA-binding proteins; and, (3) to identify trait variants, genes and their mechanisms of genetic action. The overall goals are to improve the molecular genetic and mechanistic understanding of multifactorial traits for applications to other complex phenotypes. PUBLIC HEALTH RELEVANCE: The electrocardiographic QT-interval, an intermediate trait for arrhythmias and sudden cardiac death, has 68 predominantly non-coding variants at 35 loci explaining 8% of the phenotypic (20% of the additive) variance upon meta-analyses in >76,000 individuals of European and >11,000 individuals of African ancestry: nevertheless, the molecular details remain unknown. We propose a program of research for systematically identifying the functional non-coding quantitative trait variants, the regulatory function they disrupt and the specific gene whose functions are altered, at each locus. We utilize integrative statistical genetic, computational, molecular genetics and cellular approaches for understanding the underlying genetic mechanisms in this model trait with the overall goal to improve the molecular understanding of all complex phenotypes.",GWAS TO GENE FUNCTION: NOS1AP AND OTHER QT INTERVAL GENES,9113648,R01GM104469,"['Action Potentials ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Adult ', ' Allelomorphs ', ' Alleles ', ' Engineering / Architecture ', ' Architecture ', ' Heart Arrhythmias ', ' Cardiac Arrhythmia ', ' Arrhythmia ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Base Sequence ', ' Beer ', ' Reactive Site ', ' Combining Site ', ' Binding Sites ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' cell culture ', ' Cell Culture Techniques ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Disorder ', ' Disease ', ' DNA-Binding Proteins ', ' electrophysiological ', ' Neurophysiology / Electrophysiology ', ' Electrophysiology ', ' Electrophysiology (science) ', ' Future ', ' Genes ', ' Goals ', ' Health ', ' Heart ', ' Heterogeneity ', ' Modern Man ', ' Human ', ' Allergy ', ' Hypersensitivity ', ' In Vitro ', ' Infection ', ' Laboratories ', ' Long QT Syndrome ', ' Maps ', ' Methods ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' Macromolecular Structure ', ' Molecular Structure ', ' oligos ', ' Oligo ', ' Oligonucleotides ', ' Phenotype ', ' polymorphism ', ' Genetic Polymorphism ', ' Proteins ', ' Rats Mammals ', ' Rat ', ' Common Rat Strains ', ' Rattus ', ' Research ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrum Analysis ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Weight ', ' Death, Sudden, Cardiac ', ' Enhancers ', ' Molecular Genetics ', ' promoter ', ' promotor ', ' DNA Sequence ', ' base ', ' Label ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Evaluation ', ' Individual ', ' African ', ' European ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Gene Targeting ', ' Collaborations ', ' Genetic ', ' gene function ', ' Reporter ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Complex ', ' Myocytes ', ' Muscle Cells ', ' QTL ', ' Quantitative Trait Loci ', ' trait ', ' novel ', ' Position ', ' Positioning Attribute ', ' Modeling ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Untranslated RNA ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' gel shift assay ', ' Mobility Shift Assay ', ' Bandshift Mobility Assay ', ' Band Shift Mobility Assay ', ' Electrophoretic Mobility Shift Assay ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Insulator Elements ', ' Protein Microarray ', ' Protein Chips ', ' Protein Biochips ', ' Protein Microchips ', ' Molecular Interaction ', ' Binding ', ' ChIP assay ', ' chromatin immunoprecipitation ', ' p300 ', ' histone acetyltransferase p300 ', ' KAT3B ', ' EP300 ', ' E1A Binding Protein p300 ', ' EP300 gene ', ' Affinity ', ' Data ', ' Regulatory Element ', ' Resolution ', ' in vivo ', ' Nuclear Extract ', ' Transcript ', ' Validation ', ' Molecular ', ' Ventricular ', ' Cardiac ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' epigenomics ', ' knockdown ', ' knock-down ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Neonatal ', ' Computational algorithm ', ' computer algorithm ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' differential expression ', ' transcriptional differences ', ' differentially expressed ', ' GATA4 gene ', ' GATA4 transcription factor ', ' GATA4 ', ' GATA binding protein 4 ', ' ']",NIGMS,JOHNS HOPKINS UNIVERSITY,R01,2016,604625,MD-07,0.0976757613835259
"F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes     DESCRIPTION (provided by applicant): Patient-to-patient variability in response to drugs creates a significant challenge for the safe and effective treatment of many human diseases. Pharmacogenomics seeks to address this challenge by linking drug response to patient genotypes at important loci, termed pharmacogenes, in order to better customize patient treatments. Genetic variation in pharmacogenes is extensive. For example, amongst 12 CYP genes, 10% of people carry at least one rare, potentially deleterious variant. Unfortunately, only a small number of variants have been unambiguously linked to alterations in drug response. Clearly, new approaches are needed to annotate the consequences of the huge pool of variants of unknown significance, including those already identified by existing large-scale sequencing programs, and those that will be discovered as clinical sequencing becomes routine. In this proposal, we seek to address this problem directly and at a scale never before possible by taking advantage of new technologies in sequencing and functional analysis. Our resource, termed F-CAP (Functionalization of Variants in Clinically Actionable Pharmacogenes) will test all possible substitutions at all amino acid residues in some of the most clinically important pharmacogenes and disseminate these data to the medical and research communities. In order to accomplish this, we will use deep mutational scanning, a method we have developed that allows parallelized, and quantitative measurements to be performed on libraries of genetic variants. In Aim 1 we will create these libraries, starting with five of the most important CPIC level A or B priority genes (CYP2C9, CYP2C19, CYP2D6, TPMT and VKORC1), and test the stability and enzymatic activity of each variant en masse using a pooled selection strategy. In Aim 2, we will integrate these data to create an impact score. This impact score provides a numerical value for a variant's functional effects that is amenable to easy integration into prescribing guidelines being developed by the pharmacogenomics community. Aim 3 will validate this score for a subset of variants that span the impact score spectrum using therapeutically relevant substrates for each pharmacogene. Finally, Aim 4 describes a key component of this resource: the dissemination of our findings to the entire pharmacogenomics community through partnership with CPIC and PharmGKB. In addition, we will make available our raw and processed data via a custom web resource that will also be developed in Aim 4. This resource will provide a series of fully annotated datasets describing the functional consequences of every possible single mutation in a series of key pharmacogenes, thereby greatly advancing the field of personalized medicine. PUBLIC HEALTH RELEVANCE: Pharmacogenomics seeks to identify genetic sources of inter-individual variability in drug response, with the goal of personalizing drug selection and dose to improve patient outcomes. A key barrier to using pharmacogenomic information is lack of clarity about the functional impact of variants, which hampers the provision of clear, unambiguous guidance to health care providers. We propose to connect pharmacogenomic variant discovery with novel high-throughput experimental approaches to deliver a resource to guide the use of individual pharmacogenomic information in personalizing drug treatment.",F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes,9110269,R24GM115277,"['Affect ', ' Algorithms ', ' aminoacid ', ' Amino Acids ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Systematics ', ' Classification ', ' Communities ', ' drug treatment ', ' Drug Therapy ', ' Pharmacotherapy ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Elements ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Health ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' In Vitro ', ' Libraries ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Research Resources ', ' Resources ', ' Testing ', ' Translations ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Generations ', ' Measures ', ' Medical Research ', ' Data Set ', ' Dataset ', ' Custom ', ' Guidelines ', ' improved ', ' Variation ', ' Variant ', ' Biochemical ', ' Medical ', ' Series ', ' Link ', ' Individual ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Measurement ', ' root ', ' Plant Roots ', ' Funding ', ' R24 ', ' R-24 Monoclonal Antibody ', ' MoAb R24 ', ' Monoclonal Antibody R24 ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Scanning ', ' Source ', ' interest ', ' genetic diagnosis ', ' genetic disorder diagnosis ', ' novel ', ' novel technologies ', ' new technology ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' response ', ' Pharmacogenomics ', ' data processing ', ' computerized data processing ', ' P450C2C ', ' Mephenytoin 4-Prime Hydroxylase ', ' Cytochrome P450, Subfamily IIC, Polypeptide 19 ', ' CYP2C19 ', ' CYP2C ', ' CYP2C19 gene ', ' Cytochrome P450, Subfamily IIC, Polypeptide 9 ', ' CYP2C9 ', ' CYP2C9 gene ', ' Subfamily IID-Like 1 Cytochrome P450 ', ' Subfamily IID Cytochrome P450 ', ' Sparteine Monooxygenase ', ' P450DB1 ', ' P450C2D ', ' P450-DB1 ', ' P450-2D6 ', ' Imipramine 2-Hydroxylase ', ' Debrisoquine Hydroxylase ', ' Debrisoquine 4-Monooxygenase ', ' Debrisoquine 4-Hydroxylase ', ' Cytochrome P450 Subfamily IID Polypeptide 6 ', ' Cytochrome P450 2D6 ', ' Cytochrome P-450 CYP2D6 ', ' CYPIID6 ', ' CYP2DL1 ', ' CYP2D6 ', ' CYP2D ', ' CYP 2D6 ', ' CPD6 ', ' CYP2D6 gene ', ' TPMT ', ' TPMT gene ', ' Address ', ' Dose ', ' Data ', ' Grant Proposals ', ' Applications Grants ', ' Mutate ', ' Cellular Assay ', ' Large-Scale Sequencing ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' Numerical value ', ' Output ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' user-friendly ', ' human disease ', ' effective therapy ', ' effective treatment ', ' stability testing ', ' exome ', ' exomes ', ' High-Throughput DNA Sequencing ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' genetic information ', ' variant of unknown significance ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' clinical sequencing ', ' clinically actionable ', ' genotyped patients ', ' ']",NIGMS,UNIVERSITY OF WASHINGTON,R24,2016,747826,WA-07,0.1902170025038608
"Regulation of mRNA splicing by intronic genetic variants     DESCRIPTION (provided by applicant): Genetic variations in introns commonly impact cellular functions by causing alterations in mRNA splicing. The abnormal inclusion and exclusion of exons often change protein functions and cellular phenotypes. Although many intronic variations have known functions, with the adoption of next generation sequencing, many more intronic variants have been discovered for which the functional impact is unknown. Thus, it is important to be able to predict the impact of the variants without needing to test them all in expensive and laborious assays. Although there are informatics algorithms that predict the impact of genetic variants on pre-mRNA splicing, their ability to predict the effect on protein function and ultimately disease and therapeutic phenotypes is lacking. In addition, there is a need for high-throughput cellular assays to test the results of these predictions on cellular functions. The studies proposed here will fulfill these needs by developing algorithms that prioritize the intronic variants by their potential impact on splicing and gene function, and developing a high-throughput assay to functionally test thousands of these predictions. These novel technologies will be applied to the effect of intronic variants on the pharmacogenomics of two clinically important oncology drugs, clofarabine and paclitaxel. Our long-term goals are to be able to predict the functional impact of genomic variants on human disease and therapeutic response. Our central hypothesis is that intronic genetic variants alter mRNA splicing and consequently protein function that ultimately affects the cellular response to drug therapy. Our first aim will be to develop computational algorithms that prioritize intronic variants based on their impacts on pre-mRNA splicing and protein function. Using a variety of genomic and structural features and large sets of genomic data, we will develop a bioinformatics algorithm specifically designed to prioritize intronic variants based on their potential impacts on pre-mRNA splicing and protein function. Our second aim will be to identify functional intronic variants associated with drug-induced cytotoxicity. Using existing genomics and cellular cytotoxic response data from populations of human cell lines, we will identify functional intronic variants that contribute to individuals' responses to clofarabine and paclitaxel cytotoxicity. Our third aim will be to functionally test the impact of the prioritized intronic variants on pre-mRNA splicing and drug cytotoxicity. Using our novel high- throughput functional splicing assay, we will test the effects of predicted functional variants from Aim 2 on pre- mRNA splicing. In addition, we will validate the effect of the intronic variants on cytotoxicity using exon specific siRNA and CRISPR/Cas technology to manipulate the target gene splicing. Upon completion of these studies, we expect to have developed bioinformatics algorithms that can accurately prioritize the intronic variants based on their functional impact on pre-mRNA splicing and protein function. Also, we will have tested thousands of variants in a cellular pre-mRNA splicing assay and validated the impact of several of these functional variants on paclitaxel and clofarabine cytotoxicity.         PUBLIC HEALTH RELEVANCE    Project Narrative The goal of this project is to design and implement a set of bioinformatics algorithms and high-throughput experimental assays for prioritizing functional intronic variants that contribute to phenotypic differences by affecting pre-mRNA splicing. The developed model, including a molecular validation component, will be used to systematically evaluate the functions of such variants that are associated with drug-induced cytotoxicity. The same strategy can also be used to study the etiology of complex diseases. This goal is directly relevant to the missions of NIH to improve the capability of disease diagnosis, treatment, and prevention.            ",Regulation of mRNA splicing by intronic genetic variants,9071997,R01CA213466,"['Adoption ', ' Affect ', ' Algorithms ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Alternative Splicing ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Clinical Study ', ' Clinical Research ', ' Computers ', ' Disorder ', ' Disease ', ' drug treatment ', ' Drug Therapy ', ' Pharmacotherapy ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Exons ', ' Genes ', ' Gene Splicing ', ' Spliced Genes ', ' Population Genetics ', ' Goals ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Intervening Sequences ', ' Introns ', ' Mission ', ' premRNA ', ' RNA, Messenger, Precursors ', ' Pre-mRNA ', ' mRNA Precursor ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Phenotype ', ' Publishing ', ' Research ', ' Splicing ', ' RNA Splicing ', ' mRNA ', ' Messenger RNA ', ' Testing ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Clofarabine ', ' Paclitaxel ', ' Taxol Konzentrat ', ' Taxol A ', ' Taxol ', ' Praxel ', ' Paclitaxel (Taxol) ', ' Bristaxol ', ' Asotax ', ' Anzatax ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Individual ', ' Biological Function ', ' Biological Process ', ' Oncology Cancer ', ' oncology ', ' cell mediated cytotoxicity ', ' Lymphocytotoxicity ', ' Lymphocyte Cytotoxicity ', ' Cellular Cytotoxicity ', ' Cell-Mediated Lympholysis ', ' Cell-Mediated Cytolysis ', ' Therapeutic ', ' gene function ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' Source ', ' Test Result ', ' Lytotoxicity ', ' cytotoxicity ', ' Informatics ', ' novel ', ' Exclusion ', ' Human Cell Line ', ' novel technologies ', ' new technology ', ' Prevention ', ' Regulation ', ' Modeling ', ' response ', ' High Throughput Assay ', ' high throughput screening ', ' functional genomics ', ' Genomics ', ' siRNA ', ' Short interfering RNA ', ' Small Interfering RNA ', ' Pharmacogenomics ', ' Bio-Informatics ', ' Bioinformatics ', ' structural genomics ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' protein structure ', ' cytotoxic ', ' Data ', ' Cellular Assay ', ' Validation ', ' Molecular ', ' protein function ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' multidisciplinary ', ' Computational algorithm ', ' computer algorithm ', ' human disease ', ' public health relevance ', ' treatment response ', ' therapeutic response ', ' response to treatment ', ' disease diagnosis ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' genomic variation ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR method ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' genomic data ', ' ']",NCI,INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,R01,2016,576262,IN-07,0.17735005780903945
"Integrative interpretation of the organismal consequences of non-coding variation     DESCRIPTION (provided by applicant): Our capacity to sequence human genomes has exceeded our ability to interpret genetic variation, particularly in non-coding regions. To address this challenge, we recently developed a novel framework, Combined Annotation Dependent Depletion (CADD), for estimating the deleteriousness of any genetic variant. CADD defines an objective, data-rich, and quantitative integration of many genomic annotations into a single measure of variant effect at the organismal level. The goals of this R01 proposal are to further develop the CADD framework, to apply it in the context of ongoing genetic studies of both rare and common human diseases, and to experimentally evaluate its predictions. In Specific Aim 1, we will substantially modify CADD in both straightforward and creative ways, with the goal of dramatically improving CADD's ability to annotate non- coding variants, not only to estimate their organismal effects but also to provide insights into molecular mechanisms. In Specific Aim 2, we will apply CADD to a variety of ongoing whole genome sequencing studies of human disease, especially those in which non-coding variants are either known or suspected to be causal. As part of this effort, we will develop new statistical frameworks that directly incorporat CADD into traditional genome-wide discovery approaches. In Specific Aim 3, we will perform a combination of high-throughput (massively parallel reporter assays), medium-throughput (CRISPR/Cas9), and low-throughput (in vivo mouse transgenics) experimental assays for systematic and targeted assessment of CADD predictions. This proposal includes both computational and experimental innovations, and builds on established collaborative relationships between investigators with complementary strengths. The completion of our aims will yield novel methods, data, and resources with which to annotate whole genome sequences, broadly enabling the field to more effectively identify and mechanistically understand non-coding genetic variants that are causally relevant to human disease. PUBLIC HEALTH RELEVANCE: As we enter an era of personalized medicine, a deep understanding of human genomes will be increasingly important to public health, contributing to the unraveling of the genetic basis of human disease, as well as serving an increasing role in clinical diagnostics. However, our limited understanding of the functional consequences of most genetic variants, especially those that do not alter protein sequence, represents a major obstacle. This proposal seeks to dramatically improve our ability to identify and interpret ""non-coding"" variants that causally contribute to human disease. A recently developed computational approach will be substantially improved and evaluated in a variety of genetic studies, and its predictions will be experimentally validated. This project will provide much needed methods and resources to address the looming analytical challenges associated with individual whole genome sequencing in both biomedical research and patient care.",Integrative interpretation of the organismal consequences of non-coding variation,9024484,R01CA197139,"['Algorithms ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biomedical Research ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Disorder ', ' Disease ', ' Feedback ', ' Patient Care Delivery ', ' Patient Care ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Maps ', ' Methods ', ' Transgenic Mice ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' living system ', ' Organism ', ' pedigree structure ', ' Pedigree ', ' genetic pedigree ', ' Phenotype ', ' Public Health ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Translating ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Vocabulary ', ' Vocabulary Words ', ' Weight ', ' Measures ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Training ', ' insight ', ' Individual ', ' Genetic ', ' Reporter ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' System ', ' QTL ', ' Quantitative Trait Loci ', ' trait ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' Human Biology ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' Peptide Sequence Determination ', ' Genetic analyses ', ' genetic analysis ', ' Coding System ', ' Code ', ' Property ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Untranslated RNA ', ' Genomics ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Pathogenicity ', ' RNA Binding ', ' Transcriptional Control ', ' Transcription Regulation ', ' Transcriptional Regulation ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Data ', ' Regulatory Element ', ' in vivo ', ' Molecular ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' disease phenotype ', ' Complex Genetic Trait ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' innovation ', ' innovative ', ' innovate ', ' human disease ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' genome-wide ', ' genomewide ', ' genome scale ', ' candidate identification ', ' exome ', ' exomes ', ' exome sequencing ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' human genome sequencing ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' Genetic study ', ' Genomic approach ', ' genomic strategy ', ' genomic effort ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR method ', ' whole genome ', ' entire genome ', ' ']",NCI,UNIVERSITY OF WASHINGTON,R01,2016,636532,WA-07,0.15195866583693662
"Functional genetic variations in splicing regulation DESCRIPTION (provided by applicant): Recently, tremendous success has been achieved in constructing a catalog of genetic variants in disease genomes or across population. The next great challenge is to elucidate the potential function of various genetic variants in biological an disease processes. An important type of functional variants consists of those that affect gene expression in cis. Indeed, cis-regulatory variants are involved in a broad range of diseases and they showed a consistently stronger influence on gene expression than trans-acting determinants. Alternative splicing is an essential mechanism via which cis-regulatory changes may occur. Previous studies estimated that 15- 60% of point mutations that result in human genetic diseases disrupt splicing, highlighting the importance of this regulatory step. In addition to the well-known splice site signals, splicing is closely regulated by many exonic or intronic cis elements, associated with trans-acting proteins. Disruption of these cis-regulatory elements can cause aberrant splicing. Yet this crucial regulatory aspect remains largely unexplored. We propose to combine computational, genomic and molecular approaches to study splicing changes due to genetic variations. The specific aims are: (1) To globally identify exons and genes that are under differential splicing regulation by the alternative alleles of genetic variant, via bioinformatic analysis of high-throughput sequencing of transcriptome profiles (RNA-Seq). (2) To identify causal genetic variants in splicing alteration using minigene-based experiments. (3) To develop an integrative model to predict causal genetic variants in splicing alteration, using machine learning approaches, RNA- Seq data and molecular validations. This project will elucidate functional cis-regulatory genetic variants in splicing and provide significant insight ino the involvement of genetic variations in human diseases. In addition, this work will generate valuable bioinformatic tools to make full use of the increasingly available RNA-Seq data in a wide variety of cell types for identification and prediction of disease-related genetic variants. Aberrant splicing can significantly alter gene expression and contribute to human diseases. The proposed research aims to gain a systematic understanding of the functional roles of genetic variations (e.g., mutations or polymorphisms) in the regulation of splicing. This work will provide mechanistic basis for how genetic variations may contribute to diseases, such that future interventions can target specific splicing events therapeutically.",Functional genetic variations in splicing regulation,9039648,R01HG006264,"['Affect ', ' Allelomorphs ', ' Alleles ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Alternative Splicing ', ' Cataloging ', ' Cell Body ', ' Cells ', ' Complement Proteins ', ' Complement ', ' Disorder ', ' Disease ', ' Elements ', ' Environment ', ' Exons ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Housing ', ' Human Genetics ', ' Intervening Sequences ', ' Introns ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' polymorphism ', ' Genetic Polymorphism ', ' Proteins ', ' Research ', ' Splicing ', ' RNA Splicing ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Transactivators ', ' Trans-Acting Factors ', ' Trans-Activators ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Measures ', ' Data Set ', ' Dataset ', ' Point Mutation ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' insight ', ' Reporter ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Catalogs ', ' Event ', ' cell type ', ' Pattern ', ' Techniques ', ' success ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' novel technologies ', ' new technology ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' RNA analysis ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' Data ', ' Regulatory Element ', ' Resolution ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Tissue-Specific Splicing ', ' Transcript ', ' Validation ', ' Characteristics ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' Population ', ' human disease ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' Genetic study ', ' transcriptome ', ' ']",NHGRI,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2016,308000,CA-33,0.10493672460502469
"NHGRI PAGE Coordinating Center DESCRIPTION (provided by applicant): NHGRI developed the Population Architecture Using Genomics and Epidemiology (PAGE) research program to identify and characterize genomic variants in non-European populations. To support the complexities of such an ambitious effort, we have convened a strong team of statistical, population, and molecular geneticists, computer and information scientists, biostatisticians, and project management staff with many years of related experience to serve as a Coordinating Center (CC). Specifically, the CC will serve as a centralized resource to facilitate and support the activities of the program and Study Investigators focused on characterization of causal variants by: (1) coordinating phenotype harmonization efforts, including mapping phenotype variables across studies and to the PhenX measures; (2) synthesizing individual-level data into centralized datasets to facilitate sharing of data within and outside of PAGE; (3) utilizing state-of-the-art computer and information science support and scientific workflows that will facilitate analyses, ancestry deconvolution, genotype calling and imputation, SNP annotation, and data synthesis; (4) rapidly disseminating all study data via dbGaP and/or the PAGE website or other applicable databases; and (5) serving as a centralized resource to facilitate, support, and manage program activities and logistics as requested by the Steering Committee or Project Office and as needed for successful coordination of the program. Coordination of the program will be done in a spirit of collaboration using creative and flexible approaches, while providing leadership in statistical genetic methodologies and approaches to project management. The ultimate goal of our CC is to facilitate the identification and characterization of genotype-phenotype associations, especially as relevant to non-European populations, thereby accelerating our understanding of ancestral differences in the genetic and environmental causes of common diseases. Critical to achieving this mission is the deployment of powerful methods for ancestry deconvolution, multi- and trans-ethnic mapping, and imputation. Building upon our success as the PAGE I CC, we have added additional investigators with expertise in these areas and consortium experience with next-generation sequence analysis of both whole-genome and exome data. Our collaborative team is ideally staffed to meet the challenges of the new round of PAGE. PUBLIC HEALTH RELEVANCE: The PAGE study focuses on analysis of existing large samples of primarily non- European ancestry to broaden our understanding of the ethnic differences in the genetic basis of complex disease. The PAGE coordinating center supports the functions of this study.",NHGRI PAGE Coordinating Center,9065945,U01HG007419,"['epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Engineering / Architecture ', ' Architecture ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Communication ', ' Computers ', ' Disorder ', ' Disease ', ' Protocol Screening ', ' Eligibility ', ' Eligibility Determination ', ' Methods Epidemiology ', ' Epidemiological Techniques ', ' Epidemiological Methods ', ' Epidemiologic Methods ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Future ', ' Genome ', ' Genotype ', ' Goals ', ' Group Meetings ', ' Information Sciences ', ' Informed Consent ', ' Leadership ', ' Maps ', ' Methods ', ' Methodology ', ' Mining ', ' Mission ', ' Phenotype ', ' Productivity ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Running ', ' Technology ', ' Time ', ' Voice ', ' Work ', ' formycin triphosphate ', "" formycin A 5'-triphosphate "", "" formycin 5'-triphosphate "", ' FTP ', ' Measures ', ' African American ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' symposium ', ' symposia ', ' summit ', ' convention ', ' conference ', ' Hispanics ', ' hispanic community ', ' Spanish Origin ', ' Latino Population ', ' Hispanic Populations ', ' Latino ', ' Data Set ', ' Dataset ', ' Custom ', ' Sequence Analyses ', ' SEQ-AN ', ' Sequence Analysis ', ' base ', ' improved ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Individual ', ' European ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Logistics ', ' Data Quality ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Deposit ', ' Deposition ', ' tool ', ' instrument ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Scientist ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Source ', ' meetings ', ' experience ', ' success ', ' computer science ', ' ethnicity difference ', ' ethnic difference ', ' epidemiology study ', ' Reporting ', ' Genetic analyses ', ' genetic analysis ', ' Sampling ', ' genetic epidemiologic study ', ' genetic epidemiology ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' Documentation ', ' Data ', ' genomic region ', ' Genomic Segment ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Update ', ' Monitor ', ' Molecular ', ' work group ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' website ', ' web site ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' next generation ', ' cost efficient ', ' Population ', ' wiki ', ' public health relevance ', ' database of Genotypes and Phenotypes ', ' dbGaP ', ' exome ', ' exomes ', ' sharing data ', ' flexibility ', ' flexible ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' genomic variation ', ' study population ', ' whole genome ', ' entire genome ', ' ']",NHGRI,"RUTGERS, THE STATE UNIV OF N.J.",U01,2016,728166,NJ-06,0.07844014580334506
"Inferring the effects of genetic variants on gene expression and splicing     DESCRIPTION (provided by applicant): The objective of this project is to facilitate the interpretation of genetic variants identified in clinical whole- genome and whole-exome sequencing studies through the development of computational methods to predict functional effects of individual variants. Genome-scale sequencing technologies are increasingly enabling studies of genetic variation in large numbers of individuals; however, interpreting the clinical significance of the hundreds of thousands of genetic variants identified in these studies remains a critical challenge. Gene expression regulation is one mechanism by which variants can result in disease or other clinically-significant phenotypes. This mechanism is likely to be particularly important for disease-causing variants that do not directly affect protein structure by altering an amino acid sequence. The methods developed here will enable researchers to predict whether genetic variants are likely to have a regulatory effect on gene expression. The first stage of the project is to build computational models to predict such regulatory effects using a random forest machine learning approach. These models will be trained to recognize regulatory variation using a set of variants that have been shown to be involved in expression regulation in a recent study of gene expression across hundreds of individuals. Separate algorithms will be developed to predict two different types of regulatory effects: changes in the total amount of RNA produced from a particular gene (expression level variation) and changes in the specific form of RNA produced from a particular gene (splicing or isoform ratio variation). The second stage of the project is to evaluate the performance of these models on gene expression datasets from a separate human population and from different tissues within the human body, to explore their generalizability and to determine to what extent the characteristics of regulatory variants are conserved across tissues and populations. The final stage of the project is to use genetic variants in publicly-available databases that are known to be pathogenic to characterize how well these models perform at predicting clinical significance. This stage will test the hypothesis that variants that regulate gene expression are more likely to be clinically significant than variants that do not regulate expression. This project will impact public health by providing useful tools to improve prediction of the clinical significance of genetic variants identified in genome- scale sequencing studies. In addition, the project will provide biological insight into the tissue-specificity and population-specificity of genomic features that characterize regulatory genetic variants.         PUBLIC HEALTH RELEVANCE: Genome-scale sequencing technologies are increasingly enabling studies of genetic variation in large numbers of patients and other individuals. However, interpreting the clinical significance of the hundreds of thousands of genetic variants identified in these studies remains a critical challenge. This project will provide useful tools to improve automated prediction of the clinical significance of such genetic variants as well as their regulatory effects on gene expression.            ",Inferring the effects of genetic variants on gene expression and splicing,9039466,F32HG008330,"['Affect ', ' Algorithms ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Elements ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Exons ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Gene Splicing ', ' Spliced Genes ', ' Goals ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Modern Man ', ' Human ', ' Articulation ', ' Joints ', ' Mentorship ', ' Methods ', ' Patients ', ' Phenotype ', ' Probability ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Public Health ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' Splicing ', ' RNA Splicing ', ' Specificity ', ' Technology ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Universities ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' forest ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' insight ', ' Individual ', ' European ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Human Figure ', ' Human body ', ' Genetic ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Performance ', ' Isoforms ', ' Protein Isoforms ', ' QTL ', ' Quantitative Trait Loci ', ' professor ', ' novel ', ' lymphoblastoid cell line ', ' Categories ', ' Reporting ', ' Position ', ' Positioning Attribute ', ' Regulation ', ' Modeling ', ' Genomics ', ' Transcription Start Site ', ' Transcription Initiation Site ', ' genome sequencing ', ' Address ', ' protein structure ', ' Transcript ', ' Characteristics ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Population ', ' clinically significant ', ' clinical significance ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome sequencing ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' whole genome ', ' entire genome ', ' ']",NHGRI,STANFORD UNIVERSITY,F32,2016,56118,CA-18,0.15773554392890257
"An Integrative Analysis of Structural Variation for the 1000 Genomes Project DESCRIPTION (provided by applicant): Structural variation (SV), involving deletions, duplications, insertions and inversions of DNA segments, accounts for a large proportion of human genetic diversity. Comprehensive identification and analysis of these genetic variants will help us more fully elucidate the biology of their functional effects on human health and demography. Despite recent advances, the tools and data needed to comprehensively identify all types of SVs, genotype each variant, integrate and phase these variants remain lacking. Indeed, the data released from the early phases of the 1000 Genomes Project (1000GP) (1000 Genomes Project Consortium, 2010; 1000 Genomes Project Consortium, 2012) are biased primarily towards the detection of deletions within relatively unique regions of the genome. As a consortium, we propose to pool expertise from various research groups to provide an integrative analysis of SVs by combining rigorous computational algorithmic development with extensive experimental validation. The new algorithms we develop and the high confidence lists of SVs obtained will be rapidly made available as a public resource. ",An Integrative Analysis of Structural Variation for the 1000 Genomes Project,9208745,U41HG007497,"['Accounting ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Biology ', ' Chromosomes ', ' Complement Proteins ', ' Complement ', ' Demography ', ' Deoxyribonucleic Acid ', ' DNA ', ' Future ', ' Gene Conversion ', ' Genome ', ' Genotype ', ' Goals ', ' Au element ', ' Gold ', ' Haplotypes ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Maps ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Nucleotides ', ' Reading ', ' Research ', ' Research Resources ', ' Resources ', ' Technology ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Repetitive Sequence ', ' Repetitive Regions ', ' Repetitive Element ', ' base ', ' method development ', ' improved ', ' Phase ', ' Variation ', ' Variant ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Complex ', ' Best Practice Analysis ', ' Benchmarking ', ' insertion sequence ', ' insertion element ', ' DNA Insertion Elements ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Modeling ', ' Sampling ', ' genome sequencing ', ' Data ', ' Resolution ', ' Validation ', ' Process ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' deletion detection ', ' integration site ', ' ']",NHGRI,JACKSON LABORATORY,U41,2016,2868077,ME-02,0.11924110504807471
"Statistical and computational analysis in whole genome sequencing studies. DESCRIPTION (provided by applicant): This project will investigate several issues arising from the statistical and computational analysis of whole genome sequencing (WGS) based genomics studies. In the area of data management in WGS studies, we address the rapidly increasing cost associated with the transfer and storage of the massive files for the sequence reads and their associated quality scores. We will develop data compression methods to achieve a further compression of several folds beyond current standards, with minimal incurred errors. In the area of secondary analysis, we will develop new statistical learning methods to improve variant quality score recalibration and to filter out unreliable calls. This will improve te reliability of the key information provided by the WGS data, which are the variants calls indicating the locations where the genome differs from the reference and the nature of the differences. We will study methods for case-control studies based on WGS. In particular, we will develop statistical models to enable the integrating of information from multiple types of variants to obtain more powerful tests of association. We will apply the methods developed in this aim to the analysis of WGS data from a study on abdominal aortic aneurysm. Finally, we will address selected new questions associated with population scale WGS projects. Several national programs have recently been initiated to generate WGS data for hundreds of thousands of individuals with longitudinal medical records. The availability of this comprehensive data on a population scale will open up a rich frontier for genome medicine and will pose many new challenges for statistical analysis. We will formulate some of these new challenges and develop the statistical methods needed to meet these challenges. PUBLIC HEALTH RELEVANCE: The research in this project concerns the design and implementation of statistical and computational methods for the analysis of data from whole genome sequencing studies. Methods will be developed for sequence quality score compression, variant call filtering, and methods for case-control association analysis and mega-cohort analysis based on whole genome sequencing.",Statistical and computational analysis in whole genome sequencing studies.,9103177,R01HG007834,"['Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' Genome ', ' Goals ', ' Health ', ' Medical Records ', ' Medicine ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Reading ', ' Research ', ' Testing ', ' Cohort Analysis ', ' Cohort Analyses ', ' Abdominal Aortic Aneurysm ', ' base ', ' improved ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Location ', ' meetings ', ' data management ', ' Statistical Methods ', ' case control ', ' Genomics ', ' data processing ', ' computerized data processing ', ' compression algorithm ', ' Data Compression ', ' genome sequencing ', ' Address ', ' Data ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' cost ', ' designing ', ' design ', ' Population ', ' frontier ', ' population based ', ' learning strategy ', ' learning method ', ' learning activity ', ' whole genome ', ' entire genome ', ' ']",NHGRI,STANFORD UNIVERSITY,R01,2016,300000,CA-18,0.12716769703704645
"Decrypting Variants of Uncertain Significance in Long-QT Syndrome DESCRIPTION (provided by applicant): Clinical genetic testing has become standard-of-care for many diseases including hundreds of inherited conditions. However, interpreting genetic test results is often confounded by the discovery of 'variants of unknown significance' (VUS) for which there is insufficient data or inadequate predictive tools to establish whether or not a particular variant predisposes to a disease. This problem is particularly vexing for genetic disorders with strong allelic heterogeneity and a preponderance of 'private' mutations such as the congenital long-QT syndrome (LQTS), which predisposes young adults and children to sudden death from cardiac arrhythmias. With the anticipated incorporation of personal exome or genome data into routine clinical care, interpreting VUS will become an even greater challenge especially when variants in genes associated with human disorders are incidentally discovered. Unfortunately, there are no reliable methods to predict a priori whether a given variant predisposes an individual to a particular disorder or whether the change is merely a benign rare variant. We propose to develop a novel paradigm for distinguishing disease-causing mutations from benign variants in LQTS as a model for other inherited arrhythmia syndromes and channelopathies. We will focus on variants in KCNQ1, the most commonly mutated gene in LQTS. The central hypothesis of this proposal is that a holistic predictive model that relates experimentally determined protein structure and dynamics to function and disease is highly accurate even for novel variants. Our ultimate objectives are to develop a data-trained, web-accessible algorithm that classifies VUS discovered in KCNQ1 based on reliable predictions of the structure and dynamics of the affected protein, and to achieve prediction accuracy to levels needed to inform medical decisions. The medical importance of correctly classifying KCNQ1 variants provides strong justification for having a dedicated and highly-tailored gene-specific prediction model. The ability to distinguish deleterious from neutral variants would help avoid unnecessary and potentially harmful interventions in carriers of benign alleles, and save the lives of those with true mutations. We propose to collect extensive electrophysiological, biochemical and structural data on a large set of KCNQ1 variants discovered in LQTS subjects as well as several suspected benign or neutral variants (Aims 1-2), then use these data to iteratively train and validate a machine learning based algorithm that can differentiate benign from deleterious KCNQ1 alleles among a set of new VUS (Aim 3). Our proposal is innovative in the use of a multidisciplinary approach to functionally and structurally annotate genomic variant data for a medically important gene at an unprecedented scale, and then to use these experimental findings to train/test a novel computational system to achieve clinical-grade predictions. Targeting KCNQ1 will also validate an approach for parallel work that can be utilized to predict the medical significance of variants in closely related potassium channels associated with heritable epilepsy (KCNQ2, KCNQ3) or deafness (KCNQ4). PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a method to reliably predict the consequences of genetic variants of unknown significance discovered in the course of genetic testing in the congenital long-QT syndrome (LQTS), a cause of sudden cardiac death in children and young adults. We propose a multidisciplinary experimental approach including electrophysiology, biochemistry and structural biology deployed on a large scale to generate information on at least 110 genetic variants in the main gene responsible for LQTS (KCNQ1), which encodes a potassium channel required for normal electrical activity in the heart. Our final product will be a data-trained computational strategy that will outperform existing methods for accurately predicting the functional consequences of novel KCNQ1 genetic variants, enhance the value of genetic testing in LQTS and provide for more informed medical decisions.",Decrypting Variants of Uncertain Significance in Long-QT Syndrome,9111957,R01HL122010,"['Affect ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' arrhythmic agent ', ' antiarrhythmic agent ', ' Antiarrhythmic Drugs ', ' Antiarrhythmia Drugs ', ' Antiarrhythmia Agents ', ' Anti-Arrhythmics ', ' Anti-Arrhythmia Drugs ', ' Anti-Arrhythmia Agents ', ' Heart Arrhythmias ', ' Cardiac Arrhythmia ', ' Arrhythmia ', ' Biological Chemistry ', ' Biochemistry ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Deafness ', ' Sudden Death ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' electrophysiological ', ' Neurophysiology / Electrophysiology ', ' Electrophysiology ', ' Electrophysiology (science) ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Genome ', ' Goals ', ' Heart ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Heterogeneity ', ' Modern Man ', ' Human ', ' Membrane Channels ', ' Ionic Channels ', ' Ion Channel ', ' Long QT Syndrome ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Patients ', ' Physicians ', ' Potassium Ion Channels ', ' K channel ', ' Potassium Channel ', ' Proteins ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Syndrome ', ' Testing ', ' Work ', ' Death, Sudden, Cardiac ', ' Data Set ', ' Dataset ', ' base ', ' Stimulators, Electrical, Cardiac, Shock ', ' Electric Shock Cardiac Stimulators ', ' Defibrillators ', ' Benign ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Medical ', ' Link ', ' Susceptibility ', ' Predisposition ', ' Training ', ' cardiac rhythm ', ' heart rhythm ', ' Individual ', ' young adulthood ', ' adult youth ', ' young adult ', ' Therapeutic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Hereditary ', ' Inherited ', ' System ', ' Test Result ', ' structural biology ', ' knowledgebase ', ' knowledge base ', ' Protein Trafficking ', ' protein transport ', ' trafficking ', ' Structure ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Cell surface ', ' proband ', ' Modeling ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' genome sequencing ', ' protein structure ', ' Data ', ' Mutate ', ' Protein Dynamics ', ' 1st degree relative ', ' First Degree Relative ', ' Other Genetics ', ' Molecular ', ' Cardiac ', ' protein function ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' innovation ', ' innovative ', ' innovate ', ' multidisciplinary ', ' Implant ', ' web-accessible ', ' disease-causing mutation ', ' interdisciplinary approach ', ' multidisciplinary approach ', ' public health relevance ', ' clinical care ', ' standard of care ', ' exome ', ' exomes ', ' rare variant ', ' rare allele ', ' variant of unknown significance ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' individual patient ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' predictive tools ', ' ']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2016,1277210,IL-07,0.1801325412341593
"Super-enhancer structure defines a signature of inflammatory bowel disease (IBD) DESCRIPTION (provided by applicant): The goal of this proposal is to decipher the genetic basis of inflammatory bowel disease (IBD) by integrating genome-wide association studies (GWAS) with the chromatin modification information in human immune system. Accumulating evidence suggests that IBD results from an inappropriate inflammatory response to intestinal microbes in a genetically susceptible host. Among complex diseases, GWAS methods have been successful in IBD, identifying hundreds of non-overlapping genetic risk loci. However, the majority of these disease-associated DNA variants fall into the gene-desert part of the genome, complicating their functional evaluation. There is now overwhelming evidence that the noncoding disease-associated DNA variants disrupt the action of key regulatory elements in relevant cell types. Since genomic coordinates of active regulatory elements can be charted using unique chromatin features, genome-wide profiling of chromatin modifications in relevant cell types can be used to pinpoint to DNA variants disrupting active regulatory elements.  Two recent studies discovered a novel kind of enhancers that occurs within exceptionally large genomic domains. These regions were initially dubbed as 'super-enhancers'. Super-enhancer domains occur at key identity genes in a variety of cell types. Strikingly, these enhancer domains are more sensitive to perturbation such as loss of transcription factors than typical shorter enhancers.  Because of the fragility of super-enhancers to perturbation, I postulate that super-enhancer domains of relevant immune cells harbor IBD-associated DNA variants. To test this hypothesis, in Aim 1 of this proposal, I will characterize super-enhancer structures of the human immune system. I will first develop an unsupervised machine learning technique to chart super-enhancer structures from histone acetylation (H3K27Ac) data in diverse immune cells. Using this technique, I will next delineate cell type- specific enhancer domains in the immune cells and investigate the relationship among cells types with respect to their super-enhancer structures. In Aim 2 of this proposal, I will investigate the enrichment of IBD-associated DNA variants within the super-enhancers of the most relevant immune cells. I then link these variants to genes and pathways that they regulate and are affected in disease utilizing gene expression and long-range chromatin interaction datasets. Completion of these aims, along with training opportunities associated with this proposal will establish the necessary foundation for my career as an independent investigator. PUBLIC HEALTH RELEVANCE:  Crohn's disease and ulcerative colitis, the two common forms of (IBD), affect over 2.5 million people in North America and Europe. GWAS methods have identified hundreds of non-overlapping genetic risk loci in IBD. Yet, the functional effects of mos IBD-implicated variants remain largely unexplained. The finding that nearly 90% of these sites occur outside of protein-coding sequences suggests that many associated variants may instead have a role in gene regulation. Cell context is a key determinant of gene regulation but where IBD genetic variants are functional is largely unknown. This proposal seeks to utilize the chromatin structure of human immune cells to discover the cell context for IBD-associated variants. The identification of the pathogenic cell types as well as the molecular pathways that contribute to the disease will contribute greatly to our ability to treat patients.",Super-enhancer structure defines a signature of inflammatory bowel disease (IBD),9068802,K22AI112570,"['Affect ', ' Atrophic Arthritis ', ' Rheumatoid Arthritis ', ' Bursa-Equivalent Lymphocyte ', ' Bursa-Dependent Lymphocytes ', ' B-Cells ', ' B blood cells ', ' B-Lymphocytes ', ' Reactive Site ', ' Combining Site ', ' Binding Sites ', ' Peripheral Blood Cell ', ' Blood Cells ', ' Cataloging ', ' Cell Body ', ' Cells ', ' Chromatin ', ' Ulcerated Colitis ', ' Ulcerative Colitis ', ' regional enteritis ', ' eleocolitis ', ' Granulomatous Enteritis ', "" Crohn's disorder "", "" Crohn's "", ' Crohn disease ', "" Crohn's disease "", ' Disorder ', ' Disease ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' Deoxyribonucleic Acid ', ' DNA ', ' Enhancer Elements ', ' Genetic Enhancer Element ', ' Europe ', ' Foundations ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' allergic/immunologic organ system ', ' allergic/immunologic body system ', ' Immune system ', ' Non-Specific Immunity ', ' Native Immunity ', ' Innate Immunity ', ' Natural Immunity ', ' Inflammatory Intestinal Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Bowel Disorder ', ' Inflammatory Bowel Diseases ', ' bowel ', ' Intestinal ', ' Intestines ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Maps ', ' Methods ', ' Marrow monocyte ', ' Blood monocyte ', ' monocyte ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North America ', ' Patients ', ' Play ', ' Proteins ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Risk ', ' social role ', ' Role ', ' thymus derived lymphocyte ', ' Thymus-Dependent Lymphocytes ', ' T-Cells ', ' T-Lymphocyte ', ' helper T cell ', ' T4 Lymphocytes ', ' T4 Cells ', ' CD4-Positive Lymphocytes ', ' CD4+ T-Lymphocyte ', ' CD4+ T cell ', ' CD4 lymphocyte ', ' CD4 T cells ', ' CD4 Cells ', ' CD4 Positive T Lymphocytes ', ' Testing ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Work ', ' Measures ', ' falls ', ' Enhancers ', ' CD3 Antigens ', ' T3 molecule ', ' T3 Complex ', ' T3 Antigens ', ' OKT3 antigen ', ' CD3 molecule ', ' CD3 Complex ', ' CD3 ', ' Data Set ', ' Dataset ', ' base ', ' career ', ' Site ', ' Variation ', ' Variant ', ' Link ', ' Evaluation ', ' Epithelial ', ' Individual ', ' Collaborations ', ' Genetic ', ' Inflammatory ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Catalogs ', ' Immune ', ' Complex ', ' cell type ', ' Techniques ', ' interest ', ' cohort ', ' gene desert ', ' Junk DNA ', ' Structure ', ' novel ', ' Pathogenesis ', ' Coding System ', ' Code ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Untranslated RNA ', ' Genomics ', ' Inflammatory Response ', ' chromatin modification ', ' Histone Acetylation ', ' NCAM1 ', ' NCAM ', ' CD56 ', ' NCAM1 gene ', ' LYT3 ', ' CD8B1 ', ' CD8B ', ' CD8 ', ' CD8B1 gene ', ' CD14 ', ' CD14 gene ', ' CD19 ', ' CD19 gene ', ' Address ', ' Data ', ' Regulatory Element ', ' Chromatin Structure ', ' Genetic Risk ', ' Molecular ', ' pathway ', ' Pathway interactions ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' epigenomics ', ' commensal bacteria ', ' commensal microbes ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' markov model ', ' Susceptibility Gene ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' Microbe ', ' human disease ', ' genome-wide ', ' genomewide ', ' genome scale ', ' adaptive immunity ', ' adaptive immune response ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' training opportunity ', ' ']",NIAID,UNIVERSITY OF PENNSYLVANIA,K22,2016,105224,PA-03,0.03328268953540488
"Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases     DESCRIPTION (provided by applicant): The NHGRI Genome Sequencing Program (GSP) will identify genomic variants relevant to health and disease by genome sequencing over 225,000 participants across a multitude of diseases. The GSP will also serve as a pilot for the Precision Medicine Initiative that aims to enroll and sequence more than a million people representative of U.S. ethnic diversity. Here, we propose a GSP analysis center focused on Multi- and Trans- ethnic Mapping of Mendelian and Complex Diseases. There is a growing recognition of the substantial scientific advantages, as well as public health importance, of conducting biomedical research across ethnically diverse cohorts. We propose to develop scalable methods that incorporate ancestry to optimize medical genomic study design and improve power for uncovering the role of common and rare variants in disease. Achieving this goal requires expertise across diverse domains of knowledge including: medical and population genomics, algorithm development for complex disease mapping, and expertise in management of large-scale databases. Here, we have assembled a world-class team of medical and population geneticists, computer scientists, statisticians and clinicians, with leading expertise in the development of novel and scalable strategies for characterizing sequence variants and their role in disease. Importantly, our group has been at the forefront of development of resources, study designs and methods to enable genomic research in U.S. minority populations. Our project has three main objectives. First, we will develop an Automated Scalable Ancestry Pipeline (ASAP) for common disease mapping in diverse populations. ASAP will improve the computational efficiency of existing state-of-the-art methods for ancestry inference and develop important extensions to linear mixed models (LMMs) and other mapping strategies leveraging local and global ancestry. We will also develop methods to refine phenotypes and identify common controls for disease studies and define endpoints. Secondly, we will develop tools and resources for trans- and multi-population rare variant discovery that incorporate patterns of local and sub-continental ancestry. We will also develop machine-learning tools for variant annotation that leverage ancestral information, patterns of sequence evolution, and protein structure in a unified framework. Furthermore, we will incorporate population-specific patterns of cellular phenotypes to improve functional prediction algorithms for non-coding and coding variants. Lastly, we will disseminate our results through web-based resource that empower the biomedical research community. We will augment existing resources including ClinGen by annotating and characterizing pathogenic variants across diverse populations. We will develop a secure web-server that allows sharing of summary statistics and analysis pipelines to enable discovery, fine-mapping and functional prediction of genetic variants. Our team has ample experience with NIH-funded consortia and is dedicated to meeting the overall GSP project goals through collaborative work with NHGRI leadership and other funded investigators.         PUBLIC HEALTH RELEVANCE The goal of our project is to accelerate the discovery of DNA variation relevant to health and disease by analyzing data from over 225,000 ethnically and racially diverse patients that will undergo genome sequencing. Of particular importance is ensuring we have powerful statistical methods for analyzing data from underserved groups including U.S. minority populations. Achieving this goal requires expertise across many domains of knowledge including: medical and population genomics, algorithm development for disease mapping, and expertise in large-scale databases.              ",Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases,9132536,U01HG009080,"['Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' Biomedical Research ', ' chronic disorder ', ' Chronic Illness ', ' Chronic Disease ', ' Communities ', ' Computers ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Leadership ', ' Maps ', ' Methods ', ' Methodology ', ' Methylation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Patients ', ' Phenotype ', ' Public Health ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Risk ', ' social role ', ' Role ', ' Shoulder ', ' statistics ', ' Target Populations ', ' Testing ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' United States ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Population Heterogeneity ', ' population diversity ', ' heterogeneous population ', ' diverse populations ', ' Data Set ', ' Dataset ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' programs ', ' Scientist ', ' Investigation ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Pattern ', ' meetings ', ' empowered ', ' experience ', ' cohort ', ' simulation ', ' novel ', ' Participant ', ' Coding System ', ' Code ', ' Statistical Methods ', ' Modeling ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Untranslated RNA ', ' Genomics ', ' disease control ', ' disorder control ', ' Pathogenicity ', ' genome sequencing ', ' protein structure ', ' Data ', ' Resolution ', ' Resource Development ', ' enroll ', ' Enrollment ', ' developmental ', ' Development ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' patient privacy ', ' Minority ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' large-scale database ', ' large-scale data base ', ' tool development ', ' public health relevance ', ' phenome ', ' Secure ', ' rare variant ', ' rare allele ', ' Precision Medicine Initiative ', ' genomic tools ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' ethnic diversity ', ' ethnically diverse ', ' racial diversity ', ' racially diverse ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2016,974394,CA-18,0.16988658568500095
"Clinically Relevant Genome Variation Database We propose to create the world's premier database of genetic variants relevant to clinical care (Clinically Relevant Genetic Variants Resource or CRVR). We will provide transparent data synthesis and consensus opinion on the clinical utility of a given genetic variant across a spectrum of genetic lesions including single nucleotide changes, small indels and structural variants. We will integrate with ClinVar, PharmGKB, and OMIM and draw upon NHGRI initiatives including the Genome Sequencing and Analysis and Mendelian Disorders Sequencing Centers, and the Clinical Sequencing Exploratory Research Centers. We will work closely with other CRVR sites and NHGRI funded initiatives to improve deposition of data from clinical laboratories. Our database will be built through three Aims. Aim 1 will engage and energize the clinical genomics community around CRVR efforts. We will partner with the other CRVR and U41 investigators in this activity as they will focus on engagement of professional societies, clinical testing laboratories, and the broader clinical genomics community to ensure creation of a CRVR resource that meets anticipated community needs including assembly of Disease-Specific and Mutation Type Working Groups (DSWGs and MTWGs) comprised of expert clinical geneticists and molecular diagnosticians to establish metrics for the initial classification of variants and integration of guidelines from professional organizations. Aim 2 will involve creation of a CRVR CoreDB resource through expert review of the existing literature, locus databases, and NHGRI initiatives. We will disseminate consensus findings on clinically relevant genetic variants and the clinical implications of these variants, with supporting evidence and documentation of the consensus process. Information will be aggregated using standard ontologies and advanced methodologies for handling heterogeneous data to create a Core Database (CoreDB). The consensus of expert review will be disseminated through a user-friendly web Portal (vetted by Genetic Counseling WG), web services for data mining, and consensus clinical guidelines to the appropriate clinical and research communities. The results will be organized by gene, variant, disease, pathway, and literature. Supporting evidence will also be curated and disseminated, and the resource will be updated continuously as new information accumulates. Aim 3 will involve deployment of machine-learning algorithms for semi- automatic identification of putative Clinically Relevant Variants (CRVs). We will undertake data mining of the clinical and epidemiological genetics literature and existing databases to identify putative clinically important variants. This will involve mining data from ClinVar, OMIM, CSER, and the Mendelian centers aggregated in Aim 2. The Working Groups formed in Aim 1 will establish criteria and oversee curators vetting variants. We will develop and optimize disease- and gene-specific machine learning algorithms to facilitate rapid classification of variants based on data provided by genetic testing services via ClinVar. We will integrate population-genetic data inferred from at least 25 reference populations from the 1000 Genomes Project and other large endeavors into our machine learning approaches so as to infer the global relevance of CRVs discovered here. PUBLIC HEALTH RELEVANCE: We propose to create a unified, public, and freely available database of genetic alterations relevant to clinical care. Our ultimate goal is to empower clinicians, genetic counselors, and patients to make informed decisions based on DNA testing. Because much of the information required for such decisions is scattered among public and private databases, we propose combining the medical literature, expert summary of millions of de- identified genetic tests, and results from current and past NIH-funded genetic studies into a single unified database.",Clinically Relevant Genome Variation Database,9288249,U01HG007436,"['Algorithms ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Data Sources ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Genes ', ' Genetic Counseling ', ' Clinical genetics ', ' Medical Genetics ', ' Population Genetics ', ' Genome ', ' Goals ', ' Health ', ' Human Genetics ', ' Laboratories ', ' Literature ', ' Medicine ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North Carolina ', ' Nucleotides ', ' Patients ', ' professional society ', ' professional membership ', ' professional association ', ' Professional Organizations ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Societies ', ' Testing ', ' Translating ', ' Universities ', ' Work ', ' Guidelines ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Lesion ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Funding ', ' Collaborations ', ' Letters ', ' Clinical Practice Guideline ', ' Genetic ', ' gene function ', ' Deposit ', ' Deposition ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' Catalogs ', ' Test Result ', ' meetings ', ' collegiate ', ' college ', ' Services ', ' empowered ', ' American ', ' knowledgebase ', ' knowledge base ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' response ', ' Genomics ', ' Documentation ', ' OMIM ', ' Online Mendelian Inheritance In Man ', ' Bio-Informatics ', ' Bioinformatics ', ' datamining ', ' data mining ', ' genome sequencing ', ' Data ', ' Disease Pathway ', ' Clinical Data ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' Genetic Population Study ', ' Ontology ', ' Update ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' web services ', ' work group ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' clinically relevant ', ' clinical relevance ', ' user-friendly ', ' clinical care ', ' genome-wide ', ' genomewide ', ' genome scale ', ' data exchange ', ' data transmission ', ' genome analysis ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' genetic counselor ', ' Genetic study ', ' clinical sequencing ', ' web portal ', ' internet portal ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2016,1062125,CA-18,0.19693482019914982
"EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE     DESCRIPTION (provided by applicant): The eMERGE III Clinical Center proposal from Partners HealthCare leverages a large biobank, clinical data in the electronic medical records (EMR) for >4 million participants from the largest integrated health care provider in New England, advanced bioinformatics expertise and state-of-the-art genetic analysis. We propose three aims. (1) Aim 1. Discovery. We will test the hypothesis that common and rare variants from a custom chip including 50,000 loss of function (LoF) alleles will be associated with cardiovascular, neuropsychiatric and immune-mediated phenotypes derived from the EMR. We are currently genotyping 25,000 Partners HealthCare Biobank subjects with a custom chip that includes LoF alleles from 63,000 exomes that we have analyzed. (2) Aim 2. Penetrance and Pleiotropy. We will test the hypothesis that sequencing a set of established genes or loci will allow us to discover additional variation, and define penetrance and pleiotropy using EMR phenotypes. Rare variants in genes selected by the eMERGE network will be studied for penetrance and pleiotropic outcomes by PheWAS and chart review. In addition, we are poised to perform recall-by-genotype studies because all Biobank participants have provided consent for such callback. (3) Aim 3. Implementation. We will test the hypothesis that physicians will alter their surveillance and treatment of patients based upon voluntary return of actionable variants to provide safe and cost-effective benefits to patients. We will screen our entire Biobank population of 25,000 individuals for pathogenic variants in the LDLR gene, the leading genetic cause of premature coronary artery disease, and conduct an exploratory trial in disclosing this information. Biobank participants with pathogenic variants in LDLR will be offered enrollment into a randomized trial, in which their finding will be CLIA-confirmed, and in one arm, this result will be communicated to their physicians through the EMR. Over one year, we will collect the following outcomes through participant surveys and EMR queries: physician visits, laboratory testing, changes in medication prescriptions, LDL levels, medical costs and the number of family members screened and treated as a result of the intervention. We will collaborate with the entire eMERGE III Network to incorporate what we learn from this pilot trial into large-scale implementation protocols for the genes selected by the Network for sequencing. Finally, we will participate in all Network activities to enhance the movement of genetics into clinical practice. PUBLIC HEALTH RELEVANCE: The discovery and clinical use of genetic variants associated with both rare Mendelian and more common complex diseases promises to dramatically change the practice of medicine. Our eMERGE III project will leverage a large Biobank and a rich electronic medical record to define the phenotypic impact of mutations emerging from sequencing and then return results on selected variants to Biobank participants using a clinical trial.",EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE,9134764,U01HG008685,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' Atrophic Arthritis ', ' Rheumatoid Arthritis ', ' Bronchial Asthma ', ' Asthma ', ' Biology ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardio-vascular ', ' Cardiovascular system ', ' Clinical Trials ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary Arteriosclerosis ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Coronary heart disease ', ' depression ', ' Mental Depression ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Genes ', ' Genotype ', ' Goals ', ' Health ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' chronic heart failure ', ' Heart Decompensation ', ' Cardiac Failure Congestive ', ' Congestive Heart Failure ', ' Hypercholesteremia ', ' hypercholesterolemia ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Newborn Infant ', ' Inflammatory Intestinal Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Bowel Disorder ', ' Inflammatory Bowel Diseases ', ' Laboratories ', ' Learning ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' Low-Density Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' LDL Cholesterol Lipoproteins ', ' Medicine ', ' Mining ', ' body movement ', ' Movement ', ' insular sclerosis ', ' Disseminated Sclerosis ', ' Multiple Sclerosis ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Northeastern United States ', ' New England ', ' Patients ', ' Pharmacogenetics ', ' Phenotype ', ' Physicians ', ' Public Health ', ' Research ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' stroke ', ' Survey Instrument ', ' Surveys ', ' Testing ', ' Computerized Medical Record ', ' Electronic Medical Record ', ' Family member ', ' Healthcare ', ' health care ', ' Mediating ', ' HLA-DRB1 ', ' HLA-DRB1 antigen ', ' Custom ', ' base ', ' Area ', ' Clinical ', ' prematurity ', ' premature ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Individual ', ' Funding ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Immune ', ' Complex ', ' Stream ', ' Protocol ', ' Protocols documentation ', ' Source ', ' Penetrance ', ' Visit ', ' experience ', ' pleiotropy ', ' pleiotropic effect ', ' pleiotropism ', ' Informatics ', ' TYK2 ', ' novel ', ' Participant ', ' Genetic analyses ', ' genetic analysis ', ' neuropsychiatric ', ' neuropsychiatry ', ' interventional strategy ', ' Intervention Strategies ', ' Intervention ', ' Bio-Informatics ', ' Bioinformatics ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Attention deficit hyperactivity disorder ', ' Cytotoxic T-Lymphocyte-Associated Serine Esterase-4 Gene ', ' Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene ', ' Cytotoxic T-Lymphocyte Protein 4 Gene ', ' CTLA4 ', ' CTLA-4 Gene ', ' CD152 Gene ', ' CD152 Antigen Gene ', ' CTLA4 gene ', ' Dopamine Receptor D2 Gene ', ' DRD2 ', ' D2R Gene ', ' D2R ', ' D2DR Gene ', ' D2DR ', ' D(2) Dopamine Receptor Gene ', ' DRD2 gene ', ' tumor necrosis factor  receptor ', ' tumor necrosis factor receptor 1A ', ' tumor necrosis factor alpha receptor ', ' Tumor Necrosis Factor Receptor 55 ', ' Tumor Necrosis Factor Receptor 1 ', ' TNF receptor ', ' TNFalpha receptor ', ' TNFRSF1A Receptor ', ' TNFRSF1A ', ' TNFR60 ', ' TNFR55 ', ' TNFR1 ', ' TNFR-I ', ' TNFR, 60-kD ', ' TNFR, 55-kD ', ' TNFR p60 ', ' TNFAR ', ' TNF- receptor ', ' TNF-sR55 ', ' TNF Receptor p55 ', ' CD120a Antigens ', ' CD 120a Antigen ', ' TNFRSF1A gene ', ' LDLR gene ', ' Transcription Factor 7-Like 2 ', ' TCF7L2 ', ' TCF4 ', ' TCF-4 ', ' T-Cell-Specific Transcription Factor 4 ', ' TCF7L2 gene ', ' Consent ', ' cost-effectiveness analysis ', ' cost-effective analysis ', ' cost efficient analysis ', ' cost effectiveness analyses ', ' cost effective analysis ', ' Cost Effective Analyses ', ' Cost Effectiveness Analysis ', ' Data ', ' attributable fraction ', ' Population Attributable Risks ', ' Callback ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' pilot trial ', ' cost ', ' implementation research ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' cost effective ', ' cost-effective ', ' Population ', ' loss of function ', ' clinical care ', ' clinical practice ', ' biobank ', ' biorepository ', ' exome ', ' exomes ', ' randomized trial ', ' Randomization trial ', ' arm ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' genetic information ', ' clinical sequencing ', ' clinically actionable ', ' support tools ', ' Genomic medicine ', ' biomarker panel ', ' marker panel ', ' neuropsychiatric disorder ', ' neuropsychiatric disease ', ' ']",NHGRI,BRIGHAM AND WOMEN'S HOSPITAL,U01,2016,953224,MA-07,0.12018567818483675
"Clinically Relevant Genome Variation Database We propose to create the world's premier database of genetic variants relevant to clinical care (Clinically Relevant Genetic Variants Resource or CRVR). We will provide transparent data synthesis and consensus opinion on the clinical utility of a given genetic variant across a spectrum of genetic lesions including single nucleotide changes, small indels and structural variants. We will integrate with ClinVar, PharmGKB, and OMIM and draw upon NHGRI initiatives including the Genome Sequencing and Analysis and Mendelian Disorders Sequencing Centers, and the Clinical Sequencing Exploratory Research Centers. We will work closely with other CRVR sites and NHGRI funded initiatives to improve deposition of data from clinical laboratories. Our database will be built through three Aims. Aim 1 will engage and energize the clinical genomics community around CRVR efforts. We will partner with the other CRVR and U41 investigators in this activity as they will focus on engagement of professional societies, clinical testing laboratories, and the broader clinical genomics community to ensure creation of a CRVR resource that meets anticipated community needs including assembly of Disease-Specific and Mutation Type Working Groups (DSWGs and MTWGs) comprised of expert clinical geneticists and molecular diagnosticians to establish metrics for the initial classification of variants and integration of guidelines from professional organizations. Aim 2 will involve creation of a CRVR CoreDB resource through expert review of the existing literature, locus databases, and NHGRI initiatives. We will disseminate consensus findings on clinically relevant genetic variants and the clinical implications of these variants, with supporting evidence and documentation of the consensus process. Information will be aggregated using standard ontologies and advanced methodologies for handling heterogeneous data to create a Core Database (CoreDB). The consensus of expert review will be disseminated through a user-friendly web Portal (vetted by Genetic Counseling WG), web services for data mining, and consensus clinical guidelines to the appropriate clinical and research communities. The results will be organized by gene, variant, disease, pathway, and literature. Supporting evidence will also be curated and disseminated, and the resource will be updated continuously as new information accumulates. Aim 3 will involve deployment of machine-learning algorithms for semi- automatic identification of putative Clinically Relevant Variants (CRVs). We will undertake data mining of the clinical and epidemiological genetics literature and existing databases to identify putative clinically important variants. This will involve mining data from ClinVar, OMIM, CSER, and the Mendelian centers aggregated in Aim 2. The Working Groups formed in Aim 1 will establish criteria and oversee curators vetting variants. We will develop and optimize disease- and gene-specific machine learning algorithms to facilitate rapid classification of variants based on data provided by genetic testing services via ClinVar. We will integrate population-genetic data inferred from at least 25 reference populations from the 1000 Genomes Project and other large endeavors into our machine learning approaches so as to infer the global relevance of CRVs discovered here. PUBLIC HEALTH RELEVANCE: We propose to create a unified, public, and freely available database of genetic alterations relevant to clinical care. Our ultimate goal is to empower clinicians, genetic counselors, and patients to make informed decisions based on DNA testing. Because much of the information required for such decisions is scattered among public and private databases, we propose combining the medical literature, expert summary of millions of de- identified genetic tests, and results from current and past NIH-funded genetic studies into a single unified database.",Clinically Relevant Genome Variation Database,9134491,U01HG007436,"['Algorithms ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Cataloging ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Data Sources ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Genes ', ' Genetic Counseling ', ' Clinical genetics ', ' Medical Genetics ', ' Population Genetics ', ' Genome ', ' Goals ', ' Health ', ' Human Genetics ', ' Laboratories ', ' Literature ', ' Medicine ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' North Carolina ', ' Nucleotides ', ' Patients ', ' professional society ', ' professional membership ', ' professional association ', ' Professional Organizations ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Societies ', ' Testing ', ' Translating ', ' Universities ', ' Work ', ' Guidelines ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Lesion ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Funding ', ' Collaborations ', ' Letters ', ' Clinical Practice Guideline ', ' Genetic ', ' gene function ', ' Deposit ', ' Deposition ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' Catalogs ', ' Test Result ', ' meetings ', ' collegiate ', ' college ', ' Services ', ' empowered ', ' American ', ' knowledgebase ', ' knowledge base ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' response ', ' Genomics ', ' Documentation ', ' OMIM ', ' Online Mendelian Inheritance In Man ', ' Bio-Informatics ', ' Bioinformatics ', ' datamining ', ' data mining ', ' genome sequencing ', ' Data ', ' Disease Pathway ', ' Clinical Data ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' Genetic Population Study ', ' Ontology ', ' Update ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' web services ', ' work group ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' clinically relevant ', ' clinical relevance ', ' user-friendly ', ' clinical care ', ' genome-wide ', ' genomewide ', ' genome scale ', ' data exchange ', ' data transmission ', ' genome analysis ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' genetic counselor ', ' Genetic study ', ' clinical sequencing ', ' web portal ', ' internet portal ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2016,2234652,CA-18,0.19693482019914982
"Mechanisms underlying complex trait human disease DESCRIPTION (provided by applicant): There is now an explosion of new genome scale data relating genetic variation within the human population to phenotype, and particularly to common disease. Microarray technology has identified 100s of loci where the presence of particular variants is associated with altered risk of many common diseases; complete sequencing of individual exomes in cancer samples has discovered many somatic mutations in a variety of genes; and sequencing of 1000 human genomes has provided an almost complete inventory of common population variants. Further, these data are only the first in an ever-increasing flood, as even faster and cheaper sequencing technologies come on line. The results hold promise for major advances in treatment and diagnosis of common human diseases. Extracting the expected benefits is not straightforward, and will necessitate acquiring detailed knowledge of the mechanisms linking genetic variation to disease. This project focuses on one aspect of this challenge - using the new genomic data to identify new therapeutic opportunities. We will investigate those principles underlying complex trait disease that are particularly relevant to tha goal. We introduce a three stage mechanistic framework, relating genomic variation to the function of impacted gene products, the impact of these altered functions on pathways, processes and subsystems; and finally the consequences for complex trait disease phenotypes. We will develop computational methods to address key questions concerning three major aspects of the framework (1) How large are the changes in protein function brought about by the genomic variants underlying complex trait disease? What role do different classes of genomic and protein level mechanism, such as expression, non-synonymous changes and splicing, play in these variants? (2) How complete is the set genes with strong influence on the disease phenotypes discovered by current technologies, and how can missing genes be imputed from the genomic and network data? (3) What is the distribution of coupling between the activity of genes involved in disease mechanism and disease phenotypes? The results will deepen understanding of these aspects of complex disease, and provide a basis for identifying potential new drug targets from GWAS and other genomic studies. PUBLIC HEALTH RELEVANCE: New technologies are now providing extensive information on human genetic variation associated with increased risk of a wide range of common human disease, such as Alzheimer's, diabetes, heart disease, and many cancers. These data hold the promise for the development of new therapies, and realizing those benefits requires the acquisition of complementary knowledge of the mechanisms that link genetic variation to disease risk. This project is focused on analysis of the relationship between genetic variation and common disease with the goal of identifying new therapeutic opportunities.",Mechanisms underlying complex trait human disease,9068178,R01GM104436,"['Affect ', ' Algorithms ', ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Explosion ', ' Flooding ', ' Floods ', ' Future ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Information Networks ', ' Inventory ', ' Equipment and supply inventories ', ' Methods ', ' Minor ', ' Phenotype ', ' Play ', ' Proteins ', ' Risk ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Technology ', ' Translations ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Therapeutic ', ' gene function ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Frequencies ', ' Complex ', ' Somatic Mutation ', ' trait ', ' disease risk ', ' disorder risk ', ' novel technologies ', ' new technology ', ' Network Analysis ', ' Pathway Analysis ', ' Modeling ', ' Sampling ', ' Genomics ', ' genome sequencing ', ' Address ', ' microarray technology ', ' microarray analyses ', ' Microarray-Based Analysis ', ' Microarray Analysis ', ' Data ', ' Other Genetics ', ' Molecular ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Coupled ', ' Coupling ', ' Heritability ', ' human disease ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' therapeutic target ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new drug target ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' exome sequencing ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' rare variant ', ' rare allele ', ' genetic information ', ' genomic variation ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' gene product ', ' genomic data ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2016,288036,MD-05,0.09578463956340716
"Predicted Gene Expression: High Power, Mechanism, and Direction of Effect     DESCRIPTION (provided by applicant): Although investments in genomic studies of mental disorders enabled the discovery of thousands of robustly associated variants with these complex diseases, the translation of these discoveries into actionable targets has been hampered by the lack of a mechanistic understanding on how genome variation relates to phenotype. Moreover, it has been widely shown that a substantial portion of the genetic control of complex traits, including mental disorders, is exerted through the regulation of gene expression. However, effective methods to fully harness this mechanism are lagging. To address these challenges, we propose a novel gene-based test -PrediXcan- that directly tests this regulatory mechanism and substantially improves power relative to single variant tests and other gene-based tests. PrediXcan is inherently mechanistic and provides directionality, highlighting its potential utility in identifying novel targets for therapy. The method consists of predicting the whole genome effect on expression traits and correlating this effect with disease risk to identify novel disease genes. In addition, we propose novel approaches to investigate the context-specificity of expression traits (Orthogonal Tissue Decomposition) and to quantify the collective effect of the regulated transcriptome on phenotypes of interest (Regulability). Regulability is similar to the concept of chip heritability (total variability explained collectivey by genotyped variants). First, we will develop cross-tissue, tissue-specific (for over 30 different human tissue types), and brain-region specific expression traits. We will use statistical machine learning methods to develop whole genome prediction models for these traits and extend this work to other molecular phenotypes. All models will be stored in open access databases. Next, we will apply the PrediXcan method to 7 mental disorder phenotypes. More specifically, we will compute genetically predicted levels of gene expression traits and correlate them with disease risk to identify genes involved in disease pathways. We will also quantify the collective effect of the predicted transcriptome (regulability) on mental disorder risk across multiple tissues. Finally we will extend PrediXcan method and develop a method to infer the results of PrediXcan using summary statistics data as opposed to individual level data. This will extend the applicability of the approach to all summary results generated by meta-analysis consortia and increase the power to discover novel genes given the larger sample sizes. The research we propose is driven by an extensive set of preliminary studies, and promises substantial deliverables in both new methods of analysis and public access results databases. PUBLIC HEALTH RELEVANCE: Large investments in genome studies have been made to understand the consequences of genetic variation on human traits. These have yielded many genetic variants reproducibly associated with disease but the underlying biology is still unclear. We propose a novel computational method that links mechanistically the genetic variability to disease risk and apply it to a range of mental disorder studies to provide more biological insights and enable discovery of potential targets for drug development.","Predicted Gene Expression: High Power, Mechanism, and Direction of Effect",9130902,R01MH107666,"['senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Anorexia Nervosa ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' psychological disorder ', ' psychiatric illness ', ' mental illness ', ' Psychiatric Disorder ', ' Psychiatric Disease ', ' Mental health disorders ', ' Mental disorders ', ' Biology ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' depression ', ' Mental Depression ', ' Disorder ', ' Disease ', ' Exons ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' Genotype ', ' Health ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Modern Man ', ' Human ', ' Investments ', ' Learning ', ' Methods ', ' Methylation ', ' NIMH ', ' National Institute of Mental Health ', ' Obsessive-Compulsive Neurosis ', ' Obsessive-Compulsive Disorder ', ' Phenotype ', ' Quality Control ', ' Research ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' Software ', ' Computer software ', ' Specificity ', ' statistics ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Translations ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Biological ', ' Link ', ' Training ', ' insight ', ' Individual ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Sample Size ', ' Genetic ', ' gene function ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' human tissue ', ' Source ', ' interest ', ' Performance ', ' user friendly computer software ', ' user friendly software ', ' trait ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' disease risk ', ' disorder risk ', ' Regulation ', ' Modeling ', ' drug development ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' MicroRNAs ', ' Bio-Informatics ', ' Bioinformatics ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Attention deficit hyperactivity disorder ', ' Brain region ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Address ', ' Data ', ' Disease Pathway ', ' Tissue Model ', ' Molecular ', ' Process ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' Coupled ', ' Heritability ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new drug target ', ' molecular phenotype ', ' database of Genotypes and Phenotypes ', ' dbGaP ', ' learning strategy ', ' learning method ', ' learning activity ', ' transcriptome ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' whole genome ', ' entire genome ', ' web app ', ' web application ', ' ']",NIMH,UNIVERSITY OF CHICAGO,R01,2016,430578,IL-01,0.04160953443502988
"Understanding the functional impacts of genetic variants in mental disorders     DESCRIPTION (provided by applicant): In the US, 46% are afflicted with a mental illness at some point of life. The management and treatment of mental disorders pose significant economical and social burden to the society. Many rare and common genetic variants, including SNPs and CNVs, are reported to be associated with mental disorders, yet more remain to be discovered. However, despite the large amount of high-throughput genomics data, there is a lack of integrative methods to systematically prioritize variants that confer susceptibility to mental disorders; additionally, despite the presence of many candidate variants for mental disorders, their disease-contributory mechanism remains elusive, so appropriate functional follow-up experiments cannot be designed. Altogether, these problems resulted in a large gap between the copious amount of data about genetic variation and our understanding of their functional impacts on mental diseases, which ultimately delays the development of targeted therapeutic approaches. To address these problems, we propose to develop a suite of novel bioinformatics approaches: (1) NeuroComplex, an information integration approach that leverages phenotype information and multiple sources of prior biological knowledge to rank genes by their likelihood of contributing to specific phenotypic presentations. (2) integrated MEntal-disorder GEnome Score (iMEGES), which leverages a two-layer strategy to predict the impacts of variants in personal genomes on mental disorders. The first layer uses machine learning algorithm to build variant deleteriousness scores for coding, non-coding and structural variants; the second layer integrates variant scores and NeuroComplex to assign pathogenicity scores. (3) a hierarchical model called CombOmics that incorporates cross-omics information to characterizes how variants confers disease risk, in order to help formulate hypothesis of pathogenicity and facilitate the design of functional follow-up experiments. (4) we will develop user-friendly software tools and web applications that implement all the aforementioned bioinformatics approaches, and continuously release and maintain these tools to ensure the maximum benefits to the scientific community.         PUBLIC HEALTH RELEVANCE: We will develop novel informatics approaches to understand how genetic variation impacts various mental disorders, such as schizophrenia and autism. These tools help clarify the genetic cause of mental diseases, characterize individual disease risks and develop individualized treatment strategies.            ",Understanding the functional impacts of genetic variants in mental disorders,9009397,R01MH108728,"['Algorithms ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' psychological disorder ', ' psychiatric illness ', ' mental illness ', ' Psychiatric Disorder ', ' Psychiatric Disease ', ' Mental health disorders ', ' Mental disorders ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Family ', ' Gene Expression ', ' Genes ', ' Genome ', ' Methods ', ' Patients ', ' Phenotype ', ' Psychiatry ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' social role ', ' Role ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' Societies ', ' Software ', ' Computer software ', ' Computer Software Tools ', ' Software Tools ', ' Survey Instrument ', ' Surveys ', ' Testing ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Generations ', ' Research Methodology ', ' Research Methods ', ' Uncertainty ', ' doubt ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' Susceptibility ', ' Predisposition ', ' mental ', ' Psyche structure ', ' Individual ', ' Patient Selection ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Life ', ' Source ', ' Techniques ', ' System ', ' Best Practice Analysis ', ' Benchmarking ', ' Performance ', ' success ', ' user friendly computer software ', ' user friendly software ', ' cohort ', ' Informatics ', ' skills ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' disease risk ', ' disorder risk ', ' disorder model ', ' Disease model ', ' Reporting ', ' social ', ' Protein Gene Products ', ' Gene Proteins ', ' Coding System ', ' Code ', ' Modeling ', ' Sampling ', ' response ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Untranslated RNA ', ' Genomics ', ' Pathogenicity ', ' Bio-Informatics ', ' Bioinformatics ', ' genome sequencing ', ' Candidate Gene ', ' Candidate Disease Gene ', ' Address ', ' Data ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Ontology ', ' Validation ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' Text ', ' developmental ', ' Development ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' user-friendly ', ' prototype ', ' public health relevance ', ' treatment strategy ', ' Bayesian Modeling ', ' Bayesian tracking algorithms ', ' Bayesian statistical models ', ' Bayesian spatial models ', ' Bayesian spatial image models ', ' Bayesian spatial data model ', ' Bayesian nonparametric models ', ' Bayesian network model ', ' Bayesian hierarchical model ', ' Bayesian framework ', ' Bayesian belief updating model ', ' Bayesian belief network ', ' Bayesian adaptive models ', ' Bayesian adaptive designs ', ' individualized medicine ', ' unique treatment ', ' tailored treatment ', ' tailored medical treatment ', ' individualized treatment ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' personalized therapeutic ', ' genetic information ', ' web app ', ' web application ', ' genomic data ', ' ']",NIMH,UNIVERSITY OF SOUTHERN CALIFORNIA,R01,2016,396250,CA-37,0.04758119544661363
"Biomedical Computing and Informatics Strategies for Infectious Disease Research     DESCRIPTION (provided by applicant): An important goal of infectious disease research is to develop genetic predictors of susceptibility. Our success in this endeavor will depend critically on the informatics methods and software that are available for making sense of high-dimensional genetic and genomic data. The goal of this research program is to develop, evaluate, distribute and support new and novel biomedical computing algorithms and open-source software for identifying combinations of genetic predictors of clinically important infectious disease outcomes. This application will target the growing body of rare genetic variants identified by high-throughput DNA sequencing. Our clinical application will focus on the prediction of antiretroviral response in clinical trials for HIV/AIDS. We propose here a highly innovative Hierarchical Rare Variant Collapsing Machine (HRVCM) algorithm for identifying and collapsing combinations of rare variants across gene regions (AIM 1). We will then integrate these new collapsed HRVCM variables into our popular Multifactor Dimensionality Reduction (MDR) method that will assess them in combination with common single-nucleotide polymorphisms (SNPs) from genome-wide association studies or GWAS (AIM 2). Our novel HRVCM-MDR approach will, for the first time, make it possible to assess non-additive interactions among sets of rare and common variants simultaneously in genetic studies of infectious diseases. We will apply these new and novel methods to approximately 13 million rare and common variants from nearly 3000 subjects that participated in an AIDS Clinical Trials Group (ACTG) study to evaluate risk for virologic failure with efavirenz-containing antiretroviral therapy (ART) regimens (AIM 3). Finally, we will release all methods as open source to the biomedical research community through our freely available MDR software package (AIM 4).         PUBLIC HEALTH RELEVANCE: The overall goal of this application is to develop innovative new computational methods for the genetic analysis of infectious diseases. We will focus on the development of methods that are able to detect synergistic effects of multiple genetic variants regardless of whether they are rare of common in human populations. We will apply these methods to the study of HIV/AIDS vaccination response.            ",Biomedical Computing and Informatics Strategies for Infectious Disease Research,9106116,R01AI116794,"['Algorithms ', ' Biomedical Research ', ' Clinical Trials ', ' Infectious Disorder ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Communicable Diseases ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Genome ', ' Goals ', ' Modern Man ', ' Human ', ' Methods ', ' Methodology ', ' Genetic Models ', ' Research ', ' Risk ', ' Software ', ' Computer software ', ' Time ', ' Vaccination ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' base ', ' method development ', ' Variation ', ' Variant ', ' Susceptibility ', ' Predisposition ', ' Failure ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' gene interaction ', ' success ', ' antiretroviral ', ' anti-retroviral ', ' Antiretroviral Agents ', ' Anti-Retroviral Agents ', ' Informatics ', ' efavirenz ', ' simulation ', ' Disease Outcome ', ' novel ', ' Graph ', ' HIV/AIDS problem ', ' HIV/AIDS ', ' AIDS/HIV ', ' AIDS/HIV problem ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' Genetic analyses ', ' genetic analysis ', ' Modeling ', ' response ', ' Bio-Informatics ', ' Bioinformatics ', ' acquired immunodeficiency syndrome clinical trial group ', ' acquired immunodeficiency syndrome (AIDS) clinical trial group ', ' ACTG ', ' AACTG - adult AIDS clinical trial group ', ' AACTG ', ' AIDS clinical trial group ', ' genetic association ', ' biomedical computation ', ' Biomedical Computing ', ' Data ', ' Detection ', ' Infectious Diseases / Laboratory ', ' Infectious Diseases Research ', ' genomic region ', ' Genomic Segment ', ' antiretroviral therapy ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' biomed informatics ', ' biomedical informatics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' clinical application ', ' clinical applicability ', ' open source ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' Regimen ', ' simulation software ', ' rare variant ', ' rare allele ', ' High-Throughput DNA Sequencing ', ' genetic predictors ', ' Genetic study ', ' genomic data ', ' ']",NIAID,UNIVERSITY OF PENNSYLVANIA,R01,2016,571791,PA-03,0.10185899198932535
"Statistical Tests for Mapping Genetic Determinants of Complex Traits     DESCRIPTION (provided by applicant): Genotyping and emerging sequencing technologies have enabled comprehensive interrogation of genetic variation across the human genome, thereby facilitating a study's ability to map genetic variants that influence phenotypes of interes. Nevertheless, genome-wide association studies (GWAS) and next-generation sequencing (NGS) projects have uncovered only a limited number of trait-influencing loci. While large increases in sample size will improve power to detect such variation, the ascertainment and sequencing/genotyping of such samples are costly and inefficient. Therefore, it is desirable to increase power to detect such variants without requiring additional sample collection. We propose novel methods for improved gene mapping of common and rare susceptibility variants that move beyond standard strategies typically applied to GWAS and NGS studies of complex traits. The first topic we consider is pleiotropic or cross- phenotype effects of genetic variants. Empirical studies have suggested that pleiotropy is widespread throughout the genome and that leveraging this additional information for gene mapping yields a more powerful analysis than an analysis that ignores such information. In Aim 1, we propose novel statistical methods for genetic analysis of high-dimensional phenotype data using an innovative kernel distance-covariance (KDC) framework that allows for an arbitrary number of phenotypes both continuous and/or categorical in nature, as well as an arbitrary number of genotypes (permitting gene-based testing of both rare and common variants). We will use the KDC framework to implement tests of pleiotropy as well as tests of mediation. The second topic we consider is the mapping of rare susceptibility variants using affected pedigrees, which provide many attractive features for rare-variant testing that case-control studies lack. In Aim 2, we propose a series of powerful statistical methods for rare-variant association testing in affected pedigrees that are based on a framework (recently published in AJHG) for rare-variant association testing in affected sibships. The existing framework compares rare-variant burden in a region by an affected sib pair to the number of regions that pairs shares identical by descent. We have shown the method is more powerful than case-control association testing given fixed sample size and further is robust to population stratification. In this proposal, we will extend the framework to handle affected pedigrees of arbitrary size and structure (rather than just affected sib pairs) and devise a powerful two-stage screening and validation strategy for rare-variant mapping that first compares familial cases in the pedigrees to external controls and then follows up the most interesting findings using an independent test based on our identity-by-descent sharing statistic among the affected relatives used in the first stage. We will apply the methods in Aims 1-2 to relevant data from genetic studies of complex traits in which we are directly involved. We also will implement the methods in public user-friendly software (Aim 3).         PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a set of statistical approaches to investigate two important topics in gene- mapping studies of complex human traits. First, we will develop techniques for identifying genes that have pleiotropic effects on phenotypes of possibly high dimension and further assess whether such genes have direct effects on such phenotypes or indirect effects through other possible factors. Second, we will develop tools to facilitate identification of rare polymorphic variation that increase risk for complex disease using data from affected pedigrees of arbitrary size and structure. We will evaluate these methods using simulated data and illustrate their value by applying them to genetic projects of complex traits in which we are actively involved. Application of the proposed methods to these datasets should improve our understanding of the genetic origins of various complex traits.                ",Statistical Tests for Mapping Genetic Determinants of Complex Traits,9055844,R01GM117946,"['Affect ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Disorder ', ' Disease ', ' Family ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Modern Man ', ' Human ', ' Articulation ', ' Joints ', ' Maps ', ' Methods ', ' pedigree structure ', ' Pedigree ', ' genetic pedigree ', ' Phenotype ', ' Public Health ', ' Publishing ', ' Risk ', ' Siblings ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Software ', ' Computer software ', ' statistics ', ' Technology ', ' Testing ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Procedures ', ' specimen collection ', ' sample collection ', ' Variation ', ' Variant ', ' Series ', ' Sample Size ', ' Genetic ', ' Genets ', ' Staging ', ' tool ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Investigation ', ' Dimensions ', ' Complex ', ' Techniques ', ' interest ', ' pleiotropy ', ' pleiotropic effect ', ' pleiotropism ', ' user friendly computer software ', ' user friendly software ', ' trait ', ' Structure ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' Negotiation ', ' Negotiating ', ' Mediation ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' Genetic analyses ', ' genetic analysis ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' case control ', ' genetic determinant ', ' Genetic Determinism ', ' genetic association ', ' Applied Genetics ', ' Data ', ' Stratification ', ' Validation ', ' Molecular ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' Susceptibility Gene ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' human disease ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide analysis ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' flexibility ', ' flexible ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' screening ', ' rare variant ', ' rare allele ', ' Genetic study ', ' identity by descent ', ' identical by descent ', ' IBD inference ', ' IBD analysis ', ' ']",NIGMS,EMORY UNIVERSITY,R01,2016,309883,GA-05,0.09474421181580026
"Leveraging Tissue-Specific Regulatory Grammar to Interpret Human Evolution and Non-coding Variation Project Summary  It is now possible to readily identify sequence variants that have been subject to natural selection in human populations. Adaptive variants have been shown to underlie diversity in both disease risk and morphology across human populations, suggesting that the lens of evolution remains a powerful tool for understanding human biology, yet one that is currently underutilized. One challenge to realizing this potential is that over 99% of human genetic variation is non-coding, as are most signals of selection and variants associated with human phenotypic traits. Mutations modifying transcription factor (TF) binding sites in non- coding, cis-regulatory regions are hypothesized to be more amenable to driving phenotypic evolution than coding changes. These cis-regulatory regions are major determinants of tissue-specific gene expression and variation within enhancers has been indicated to play role in selection and disease. However, enhancer `regulatory grammar'  the complex pattern of sequences that interact with TFs to control gene expression, is poorly understood. The challenge of linking a regulatory variant under selection to an adaptive phenotype is similar to that facing disease association studies: the targeted gene, cell type, and biological process are often unknown, hindering further investigation.  Machine learning algorithms automate the discovery of patterns, making them well-suited to uncover sequence constraints and the combinatorial TF binding patterns of enhancers without relying on limited motif databases. I will optimize support vector machine classifiers to elucidate regulatory grammar from over 100 cell types and tissues. These models will be used to predict the impact of sequence variants on cis-regulatory sites, expanding the utility of the NHGRI's ENCODE and Roadmap projects. I will then apply these tissue- specific predictions to signals of selection and/or disease from the NHGRI's 1000 Genomes Project and its genome-wide association studies catalog. By describing the regulatory impact of signals of selection, I will globally describe patterns of functional adaptation across populations, identifying genes, and gene networks targeted by selection and/or disease. I will functionally characterize variants using massively parallel reporter assays and genome editing to give deeper insight into specific cases of evolution relevant for human health.   This project seeks to develop tools and resources to describe the structure and function of sequence variation in the human genome. This proposal seeks to vastly increase the number of elucidated cases of human evolution, and specifically characterize those adaptive variants associated with disease. We will share the functional regulatory predictions for the use in interpreting a broad range of genomic datasets. This work has broad implications, from interpreting genetic variants in populations and understanding functional targets of evolution, to prioritizing non-coding mutations for precision genomic medicine and beyond. Project Narrative While thousands of genomic regions have been linked to human evolution and diseases, many of the genetic variants responsible are non-coding and thus difficult to interpret. I propose to describe the tissue-specific effects of regulatory variants using machine learning algorithms, and then integrate these functional predictions with signals of selection and/or disease association in order to pinpoint genetic variants important for human evolution and health.",Leveraging Tissue-Specific Regulatory Grammar to Interpret Human Evolution and Non-coding Variation,9502066,F32HG009226,"['Algorithms ', ' driving ', ' Automobile Driving ', ' Reactive Site ', ' Combining Site ', ' Binding Sites ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biology ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Gene Expression ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Logic ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Phenotype ', ' Play ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Enhancers ', ' Experimental Models ', ' Mediating ', ' Natural Selections ', ' Dataset ', ' Data Set ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Link ', ' Training ', ' insight ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Gene Targeting ', ' Biological Function ', ' Biological Process ', ' Genetic ', ' Morphology ', ' Reporter ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Mechanics ', ' mechanical ', ' Investigation ', ' Complex ', ' human tissue ', ' cell type ', ' Pattern ', ' Techniques ', ' interest ', ' trait ', ' Structure ', ' Human Biology ', ' disorder risk ', ' disease risk ', ' Code ', ' Coding System ', ' Modeling ', ' functional genomics ', ' genome database ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Binding ', ' Molecular Interaction ', ' Data ', ' genomic region ', ' Genomic Segment ', ' Tissue-Specific Differential Gene Expression ', ' Differential Gene Expression ', ' Tissue-Specific Gene Expression ', ' trend ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Outcome ', ' Population ', ' combinatorial ', ' lens ', ' lenses ', ' genome-wide ', ' genomewide ', ' genome scale ', ' epigenome ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' genome editing ', ' genomic editing ', ' functional adaptation ', ' precision genomic medicine ', ' genomic data ', ' web-based tool ', ' ']",NHGRI,HARVARD UNIVERSITY,F32,2017,2400,MA-05,0.08756717362608825
"Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea ABSTRACT  Obstructive sleep apnea (OSA) is recognized as an extremely common disorder that results in excessive daytime sleepiness and an increased risk of automobile crashes. It is also an independent risk factor for insulin resistance, hypertension, cardiovascular events, increased cancer rates and cancer mortality, and accelerates the progression of neurodegenerative disorders. OSA is a systemic disorder and the cyclical intermittent hypoxia that occurs during sleep affects every organ system. OSA is heritable, with first degree relatives of individuals with OSA having a two-fold increased risk of the disorder. Although this has been known for over two decades, there are very limited data on gene variants conferring risk or protection for OSA. This is likely the result of underpowered studies and GENETIC HETEROGENEITY. There are multiple pathways to OSA. Obesity is a major risk factor, as are craniofacial dimensions. The relative risk of these different risk factors varies by ethnic group. There are also neuronal mechanisms and other physiological risk factors. This proposal seeks to directly address the issue of genetic heterogeneity using a very large sample of patients and state-of- the-art analysis techniques. Towards this end, we have assembled by far the largest sample of well characterized and genotyped patients with OSA. This is the result of collaboration with key sites in the eMERGE Network [Geisinger, Vanderbilt, Mayo Clinic, Northwestern], Kaiser Permanente Southern California, and the University of Pennsylvania. We propose to carry out a robust genome-wide association studies (GWAS) using an electronic health record (EHR) derived case definition and quantitative trait analysis of OSA severity. We will use novel machine learning approaches to specifically address genetic heterogeneity. The GWAS approach will be complimented by a PheWAS strategy as another approach to identifying common variants and related clinical phenotypes. Specifically, we will look for variants that associate with OSA and other clinical diagnoses in the EHR. It is likely that gene variants for OSA will have pleiotropic effects. Gene variants identified from GWAS and/or PheWAS will be further assessed. First, we will use available whole exome sequencing data to see if there are relevant rare variants in these genes, as well as to perform exploratory discovery analyses to look for novel rare variation. The functional role of the genes identified will be studied by functional network analysis. Finally, we will assess associations with quantitative data on intermediate traits identified by high throughput craniofacial and intra-oral photography. These data are currently available within the Sleep Apnea Global Interdisciplinary Consortium (SAGIC). Future directions will assess the function of the genes identified in model systems and the clinical utility of utilizing variants as part of risk stratification for OSA. PROJECT NARRATIVE  Obstructive sleep apnea (OSA) is a common disorder with multiple adverse consequences. It is known that OSA has a genetic basis, but to date no convincing gene variants have been identified. This study uses state of the art approaches to identifying relevant genes based on a very large sample of patients with OSA obtained from multiple institutions in the United States. It is by far the largest study ever proposed for identifying genes for this common sleep disorder.",Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea,9331729,R01HL134015,"['Affect ', ' Algorithms ', ' Automobiles ', ' urinary bladder ', ' Bladder Urinary System ', ' Bladder ', ' California ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardio-vascular ', ' Cardiovascular system ', ' Diagnosis ', ' Disorder ', ' Disease ', ' ethnicity group ', ' Ethnic group ', ' Fats ', ' Fatty acid glycerol esters ', ' Foundations ', ' Future ', ' Genes ', ' Genotype ', ' Heterogeneity ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Hypertension ', ' Insulin Resistance ', ' insulin resistant ', ' Learning ', ' men ', "" men's "", ' Methodology ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' mortality ', ' Neurons ', ' neuronal ', ' Neurocyte ', ' Neural Cell ', ' Nerve Unit ', ' Nerve Cells ', ' Obesity ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Patients ', ' Pennsylvania ', ' Periodicity ', ' Rhythmicity ', ' Cyclicity ', ' Phenotype ', ' Photography ', ' Play ', ' Public Health ', ' Research ', ' Resources ', ' Research Resources ', ' Risk ', ' Risk Factors ', ' Role ', ' social role ', ' Sleep ', ' Sleep Apnea Syndromes ', ' sleep-related breathing disorder ', ' Sleep-Disordered Breathing ', ' Sleep Hypopnea ', ' Sleep Apnea ', ' Thinness ', ' Leanness ', ' Tissues ', ' Body Tissues ', ' United States ', ' Universities ', ' Woman ', ' Measures ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' soft tissue ', ' Individual ', ' Oxygen Deficiency ', ' Hypoxic ', ' Hypoxia ', ' Relative Risks ', ' Genetic Heterogeneity ', ' Collaborations ', ' Genetic ', ' gene function ', ' clinical Diagnosis ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Dimensions ', ' Severities ', ' Complex ', ' Event ', ' Clinic ', ' Techniques ', ' System ', ' body system ', ' Organ System ', ' Obstructive Sleep Apnea ', ' Syndrome, Sleep Apnea, Obstructive ', ' Severity of illness ', ' disease severity ', ' Neurodegenerative Disorders ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neuro-degenerative Disorders ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' craniofacial ', ' craniofacies ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' cohort ', ' trait ', ' Structure ', ' novel ', ' Participant ', ' disorder risk ', ' disease risk ', ' Excessive Daytime Sleepiness ', ' Excessive daytime somnolence ', ' Code ', ' Coding System ', ' cardiovascular risk factor ', ' cardiovascular risk ', ' Sleep Disorders ', ' sleep problem ', ' Pathway Analysis ', ' Network Analysis ', ' Sampling ', ' case control ', ' Genomics ', ' Institution ', ' genetic association ', ' Address ', ' Data ', ' Collection ', ' 1st degree relative ', ' First Degree Relative ', ' Process ', ' Electronic Health Record ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Vehicle crash ', ' Vehicular crash ', ' Vehicular collision ', ' Motor vehicle crash ', ' Motor vehicle collision ', ' Car crash ', ' Car collision ', ' Automobile crash ', ' Automobile collision ', ' innovation ', ' innovative ', ' innovate ', ' Heritability ', ' gene discovery ', ' discover genes ', ' high risk ', ' genome-wide ', ' genomewide ', ' genome scale ', ' phenome ', ' exome ', ' exomes ', ' adverse outcome ', ' adverse consequence ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' precision medicine ', ' learning strategy ', ' learning method ', ' learning activity ', ' genotyped patients ', ' genomic data ', ' Risk stratification ', ' secondary analysis ', ' ']",NHLBI,UNIVERSITY OF PENNSYLVANIA,R01,2017,650526,PA-03,-0.01804975114259039
"Biomedical Computing and Informatics Strategies for Infectious Disease Research     DESCRIPTION (provided by applicant): An important goal of infectious disease research is to develop genetic predictors of susceptibility. Our success in this endeavor will depend critically on the informatics methods and software that are available for making sense of high-dimensional genetic and genomic data. The goal of this research program is to develop, evaluate, distribute and support new and novel biomedical computing algorithms and open-source software for identifying combinations of genetic predictors of clinically important infectious disease outcomes. This application will target the growing body of rare genetic variants identified by high-throughput DNA sequencing. Our clinical application will focus on the prediction of antiretroviral response in clinical trials for HIV/AIDS. We propose here a highly innovative Hierarchical Rare Variant Collapsing Machine (HRVCM) algorithm for identifying and collapsing combinations of rare variants across gene regions (AIM 1). We will then integrate these new collapsed HRVCM variables into our popular Multifactor Dimensionality Reduction (MDR) method that will assess them in combination with common single-nucleotide polymorphisms (SNPs) from genome-wide association studies or GWAS (AIM 2). Our novel HRVCM-MDR approach will, for the first time, make it possible to assess non-additive interactions among sets of rare and common variants simultaneously in genetic studies of infectious diseases. We will apply these new and novel methods to approximately 13 million rare and common variants from nearly 3000 subjects that participated in an AIDS Clinical Trials Group (ACTG) study to evaluate risk for virologic failure with efavirenz-containing antiretroviral therapy (ART) regimens (AIM 3). Finally, we will release all methods as open source to the biomedical research community through our freely available MDR software package (AIM 4). PUBLIC HEALTH RELEVANCE: The overall goal of this application is to develop innovative new computational methods for the genetic analysis of infectious diseases. We will focus on the development of methods that are able to detect synergistic effects of multiple genetic variants regardless of whether they are rare of common in human populations. We will apply these methods to the study of HIV/AIDS vaccination response.",Biomedical Computing and Informatics Strategies for Infectious Disease Research,9232970,R01AI116794,"['Algorithms ', ' Biomedical Research ', ' Clinical Trials ', ' Infectious Disorder ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Communicable Diseases ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Genome ', ' Goals ', ' Modern Man ', ' Human ', ' Methods ', ' Methodology ', ' Genetic Models ', ' Research ', ' Risk ', ' Computer software ', ' Software ', ' Time ', ' Vaccination ', ' Genetic Diversity ', ' Genetic Variation ', ' virology ', ' Measures ', ' base ', ' method development ', ' Variation ', ' Variant ', ' Susceptibility ', ' Predisposition ', ' Failure ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Dimensions ', ' gene interaction ', ' success ', ' Anti-Retroviral Agents ', ' antiretroviral ', ' anti-retroviral ', ' Antiretroviral Agents ', ' Informatics ', ' efavirenz ', ' simulation ', ' Disease Outcome ', ' novel ', ' Graph ', ' AIDS/HIV problem ', ' HIV/AIDS problem ', ' HIV/AIDS ', ' AIDS/HIV ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' response ', ' Bioinformatics ', ' Bio-Informatics ', ' AIDS clinical trial group ', ' acquired immunodeficiency syndrome clinical trial group ', ' acquired immunodeficiency syndrome (AIDS) clinical trial group ', ' ACTG ', ' AACTG - adult AIDS clinical trial group ', ' AACTG ', ' genetic association ', ' Biomedical Computing ', ' biomedical computation ', ' Data ', ' Detection ', ' Infectious Diseases Research ', ' Infectious Diseases / Laboratory ', ' genomic region ', ' Genomic Segment ', ' antiretroviral therapy ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' biomed informatics ', ' biomedical informatics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' clinical application ', ' clinical applicability ', ' open source ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' Regimen ', ' rare variant ', ' rare allele ', ' High-Throughput DNA Sequencing ', ' Algorithmic Analysis ', ' Analysis of Algorithms ', ' Analyses of Algorithms ', ' Algorithmic Analyses ', ' clinical predictors ', ' genetic predictors ', ' Genetic study ', ' genomic data ', ' high dimensionality ', ' ']",NIAID,UNIVERSITY OF PENNSYLVANIA,R01,2017,536755,PA-03,0.10185899198932535
"Integrative interpretation of the organismal consequences of non-coding variation     DESCRIPTION (provided by applicant): Our capacity to sequence human genomes has exceeded our ability to interpret genetic variation, particularly in non-coding regions. To address this challenge, we recently developed a novel framework, Combined Annotation Dependent Depletion (CADD), for estimating the deleteriousness of any genetic variant. CADD defines an objective, data-rich, and quantitative integration of many genomic annotations into a single measure of variant effect at the organismal level. The goals of this R01 proposal are to further develop the CADD framework, to apply it in the context of ongoing genetic studies of both rare and common human diseases, and to experimentally evaluate its predictions. In Specific Aim 1, we will substantially modify CADD in both straightforward and creative ways, with the goal of dramatically improving CADD's ability to annotate non- coding variants, not only to estimate their organismal effects but also to provide insights into molecular mechanisms. In Specific Aim 2, we will apply CADD to a variety of ongoing whole genome sequencing studies of human disease, especially those in which non-coding variants are either known or suspected to be causal. As part of this effort, we will develop new statistical frameworks that directly incorporat CADD into traditional genome-wide discovery approaches. In Specific Aim 3, we will perform a combination of high-throughput (massively parallel reporter assays), medium-throughput (CRISPR/Cas9), and low-throughput (in vivo mouse transgenics) experimental assays for systematic and targeted assessment of CADD predictions. This proposal includes both computational and experimental innovations, and builds on established collaborative relationships between investigators with complementary strengths. The completion of our aims will yield novel methods, data, and resources with which to annotate whole genome sequences, broadly enabling the field to more effectively identify and mechanistically understand non-coding genetic variants that are causally relevant to human disease. PUBLIC HEALTH RELEVANCE: As we enter an era of personalized medicine, a deep understanding of human genomes will be increasingly important to public health, contributing to the unraveling of the genetic basis of human disease, as well as serving an increasing role in clinical diagnostics. However, our limited understanding of the functional consequences of most genetic variants, especially those that do not alter protein sequence, represents a major obstacle. This proposal seeks to dramatically improve our ability to identify and interpret ""non-coding"" variants that causally contribute to human disease. A recently developed computational approach will be substantially improved and evaluated in a variety of genetic studies, and its predictions will be experimentally validated. This project will provide much needed methods and resources to address the looming analytical challenges associated with individual whole genome sequencing in both biomedical research and patient care.",Integrative interpretation of the organismal consequences of non-coding variation,9228346,R01CA197139,"['Algorithms ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biomedical Research ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Disorder ', ' Disease ', ' Feedback ', ' Patient Care Delivery ', ' Patient Care ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Methods ', ' Transgenic Mice ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Organism ', ' living system ', ' genetic pedigree ', ' pedigree structure ', ' Pedigree ', ' Phenotype ', ' Public Health ', ' Research ', ' Research Design ', ' study design ', ' Study Type ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' RNA Splicing ', ' Splicing ', ' Role ', ' social role ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Translating ', ' Genetic Diversity ', ' Genetic Variation ', ' Vocabulary Words ', ' Vocabulary ', ' Weight ', ' Measures ', ' Dataset ', ' Data Set ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' insight ', ' Individual ', ' Genetic ', ' Reporter ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Event ', ' System ', ' Quantitative Trait Loci ', ' QTL ', ' trait ', ' Structure ', ' Human Biology ', ' novel ', ' genetic analysis ', ' Genetic analyses ', ' Code ', ' Coding System ', ' Property ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Pathogenicity ', ' RNA Binding ', ' RNA bound ', ' Transcriptional Regulation ', ' Transcriptional Control ', ' Transcription Regulation ', ' Binding ', ' Molecular Interaction ', ' genome sequencing ', ' Address ', ' Data ', ' Regulatory Element ', ' in vivo ', ' Molecular ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' innovation ', ' innovative ', ' innovate ', ' human disease ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' candidate identification ', ' exome ', ' exomes ', ' exome sequencing ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' Genetic study ', ' Genomic approach ', ' genomic strategy ', ' genomic effort ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR method ', ' whole genome ', ' entire genome ', ' clinical diagnostics ', ' experimental study ', ' experimental research ', ' experiment ', ' data resource ', ' ']",NCI,UNIVERSITY OF WASHINGTON,R01,2017,632716,WA-07,0.15195866583693662
"Regulation of mRNA splicing by intronic genetic variants     DESCRIPTION (provided by applicant): Genetic variations in introns commonly impact cellular functions by causing alterations in mRNA splicing. The abnormal inclusion and exclusion of exons often change protein functions and cellular phenotypes. Although many intronic variations have known functions, with the adoption of next generation sequencing, many more intronic variants have been discovered for which the functional impact is unknown. Thus, it is important to be able to predict the impact of the variants without needing to test them all in expensive and laborious assays. Although there are informatics algorithms that predict the impact of genetic variants on pre-mRNA splicing, their ability to predict the effect on protein function and ultimately disease and therapeutic phenotypes is lacking. In addition, there is a need for high-throughput cellular assays to test the results of these predictions on cellular functions. The studies proposed here will fulfill these needs by developing algorithms that prioritize the intronic variants by their potential impact on splicing and gene function, and developing a high-throughput assay to functionally test thousands of these predictions. These novel technologies will be applied to the effect of intronic variants on the pharmacogenomics of two clinically important oncology drugs, clofarabine and paclitaxel. Our long-term goals are to be able to predict the functional impact of genomic variants on human disease and therapeutic response. Our central hypothesis is that intronic genetic variants alter mRNA splicing and consequently protein function that ultimately affects the cellular response to drug therapy. Our first aim will be to develop computational algorithms that prioritize intronic variants based on their impacts on pre-mRNA splicing and protein function. Using a variety of genomic and structural features and large sets of genomic data, we will develop a bioinformatics algorithm specifically designed to prioritize intronic variants based on their potential impacts on pre-mRNA splicing and protein function. Our second aim will be to identify functional intronic variants associated with drug-induced cytotoxicity. Using existing genomics and cellular cytotoxic response data from populations of human cell lines, we will identify functional intronic variants that contribute to individuals' responses to clofarabine and paclitaxel cytotoxicity. Our third aim will be to functionally test the impact of the prioritized intronic variants on pre-mRNA splicing and drug cytotoxicity. Using our novel high- throughput functional splicing assay, we will test the effects of predicted functional variants from Aim 2 on pre- mRNA splicing. In addition, we will validate the effect of the intronic variants on cytotoxicity using exon specific siRNA and CRISPR/Cas technology to manipulate the target gene splicing. Upon completion of these studies, we expect to have developed bioinformatics algorithms that can accurately prioritize the intronic variants based on their functional impact on pre-mRNA splicing and protein function. Also, we will have tested thousands of variants in a cellular pre-mRNA splicing assay and validated the impact of several of these functional variants on paclitaxel and clofarabine cytotoxicity. PUBLIC HEALTH RELEVANCE    Project Narrative The goal of this project is to design and implement a set of bioinformatics algorithms and high-throughput experimental assays for prioritizing functional intronic variants that contribute to phenotypic differences by affecting pre-mRNA splicing. The developed model, including a molecular validation component, will be used to systematically evaluate the functions of such variants that are associated with drug-induced cytotoxicity. The same strategy can also be used to study the etiology of complex diseases. This goal is directly relevant to the missions of NIH to improve the capability of disease diagnosis, treatment, and prevention.",Regulation of mRNA splicing by intronic genetic variants,9280888,R01CA213466,"['Adoption ', ' Affect ', ' Algorithms ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Alternative Splicing ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Clinical Study ', ' Clinical Research ', ' Computers ', ' Disorder ', ' Disease ', ' drug treatment ', ' Drug Therapy ', ' Pharmacotherapy ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Exons ', ' Genes ', ' Gene Splicing ', ' Spliced Genes ', ' Population Genetics ', ' Goals ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Introns ', ' Intervening Sequences ', ' Mission ', ' mRNA Precursor ', ' premRNA ', ' RNA, Messenger, Precursors ', ' Pre-mRNA ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Phenotype ', ' Publishing ', ' Research ', ' RNA Splicing ', ' Splicing ', ' Messenger RNA ', ' mRNA ', ' Testing ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Clofarabine ', ' Taxol Konzentrat ', ' Taxol A ', ' Taxol ', ' Praxel ', ' Paclitaxel (Taxol) ', ' Bristaxol ', ' Asotax ', ' Anzatax ', ' Paclitaxel ', ' base ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Individual ', ' Gene Targeting ', ' Biological Function ', ' Biological Process ', ' Oncology Cancer ', ' oncology ', ' Cell-Mediated Cytolysis ', ' cell mediated cytotoxicity ', ' Lymphocytotoxicity ', ' Lymphocyte Cytotoxicity ', ' Cellular Cytotoxicity ', ' Cell-Mediated Lympholysis ', ' Therapeutic ', ' gene function ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Source ', ' cell type ', ' Test Result ', ' cytotoxicity ', ' Lytotoxicity ', ' Informatics ', ' novel ', ' Exclusion ', ' Human Cell Line ', ' new technology ', ' novel technologies ', ' Prevention ', ' Regulation ', ' Modeling ', ' response ', ' high throughput screening ', ' High Throughput Assay ', ' functional genomics ', ' Genomics ', ' Small Interfering RNA ', ' siRNA ', ' Short interfering RNA ', ' Pharmacogenomics ', ' Bioinformatics ', ' Bio-Informatics ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' protein structure ', ' cytotoxic ', ' Data ', ' Cellular Assay ', ' Validation ', ' Molecular ', ' protein function ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' multidisciplinary ', ' Computational algorithm ', ' computer algorithm ', ' human disease ', ' public health relevance ', ' treatment response ', ' therapeutic response ', ' response to treatment ', ' disease diagnosis ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' genomic variation ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR method ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' genomic data ', ' genomic predictors ', ' ']",NCI,INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,R01,2017,557164,IN-07,0.17735005780903945
"EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE     DESCRIPTION (provided by applicant): The eMERGE III Clinical Center proposal from Partners HealthCare leverages a large biobank, clinical data in the electronic medical records (EMR) for >4 million participants from the largest integrated health care provider in New England, advanced bioinformatics expertise and state-of-the-art genetic analysis. We propose three aims. (1) Aim 1. Discovery. We will test the hypothesis that common and rare variants from a custom chip including 50,000 loss of function (LoF) alleles will be associated with cardiovascular, neuropsychiatric and immune-mediated phenotypes derived from the EMR. We are currently genotyping 25,000 Partners HealthCare Biobank subjects with a custom chip that includes LoF alleles from 63,000 exomes that we have analyzed. (2) Aim 2. Penetrance and Pleiotropy. We will test the hypothesis that sequencing a set of established genes or loci will allow us to discover additional variation, and define penetrance and pleiotropy using EMR phenotypes. Rare variants in genes selected by the eMERGE network will be studied for penetrance and pleiotropic outcomes by PheWAS and chart review. In addition, we are poised to perform recall-by-genotype studies because all Biobank participants have provided consent for such callback. (3) Aim 3. Implementation. We will test the hypothesis that physicians will alter their surveillance and treatment of patients based upon voluntary return of actionable variants to provide safe and cost-effective benefits to patients. We will screen our entire Biobank population of 25,000 individuals for pathogenic variants in the LDLR gene, the leading genetic cause of premature coronary artery disease, and conduct an exploratory trial in disclosing this information. Biobank participants with pathogenic variants in LDLR will be offered enrollment into a randomized trial, in which their finding will be CLIA-confirmed, and in one arm, this result will be communicated to their physicians through the EMR. Over one year, we will collect the following outcomes through participant surveys and EMR queries: physician visits, laboratory testing, changes in medication prescriptions, LDL levels, medical costs and the number of family members screened and treated as a result of the intervention. We will collaborate with the entire eMERGE III Network to incorporate what we learn from this pilot trial into large-scale implementation protocols for the genes selected by the Network for sequencing. Finally, we will participate in all Network activities to enhance the movement of genetics into clinical practice. PUBLIC HEALTH RELEVANCE: The discovery and clinical use of genetic variants associated with both rare Mendelian and more common complex diseases promises to dramatically change the practice of medicine. Our eMERGE III project will leverage a large Biobank and a rich electronic medical record to define the phenotypic impact of mutations emerging from sequencing and then return results on selected variants to Biobank participants using a clinical trial.",EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE,9284512,U01HG008685,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' Atrophic Arthritis ', ' Rheumatoid Arthritis ', ' Bronchial Asthma ', ' Asthma ', ' Biology ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardio-vascular ', ' Cardiovascular system ', ' Clinical Trials ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary Arteriosclerosis ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Coronary heart disease ', ' depression ', ' Mental Depression ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Genes ', ' Genotype ', ' Goals ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' chronic heart failure ', ' Heart Decompensation ', ' Cardiac Failure Congestive ', ' Congestive Heart Failure ', ' Hypercholesteremia ', ' hypercholesterolemia ', ' Newborn Infant ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Inflammatory Bowel Diseases ', ' Inflammatory Intestinal Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Bowel Disorder ', ' Laboratories ', ' Learning ', ' Low-Density Lipoproteins ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' LDL Cholesterol Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' Medicine ', ' Mining ', ' Movement ', ' body movement ', ' Multiple Sclerosis ', ' insular sclerosis ', ' Disseminated Sclerosis ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' New England ', ' Northeastern United States ', ' Patients ', ' Pharmacogenetics ', ' Phenotype ', ' Physicians ', ' Public Health ', ' Research ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' stroke ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' Surveys ', ' Survey Instrument ', ' Testing ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' Family member ', ' health care ', ' Healthcare ', ' Mediating ', ' HLA-DRB1 antigen ', ' HLA-DRB1 ', ' Custom ', ' base ', ' Area ', ' Clinical ', ' prematurity ', ' premature ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Individual ', ' Funding ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Immune ', ' Immunes ', ' Complex ', ' Stream ', ' Protocols documentation ', ' Protocol ', ' Source ', ' Penetrance ', ' Visit ', ' experience ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' Informatics ', ' TYK2 ', ' novel ', ' Participant ', ' genetic analysis ', ' Genetic analyses ', ' neuropsychiatry ', ' neuropsychiatric ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' Attention deficit hyperactivity disorder ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' CTLA4 gene ', ' Cytotoxic T-Lymphocyte-Associated Serine Esterase-4 Gene ', ' Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene ', ' Cytotoxic T-Lymphocyte Protein 4 Gene ', ' CTLA4 ', ' CTLA-4 Gene ', ' CD152 Gene ', ' CD152 Antigen Gene ', ' DRD2 gene ', ' Dopamine Receptor D2 Gene ', ' DRD2 ', ' D2R Gene ', ' D2R ', ' D2DR Gene ', ' D2DR ', ' D(2) Dopamine Receptor Gene ', ' TNFRSF1A gene ', ' tumor necrosis factor  receptor ', ' tumor necrosis factor receptor 1A ', ' tumor necrosis factor alpha receptor ', ' Tumor Necrosis Factor Receptor 55 ', ' Tumor Necrosis Factor Receptor 1 ', ' TNF receptor ', ' TNFalpha receptor ', ' TNFRSF1A Receptor ', ' TNFRSF1A ', ' TNFR60 ', ' TNFR55 ', ' TNFR1 ', ' TNFR-I ', ' TNFR, 60-kD ', ' TNFR, 55-kD ', ' TNFR p60 ', ' TNFAR ', ' TNF- receptor ', ' TNF-sR55 ', ' TNF Receptor p55 ', ' CD120a Antigens ', ' CD 120a Antigen ', ' LDLR gene ', ' TCF7L2 gene ', ' Transcription Factor 7-Like 2 ', ' TCF7L2 ', ' TCF4 ', ' TCF-4 ', ' T-Cell-Specific Transcription Factor 4 ', ' Consent ', ' Cost Effectiveness Analysis ', ' cost-effectiveness analysis ', ' cost-effective analysis ', ' cost efficient analysis ', ' cost effectiveness analyses ', ' cost effective analysis ', ' Cost Effective Analyses ', ' Data ', ' Population Attributable Risks ', ' attributable fraction ', ' Callback ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' pilot trial ', ' cost ', ' implementation research ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' cost effective ', ' cost-effective ', ' Population ', ' loss of function ', ' public health relevance ', ' clinical care ', ' clinical practice ', ' biobank ', ' biorepository ', ' exome ', ' exomes ', ' randomized trial ', ' Randomization trial ', ' arm ', ' rare variant ', ' rare allele ', ' genetic information ', ' clinical sequencing ', ' clinically actionable ', ' support tools ', ' Genomic medicine ', ' biomarker panel ', ' marker panel ', ' neuropsychiatric disorder ', ' neuropsychiatric disease ', ' ']",NHGRI,BRIGHAM AND WOMEN'S HOSPITAL,U01,2017,916160,MA-07,0.12018567818483675
"F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes     DESCRIPTION (provided by applicant): Patient-to-patient variability in response to drugs creates a significant challenge for the safe and effective treatment of many human diseases. Pharmacogenomics seeks to address this challenge by linking drug response to patient genotypes at important loci, termed pharmacogenes, in order to better customize patient treatments. Genetic variation in pharmacogenes is extensive. For example, amongst 12 CYP genes, 10% of people carry at least one rare, potentially deleterious variant. Unfortunately, only a small number of variants have been unambiguously linked to alterations in drug response. Clearly, new approaches are needed to annotate the consequences of the huge pool of variants of unknown significance, including those already identified by existing large-scale sequencing programs, and those that will be discovered as clinical sequencing becomes routine. In this proposal, we seek to address this problem directly and at a scale never before possible by taking advantage of new technologies in sequencing and functional analysis. Our resource, termed F-CAP (Functionalization of Variants in Clinically Actionable Pharmacogenes) will test all possible substitutions at all amino acid residues in some of the most clinically important pharmacogenes and disseminate these data to the medical and research communities. In order to accomplish this, we will use deep mutational scanning, a method we have developed that allows parallelized, and quantitative measurements to be performed on libraries of genetic variants. In Aim 1 we will create these libraries, starting with five of the most important CPIC level A or B priority genes (CYP2C9, CYP2C19, CYP2D6, TPMT and VKORC1), and test the stability and enzymatic activity of each variant en masse using a pooled selection strategy. In Aim 2, we will integrate these data to create an impact score. This impact score provides a numerical value for a variant's functional effects that is amenable to easy integration into prescribing guidelines being developed by the pharmacogenomics community. Aim 3 will validate this score for a subset of variants that span the impact score spectrum using therapeutically relevant substrates for each pharmacogene. Finally, Aim 4 describes a key component of this resource: the dissemination of our findings to the entire pharmacogenomics community through partnership with CPIC and PharmGKB. In addition, we will make available our raw and processed data via a custom web resource that will also be developed in Aim 4. This resource will provide a series of fully annotated datasets describing the functional consequences of every possible single mutation in a series of key pharmacogenes, thereby greatly advancing the field of personalized medicine. PUBLIC HEALTH RELEVANCE: Pharmacogenomics seeks to identify genetic sources of inter-individual variability in drug response, with the goal of personalizing drug selection and dose to improve patient outcomes. A key barrier to using pharmacogenomic information is lack of clarity about the functional impact of variants, which hampers the provision of clear, unambiguous guidance to health care providers. We propose to connect pharmacogenomic variant discovery with novel high-throughput experimental approaches to deliver a resource to guide the use of individual pharmacogenomic information in personalizing drug treatment.",F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes,9302807,R24GM115277,"['Affect ', ' Algorithms ', ' aminoacid ', ' Amino Acids ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Systematics ', ' Classification ', ' Communities ', ' drug treatment ', ' Drug Therapy ', ' Pharmacotherapy ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Elements ', ' genetic library ', ' Gene Library ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' In Vitro ', ' Libraries ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Resources ', ' Research Resources ', ' Testing ', ' Translations ', ' Genetic Diversity ', ' Genetic Variation ', ' Generations ', ' Measures ', ' Medical Research ', ' Dataset ', ' Data Set ', ' Custom ', ' Guidelines ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Biochemical ', ' Medical ', ' Series ', ' Link ', ' Individual ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Measurement ', ' root ', ' Plant Roots ', ' Funding ', ' R24 ', ' R-24 Monoclonal Antibody ', ' MoAb R24 ', ' Monoclonal Antibody R24 ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' programs ', ' Source ', ' interest ', ' genetic disorder diagnosis ', ' genetic diagnosis ', ' novel ', ' new technology ', ' novel technologies ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' response ', ' Pharmacogenomics ', ' Therapeutic Uses ', ' CYP2C19 gene ', ' P450C2C ', ' Mephenytoin 4-Prime Hydroxylase ', ' Cytochrome P450, Subfamily IIC, Polypeptide 19 ', ' CYP2C19 ', ' CYP2C ', ' CYP2C9 gene ', ' Cytochrome P450, Subfamily IIC, Polypeptide 9 ', ' CYP2C9 ', ' CYP2D6 gene ', ' Subfamily IID-Like 1 Cytochrome P450 ', ' Subfamily IID Cytochrome P450 ', ' Sparteine Monooxygenase ', ' P450DB1 ', ' P450C2D ', ' P450-DB1 ', ' P450-2D6 ', ' Imipramine 2-Hydroxylase ', ' Debrisoquine Hydroxylase ', ' Debrisoquine 4-Monooxygenase ', ' Debrisoquine 4-Hydroxylase ', ' Cytochrome P450 Subfamily IID Polypeptide 6 ', ' Cytochrome P450 2D6 ', ' Cytochrome P-450 CYP2D6 ', ' CYPIID6 ', ' CYP2DL1 ', ' CYP2D6 ', ' CYP2D ', ' CYP 2D6 ', ' CPD6 ', ' TPMT gene ', ' TPMT ', ' Address ', ' Dose ', ' Data ', ' Applications Grants ', ' Grant Proposals ', ' Mutate ', ' Cellular Assay ', ' Large-Scale Sequencing ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' Process ', ' Numerical value ', ' Output ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' user-friendly ', ' human disease ', ' public health relevance ', ' effective therapy ', ' effective treatment ', ' stability testing ', ' exome ', ' exomes ', ' High-Throughput DNA Sequencing ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' genetic information ', ' variant of unknown significance ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' clinical sequencing ', ' clinically actionable ', ' genotyped patients ', ' mutation screening ', ' mutation scanning ', ' online resource ', ' web-based resource ', ' web resource ', ' on-line resource ', ' internet resource ', ' ']",NIGMS,UNIVERSITY OF WASHINGTON,R24,2017,737011,WA-07,0.1902170025038608
"Optimizing Genetic Testing for Deafness for Clinical Diagnostics Project Summary  Hearing loss is the most common sensory deficit in humans. It is diagnosed in 1 in 500 newborns and affects half of all octogenarians. Although causality is multifactorial, in developed countries a large fraction of hearing loss is genetic and non-syndromic, i.e. not associated with other phenotypes.  During the prior granting period, we implemented and integrated comprehensive genetic testing as a cornerstone in the evaluation of the deaf and hard-of-hearing person. The American College of Medical Genetics has recognized the merit of this approach, and in 2014 included comprehensive genetic testing for the evaluation of deafness in their newest treatment guidelines. In the largest study to date to corroborate this decision, we found an underlying genetic cause for hearing loss in 440 (39%) of 1119 sequentially accrued patients chosen without exclusion criteria. Pathogenic variants were present in 49 genes and included missense variants (49%), copy number changes (18%), indels (18%), nonsense variants (8%), splice-site alterations (6%) and promoter variants (<1%), making comprehensive genetic testing the single best test to order in the diagnosis of hearing loss after an audiogram.  In this competitive renewal, we will build on these accomplishments by completing the following aims:  Specific Aim 1: To optimize phenotype-genotype integration in the analysis of hereditary hearing loss  by refining the use of hierarchical surface clustering and audioprofile surface analysis to determine  which types of genetic hearing loss are associated with clinically meaningful sub-clusters  Specific Aim 2: To validate and integrate physics-based protein modeling as a tool within the Deafness  Variation Database to predict variant effect and the molecular and patient phenotype  Specific Aim 3: To identify genetic modifiers of specific deafness-causing genes predicted by  hierarchical surface clustering and validated by physics-based potential free-energy modeling  The successful completion of this grant will improve the clinical care of persons with hearing loss by enhancing phenome-genome integration and by making variant interpretation more robust. Knowledge gained from this proposal will also lay the foundation for refined studies focused on the identification of genetic modifiers  both positive and negative  associated with complex phenotypes such as noise- induced and age-related hearing loss. This competitive renewal addresses the increasingly daunting challenge of variant interpretation. We will seamlessly integrate AudioGene into the OtoSCOPE pipeline, explore hierarchical surfaces clustering at all loci, enhance the utility of the Deafness Variation Database by adding physics-based potential free-energy modeling, and using these tools, identify genetic modifiers of select types of genetic hearing loss. The completion of these aims will lay the foundation for more refined studies focused on the identification of genetic modifiers  both positive and negative  associated with complex hearing loss phenotypes including noise-induced and age-related hearing loss.",Optimizing Genetic Testing for Deafness for Clinical Diagnostics,9232830,R01DC012049,"['Adoption ', ' Affect ', ' Algorithms ', ' Audiometric Test ', ' Audiogram ', ' Audiometry ', ' Biology ', ' Systematics ', ' Classification ', ' Clinical Trials ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Mucoviscidosis ', ' Cystic Fibrosis ', ' Deafness ', ' Decision Making ', ' Decision Trees ', ' Under-Developed Nations ', ' Under-Developed Countries ', ' Third-World Nations ', ' Third-World Countries ', ' Less-Developed Nations ', ' Less-Developed Countries ', ' Developing Nations ', ' Developing Countries ', ' Diagnosis ', ' pseudohypertrophic muscular paralysis ', ' pseudohypertrophic adult muscular dystrophy ', ' progressive muscular dystrophy of childhood ', ' mild X-linked recessive muscular dystrophy ', ' classic X-linked recessive muscular dystrophy ', ' childhood pseudohypertrophic muscular dystrophy ', ' benign X-linked recessive muscular dystrophy ', ' X-linked recessive muscular dystrophy ', ' X-linked muscular dystrophy ', ' X-linked dilated cardiomyopathy ', ' Pseudohypertrophic Muscular Dystrophy ', ' Ellis-van Creveld (EvC) syndrome ', ' Duchenne-Griesinger syndrome ', ' Duchenne ', ' Duchene ', ' Duchenne muscular dystrophy ', ' Foundations ', ' genetic therapy ', ' gene-based therapy ', ' Genetic Intervention ', ' Gene-Tx ', ' Gene Transfer Procedure ', ' Gene Transfer Clinical ', ' Gene Therapy Molecular Biology ', ' DNA Therapy ', ' gene therapy ', ' Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Genome ', ' Genotype ', ' Grant ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' sound perception ', ' hearing perception ', ' Hearing ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Human ', ' Newborn Infant ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Methods ', ' Persons ', ' Noise ', ' Octogenarian ', ' Patients ', ' Phenotype ', ' Physics ', ' Presbycusis ', ' age related hearing loss ', ' Presbyacusis ', ' Biological Preservation ', ' preservation ', ' Biologic Preservation ', ' Proteins ', ' Research ', ' RNA Splicing ', ' Splicing ', ' medical schools ', ' school of medicine ', ' medical college ', ' Technology ', ' Testing ', ' falls ', ' case report ', ' Case Study ', ' health care ', ' Healthcare ', ' promotor ', ' promoter ', ' Guidelines ', ' base ', ' evaluation/testing ', ' Otoscopes ', ' improved ', ' Site ', ' Area ', ' Surface ', ' Clinical ', ' Variation ', ' Variant ', ' Evaluation ', ' prognostic ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Industrialized Nations ', ' Industrialized Countries ', ' Developed Nations ', ' Developed Countries ', ' Therapeutic ', ' Cochlear implant procedure ', ' Cochlear Prosthesis Implantation ', ' Cochlear Implantation ', ' Genetic ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Inherited ', ' Hereditary ', ' Complex ', ' Sensory ', ' Techniques ', ' Hearing Impaired Persons ', ' Persons With Hearing Impairments ', ' Hard of Hearing Persons ', ' Deaf ', ' American ', ' genetic disorder diagnosis ', ' genetic diagnosis ', ' cohort ', ' Free Energy ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Reporting ', ' Modeling ', ' Genomics ', ' Pathogenicity ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' hearing impairment ', ' Hypoacusis ', ' Hypoacuses ', ' Hearing Loss ', ' Address ', ' Data ', ' Research Infrastructure ', ' Infrastructure ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' enroll ', ' Enrollment ', ' Exclusion Criteria ', ' Molecular ', ' clinical phenotype ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' software systems ', ' designing ', ' design ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Heritability ', ' clinically significant ', ' clinical significance ', ' clinical care ', ' phenome ', ' clinical decision-making ', ' Massive Parallel Sequencing ', ' Massively Parallel Sequencing ', ' Massively Parallel DNA Sequencing ', ' clinical diagnostics ', ' ']",NIDCD,UNIVERSITY OF IOWA,R01,2017,564086,IA-02,0.06534042336241784
"An integrative approach to functionalize GWAS hits in MI and stroke     DESCRIPTION (provided by applicant): Coronary heart disease (CHD) and cerebrovascular disease result from platelet thrombus formation at the site of a ruptured atherosclerotic plaque. Numerous studies have shown enhanced platelet reactivity, and increased platelet count and volume are risk factors for CHD events and fatality, and a recent NHLBI Working Group concluded that variation in platelet reactivity is a major determinant of ischemic events, like MI or stroke. Genome wide association studies (GWASs) have identified numerous common genetic variants associated with the risk of CHD and platelet function parameters, but most of the positive ""hits"" are not causative of the phenotype. To understand the cellular mechanisms by which these variants affect platelet function it is imperative to know the repertoire of mRNAs, miRNAs and lncRNAs expressed in the cell of interest. Our team has been a leader in the field of platelet transcriptomics as well as functional assessment of variants in platelet genes. We have profiled mRNAs and miRNAs from 183 subjects using multiple platforms and have also performed platelet RNA-seq on 14 different subjects. This information provides a critical ability to filter, prioritize and obtain variant functional insights for evaluating GWAS SNPs associated with MI, stroke and platelet parameters. We have identified 142 mRNAs and 9 miRNAs that are expressed in platelets and linked to these GWAS hits. The goals of this proposal are to identify, assay, and validate functional variation previously tagged in GWASs of platelet-mediated ischemic arterial disease and of platelet phenotypes. Aim 1 will identify GWAS-linked mRNAs, miRNAs and lncRNAs that are functional in platelets. Candidate RNAs will be refined by association with platelet function, eQTLs and QTLs using our previously generated platelet RNA data. We will develop a supervised machine-learning, statistical pattern matching algorithm to prioritize likely platelet-functional genes. Gene-level assays in which we knock down mRNA, miRNA and lncRNA in our human megakaryocyte culture system, followed by assays for integrin activation and quantification of platelet number and volume will be used to confirm platelet functionality. Aim 2 will identify functionally divergent SNPs and haplotypes. We will impute missing SNPs and perform fine-mapping to the phenotypes of interest. Variants will be prioritized by association strength, annotation data, and predicted function using publically available resources and our own platelet eQTL data. Non-coding candidates will be tested by reporter gene assay and non-synonymous variants will be tested using functional assays in cell lines in which the endogenous gene has been silenced. We will validate our findings with a replication analysis in which we use an independent cohort dataset to quantify the association of the tested variants with the original GWAS phenotype. PUBLIC HEALTH RELEVANCE:  Platelet-mediated arterial thrombosis in the coronary or cerebrovascular circulation is the major cause of mortality and morbidity in the U.S. Numerous DNA variations have been associated with these disorders, but the causal genes are unknown. This research will test whether genes near these DNA variations - and candidate variations themselves - alter platelet function or number to understand better the molecular mechanisms causing heart attacks and strokes.",An integrative approach to functionalize GWAS hits in MI and stroke,9276780,R01HL128234,"['Affect ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' aminoacid ', ' Amino Acids ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' thrombocyte/platelet ', ' Thrombocytes ', ' Platelets Reticuloendothelial System ', ' Platelets ', ' Marrow platelet ', "" Hayem's elementary corpuscle "", "" Deetjeen's body "", "" Bizzozero's corpuscle/cell "", ' Blood Platelets ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cell Body ', ' Cells ', ' cerebrovascular blood flow ', ' cerebrocirculation ', ' cerebral circulation ', ' cerebral blood flow ', ' brain blood flow ', ' Cerebrovascular Circulation ', ' intracranial vascular dysfunction ', ' cerebrovascular dysfunction ', ' cerebral vascular dysfunction ', ' cerebral vascular disease ', ' brain vascular dysfunction ', ' brain vascular disease ', ' Intracranial Vascular Disorders ', ' Intracranial Vascular Diseases ', ' Cerebrovascular Disease ', ' Brain Vascular Disorders ', ' Cerebrovascular Disorders ', ' Coronary Circulation ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Coronary heart disease ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' vulnerable plaque ', ' atherosclerotic plaque ', ' atherosclerotic lesions ', ' atherosclerosis plaque ', ' Atheromatous plaque ', ' Atheromatous degeneration ', ' Atheromatous ', ' Atheroma ', ' Arterial Fatty Streaks ', ' Arterial Fatty Streak ', ' Gene Expression ', ' Genes ', ' Genotype ', ' Goals ', ' Haplotypes ', ' Modern Man ', ' Human ', ' Integrins ', ' Integrins Extracellular Matrix ', ' Introns ', ' Intervening Sequences ', ' Laboratories ', ' Maps ', ' Megakaryocytes ', ' Megalokaryocyte ', ' Blood megakaryocyte ', ' Methods ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Myocardial Infarction ', ' heart infarction ', ' heart infarct ', ' heart attack ', ' coronary infarction ', ' coronary infarct ', ' coronary attack ', ' cardiac infarct ', ' Myocardial Infarct ', ' Cardiac infarction ', ' Phenotype ', ' Platelet Count measurement ', ' Platelet Number ', ' Platelet Count ', ' Blood Platelet Number ', ' Blood Platelet Count ', ' Production ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Research ', ' Resources ', ' Research Resources ', ' Risk ', ' Risk Factors ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Messenger RNA ', ' mRNA ', ' Role ', ' social role ', ' stroke ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' Supervision ', ' Testing ', ' Thrombosis ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Measures ', ' falls ', ' Enhancers ', ' Mediating ', ' promotor ', ' promoter ', ' Thrombus ', ' Dataset ', ' Data Set ', ' base ', ' human subject ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Reporter Genes ', ' Link ', ' insight ', ' Individual ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Event ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' System ', ' interest ', ' cohort ', ' Untranslated Regions ', ' UTRs ', ' Prevention ', ' Reporting ', ' Intergenic Sequence ', ' Intercistronic Sequence ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Sentinel ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' Binding ', ' Molecular Interaction ', ' CD34 gene ', ' HPCA1 ', ' CD34 ', ' Mediator of activation protein ', ' Mediator of Activation ', ' Mediator ', ' Data ', ' Reproducibility ', ' Pathologic ', ' Molecular ', ' protein function ', ' work group ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' clinical phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' knockdown ', ' knock-down ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Rupture ', ' Coupled ', ' Heritability ', ' small hairpin RNA ', ' short hairpin RNA ', ' shRNA ', ' transcriptomics ', ' clinically relevant ', ' clinical relevance ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' database of Genotypes and Phenotypes ', ' dbGaP ', ' ChIP-seq ', ' chromatin immunoprecipitation-sequencing ', ' ChIP Sequencing ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' screening ', ' transcriptome ', ' inter-individual variation ', ' interindividual variation ', ' Chromatin Interaction Analysis by Paired-End Tag Sequencing ', ' ChIA-PET ', ' ']",NHLBI,THOMAS JEFFERSON UNIVERSITY,R01,2017,392409,PA-03,0.04809103870656848
"Inferring the effects of genetic variants on gene expression and splicing     DESCRIPTION (provided by applicant): The objective of this project is to facilitate the interpretation of genetic variants identified in clinical whole- genome and whole-exome sequencing studies through the development of computational methods to predict functional effects of individual variants. Genome-scale sequencing technologies are increasingly enabling studies of genetic variation in large numbers of individuals; however, interpreting the clinical significance of the hundreds of thousands of genetic variants identified in these studies remains a critical challenge. Gene expression regulation is one mechanism by which variants can result in disease or other clinically-significant phenotypes. This mechanism is likely to be particularly important for disease-causing variants that do not directly affect protein structure by altering an amino acid sequence. The methods developed here will enable researchers to predict whether genetic variants are likely to have a regulatory effect on gene expression. The first stage of the project is to build computational models to predict such regulatory effects using a random forest machine learning approach. These models will be trained to recognize regulatory variation using a set of variants that have been shown to be involved in expression regulation in a recent study of gene expression across hundreds of individuals. Separate algorithms will be developed to predict two different types of regulatory effects: changes in the total amount of RNA produced from a particular gene (expression level variation) and changes in the specific form of RNA produced from a particular gene (splicing or isoform ratio variation). The second stage of the project is to evaluate the performance of these models on gene expression datasets from a separate human population and from different tissues within the human body, to explore their generalizability and to determine to what extent the characteristics of regulatory variants are conserved across tissues and populations. The final stage of the project is to use genetic variants in publicly-available databases that are known to be pathogenic to characterize how well these models perform at predicting clinical significance. This stage will test the hypothesis that variants that regulate gene expression are more likely to be clinically significant than variants that do not regulate expression. This project will impact public health by providing useful tools to improve prediction of the clinical significance of genetic variants identified in genome- scale sequencing studies. In addition, the project will provide biological insight into the tissue-specificity and population-specificity of genomic features that characterize regulatory genetic variants. PUBLIC HEALTH RELEVANCE: Genome-scale sequencing technologies are increasingly enabling studies of genetic variation in large numbers of patients and other individuals. However, interpreting the clinical significance of the hundreds of thousands of genetic variants identified in these studies remains a critical challenge. This project will provide useful tools to improve automated prediction of the clinical significance of such genetic variants as well as their regulatory effects on gene expression.",Inferring the effects of genetic variants on gene expression and splicing,9174089,F32HG008330,"['Affect ', ' Algorithms ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Elements ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Exons ', ' Followup Studies ', ' Follow-Up Studies ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Gene Splicing ', ' Spliced Genes ', ' Goals ', ' Modern Man ', ' Human ', ' Joints ', ' Mentorship ', ' Methods ', ' Patients ', ' Phenotype ', ' Probability ', ' Prostate ', ' Prostatic Gland ', ' Prostate Gland ', ' Public Health ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA Splicing ', ' Splicing ', ' Specificity ', ' Technology ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Genetic Diversity ', ' Genetic Variation ', ' forest ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' insight ', ' Individual ', ' European ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Human Figure ', ' Human body ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Performance ', ' Protein Isoforms ', ' Isoforms ', ' Quantitative Trait Loci ', ' QTL ', ' professor ', ' novel ', ' lymphoblastoid cell line ', ' Categories ', ' Reporting ', ' Positioning Attribute ', ' Position ', ' Regulation ', ' Modeling ', ' Genomics ', ' Transcription Initiation Site ', ' Transcription Start Site ', ' Pathogenicity ', ' genome sequencing ', ' Address ', ' protein structure ', ' Transcript ', ' Characteristics ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Population ', ' clinically significant ', ' clinical significance ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome sequencing ', ' clinical predictors ', ' Genetic study ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' whole genome ', ' entire genome ', ' ']",NHGRI,STANFORD UNIVERSITY,F32,2017,46587,CA-18,0.15773554392890257
"Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases     DESCRIPTION (provided by applicant) Over the past 10 years human genetics studies made unprecedented numbers of discoveries relating genome variation to common diseases. While it is unquestionably true that we have learned substantially from the discoveries made to date, we must also acknowledge that with respect to the identification and characterization of the genome variation affecting risk of common human diseases - those accounting for the overwhelming majority of public health care expenditures - our discoveries have not generated nearly the knowledge of disease etiology that we would have expected given the sheer number of these discoveries. The combination of these observations coupled with the dramatic reduction in the cost of sequencing is driving the case for moving to whole genome sequencing studies for common disease. We have focused our application on three critical challenges for methods development and analysis of whole genome sequence data. While there has been substantial progress in methods development for analysis of exome sequencing, with gene-based tests that are relatively robust to the direction of effects of rare coding variants as well as the proportionof the gene's rare variants contributing to phenotype, it is clear that methods integrating the analysis of common and rare variation as well as functional genomics data will be essential for appropriate analysis of whole genome sequence data. Thus, we propose in Specific Aim 1 to develop novel methods, software and analysis pipelines for integrated analysis of common and rare variants for the analysis of whole genome sequence on 50,000- 100,000 individuals for any given common disease, and in Specific Aim 2 to develop and apply novel approaches for prioritizing results from these large-scale sequencing studies using BioVU, the 200,000 member biobank at Vanderbilt that is associated with 30 years of high quality electronic health records, and in Specific Aim 3 to develop queriable results databases and a comprehensive web portal to serve results of our studies on the sequence data for both the internal sequencing community and for the broader scientific community. PUBLIC HEALTH RELEVANCE Large-scale whole genome sequencing studies are being carried out to understand the genetic architecture of human complex diseases. It remains challenging to decipher the genetic mechanisms of disease etiology. In this application we aim to develop a suite of statistical and computational methods to identify genes and variants associated with complex disease and use BioVU, a DNA BioBank linked to electronic health records, to validate and investigate genetic architecture of multiple complex diseases.","Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases",9275537,U01HG009086,"['Accounting ', ' Affect ', ' Engineering / Architecture ', ' Architecture ', ' driving ', ' Automobile Driving ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' health care expenditure ', ' Health Expenditures ', ' facial ', ' faces ', ' Face ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' Government ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Methods ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Phenotype ', ' Public Health ', ' Research ', ' Resources ', ' Research Resources ', ' Risk ', ' Science ', ' Computer software ', ' Software ', ' Technology ', ' Time ', ' Tissues ', ' Body Tissues ', ' Generations ', ' Dataset ', ' Data Set ', ' base ', ' method development ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Policies ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetically predisposed ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Complex ', ' experience ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' success ', ' expectation ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' member ', ' Reporting ', ' Code ', ' Coding System ', ' Statistical Methods ', ' functional genomics ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' genome sequencing ', ' Data ', ' Large-Scale Sequencing ', ' Validation ', ' Electronic Health Record ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' cost ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Coupled ', ' human disease ', ' public health relevance ', ' biobank ', ' biorepository ', ' exome ', ' exomes ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' Genetic study ', ' web portal ', ' internet portal ', ' human genomics ', ' whole genome ', ' entire genome ', ' genomic data ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NHGRI,VANDERBILT UNIVERSITY,U01,2017,864186,TN-05,0.12227602667964475
"Predicting causal non-coding variants in a founder population DESCRIPTION (provided by applicant): In order to characterize the molecular and cellular causes of human disease, it will be essential to unravel the functional impact of genetic variation. However, we are currently unable to predict the impact of the majority genetic variants that lie in non-coding regions of the genome, where indeed most complex disease-associated variants are found. Additionally, recent evidence suggests that a significant fraction of the non-coding genome is likely to be functional, often playing a role in gene regulation. Therefore, our limited understanding of non- coding variation is a critical hurdle to characterizing the genetic basis of disease. The goal of this project is to develop methods for interpreting non-coding genetic variation: to provide a robust and extensible Bayesian method for predicting causal variants from full genomes, to identify and validate a large set of functional non- coding variants using CRISPR technology, and to predict disease-relevant traits likely to be affected by each variant. Our project will leverage a unique cohort from a founder population in Sardinia, with genome sequence and/or transcriptome data available from 3000 individuals, along with extensive phenotyping for hundreds of traits. We will combine advanced statistical modeling with experimental validation based on genome engineering to identify causal non-coding variants affecting biomedical traits in the cohort, along with predicting functional mechanisms through which these variants ultimately perturb the cell. In Aim 1, we develop computational methods for predicting causal non-coding variation from full genomes, incorporating informative genomic features including epigenetic data, sequence motifs, and conservation information into a Bayesian approach jointly modeling multiple transcriptomic signals. We will optimize and apply these methods on genome and transcriptome data available for the Sardinia cohort to identify a large set of variants predicted to causally affect gene expression. Based on these predictions, in Aim 2, we connect putative causal variants with the diverse set of disease-relevant traits measured in the cohort, using network inference to capture the cascade from genetic variation to gene expression to disease. We will develop methods to integrate across variants, using the models in Aim 1, to identify the common causal mechanisms related to each trait. In Aim 3, we validate the causal impact of non-coding variants predicted to affect high-level traits. We will us genome editing through CRISPR to introduce individual genetic variants into cell lines and use qPCR to validate the predicted effects on gene expression. Finally, a major goal throughout this proposal will be to provide the research community with convenient computational tools for the prediction of causal non-coding variants from individual genomes, updated on an ongoing basis to integrate the most recent genomic annotations and public data in order to provide the best possible accuracy in predicting causal variants and the traits they are likely to affect. Our projet will greatly advance our understanding of non-coding genetic variation, the specific mechanisms affected by causal variants, and the downstream consequences to the cell and individual health. PUBLIC HEALTH RELEVANCE:  Understanding the impact of variation in the entire genome, beyond the well-studied protein-coding regions, is essential to understanding the relationship between genetics and human health. This proposal addresses the problem of identifying functional non-coding genetic variants and predicting the impact of each variant on hundreds of disease-relevant traits. Our approach will focus on integrative, transformative methods for understanding mechanisms underlying the function of the human genome.",Predicting causal non-coding variants in a founder population,9306895,R01HG008150,"['Affect ', ' Allelomorphs ', ' Alleles ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biology ', ' Cataloging ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cell Body ', ' Cells ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Family ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Linkage Disequilibrium ', ' Maps ', ' Methods ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Phenotype ', ' Play ', ' Research ', ' Resources ', ' Research Resources ', ' RNA Splicing ', ' Splicing ', ' Role ', ' social role ', ' Sardinia ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Supervision ', ' Testing ', ' Genetic Diversity ', ' Genetic Variation ', ' Measures ', ' Protein Coding Region ', ' ORFs ', ' Open Reading Frames ', ' Dataset ', ' Data Set ', ' base ', ' density ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' Individual ', ' Bayesian posterior distribution ', ' Bayesian classification procedure ', ' Bayesian classification method ', ' Bayesian approaches ', ' Bayesian Statistical Method ', ' Bayesian Methodology ', ' Bayesian Method ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Dimensions ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' Techniques ', ' System ', ' human data ', ' cohort ', ' trait ', ' novel ', ' Categories ', ' disorder risk ', ' disease risk ', ' Pathogenesis ', ' genetic linkage analysis ', ' linkage analyses ', ' genetic linkage analyses ', ' family based linkage study ', ' Linkage Analysis ', ' Widespread Disease ', ' Generalized Disease ', ' Extensive Disease ', ' Modeling ', ' Sampling ', ' Property ', ' functional genomics ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' genome sequencing ', ' Address ', ' Data ', ' Resolution ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' founder population ', ' Founder Generation ', ' genomic region ', ' Genomic Segment ', ' Transcript ', ' Update ', ' Validation ', ' Molecular ', ' developmental ', ' Development ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' data modeling ', ' computational tools ', ' computerized tools ', ' Genome engineering ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' transcriptomics ', ' human disease ', ' public health relevance ', ' molecular phenotype ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' genome annotation ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' Algorithmic Analysis ', ' Analysis of Algorithms ', ' Analyses of Algorithms ', ' Algorithmic Analyses ', ' genetic predictors ', ' genomic variation ', ' human genome sequencing ', ' genome editing ', ' genomic editing ', ' learning strategy ', ' learning method ', ' learning activity ', ' transcriptome ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR method ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' whole genome ', ' entire genome ', ' genomic data ', ' ']",NHGRI,STANFORD UNIVERSITY,R01,2017,454272,CA-18,0.19317893142270912
"Discovery of pathogenic germline variants in pediatric cancers using genomics. Project Summary/Abstract Genomic alterations drive cancer development in pediatric and adult patients, but pediatric cancers display a relative scarcity of somatic variants. This observation coupled with the earlier age of onset in familial cancer syndromes suggests that germline variants contribute to the development of many pediatric cancers. Many known pathogenic germline variants exhibit biological features such as loss of heterozygosity and rarity within the general population; certain germline cancer-causing variants also cause cancer when acquired somatically. Identifying pathogenic germline variants from whole exome sequence (WES) data would clarify the pathogenesis of pediatric cancers, and might support improved treatments for cancer subtypes with poor prognosis such as relapsed acute lymphoblastic leukemia (ALL), high-grade glioma (glioma), and ependymoma. The long-term goal of this research is to understand the role of germline variants in pediatric cancer development using genomic data. The objective of this application is to develop a computational biology tool that identifies pathogenic germline variants from WES data, and to apply this tool to analyze germline variants in relapse ALL, glioma, and ependymoma. This application's central hypothesis is that pathogenic germline variants have biological and cohort-specific features that distinguish them from benign variants, such that a machine learning pipeline trained on these features can predict pathogenic germline variants. Aim 1 will call germline variants in WES data from 1) pediatric patients with known cancer-causing germline variants and 2) control patients without cancer; patients in data set 1) are randomly divided into a training and test set. A bioinformatics pipeline will call variants, add annotation, and filter out low quality variants. Aim 2 will use the training set to train and optimize a machine-learning algorithm to predict high confidence germline driver variants. Aim 3 will apply the final pipeline to validation sets of pediatric relapsed ALL, glioma, and ependymoma samples. These aims will generate a computational pipeline that predicts pathogenicity of germline variants using a pediatric cancer cohort, enabling improved understanding of the contribution of germline variants to multiple pediatric cancers. Project Narrative Improved understanding how certain germline DNA variants (those DNA changes that are inherited or occur early in development) promote cancer might lead to better treatments for pediatric cancers. However, identifying which germline variants cause cancer is challenging without genetic information from family members. To address this, this research proposal develops a computational tool that learns from germline variants known to cause cancer and then predicts cancer-causing variants from pediatric cancer patient DNA sequences in the absence of family information; these predicted variants will undergo computational and experimental testing, and may clarify how pediatric cancers like relapsed acute lymphoblastic leukemia, glioma, and ependymoma develop.",Discovery of pathogenic germline variants in pediatric cancers using genomics.,9313620,F31CA210607,"['adulthood ', ' Adult Human ', ' 21+ years old ', ' Adult ', ' Affect ', ' ages ', ' Age ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Control Groups ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' WHO Grade II Ependymal Tumor ', ' WHO Grade II Ependymal Neoplasm ', ' Ependymoma ', ' Exhibits ', ' Family ', ' Genes ', ' neuroglia tumor ', ' neuroglia neoplasm ', ' glial-derived tumor ', ' Neuroglial Tumor ', ' Neuroglial Neoplasm ', ' Glial Tumor ', ' Glial Neoplasm ', ' Glial Cell Tumors ', ' Glioma ', ' Goals ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Acute Lymphocytic Leukemia ', ' acute lymphomatic leukemia ', ' acute lymphogenous leukemia ', ' acute lymphatic leukemia ', ' Precursor Lymphoblastic Leukemia ', ' Precursor Cell Lymphoblastic Leukemia ', ' Acute Lymphoid Leukemia ', ' Acute Lymphoblastic Leukemia ', ' ALL - Acute Lymphocytic Leukemia ', ' Leukemia, Lymphocytic, Acute, L1 ', ' infant ALL ', ' Pediatric Acute Lymphoid Leukemia ', ' Pediatric Acute Lymphogenous Leukemia ', ' Pediatric Acute Lymphocytic Leukemia ', ' Pediatric Acute Lymphoblastic Leukemia ', ' Pediatric ALL ', ' Lymphoblastic Leukemia, Acute, L1 ', ' L1 Lymphocytic Leukemia ', ' Childhood Acute Lymphoid Leukemia ', ' Childhood Acute Lymphogenous Leukemia ', ' Childhood Acute Lymphocytic Leukemia ', ' Childhood Acute Lymphoblastic Leukemia ', ' Childhood ALL ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' outcome forecast ', ' Prognosis ', ' Relapse ', ' Research ', ' Research Proposals ', ' Role ', ' social role ', ' Syndrome ', ' Testing ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' Tumor Suppressor Genes ', ' Family member ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Benign ', ' Variation ', ' Variant ', ' Biological ', ' Age of Onset ', ' Training ', ' pediatric ', ' Childhood ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' pediatric malignancy ', ' pediatric cancer ', ' children with cancer ', ' childhood malignancy ', ' child with cancer ', ' cancer in children ', ' cancer in a child ', ' Malignant childhood cancer ', ' Malignant Pediatric Tumor ', ' Malignant Pediatric Neoplasm ', ' Malignant Childhood Tumor ', ' Childhood Cancers ', ' Malignant Childhood Neoplasm ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' computer biology ', ' Inherited ', ' Hereditary ', ' Techniques ', ' Loss of Heterozygosity ', ' Allelic Loss ', ' Penetrance ', ' Somatic Mutation ', ' neoplastic cell ', ' Tumor Cell ', ' Performance ', ' cohort ', ' General Population ', ' General Public ', ' Pathogenesis ', ' Cancer Relapse ', ' Modeling ', ' Sampling ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' tumorigenesis ', ' Oncogenesis ', ' Hereditary Malignant Neoplasm ', ' familial cancer ', ' Hereditary Cancer ', ' Familiar Malignant Neoplasm ', ' Pediatric Neoplasm ', ' Pediatric Tumor ', ' Childhood Tumor ', ' Childhood Neoplasm ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Validation ', ' Characteristics ', ' developmental ', ' Development ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' computational tools ', ' computerized tools ', ' Population ', ' Coupled ', ' Susceptibility Gene ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' Oncogenic ', ' functional loss ', ' tumor ', ' effective therapy ', ' effective treatment ', ' exome ', ' exomes ', ' Childhood Cancer Treatment ', ' Pediatric Cancer Treatment ', ' pediatric patients ', ' child patients ', ' genetic information ', ' tumor DNA ', ' tumor-specific DNA ', ' tumor cell DNA ', ' cancer subtypes ', ' cancer sub-types ', ' genomic data ', ' ']",NCI,COLUMBIA UNIVERSITY HEALTH SCIENCES,F31,2017,40106,NY-13,0.18637022043195645
"Predicted Gene Expression: High Power, Mechanism, and Direction of Effect     DESCRIPTION (provided by applicant): Although investments in genomic studies of mental disorders enabled the discovery of thousands of robustly associated variants with these complex diseases, the translation of these discoveries into actionable targets has been hampered by the lack of a mechanistic understanding on how genome variation relates to phenotype. Moreover, it has been widely shown that a substantial portion of the genetic control of complex traits, including mental disorders, is exerted through the regulation of gene expression. However, effective methods to fully harness this mechanism are lagging. To address these challenges, we propose a novel gene-based test -PrediXcan- that directly tests this regulatory mechanism and substantially improves power relative to single variant tests and other gene-based tests. PrediXcan is inherently mechanistic and provides directionality, highlighting its potential utility in identifying novel targets for therapy. The method consists of predicting the whole genome effect on expression traits and correlating this effect with disease risk to identify novel disease genes. In addition, we propose novel approaches to investigate the context-specificity of expression traits (Orthogonal Tissue Decomposition) and to quantify the collective effect of the regulated transcriptome on phenotypes of interest (Regulability). Regulability is similar to the concept of chip heritability (total variability explained collectivey by genotyped variants). First, we will develop cross-tissue, tissue-specific (for over 30 different human tissue types), and brain-region specific expression traits. We will use statistical machine learning methods to develop whole genome prediction models for these traits and extend this work to other molecular phenotypes. All models will be stored in open access databases. Next, we will apply the PrediXcan method to 7 mental disorder phenotypes. More specifically, we will compute genetically predicted levels of gene expression traits and correlate them with disease risk to identify genes involved in disease pathways. We will also quantify the collective effect of the predicted transcriptome (regulability) on mental disorder risk across multiple tissues. Finally we will extend PrediXcan method and develop a method to infer the results of PrediXcan using summary statistics data as opposed to individual level data. This will extend the applicability of the approach to all summary results generated by meta-analysis consortia and increase the power to discover novel genes given the larger sample sizes. The research we propose is driven by an extensive set of preliminary studies, and promises substantial deliverables in both new methods of analysis and public access results databases. PUBLIC HEALTH RELEVANCE: Large investments in genome studies have been made to understand the consequences of genetic variation on human traits. These have yielded many genetic variants reproducibly associated with disease but the underlying biology is still unclear. We propose a novel computational method that links mechanistically the genetic variability to disease risk and apply it to a range of mental disorder studies to provide more biological insights and enable discovery of potential targets for drug development.","Predicted Gene Expression: High Power, Mechanism, and Direction of Effect",9301667,R01MH107666,"['senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Anorexia Nervosa ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' psychological disorder ', ' psychiatric illness ', ' mental illness ', ' Psychiatric Disorder ', ' Psychiatric Disease ', ' Mental health disorders ', ' Mental disorders ', ' Biology ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' depression ', ' Mental Depression ', ' Disorder ', ' Disease ', ' Exons ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' Genotype ', ' Modern Man ', ' Human ', ' Investments ', ' Mathematics ', ' Math ', ' Methods ', ' Methylation ', ' National Institute of Mental Health ', ' NIMH ', ' Obsessive-Compulsive Disorder ', ' Obsessive-Compulsive Neurosis ', ' Phenotype ', ' Quality Control ', ' Research ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Computer software ', ' Software ', ' Specificity ', ' statistics ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Translations ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Biological ', ' Link ', ' Training ', ' insight ', ' Individual ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Sample Size ', ' Genetic ', ' gene function ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' human tissue ', ' Source ', ' interest ', ' Performance ', ' user friendly software ', ' user friendly computer software ', ' trait ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' disorder risk ', ' disease risk ', ' Regulation ', ' Modeling ', ' drug development ', ' Genomics ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' Attention deficit hyperactivity disorder ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Brain region ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Address ', ' Data ', ' Disease Pathway ', ' Tissue Model ', ' Molecular ', ' Process ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' Coupled ', ' Heritability ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' public health relevance ', ' molecular phenotype ', ' database of Genotypes and Phenotypes ', ' dbGaP ', ' Drug Targeting ', ' learning strategy ', ' learning method ', ' learning activity ', ' transcriptome ', ' phenotypic data ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' whole genome ', ' entire genome ', ' web app ', ' web application ', ' ']",NIMH,UNIVERSITY OF CHICAGO,R01,2017,430578,IL-01,0.04160953443502988
"An Integrative Analysis of Structural Variation for the 1000 Genomes Project DESCRIPTION (provided by applicant): Structural variation (SV), involving deletions, duplications, insertions and inversions of DNA segments, accounts for a large proportion of human genetic diversity. Comprehensive identification and analysis of these genetic variants will help us more fully elucidate the biology of their functional effects on human health and demography. Despite recent advances, the tools and data needed to comprehensively identify all types of SVs, genotype each variant, integrate and phase these variants remain lacking. Indeed, the data released from the early phases of the 1000 Genomes Project (1000GP) (1000 Genomes Project Consortium, 2010; 1000 Genomes Project Consortium, 2012) are biased primarily towards the detection of deletions within relatively unique regions of the genome. As a consortium, we propose to pool expertise from various research groups to provide an integrative analysis of SVs by combining rigorous computational algorithmic development with extensive experimental validation. The new algorithms we develop and the high confidence lists of SVs obtained will be rapidly made available as a public resource. ",An Integrative Analysis of Structural Variation for the 1000 Genomes Project,9528959,U41HG007497,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' Biology ', ' Chromosomes ', ' Complement Proteins ', ' Complement ', ' Demography ', ' Deoxyribonucleic Acid ', ' DNA ', ' Future ', ' Gene Conversion ', ' Genome ', ' Genotype ', ' Goals ', ' Gold ', ' Haplotypes ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Maps ', ' Methods ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Nucleotides ', ' Phenotype ', ' Research ', ' Resources ', ' Research Resources ', ' Technology ', ' Genetic Diversity ', ' Genetic Variation ', ' Repetitive Regions ', ' Repetitive Element ', ' Repetitive Sequence ', ' base ', ' method development ', ' improved ', ' Phase ', ' Variation ', ' Variant ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Complex ', ' Benchmarking ', ' Best Practice Analysis ', ' DNA Insertion Elements ', ' insertion sequence ', ' insertion element ', ' novel ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' Sampling ', ' Data ', ' Resolution ', ' Validation ', ' Process ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' Computational algorithm ', ' computer algorithm ', ' deletion detection ', ' integration site ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NHGRI,JACKSON LABORATORY,U41,2017,1986604,ME-02,0.11924110504807471
"Whole Genome Sequencing in Irish Multiplex Schizophrenia Families Project Summary: Although affected members of multiplex schizophrenia pedigrees have substantially elevated recurrence risk compared to singleton cases, the mean polygenic risk scores between these groups do not differ, suggesting that one source of this higher familial recurrence risk is rare, higher impact variation. We will collect whole genome sequence (WGS) from 600 affected members of multiplex schizophrenia pedigrees to identify rare variation shared by affected individuals within and between pedigrees potentially accounting for the increased recurrence risk, and reducing the `variant space' under consideration. After QC and calling in our existing pipeline, a) familial sequence variants in the exome will be directly analyzed in 2000 Irish cases and 2000 Irish controls with 30X exome sequence data in production currently, and b) variants outside the exome will be imputed into 3600 Irish singleton schizophrenia or bipolar disorder cases and 3000 Irish population controls with GWAS framework data; 3781 additional UK10K controls with 10X WGS are available to increase analysis power. This imputed dataset will be analyzed using recently developed methods for kernel-based tests of variation aggregated over a defined interval (such as a gene) that avoid the inflation of type-1 error. We use multiple sources of genomic information to develop weights for each position in the genome (indexing the prior probability that a change at the site has functional consequence) and each variant detected (indexing the probability that observed changes have functional consequence), and we propose to improve the existing genomic information sources for this weighting in a number of ways. In aim 3, prioritized variants from aim 2a/2b will be directly genotyped in the case/control samples by custom microarray; individual genes or genesets showing enrichment of variation in cases (if any are observed) will be resequenced in the case/control sample. In Aim 4, the directly assessed genotypic and sequence data from aim 3 will be analyzed using standard methods to identify individual associated variants, and variant-enriched genes, genesets or other functional sequences. We seek to unambiguously identify 1) individual variants that are significantly more common in cases, or 2) individual genes or other functional sequences or 3) gene- or functional sequence sets enriched for variation in cases to provide critical information about the brain systems perturbed in schizophrenia, and the mechanisms by which such alleles increase risk. Project Narrative Rare sequence variation has been implicated in many human complex traits, incuding schizophrenia, and has been studied in unrelated cases and controls and parent:offspring trios, but remains unstudied in multiplex families. Sequencing the genomes of such families will allow conprehensive identification of variation in protein coding genes, non-coding expressed loci, regulatory sequences, and evolutionarily conserved regions, as well as detection of structural variation, and testing these alleles in a large case/control series of the same ethnic and geographic origin offers significant advantages over prior study designs, and has the potential to identify individual alleles, variant enriched genes, variant enriched non-genic sequences, and/or variant enriched genesets contributing to SCH risk in the Irish population. Such variants offer great potential for understanding the functional impact of risk alleles and improving mechanistic understanding of schizophrenia and related disorders.",Whole Genome Sequencing in Irish Multiplex Schizophrenia Families,9403711,R01MH114593,"['Accounting ', ' Affect ', ' Allelomorphs ', ' Alleles ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biology ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Diagnosis ', ' Disorder ', ' Disease ', ' facial ', ' faces ', ' Face ', ' Family ', ' Genes ', ' Genome ', ' Genotype ', ' Geography ', ' Goals ', ' Modern Man ', ' Human ', ' indexing ', ' Economic Inflation ', ' Inflation ', ' Ireland ', ' Irish Free State ', ' Eire ', ' Linkage Disequilibrium ', ' Methods ', ' Nucleotides ', ' Parents ', ' genetic pedigree ', ' pedigree structure ', ' Pedigree ', ' Population Control ', ' Probability ', ' Production ', ' Proteins ', ' Psychotic Disorders ', ' psychotic illness ', ' Psychoses ', ' Recurrence ', ' Recurrent ', ' Research Design ', ' study design ', ' Study Type ', ' Resources ', ' Research Resources ', ' Risk ', ' Risk Factors ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Genetic Diversity ', ' Genetic Variation ', ' Weight ', ' Measures ', ' Dataset ', ' Data Set ', ' Custom ', ' base ', ' improved ', ' specimen collection ', ' sample collection ', ' Site ', ' Phase ', ' Variation ', ' Variant ', ' Series ', ' Individual ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Dimensions ', ' Complex ', ' Source ', ' System ', ' trait ', ' member ', ' offspring ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Sampling ', ' case control ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' genome sequencing ', ' LGALS3BP gene ', ' MAC-2-BP ', ' 90K ', ' Data ', ' Detection ', ' Principal Investigator ', ' Process ', ' work group ', ' working group ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' effective therapy ', ' effective treatment ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' power analysis ', ' whole genome ', ' entire genome ', ' genomic data ', ' ']",NIMH,VIRGINIA COMMONWEALTH UNIVERSITY,R01,2017,464747,VA-04,0.16502677022568615
"NHGRI PAGE Coordinating Center DESCRIPTION (provided by applicant): NHGRI developed the Population Architecture Using Genomics and Epidemiology (PAGE) research program to identify and characterize genomic variants in non-European populations. To support the complexities of such an ambitious effort, we have convened a strong team of statistical, population, and molecular geneticists, computer and information scientists, biostatisticians, and project management staff with many years of related experience to serve as a Coordinating Center (CC). Specifically, the CC will serve as a centralized resource to facilitate and support the activities of the program and Study Investigators focused on characterization of causal variants by: (1) coordinating phenotype harmonization efforts, including mapping phenotype variables across studies and to the PhenX measures; (2) synthesizing individual-level data into centralized datasets to facilitate sharing of data within and outside of PAGE; (3) utilizing state-of-the-art computer and information science support and scientific workflows that will facilitate analyses, ancestry deconvolution, genotype calling and imputation, SNP annotation, and data synthesis; (4) rapidly disseminating all study data via dbGaP and/or the PAGE website or other applicable databases; and (5) serving as a centralized resource to facilitate, support, and manage program activities and logistics as requested by the Steering Committee or Project Office and as needed for successful coordination of the program. Coordination of the program will be done in a spirit of collaboration using creative and flexible approaches, while providing leadership in statistical genetic methodologies and approaches to project management. The ultimate goal of our CC is to facilitate the identification and characterization of genotype-phenotype associations, especially as relevant to non-European populations, thereby accelerating our understanding of ancestral differences in the genetic and environmental causes of common diseases. Critical to achieving this mission is the deployment of powerful methods for ancestry deconvolution, multi- and trans-ethnic mapping, and imputation. Building upon our success as the PAGE I CC, we have added additional investigators with expertise in these areas and consortium experience with next-generation sequence analysis of both whole-genome and exome data. Our collaborative team is ideally staffed to meet the challenges of the new round of PAGE. PUBLIC HEALTH RELEVANCE: The PAGE study focuses on analysis of existing large samples of primarily non- European ancestry to broaden our understanding of the ethnic differences in the genetic basis of complex disease. The PAGE coordinating center supports the functions of this study.",NHGRI PAGE Coordinating Center,9461800,U01HG007419,"['Engineering / Architecture ', ' Architecture ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Communication ', ' Computers ', ' Disorder ', ' Disease ', ' Protocol Screening ', ' Eligibility ', ' Eligibility Determination ', ' Methods Epidemiology ', ' Epidemiological Techniques ', ' Epidemiological Methods ', ' Epidemiologic Methods ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Future ', ' Genome ', ' Genotype ', ' Goals ', ' Group Meetings ', ' Information Sciences ', ' Informed Consent ', ' Leadership ', ' Methods ', ' Methodology ', ' Mining ', ' Mission ', ' Phenotype ', ' Productivity ', ' Publications ', ' Scientific Publication ', ' Recruitment Activity ', ' recruit ', ' active recruitment ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Running ', ' Standardization ', ' Technology ', ' Time ', ' Voice ', ' Work ', "" formycin A 5'-triphosphate "", "" formycin 5'-triphosphate "", ' FTP ', ' formycin triphosphate ', ' Measures ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' symposia ', ' summit ', ' convention ', ' conference ', ' symposium ', ' hispanic community ', ' Spanish Origin ', ' Latino Population ', ' Hispanic Populations ', ' Hispanics ', ' Latino ', ' Dataset ', ' Data Set ', ' Custom ', ' Sequence Analyses ', ' SEQ-AN ', ' Sequence Analysis ', ' base ', ' improved ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Individual ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Logistics ', ' Data Quality ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Deposition ', ' Deposit ', ' tool ', ' instrument ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' programs ', ' Scientist ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Source ', ' meetings ', ' experience ', ' success ', ' computer science ', ' ethnic difference ', ' ethnicity difference ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' Reporting ', ' genetic analysis ', ' Genetic analyses ', ' Sampling ', ' genetic epidemiology ', ' genetic epidemiologic study ', ' software development ', ' developing computer software ', ' develop software ', ' Documentation ', ' Data ', ' genomic region ', ' Genomic Segment ', ' translation research ', ' Translational Science ', ' Translational Research ', ' Update ', ' Monitor ', ' Molecular ', ' work group ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' website ', ' web site ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' next generation ', ' cost efficient ', ' Population ', ' wiki ', ' public health relevance ', ' database of Genotypes and Phenotypes ', ' dbGaP ', ' exome ', ' exomes ', ' sharing data ', ' flexibility ', ' flexible ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' genomic variation ', ' study population ', ' whole genome ', ' entire genome ', ' genomic epidemiology ', ' ']",NHGRI,"RUTGERS, THE STATE UNIV OF N.J.",U01,2017,710189,NJ-06,0.07844014580334506
"Statistical Tests for Mapping Genetic Determinants of Complex Traits     DESCRIPTION (provided by applicant): Genotyping and emerging sequencing technologies have enabled comprehensive interrogation of genetic variation across the human genome, thereby facilitating a study's ability to map genetic variants that influence phenotypes of interes. Nevertheless, genome-wide association studies (GWAS) and next-generation sequencing (NGS) projects have uncovered only a limited number of trait-influencing loci. While large increases in sample size will improve power to detect such variation, the ascertainment and sequencing/genotyping of such samples are costly and inefficient. Therefore, it is desirable to increase power to detect such variants without requiring additional sample collection. We propose novel methods for improved gene mapping of common and rare susceptibility variants that move beyond standard strategies typically applied to GWAS and NGS studies of complex traits. The first topic we consider is pleiotropic or cross- phenotype effects of genetic variants. Empirical studies have suggested that pleiotropy is widespread throughout the genome and that leveraging this additional information for gene mapping yields a more powerful analysis than an analysis that ignores such information. In Aim 1, we propose novel statistical methods for genetic analysis of high-dimensional phenotype data using an innovative kernel distance-covariance (KDC) framework that allows for an arbitrary number of phenotypes both continuous and/or categorical in nature, as well as an arbitrary number of genotypes (permitting gene-based testing of both rare and common variants). We will use the KDC framework to implement tests of pleiotropy as well as tests of mediation. The second topic we consider is the mapping of rare susceptibility variants using affected pedigrees, which provide many attractive features for rare-variant testing that case-control studies lack. In Aim 2, we propose a series of powerful statistical methods for rare-variant association testing in affected pedigrees that are based on a framework (recently published in AJHG) for rare-variant association testing in affected sibships. The existing framework compares rare-variant burden in a region by an affected sib pair to the number of regions that pairs shares identical by descent. We have shown the method is more powerful than case-control association testing given fixed sample size and further is robust to population stratification. In this proposal, we will extend the framework to handle affected pedigrees of arbitrary size and structure (rather than just affected sib pairs) and devise a powerful two-stage screening and validation strategy for rare-variant mapping that first compares familial cases in the pedigrees to external controls and then follows up the most interesting findings using an independent test based on our identity-by-descent sharing statistic among the affected relatives used in the first stage. We will apply the methods in Aims 1-2 to relevant data from genetic studies of complex traits in which we are directly involved. We also will implement the methods in public user-friendly software (Aim 3). PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a set of statistical approaches to investigate two important topics in gene- mapping studies of complex human traits. First, we will develop techniques for identifying genes that have pleiotropic effects on phenotypes of possibly high dimension and further assess whether such genes have direct effects on such phenotypes or indirect effects through other possible factors. Second, we will develop tools to facilitate identification of rare polymorphic variation that increase risk for complex disease using data from affected pedigrees of arbitrary size and structure. We will evaluate these methods using simulated data and illustrate their value by applying them to genetic projects of complex traits in which we are actively involved. Application of the proposed methods to these datasets should improve our understanding of the genetic origins of various complex traits.",Statistical Tests for Mapping Genetic Determinants of Complex Traits,9207474,R01GM117946,"['Affect ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Disorder ', ' Disease ', ' Family ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Modern Man ', ' Human ', ' Joints ', ' Maps ', ' Methods ', ' genetic pedigree ', ' pedigree structure ', ' Pedigree ', ' Phenotype ', ' Public Health ', ' Publishing ', ' Risk ', ' Siblings ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Computer software ', ' Software ', ' Technology ', ' Testing ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Procedures ', ' specimen collection ', ' sample collection ', ' Variation ', ' Variant ', ' Series ', ' Sample Size ', ' Genetic ', ' Genets ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Dimensions ', ' Complex ', ' Techniques ', ' interest ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' user friendly software ', ' user friendly computer software ', ' trait ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Mediation ', ' Negotiation ', ' Negotiating ', ' Categories ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' genetic analysis ', ' Genetic analyses ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' case control ', ' Genetic Determinism ', ' genetic determinant ', ' genetic association ', ' Applied Genetics ', ' Data ', ' Validation ', ' Molecular ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' cost ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' innovation ', ' innovative ', ' innovate ', ' Susceptibility Gene ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' human disease ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide analysis ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' flexibility ', ' flexible ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' screening ', ' rare variant ', ' rare allele ', ' Genetic study ', ' identity by descent ', ' identical by descent ', ' IBD inference ', ' IBD analysis ', ' phenotypic data ', ' population stratification ', ' high dimensionality ', ' ']",NIGMS,EMORY UNIVERSITY,R01,2017,297842,GA-05,0.09474421181580026
"EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE     DESCRIPTION (provided by applicant): The eMERGE III Clinical Center proposal from Partners HealthCare leverages a large biobank, clinical data in the electronic medical records (EMR) for >4 million participants from the largest integrated health care provider in New England, advanced bioinformatics expertise and state-of-the-art genetic analysis. We propose three aims. (1) Aim 1. Discovery. We will test the hypothesis that common and rare variants from a custom chip including 50,000 loss of function (LoF) alleles will be associated with cardiovascular, neuropsychiatric and immune-mediated phenotypes derived from the EMR. We are currently genotyping 25,000 Partners HealthCare Biobank subjects with a custom chip that includes LoF alleles from 63,000 exomes that we have analyzed. (2) Aim 2. Penetrance and Pleiotropy. We will test the hypothesis that sequencing a set of established genes or loci will allow us to discover additional variation, and define penetrance and pleiotropy using EMR phenotypes. Rare variants in genes selected by the eMERGE network will be studied for penetrance and pleiotropic outcomes by PheWAS and chart review. In addition, we are poised to perform recall-by-genotype studies because all Biobank participants have provided consent for such callback. (3) Aim 3. Implementation. We will test the hypothesis that physicians will alter their surveillance and treatment of patients based upon voluntary return of actionable variants to provide safe and cost-effective benefits to patients. We will screen our entire Biobank population of 25,000 individuals for pathogenic variants in the LDLR gene, the leading genetic cause of premature coronary artery disease, and conduct an exploratory trial in disclosing this information. Biobank participants with pathogenic variants in LDLR will be offered enrollment into a randomized trial, in which their finding will be CLIA-confirmed, and in one arm, this result will be communicated to their physicians through the EMR. Over one year, we will collect the following outcomes through participant surveys and EMR queries: physician visits, laboratory testing, changes in medication prescriptions, LDL levels, medical costs and the number of family members screened and treated as a result of the intervention. We will collaborate with the entire eMERGE III Network to incorporate what we learn from this pilot trial into large-scale implementation protocols for the genes selected by the Network for sequencing. Finally, we will participate in all Network activities to enhance the movement of genetics into clinical practice. PUBLIC HEALTH RELEVANCE: The discovery and clinical use of genetic variants associated with both rare Mendelian and more common complex diseases promises to dramatically change the practice of medicine. Our eMERGE III project will leverage a large Biobank and a rich electronic medical record to define the phenotypic impact of mutations emerging from sequencing and then return results on selected variants to Biobank participants using a clinical trial.",EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE,9477855,U01HG008685,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' Atrophic Arthritis ', ' Rheumatoid Arthritis ', ' Bronchial Asthma ', ' Asthma ', ' Biology ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardio-vascular ', ' Cardiovascular system ', ' Clinical Trials ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary Arteriosclerosis ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Coronary heart disease ', ' depression ', ' Mental Depression ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Genes ', ' Genotype ', ' Goals ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' chronic heart failure ', ' Heart Decompensation ', ' Cardiac Failure Congestive ', ' Congestive Heart Failure ', ' Hypercholesteremia ', ' hypercholesterolemia ', ' Newborn Infant ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Inflammatory Bowel Diseases ', ' Inflammatory Intestinal Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Bowel Disorder ', ' Laboratories ', ' Learning ', ' Low-Density Lipoproteins ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' LDL Cholesterol Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' Medicine ', ' Mining ', ' Movement ', ' body movement ', ' Multiple Sclerosis ', ' insular sclerosis ', ' Disseminated Sclerosis ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' New England ', ' Northeastern United States ', ' Patients ', ' Pharmacogenetics ', ' Phenotype ', ' Physicians ', ' Public Health ', ' Research ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' stroke ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' Surveys ', ' Survey Instrument ', ' Testing ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' Family member ', ' health care ', ' Healthcare ', ' Mediating ', ' HLA-DRB1 antigen ', ' HLA-DRB1 ', ' Custom ', ' base ', ' Area ', ' Clinical ', ' prematurity ', ' premature ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Individual ', ' Funding ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Immune ', ' Immunes ', ' Complex ', ' Stream ', ' Protocols documentation ', ' Protocol ', ' Source ', ' Penetrance ', ' Visit ', ' experience ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' Informatics ', ' TYK2 ', ' novel ', ' Participant ', ' genetic analysis ', ' Genetic analyses ', ' neuropsychiatry ', ' neuropsychiatric ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' Attention deficit hyperactivity disorder ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' CTLA4 gene ', ' Cytotoxic T-Lymphocyte-Associated Serine Esterase-4 Gene ', ' Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene ', ' Cytotoxic T-Lymphocyte Protein 4 Gene ', ' CTLA4 ', ' CTLA-4 Gene ', ' CD152 Gene ', ' CD152 Antigen Gene ', ' DRD2 gene ', ' Dopamine Receptor D2 Gene ', ' DRD2 ', ' D2R Gene ', ' D2R ', ' D2DR Gene ', ' D2DR ', ' D(2) Dopamine Receptor Gene ', ' TNFRSF1A gene ', ' tumor necrosis factor  receptor ', ' tumor necrosis factor receptor 1A ', ' tumor necrosis factor alpha receptor ', ' Tumor Necrosis Factor Receptor 55 ', ' Tumor Necrosis Factor Receptor 1 ', ' TNF receptor ', ' TNFalpha receptor ', ' TNFRSF1A Receptor ', ' TNFRSF1A ', ' TNFR60 ', ' TNFR55 ', ' TNFR1 ', ' TNFR-I ', ' TNFR, 60-kD ', ' TNFR, 55-kD ', ' TNFR p60 ', ' TNFAR ', ' TNF- receptor ', ' TNF-sR55 ', ' TNF Receptor p55 ', ' CD120a Antigens ', ' CD 120a Antigen ', ' LDLR gene ', ' TCF7L2 gene ', ' Transcription Factor 7-Like 2 ', ' TCF7L2 ', ' TCF4 ', ' TCF-4 ', ' T-Cell-Specific Transcription Factor 4 ', ' Consent ', ' Cost Effectiveness Analysis ', ' cost-effectiveness analysis ', ' cost-effective analysis ', ' cost efficient analysis ', ' cost effectiveness analyses ', ' cost effective analysis ', ' Cost Effective Analyses ', ' Data ', ' Population Attributable Risks ', ' attributable fraction ', ' Callback ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' pilot trial ', ' cost ', ' implementation research ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' cost effective ', ' cost-effective ', ' Population ', ' loss of function ', ' public health relevance ', ' clinical care ', ' clinical practice ', ' biobank ', ' biorepository ', ' exome ', ' exomes ', ' randomized trial ', ' Randomization trial ', ' arm ', ' rare variant ', ' rare allele ', ' genetic information ', ' clinical sequencing ', ' clinically actionable ', ' support tools ', ' Genomic medicine ', ' biomarker panel ', ' marker panel ', ' neuropsychiatric disorder ', ' neuropsychiatric disease ', ' ']",NHGRI,BRIGHAM AND WOMEN'S HOSPITAL,U01,2017,100000,MA-07,0.12018567818483675
"Decrypting Variants of Uncertain Significance in Long-QT Syndrome DESCRIPTION (provided by applicant): Clinical genetic testing has become standard-of-care for many diseases including hundreds of inherited conditions. However, interpreting genetic test results is often confounded by the discovery of 'variants of unknown significance' (VUS) for which there is insufficient data or inadequate predictive tools to establish whether or not a particular variant predisposes to a disease. This problem is particularly vexing for genetic disorders with strong allelic heterogeneity and a preponderance of 'private' mutations such as the congenital long-QT syndrome (LQTS), which predisposes young adults and children to sudden death from cardiac arrhythmias. With the anticipated incorporation of personal exome or genome data into routine clinical care, interpreting VUS will become an even greater challenge especially when variants in genes associated with human disorders are incidentally discovered. Unfortunately, there are no reliable methods to predict a priori whether a given variant predisposes an individual to a particular disorder or whether the change is merely a benign rare variant. We propose to develop a novel paradigm for distinguishing disease-causing mutations from benign variants in LQTS as a model for other inherited arrhythmia syndromes and channelopathies. We will focus on variants in KCNQ1, the most commonly mutated gene in LQTS. The central hypothesis of this proposal is that a holistic predictive model that relates experimentally determined protein structure and dynamics to function and disease is highly accurate even for novel variants. Our ultimate objectives are to develop a data-trained, web-accessible algorithm that classifies VUS discovered in KCNQ1 based on reliable predictions of the structure and dynamics of the affected protein, and to achieve prediction accuracy to levels needed to inform medical decisions. The medical importance of correctly classifying KCNQ1 variants provides strong justification for having a dedicated and highly-tailored gene-specific prediction model. The ability to distinguish deleterious from neutral variants would help avoid unnecessary and potentially harmful interventions in carriers of benign alleles, and save the lives of those with true mutations. We propose to collect extensive electrophysiological, biochemical and structural data on a large set of KCNQ1 variants discovered in LQTS subjects as well as several suspected benign or neutral variants (Aims 1-2), then use these data to iteratively train and validate a machine learning based algorithm that can differentiate benign from deleterious KCNQ1 alleles among a set of new VUS (Aim 3). Our proposal is innovative in the use of a multidisciplinary approach to functionally and structurally annotate genomic variant data for a medically important gene at an unprecedented scale, and then to use these experimental findings to train/test a novel computational system to achieve clinical-grade predictions. Targeting KCNQ1 will also validate an approach for parallel work that can be utilized to predict the medical significance of variants in closely related potassium channels associated with heritable epilepsy (KCNQ2, KCNQ3) or deafness (KCNQ4). PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a method to reliably predict the consequences of genetic variants of unknown significance discovered in the course of genetic testing in the congenital long-QT syndrome (LQTS), a cause of sudden cardiac death in children and young adults. We propose a multidisciplinary experimental approach including electrophysiology, biochemistry and structural biology deployed on a large scale to generate information on at least 110 genetic variants in the main gene responsible for LQTS (KCNQ1), which encodes a potassium channel required for normal electrical activity in the heart. Our final product will be a data-trained computational strategy that will outperform existing methods for accurately predicting the functional consequences of novel KCNQ1 genetic variants, enhance the value of genetic testing in LQTS and provide for more informed medical decisions.",Decrypting Variants of Uncertain Significance in Long-QT Syndrome,9313321,R01HL122010,"['Affect ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' arrhythmic agent ', ' antiarrhythmic agent ', ' Antiarrhythmic Drugs ', ' Antiarrhythmia Drugs ', ' Antiarrhythmia Agents ', ' Anti-Arrhythmics ', ' Anti-Arrhythmia Drugs ', ' Anti-Arrhythmia Agents ', ' Heart Arrhythmias ', ' Cardiac Arrhythmia ', ' Arrhythmia ', ' Biological Chemistry ', ' Biochemistry ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Dangerousness ', ' Deafness ', ' Sudden Death ', ' Disorder ', ' Disease ', ' electrophysiological ', ' Neurophysiology / Electrophysiology ', ' Electrophysiology ', ' Electrophysiology (science) ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Patient Care Delivery ', ' Patient Care ', ' Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Genome ', ' Goals ', ' Heart ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Heterogeneity ', ' Modern Man ', ' Human ', ' Ion Channel ', ' Membrane Channels ', ' Ionic Channels ', ' Long QT Syndrome ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Online Systems ', ' web based ', ' online computer ', ' On-Line Systems ', ' Patients ', ' Physicians ', ' Potassium Channel ', ' Potassium Ion Channels ', ' K channel ', ' Privatization ', ' Proteins ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Syndrome ', ' Testing ', ' Work ', ' Death, Sudden, Cardiac ', ' Dataset ', ' Data Set ', ' base ', ' Stimulators, Electrical, Cardiac, Shock ', ' Electric Shock Cardiac Stimulators ', ' Defibrillators ', ' Benign ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Medical ', ' Link ', ' Susceptibility ', ' Predisposition ', ' Training ', ' cardiac rhythm ', ' heart rhythm ', ' Individual ', ' young adulthood ', ' adult youth ', ' young adult ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Inherited ', ' Hereditary ', ' System ', ' Test Result ', ' structural biology ', ' knowledge base ', ' knowledgebase ', ' protein transport ', ' Protein Trafficking ', ' trafficking ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Cell surface ', ' proband ', ' Modeling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' protein structure ', ' Data ', ' Mutate ', ' Protein Dynamics ', ' 1st degree relative ', ' First Degree Relative ', ' Other Genetics ', ' Molecular ', ' Cardiac ', ' protein function ', ' developmental ', ' Development ', ' cost ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' innovation ', ' innovative ', ' innovate ', ' Heritability ', ' Impairment ', ' multidisciplinary ', ' Implant ', ' web-accessible ', ' disease-causing mutation ', ' interdisciplinary approach ', ' multidisciplinary approach ', ' public health relevance ', ' clinical care ', ' standard of care ', ' exome ', ' exomes ', ' rare variant ', ' rare allele ', ' variant of unknown significance ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' individual patient ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' predictive tools ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NHLBI,NORTHWESTERN UNIVERSITY AT CHICAGO,R01,2017,1280593,IL-07,0.1801325412341593
"GWAS TO GENE FUNCTION: NOS1AP AND OTHER QT INTERVAL GENES DESCRIPTION (provided by applicant): Genome-wide association studies (GWAS) of the electrographic QT-interval, an intermediate trait that impacts the risks of long QT syndrome and sudden cardiac death, have identified 68 independent variants at 35 loci, explaining 8% of the phenotypic (20% of the additive) variance. Nevertheless, the identity, function and mechanisms of action of the underlying DNA sequence variants and genes remain unknown, and are major impediments for understanding the molecular structure and functional architecture of this complex phenotype. We hypothesize that the majority of functional trait variants are polymorphic, non-coding and perturb transcription of a specific gene by altering the functions of their cis-regulatory elements. We propose a research paradigm for systematically identifying these non-coding trait variants, the regulatory functions they disrupt and the specific genes whose functions are altered at each quantitative trait locus. We will utilize integrative statisticl genetic, computational, molecular genetics and cellular approaches for elucidating the underlying mechanisms, using QT interval as a model 'system'. Our specific aims are: (1) to perform high- resolution mapping of GWAS signals to identify all polymorphic (>1%) and rare variants at loci that modulate the QT-interval; (2) to conduct in silico and in vitro analysis to predict and prioritize all cardiac regulatory (enhancer, silencer, insulator) elements and their cognate DNA-binding proteins; and, (3) to identify trait variants, genes and their mechanisms of genetic action. The overall goals are to improve the molecular genetic and mechanistic understanding of multifactorial traits for applications to other complex phenotypes. PUBLIC HEALTH RELEVANCE: The electrocardiographic QT-interval, an intermediate trait for arrhythmias and sudden cardiac death, has 68 predominantly non-coding variants at 35 loci explaining 8% of the phenotypic (20% of the additive) variance upon meta-analyses in >76,000 individuals of European and >11,000 individuals of African ancestry: nevertheless, the molecular details remain unknown. We propose a program of research for systematically identifying the functional non-coding quantitative trait variants, the regulatory function they disrupt and the specific gene whose functions are altered, at each locus. We utilize integrative statistical genetic, computational, molecular genetics and cellular approaches for understanding the underlying genetic mechanisms in this model trait with the overall goal to improve the molecular understanding of all complex phenotypes.",GWAS TO GENE FUNCTION: NOS1AP AND OTHER QT INTERVAL GENES,9321841,R01GM104469,"['Action Potentials ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Adult ', ' Allelomorphs ', ' Alleles ', ' Engineering / Architecture ', ' Architecture ', ' Heart Arrhythmias ', ' Cardiac Arrhythmia ', ' Arrhythmia ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Base Sequence ', ' Beer ', ' Reactive Site ', ' Combining Site ', ' Binding Sites ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' cell culture ', ' Cell Culture Techniques ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Disorder ', ' Disease ', ' DNA-Binding Proteins ', ' electrophysiological ', ' Neurophysiology / Electrophysiology ', ' Electrophysiology ', ' Electrophysiology (science) ', ' Future ', ' Genes ', ' Goals ', ' Heart ', ' Heterogeneity ', ' Modern Man ', ' Human ', ' Hybrids ', ' Allergy ', ' Hypersensitivity ', ' In Vitro ', ' Infection ', ' Laboratories ', ' Long QT Syndrome ', ' Maps ', ' Methods ', ' Molecular Structure ', ' Macromolecular Structure ', ' Oligonucleotides ', ' oligos ', ' Oligo ', ' Phenotype ', ' Genetic Polymorphism ', ' polymorphism ', ' Proteins ', ' Rattus ', ' Rats Mammals ', ' Rat ', ' Common Rat Strains ', ' Research ', ' Risk ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Mass Spectrum Analysis ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Tissues ', ' Body Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Weight ', ' Genome Mappings ', ' Death, Sudden, Cardiac ', ' Enhancers ', ' Molecular Genetics ', ' promotor ', ' promoter ', ' DNA Sequence ', ' Label ', ' improved ', ' Variation ', ' Variant ', ' Evaluation ', ' Individual ', ' African ', ' European ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Gene Targeting ', ' Collaborations ', ' Genetic ', ' gene function ', ' Reporter ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Complex ', ' System ', ' Muscle Cells ', ' Myocytes ', ' Quantitative Trait Loci ', ' QTL ', ' trait ', ' novel ', ' Positioning Attribute ', ' Position ', ' Modeling ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Electrophoretic Mobility Shift Assay ', ' gel shift assay ', ' Mobility Shift Assay ', ' Bandshift Mobility Assay ', ' Band Shift Mobility Assay ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Insulator Elements ', ' Protein Microchips ', ' Protein Microarray ', ' Protein Chips ', ' Protein Biochips ', ' Binding ', ' Molecular Interaction ', ' chromatin immunoprecipitation ', ' ChIP assay ', ' EP300 gene ', ' p300 ', ' histone acetyltransferase p300 ', ' KAT3B ', ' EP300 ', ' E1A Binding Protein p300 ', ' Affinity ', ' Data ', ' Regulatory Element ', ' Resolution ', ' in vivo ', ' Nuclear Extract ', ' Transcript ', ' Validation ', ' Molecular ', ' Ventricular ', ' Cardiac ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' epigenomics ', ' knockdown ', ' knock-down ', ' Neonatal ', ' Computational algorithm ', ' computer algorithm ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' exome sequencing ', ' rare variant ', ' rare allele ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' differential expression ', ' transcriptional differences ', ' differentially expressed ', ' GATA4 gene ', ' GATA4 transcription factor ', ' GATA4 ', ' GATA binding protein 4 ', ' ']",NIGMS,JOHNS HOPKINS UNIVERSITY,R01,2017,186010,MD-07,0.0976757613835259
"Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases     DESCRIPTION (provided by applicant): The NHGRI Genome Sequencing Program (GSP) will identify genomic variants relevant to health and disease by genome sequencing over 225,000 participants across a multitude of diseases. The GSP will also serve as a pilot for the Precision Medicine Initiative that aims to enroll and sequence more than a million people representative of U.S. ethnic diversity. Here, we propose a GSP analysis center focused on Multi- and Trans- ethnic Mapping of Mendelian and Complex Diseases. There is a growing recognition of the substantial scientific advantages, as well as public health importance, of conducting biomedical research across ethnically diverse cohorts. We propose to develop scalable methods that incorporate ancestry to optimize medical genomic study design and improve power for uncovering the role of common and rare variants in disease. Achieving this goal requires expertise across diverse domains of knowledge including: medical and population genomics, algorithm development for complex disease mapping, and expertise in management of large-scale databases. Here, we have assembled a world-class team of medical and population geneticists, computer scientists, statisticians and clinicians, with leading expertise in the development of novel and scalable strategies for characterizing sequence variants and their role in disease. Importantly, our group has been at the forefront of development of resources, study designs and methods to enable genomic research in U.S. minority populations. Our project has three main objectives. First, we will develop an Automated Scalable Ancestry Pipeline (ASAP) for common disease mapping in diverse populations. ASAP will improve the computational efficiency of existing state-of-the-art methods for ancestry inference and develop important extensions to linear mixed models (LMMs) and other mapping strategies leveraging local and global ancestry. We will also develop methods to refine phenotypes and identify common controls for disease studies and define endpoints. Secondly, we will develop tools and resources for trans- and multi-population rare variant discovery that incorporate patterns of local and sub-continental ancestry. We will also develop machine-learning tools for variant annotation that leverage ancestral information, patterns of sequence evolution, and protein structure in a unified framework. Furthermore, we will incorporate population-specific patterns of cellular phenotypes to improve functional prediction algorithms for non-coding and coding variants. Lastly, we will disseminate our results through web-based resource that empower the biomedical research community. We will augment existing resources including ClinGen by annotating and characterizing pathogenic variants across diverse populations. We will develop a secure web-server that allows sharing of summary statistics and analysis pipelines to enable discovery, fine-mapping and functional prediction of genetic variants. Our team has ample experience with NIH-funded consortia and is dedicated to meeting the overall GSP project goals through collaborative work with NHGRI leadership and other funded investigators. PUBLIC HEALTH RELEVANCE The goal of our project is to accelerate the discovery of DNA variation relevant to health and disease by analyzing data from over 225,000 ethnically and racially diverse patients that will undergo genome sequencing. Of particular importance is ensuring we have powerful statistical methods for analyzing data from underserved groups including U.S. minority populations. Achieving this goal requires expertise across many domains of knowledge including: medical and population genomics, algorithm development for disease mapping, and expertise in large-scale databases.",Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases,9268656,U01HG009080,"['Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' Biomedical Research ', ' chronic disorder ', ' Chronic Illness ', ' Chronic Disease ', ' Communities ', ' Computers ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Leadership ', ' Methods ', ' Methodology ', ' Methylation ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Patients ', ' Phenotype ', ' Privatization ', ' Public Health ', ' Research ', ' Research Design ', ' study design ', ' Study Type ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Risk ', ' Role ', ' social role ', ' Shoulder ', ' statistics ', ' Target Populations ', ' Testing ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' United States ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' population diversity ', ' heterogeneous population ', ' diverse populations ', ' Population Heterogeneity ', ' Dataset ', ' Data Set ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' programs ', ' Scientist ', ' Investigation ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' meetings ', ' experience ', ' cohort ', ' simulation ', ' novel ', ' Participant ', ' Code ', ' Coding System ', ' Statistical Methods ', ' Modeling ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' disorder control ', ' disease control ', ' Pathogenicity ', ' genome sequencing ', ' protein structure ', ' Data ', ' Resolution ', ' Resource Development ', ' enroll ', ' Enrollment ', ' developmental ', ' Development ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' patient privacy ', ' Minority ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' large-scale database ', ' large-scale data base ', ' tool development ', ' public health relevance ', ' phenome ', ' Secure ', ' rare variant ', ' rare allele ', ' Precision Medicine Initiative ', ' genomic tools ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' ethnic diversity ', ' ethnically diverse ', ' racial diversity ', ' racially diverse ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' online resource ', ' web-based resource ', ' web resource ', ' on-line resource ', ' internet resource ', ' web-based tool ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2017,923476,CA-18,0.16988658568500095
"UNDERSTANDING THE FUNCTIONAL IMPACTS OF GENETIC VARIANTS IN MENTAL DISORDERS     DESCRIPTION (provided by applicant): In the US, 46% are afflicted with a mental illness at some point of life. The management and treatment of mental disorders pose significant economical and social burden to the society. Many rare and common genetic variants, including SNPs and CNVs, are reported to be associated with mental disorders, yet more remain to be discovered. However, despite the large amount of high-throughput genomics data, there is a lack of integrative methods to systematically prioritize variants that confer susceptibility to mental disorders; additionally, despite the presence of many candidate variants for mental disorders, their disease-contributory mechanism remains elusive, so appropriate functional follow-up experiments cannot be designed. Altogether, these problems resulted in a large gap between the copious amount of data about genetic variation and our understanding of their functional impacts on mental diseases, which ultimately delays the development of targeted therapeutic approaches. To address these problems, we propose to develop a suite of novel bioinformatics approaches: (1) NeuroComplex, an information integration approach that leverages phenotype information and multiple sources of prior biological knowledge to rank genes by their likelihood of contributing to specific phenotypic presentations. (2) integrated MEntal-disorder GEnome Score (iMEGES), which leverages a two-layer strategy to predict the impacts of variants in personal genomes on mental disorders. The first layer uses machine learning algorithm to build variant deleteriousness scores for coding, non-coding and structural variants; the second layer integrates variant scores and NeuroComplex to assign pathogenicity scores. (3) a hierarchical model called CombOmics that incorporates cross-omics information to characterizes how variants confers disease risk, in order to help formulate hypothesis of pathogenicity and facilitate the design of functional follow-up experiments. (4) we will develop user-friendly software tools and web applications that implement all the aforementioned bioinformatics approaches, and continuously release and maintain these tools to ensure the maximum benefits to the scientific community.         PUBLIC HEALTH RELEVANCE: We will develop novel informatics approaches to understand how genetic variation impacts various mental disorders, such as schizophrenia and autism. These tools help clarify the genetic cause of mental diseases, characterize individual disease risks and develop individualized treatment strategies.            ",UNDERSTANDING THE FUNCTIONAL IMPACTS OF GENETIC VARIANTS IN MENTAL DISORDERS,9389287,R01MH108728,"['Algorithms ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' psychological disorder ', ' psychiatric illness ', ' mental illness ', ' Psychiatric Disorder ', ' Psychiatric Disease ', ' Mental health disorders ', ' Mental disorders ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Family ', ' Gene Expression ', ' Genes ', ' Genome ', ' Methods ', ' Patients ', ' Phenotype ', ' Psychiatry ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Societies ', ' Computer software ', ' Software ', ' Software Tools ', ' Computer Software Tools ', ' Surveys ', ' Survey Instrument ', ' Testing ', ' Genetic Diversity ', ' Genetic Variation ', ' Generations ', ' Research Methods ', ' Research Methodology ', ' doubt ', ' Uncertainty ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' Susceptibility ', ' Predisposition ', ' mental ', ' Psyche structure ', ' Individual ', ' Patient Selection ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Life ', ' Source ', ' Techniques ', ' System ', ' Benchmarking ', ' Best Practice Analysis ', ' Performance ', ' success ', ' user friendly software ', ' user friendly computer software ', ' cohort ', ' Informatics ', ' skills ', ' novel ', ' disorder risk ', ' disease risk ', ' Disease model ', ' disorder model ', ' Reporting ', ' social ', ' Gene Proteins ', ' Protein Gene Products ', ' Code ', ' Coding System ', ' Modeling ', ' Sampling ', ' response ', ' Untranslated RNA ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Address ', ' Data ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Ontology ', ' Validation ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' Text ', ' developmental ', ' Development ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' Genetic Annotation ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' user-friendly ', ' prototype ', ' public health relevance ', ' treatment strategy ', ' Bayesian Modeling ', ' Bayesian tracking algorithms ', ' Bayesian statistical models ', ' Bayesian spatial models ', ' Bayesian spatial image models ', ' Bayesian spatial data model ', ' Bayesian nonparametric models ', ' Bayesian network model ', ' Bayesian hierarchical model ', ' Bayesian framework ', ' Bayesian belief updating model ', ' Bayesian belief network ', ' Bayesian adaptive models ', ' Bayesian adaptive designs ', ' individualized medicine ', ' unique treatment ', ' tailored treatment ', ' tailored medical treatment ', ' individualized treatment ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' personalized therapeutic ', ' genetic information ', ' web app ', ' web application ', ' genomic data ', ' experimental study ', ' experimental research ', ' experiment ', ' knowledge integration ', ' high dimensionality ', ' ']",NIMH,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2017,381539,NY-13,0.04758119544661363
"Regulation of mRNA splicing by intronic genetic variants     DESCRIPTION (provided by applicant): Genetic variations in introns commonly impact cellular functions by causing alterations in mRNA splicing. The abnormal inclusion and exclusion of exons often change protein functions and cellular phenotypes. Although many intronic variations have known functions, with the adoption of next generation sequencing, many more intronic variants have been discovered for which the functional impact is unknown. Thus, it is important to be able to predict the impact of the variants without needing to test them all in expensive and laborious assays. Although there are informatics algorithms that predict the impact of genetic variants on pre-mRNA splicing, their ability to predict the effect on protein function and ultimately disease and therapeutic phenotypes is lacking. In addition, there is a need for high-throughput cellular assays to test the results of these predictions on cellular functions. The studies proposed here will fulfill these needs by developing algorithms that prioritize the intronic variants by their potential impact on splicing and gene function, and developing a high-throughput assay to functionally test thousands of these predictions. These novel technologies will be applied to the effect of intronic variants on the pharmacogenomics of two clinically important oncology drugs, clofarabine and paclitaxel. Our long-term goals are to be able to predict the functional impact of genomic variants on human disease and therapeutic response. Our central hypothesis is that intronic genetic variants alter mRNA splicing and consequently protein function that ultimately affects the cellular response to drug therapy. Our first aim will be to develop computational algorithms that prioritize intronic variants based on their impacts on pre-mRNA splicing and protein function. Using a variety of genomic and structural features and large sets of genomic data, we will develop a bioinformatics algorithm specifically designed to prioritize intronic variants based on their potential impacts on pre-mRNA splicing and protein function. Our second aim will be to identify functional intronic variants associated with drug-induced cytotoxicity. Using existing genomics and cellular cytotoxic response data from populations of human cell lines, we will identify functional intronic variants that contribute to individuals' responses to clofarabine and paclitaxel cytotoxicity. Our third aim will be to functionally test the impact of the prioritized intronic variants on pre-mRNA splicing and drug cytotoxicity. Using our novel high- throughput functional splicing assay, we will test the effects of predicted functional variants from Aim 2 on pre- mRNA splicing. In addition, we will validate the effect of the intronic variants on cytotoxicity using exon specific siRNA and CRISPR/Cas technology to manipulate the target gene splicing. Upon completion of these studies, we expect to have developed bioinformatics algorithms that can accurately prioritize the intronic variants based on their functional impact on pre-mRNA splicing and protein function. Also, we will have tested thousands of variants in a cellular pre-mRNA splicing assay and validated the impact of several of these functional variants on paclitaxel and clofarabine cytotoxicity. PUBLIC HEALTH RELEVANCE    Project Narrative The goal of this project is to design and implement a set of bioinformatics algorithms and high-throughput experimental assays for prioritizing functional intronic variants that contribute to phenotypic differences by affecting pre-mRNA splicing. The developed model, including a molecular validation component, will be used to systematically evaluate the functions of such variants that are associated with drug-induced cytotoxicity. The same strategy can also be used to study the etiology of complex diseases. This goal is directly relevant to the missions of NIH to improve the capability of disease diagnosis, treatment, and prevention.",Regulation of mRNA splicing by intronic genetic variants,9491760,R01CA213466,"['Adoption ', ' Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Clinical Research ', ' Clinical Study ', ' Computers ', ' Disease ', ' Disorder ', ' Pharmacotherapy ', ' drug treatment ', ' Drug Therapy ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Exons ', ' Genes ', ' Spliced Genes ', ' Gene Splicing ', ' Population Genetics ', ' Goals ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Introns ', ' Intervening Sequences ', ' Mission ', ' mRNA Precursor ', ' premRNA ', ' RNA, Messenger, Precursors ', ' Pre-mRNA ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Phenotype ', ' Publishing ', ' Research ', ' RNA Splicing ', ' Splicing ', ' Messenger RNA ', ' mRNA ', ' Testing ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Clofarabine ', ' Paclitaxel ', ' Taxol Konzentrat ', ' Taxol A ', ' Taxol ', ' Praxel ', ' Paclitaxel (Taxol) ', ' Bristaxol ', ' Asotax ', ' Anzatax ', ' base ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Gene Targeting ', ' Biological Function ', ' Biological Process ', ' Oncology Cancer ', ' oncology ', ' Cell-Mediated Cytolysis ', ' cell mediated cytotoxicity ', ' Lymphocytotoxicity ', ' Lymphocyte Cytotoxicity ', ' Cellular Cytotoxicity ', ' Cell-Mediated Lympholysis ', ' Therapeutic ', ' gene function ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Source ', ' cell type ', ' Test Result ', ' cytotoxicity ', ' Lytotoxicity ', ' Informatics ', ' novel ', ' Exclusion ', ' Human Cell Line ', ' new technology ', ' novel technologies ', ' Prevention ', ' Regulation ', ' Modeling ', ' response ', ' high throughput screening ', ' High Throughput Assay ', ' functional genomics ', ' Genomics ', ' Small Interfering RNA ', ' siRNA ', ' Short interfering RNA ', ' Pharmacogenomics ', ' Bioinformatics ', ' Bio-Informatics ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' protein structure ', ' cytotoxic ', ' Data ', ' cell assay ', ' Cellular Assay ', ' Validation ', ' Molecular ', ' protein function ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' multidisciplinary ', ' computer algorithm ', ' Computational algorithm ', ' human disease ', ' public health relevance ', ' therapeutic response ', ' response to treatment ', ' treatment response ', ' disease diagnosis ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' genomic variation ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' CRISPR/Cas technology ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' genomic data ', ' genomic predictors ', ' individualized response ', ' individual response ', ' ']",NCI,INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,R01,2018,558312,IN-07,0.17735005780903945
"Optimizing Genetic Testing for Deafness for Clinical Diagnostics Project Summary  Hearing loss is the most common sensory deficit in humans. It is diagnosed in 1 in 500 newborns and affects half of all octogenarians. Although causality is multifactorial, in developed countries a large fraction of hearing loss is genetic and non-syndromic, i.e. not associated with other phenotypes.  During the prior granting period, we implemented and integrated comprehensive genetic testing as a cornerstone in the evaluation of the deaf and hard-of-hearing person. The American College of Medical Genetics has recognized the merit of this approach, and in 2014 included comprehensive genetic testing for the evaluation of deafness in their newest treatment guidelines. In the largest study to date to corroborate this decision, we found an underlying genetic cause for hearing loss in 440 (39%) of 1119 sequentially accrued patients chosen without exclusion criteria. Pathogenic variants were present in 49 genes and included missense variants (49%), copy number changes (18%), indels (18%), nonsense variants (8%), splice-site alterations (6%) and promoter variants (<1%), making comprehensive genetic testing the single best test to order in the diagnosis of hearing loss after an audiogram.  In this competitive renewal, we will build on these accomplishments by completing the following aims:  Specific Aim 1: To optimize phenotype-genotype integration in the analysis of hereditary hearing loss  by refining the use of hierarchical surface clustering and audioprofile surface analysis to determine  which types of genetic hearing loss are associated with clinically meaningful sub-clusters  Specific Aim 2: To validate and integrate physics-based protein modeling as a tool within the Deafness  Variation Database to predict variant effect and the molecular and patient phenotype  Specific Aim 3: To identify genetic modifiers of specific deafness-causing genes predicted by  hierarchical surface clustering and validated by physics-based potential free-energy modeling  The successful completion of this grant will improve the clinical care of persons with hearing loss by enhancing phenome-genome integration and by making variant interpretation more robust. Knowledge gained from this proposal will also lay the foundation for refined studies focused on the identification of genetic modifiers  both positive and negative  associated with complex phenotypes such as noise- induced and age-related hearing loss. This competitive renewal addresses the increasingly daunting challenge of variant interpretation. We will seamlessly integrate AudioGene into the OtoSCOPE pipeline, explore hierarchical surfaces clustering at all loci, enhance the utility of the Deafness Variation Database by adding physics-based potential free-energy modeling, and using these tools, identify genetic modifiers of select types of genetic hearing loss. The completion of these aims will lay the foundation for more refined studies focused on the identification of genetic modifiers  both positive and negative  associated with complex hearing loss phenotypes including noise-induced and age-related hearing loss.",Optimizing Genetic Testing for Deafness for Clinical Diagnostics,9393258,R01DC012049,"['Adoption ', ' Affect ', ' Algorithms ', ' Audiometry ', ' Audiometric Test ', ' Audiogram ', ' Biology ', ' Classification ', ' Systematics ', ' Clinical Trials ', ' Communities ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Cystic Fibrosis ', ' Mucoviscidosis ', ' Deafness ', ' Decision Making ', ' Decision Trees ', ' Developing Countries ', ' Under-Developed Nations ', ' Under-Developed Countries ', ' Third-World Nations ', ' Third-World Countries ', ' Less-Developed Nations ', ' Less-Developed Countries ', ' Developing Nations ', ' Diagnosis ', ' Duchenne muscular dystrophy ', ' pseudohypertrophic muscular paralysis ', ' pseudohypertrophic adult muscular dystrophy ', ' progressive muscular dystrophy of childhood ', ' mild X-linked recessive muscular dystrophy ', ' classic X-linked recessive muscular dystrophy ', ' childhood pseudohypertrophic muscular dystrophy ', ' benign X-linked recessive muscular dystrophy ', ' X-linked recessive muscular dystrophy ', ' X-linked muscular dystrophy ', ' X-linked dilated cardiomyopathy ', ' Pseudohypertrophic Muscular Dystrophy ', ' Ellis-van Creveld (EvC) syndrome ', ' Duchenne-Griesinger syndrome ', ' Duchenne ', ' Duchene ', ' Foundations ', ' gene therapy ', ' genetic therapy ', ' gene-based therapy ', ' Genetic Intervention ', ' Gene Transfer Clinical ', ' DNA Therapy ', ' Genes ', ' Medical Genetics ', ' Clinical genetics ', ' Genome ', ' Genotype ', ' Grant ', ' Health Personnel ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health workforce ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Hearing ', ' sound perception ', ' hearing perception ', ' Human ', ' Modern Man ', ' Newborn Infant ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Methods ', ' Persons ', ' Noise ', ' Octogenarian ', ' Patients ', ' Phenotype ', ' Physics ', ' Presbycusis ', ' age related hearing loss ', ' Presbyacusis ', ' Proteins ', ' Research ', ' RNA Splicing ', ' Splicing ', ' medical schools ', ' school of medicine ', ' medical college ', ' Technology ', ' Testing ', ' falls ', ' Case Study ', ' case report ', ' Healthcare ', ' health care ', ' promoter ', ' promotor ', ' Guidelines ', ' base ', ' evaluation/testing ', ' Otoscopes ', ' improved ', ' Site ', ' Area ', ' Surface ', ' Clinical ', ' Variation ', ' Variant ', ' Evaluation ', ' prognostic ', ' data base ', ' Data Bases ', ' Databases ', ' Industrialized Nations ', ' Industrialized Countries ', ' Developed Nations ', ' Developed Countries ', ' Therapeutic ', ' Cochlear implant procedure ', ' Cochlear Prosthesis Implantation ', ' Cochlear Implantation ', ' Genetic ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Inherited ', ' Hereditary ', ' Complex ', ' Sensory ', ' Techniques ', ' Hearing Impaired Persons ', ' Persons With Hearing Impairments ', ' Hard of Hearing Persons ', ' Deaf ', ' American ', ' genetic disorder diagnosis ', ' genetic diagnosis ', ' cohort ', ' Free Energy ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Reporting ', ' Modeling ', ' Genomics ', ' Pathogenicity ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' hearing impairment ', ' Hypoacusis ', ' Hypoacuses ', ' Hearing Loss ', ' Address ', ' Data ', ' Research Infrastructure ', ' Infrastructure ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' enroll ', ' Enrollment ', ' Exclusion Criteria ', ' Molecular ', ' clinical phenotype ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' software systems ', ' designing ', ' design ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Heritability ', ' clinical significance ', ' clinically significant ', ' clinical care ', ' phenome ', ' clinical decision-making ', ' Massively Parallel Sequencing ', ' Massively Parallel DNA Sequencing ', ' Massive Parallel Sequencing ', ' personalized genetics ', ' precision genetics ', ' clinical diagnostics ', ' preservation ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' clinical implementation ', ' treatment guidelines ', ' ']",NIDCD,UNIVERSITY OF IOWA,R01,2018,564086,IA-02,0.06534042336241784
"An integrative approach to functionalize GWAS hits in MI and stroke     DESCRIPTION (provided by applicant): Coronary heart disease (CHD) and cerebrovascular disease result from platelet thrombus formation at the site of a ruptured atherosclerotic plaque. Numerous studies have shown enhanced platelet reactivity, and increased platelet count and volume are risk factors for CHD events and fatality, and a recent NHLBI Working Group concluded that variation in platelet reactivity is a major determinant of ischemic events, like MI or stroke. Genome wide association studies (GWASs) have identified numerous common genetic variants associated with the risk of CHD and platelet function parameters, but most of the positive ""hits"" are not causative of the phenotype. To understand the cellular mechanisms by which these variants affect platelet function it is imperative to know the repertoire of mRNAs, miRNAs and lncRNAs expressed in the cell of interest. Our team has been a leader in the field of platelet transcriptomics as well as functional assessment of variants in platelet genes. We have profiled mRNAs and miRNAs from 183 subjects using multiple platforms and have also performed platelet RNA-seq on 14 different subjects. This information provides a critical ability to filter, prioritize and obtain variant functional insights for evaluating GWAS SNPs associated with MI, stroke and platelet parameters. We have identified 142 mRNAs and 9 miRNAs that are expressed in platelets and linked to these GWAS hits. The goals of this proposal are to identify, assay, and validate functional variation previously tagged in GWASs of platelet-mediated ischemic arterial disease and of platelet phenotypes. Aim 1 will identify GWAS-linked mRNAs, miRNAs and lncRNAs that are functional in platelets. Candidate RNAs will be refined by association with platelet function, eQTLs and QTLs using our previously generated platelet RNA data. We will develop a supervised machine-learning, statistical pattern matching algorithm to prioritize likely platelet-functional genes. Gene-level assays in which we knock down mRNA, miRNA and lncRNA in our human megakaryocyte culture system, followed by assays for integrin activation and quantification of platelet number and volume will be used to confirm platelet functionality. Aim 2 will identify functionally divergent SNPs and haplotypes. We will impute missing SNPs and perform fine-mapping to the phenotypes of interest. Variants will be prioritized by association strength, annotation data, and predicted function using publically available resources and our own platelet eQTL data. Non-coding candidates will be tested by reporter gene assay and non-synonymous variants will be tested using functional assays in cell lines in which the endogenous gene has been silenced. We will validate our findings with a replication analysis in which we use an independent cohort dataset to quantify the association of the tested variants with the original GWAS phenotype. PUBLIC HEALTH RELEVANCE:  Platelet-mediated arterial thrombosis in the coronary or cerebrovascular circulation is the major cause of mortality and morbidity in the U.S. Numerous DNA variations have been associated with these disorders, but the causal genes are unknown. This research will test whether genes near these DNA variations - and candidate variations themselves - alter platelet function or number to understand better the molecular mechanisms causing heart attacks and strokes.",An integrative approach to functionalize GWAS hits in MI and stroke,9528639,R01HL128234,"['Affect ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Amino Acids ', ' aminoacid ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Blood Platelets ', ' thrombocyte/platelet ', ' Thrombocytes ', ' Platelets Reticuloendothelial System ', ' Platelets ', ' Marrow platelet ', "" Hayem's elementary corpuscle "", "" Deetjeen's body "", "" Bizzozero's corpuscle/cell "", ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cells ', ' Cell Body ', ' Cerebrovascular Circulation ', ' cerebrovascular blood flow ', ' cerebrocirculation ', ' cerebral circulation ', ' cerebral blood flow ', ' brain blood flow ', ' Cerebrovascular Disorders ', ' intracranial vascular dysfunction ', ' cerebrovascular dysfunction ', ' cerebral vascular dysfunction ', ' cerebral vascular disease ', ' brain vascular dysfunction ', ' brain vascular disease ', ' Intracranial Vascular Disorders ', ' Intracranial Vascular Diseases ', ' Cerebrovascular Disease ', ' Brain Vascular Disorders ', ' Coronary Circulation ', ' Coronary heart disease ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Gene Expression ', ' Genes ', ' Genotype ', ' Goals ', ' Haplotypes ', ' Human ', ' Modern Man ', ' Integrins ', ' Integrins Extracellular Matrix ', ' Introns ', ' Intervening Sequences ', ' Laboratories ', ' Maps ', ' Megakaryocytes ', ' Megalokaryocyte ', ' Blood megakaryocyte ', ' Methods ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Myocardial Infarction ', ' heart infarction ', ' heart infarct ', ' heart attack ', ' coronary infarction ', ' coronary infarct ', ' coronary attack ', ' cardiac infarct ', ' Myocardial Infarct ', ' Cardiac infarction ', ' Phenotype ', ' Platelet Count measurement ', ' Platelet Number ', ' Platelet Count ', ' Blood Platelet Number ', ' Blood Platelet Count ', ' Production ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Research ', ' Resources ', ' Research Resources ', ' Risk ', ' Risk Factors ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Messenger RNA ', ' mRNA ', ' Role ', ' social role ', ' Stroke ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' Supervision ', ' Testing ', ' Thrombosis ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Measures ', ' falls ', ' Enhancers ', ' Mediating ', ' promoter ', ' promotor ', ' Thrombus ', ' Data Set ', ' Dataset ', ' base ', ' human subject ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Reporter Genes ', ' Link ', ' insight ', ' Individual ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Event ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' System ', ' interest ', ' cohort ', ' Untranslated Regions ', ' UTRs ', ' Prevention ', ' Reporting ', ' Intergenic Sequence ', ' Intercistronic Sequence ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Sentinel ', ' MicroRNAs ', ' miRNAs ', ' miRNA ', ' Micro RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' Binding ', ' Molecular Interaction ', ' CD34 gene ', ' HPCA1 ', ' CD34 ', ' Mediator of activation protein ', ' Mediator of Activation ', ' Mediator ', ' Data ', ' Reproducibility ', ' Pathologic ', ' Molecular ', ' protein function ', ' work group ', ' working group ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' clinical phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' knockdown ', ' knock-down ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Coupled ', ' Heritability ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' transcriptomics ', ' clinical relevance ', ' clinically relevant ', ' public health relevance ', ' genomewide ', ' genome scale ', ' genome-wide ', ' dbGaP ', ' database of Genotypes and Phenotypes ', ' chromatin immunoprecipitation-sequencing ', ' ChIP Sequencing ', ' ChIP-seq ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' screening ', ' global transcription profile ', ' global gene expression ', ' transcriptome ', ' interindividual variation ', ' inter-individual variability ', ' inter-individual variation ', ' Chromosome Interaction Analysis with Paired-End Tags ', ' ChIA-PET ', ' Chromatin Interaction Analysis by Paired-End Tag Sequencing ', ' atherosclerotic plaque rupture ', ' ']",NHLBI,THOMAS JEFFERSON UNIVERSITY,R01,2018,392470,PA-03,0.04809103870656848
"Interrogating regulatory variants by multiplexed genome editing A major result from recent genome wide association studies (GWAS) is that the majority of genetic variants driving common human diseases lie in regulatory, rather than protein-coding, regions. Massive efforts to map epigenomic features such as localization of histone modifications (HMs) and transcription factors (TFs) have paved the way toward understanding the regulatory genome. However, dissecting the impact of an individual non-coding variant remains an unsolved challenge.  A variety of computational methods have been proposed, such as quantitative trait loci (QTL) studies and machine learning techniques. However, these methods still do not provide conclusive information about causality of any specific non-coding mutation and lack gold-standard experimental results for evaluation. Several techniques are used to experimentally test the impact of individual regulatory variants. For example, massively parallel reporter assays (MPRA) synthesize thousands of oligonucleotides encoding mutated versions of putative regulatory elements placed in plasmids upstream of reporter genes. However, a major limitation is that tested sequences are outside of their endogenous chromosomal locus, and hence do not necessarily provide physiological relevance.  CRISPR enables targeted editing of genomic DNA. Indeed, CRISPR is widely used, but studies of individual point mutations have been primarily on a small scale and are usually limited to a handful of variants or to a single gene. The major throughput challenge in studying a specific variant using genome editing is in tying genotype to phenotype. Introducing individual mutations exhibits low efficiency, and thus there is a need for enrichment of the genotype or phenotype of interest prior to assessing the impact of a mutation on a phenotype, such as gene expression. Current enrichment methods either disrupt the physiological context or are low throughput. Recent efforts overcame these challenges using pooled editing to analyze thousands of mutations simultaneously, but were limited to variants in protein coding regions.  This proposal aims to develop a novel technique merging multiplexed genome editing of putative regulatory variants followed by chromatin immunoprecipitation sequencing (ChIP-seq) to simultaneously measure the impact of hundreds of non-coding variants on regulatory potential in their native genomic context. The key insight of the proposed approach is that mutations impacting epigenomic features can be measured both in genomic DNA and in phenotypic readouts such as ChIP-seq of TFs or HMs, avoiding the need for a selection step to connect genotypes with phenotypes. Aim 1 develops the pooled editing technique on a pilot set of previously validated regulatory variants. Aim 2 scales this approach to interrogate thousands of mutations at once. Aim 3 integrates experimental predictions with state of the art machine learning methods to evaluate and optimize computational methods for regulatory variant effect prediction. Recent studies have demonstrated that the majority of genetic changes in the population contributing to common human diseases, such as schizophrenia, heart disease, and diabetes, lie in regions of the genome that do not code for proteins, but rather regulate the expression of genes. Despite massive efforts to map regulatory regions across dozens of human cell types, it is still difficult to predict the effect of an individual non-coding mutation. This project develops a high-throughput genome editing technique to simultaneously measure the impact of hundreds of non-coding mutations on regulatory potential in their native genomic context, with the ultimate goal of interpreting genetic changes leading to human disease.",Interrogating regulatory variants by multiplexed genome editing,9509167,R21HG010070,"['Affect ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Cells ', ' Cell Body ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Diabetes Mellitus ', ' diabetes ', ' DNA ', ' Deoxyribonucleic Acid ', ' Exhibits ', ' Gene Expression ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Gold ', ' Heart Diseases ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Primary carcinoma of the liver cells ', ' liver carcinoma ', ' Liver Cells Carcinoma ', ' Hepatoma ', ' Hepatocellular cancer ', ' Hepatocellular Carcinoma ', ' Hepatocarcinoma ', ' Human ', ' Modern Man ', ' Maps ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Oligonucleotides ', ' oligos ', ' Oligo ', ' Phenotype ', ' Plasmids ', ' Proteins ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Resources ', ' Research Resources ', ' Messenger RNA ', ' mRNA ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Testing ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Measures ', ' Open Reading Frames ', ' Protein Coding Region ', ' ORFs ', ' Enhancers ', ' Data Set ', ' Dataset ', ' Point Mutation ', ' improved ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Reporter Genes ', ' Evaluation ', ' Liver Cells ', ' Hepatic Parenchymal Cell ', ' Hepatic Cells ', ' Hepatocyte ', ' insight ', ' Individual ', ' Reporter ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' cell type ', ' Techniques ', ' interest ', ' Quantitative Trait Loci ', ' QTL ', ' novel ', ' Sorting - Cell Movement ', ' sorting ', ' Cell Fraction ', ' Code ', ' Coding System ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Allelic Imbalance ', ' Genomics ', ' histone modification ', ' Binding ', ' Molecular Interaction ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Address ', ' Mutate ', ' Regulatory Element ', ' mRNA Expression ', ' Carcinoma Cell ', ' Malignant Epithelial Cell ', ' Molecular ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' epigenomics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' innovative ', ' innovate ', ' innovation ', ' human disease ', ' molecular phenotype ', ' chromatin immunoprecipitation-sequencing ', ' ChIP Sequencing ', ' ChIP-seq ', ' gDNA ', ' Genomic DNA ', ' genomic editing ', ' genome editing ', ' HepG2 cell line ', ' Hep G2 ', ' HepG2 ', ' Transcription Factor 14, Hepatic Nuclear Factor ', ' TCF14 ', ' Hepatocyte Nuclear Factor, 4 ', ' Hepatocyte Nuclear Factor 4-Alpha ', ' HNF4A ', ' HNF4-Alpha ', ' HNF4 ', ' HNF4A gene ', ' learning method ', ' learning activity ', ' learning strategy ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' CRISPR/Cas technology ', ' ']",NHGRI,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R21,2018,196302,CA-52,0.0003235263490157797
"Inferring Molecular Mechanisms of Complex Disease by Integrating Patterns of Epistasis with Functional Genomic Networks The goal of this proposal is to develop computational methods that will identify genes driving epistasis between quantitative trait loci. Genetic association studies in both humans and model organisms have been increasingly able to detect interactions among genetic variants that influence disease risk and pathogenesis. However, identifying which genes are represented by individual variants is a major challenge. Many variants influencing disease are situated between genes, and even those that are in genes may be representing an effect from a neighboring gene. In model organism studies the situation is even more problematic. In breeding experiments, genetic associations with phenotypes typically encompass large regions of DNA with many genes, and experimental follow-up to identify the genes responsible for the association is resource-intensive. To address this problem, we are developing computational tools to prioritize putative gene interactions in interacting genomic regions for biological follow-up. We use machine learning classifiers trained on functional gene-gene interaction networks and combinatorial optimization to identify likely candidate gene-gene interactions responsible for epistatic interactions between genomic regions. Our methods sift through enormous spaces of candidate interactions, retaining only those whose functional interactions identify as plausible for supporting the epistatic interaction. These tools hold promise to dramatically limit the resource-intensity of biological follow up of putative epistasis and to clarify the genetic architecture of complex disease. Genetic studies in humans and model organisms are critical to understanding how genes interact to influence disease. Standard association studies, however, do not identify individual genes, but rather large genetic regions containing many genes, and determining individual genes responsible for phenotypic effects requires resource-intensive biological follow-up experiments. We are developing computational methods to prioritize genes in these regions for biological follow-up, with the ultimate goal of speeding the discovery of novel roles of genes in disease.",Inferring Molecular Mechanisms of Complex Disease by Integrating Patterns of Epistasis with Functional Genomic Networks,9528022,R21LM012615,"['Algorithms ', ' Automobile Driving ', ' driving ', ' Bacteria ', ' Breeding ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Engineering ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' epistatic relationship ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Future ', ' Genes ', ' Goals ', ' Gold ', ' Chronic Kidney Failure ', ' chronic kidney disease ', ' Chronic Renal Failure ', ' Chronic Renal Disease ', ' Learning ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Phenotype ', ' Play ', ' Proteins ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Systemic Scleroderma ', ' progressive systemic sclerosis ', ' Systemic Sclerosis ', ' Supervision ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Training Support ', ' Work ', ' Yeasts ', ' Data Set ', ' Dataset ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' Individual ', ' Letters ', ' Genetic ', ' gene function ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Source ', ' Pattern ', ' System ', ' interest ', ' gene interaction ', ' mutant ', ' Quantitative Trait Loci ', ' QTL ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' trait ', ' Base Pairing ', ' Speed ', ' novel ', ' disorder risk ', ' disease risk ', ' Pathogenesis ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' functional genomics ', ' Genomics ', ' genetic association ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Address ', ' Copy Number Polymorphism ', ' copy number variation ', ' copy number variant ', ' Data ', ' The Jackson Laboratory ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' genomic region ', ' Genomic Segment ', ' Lower Organism ', ' Ontology ', ' Molecular ', ' Knockout ', ' Knock-out ', ' Modification ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' computational tools ', ' computerized tools ', ' combinatorial ', ' human disease ', ' murine model ', ' mouse model ', ' alzheimer model ', ' AD model ', "" Alzheimer's disease model "", ' systemic autoimmune disorder ', ' systemic autoimmune disease ', ' Combinatorial Optimization ', ' Genetic study ', ' learning method ', ' learning activity ', ' learning strategy ', ' genomic marker ', ' genomic biomarker ', ' genomic data ', ' experimental research ', ' experiment ', ' experimental study ', ' high dimensionality ', ' human model ', ' genetic architecture ', ' ']",NLM,JACKSON LABORATORY,R21,2018,200175,ME-02,0.06680903808895139
"A predictive model of mRNA stability and translation for variant interpretation and mRNA therapeutics The leading and trailing untranslated regions (UTRs) of an mRNA, along with the coding sequence (CDS), control protein production by modulating translation and mRNA stability. However, although we have identified a vast number of regulatory features in these regions, we are still far from being able to predict, for example, whether and how a sequence variant affects the levels of protein being made. Here, we propose to combine high-throughput experimental characterization of protein expression in synthetic libraries with machine learning to create predictive models of translation and mRNA stability, addressing an urgent need. Recent progress in machine vision, voice recognition and other fields of computer science has been driven by the availability of enormous data sets on which to train models. Machine learning approaches have also had remarkable impact in biology, but biological data sets often are comparatively small, limiting the quality of models that can be learned. For example, there are only around 20,000 genes in the human genome, a restrictively small set of examples for training a predictive model that captures the full extent of the genomes regulatory code. In this proposal, we aim to overcome this data size limitation by training predictive models of protein expression on data from millions of synthetic constructs -- a data set several orders of magnitude larger than the number of genes in the genome. Specifically, we will create libraries of in vitro transcribed mRNA with targeted variation in the UTRs and CDS and will assay protein expression of each library member by performing high-throughput polysome profiling, ribosome profiling, and mRNA stability assays. We will then use neural network approaches to learn predictive models of the relationship between mRNA sequence and levels of protein production. We will apply our models to three applications of practical importance: first, we expect to uncover novel biology, for example identifying regulatory sequence elements and interactions between them. Second, we will validate our models through the de novo design and experimental testing of sequences that result in higher levels or protein production than any of the millions of randomly generated members of the original library or than the endogenous UTR sequences currently used in biotechnology. Such stable and highly translating mRNA constructs would be of particular value for the field or mRNA therapeutics. Third, we will predict the functional consequences of genetic variation in UTRs on protein production and we will validate these predictions experimentally. We are far from understanding which genetic variants compromise gene regulatory function in ways that may contribute to disease, making such a comprehensive and quantitative analysis of variants valuable. This research project aims to use machine learning to build predictive models of translation and mRNA stability. Models are trained on data obtained by measuring protein production for millions of synthetic RNA constructs. Models will then be applied for understanding the consequences of genetic variation in humans and for the design of mRNA therapeutics.",A predictive model of mRNA stability and translation for variant interpretation and mRNA therapeutics,9421497,R01HG009892,"['Affect ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Biotechnology ', ' Biotech ', ' Disease ', ' Disorder ', ' Elements ', ' Engineering ', ' Gene Expression ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Human ', ' Modern Man ', ' Human Engineering ', ' Human Genetics ', ' In Vitro ', ' Learning ', ' Libraries ', ' Methods ', ' Polyribosomes ', ' Polysomes ', ' Production ', ' Proteins ', ' Ribosomes ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA Splicing ', ' Splicing ', ' Messenger RNA ', ' mRNA ', ' Role ', ' social role ', ' Testing ', ' Thiouridine ', ' 4-thio-uridine ', ' 4-Thiouridine ', ' Time ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Translating ', ' Genetic Translation ', ' mRNA Translation ', ' Translations ', ' Genetic Variation ', ' Genetic Diversity ', ' Vision ', ' visual function ', ' Sight ', ' Work ', ' Measures ', ' RNA-Binding Proteins ', ' Data Set ', ' Dataset ', ' base ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Source ', ' Techniques ', ' Performance ', ' stable cell line ', ' synthetic construct ', ' synthetic DNA ', ' Biological Neural Networks ', ' neural network ', ' computer science ', "" 5' Untranslated Regions "", ' mRNA Leader Sequences ', "" 5'UTR "", "" 3' Untranslated Regions "", "" 3'UTR "", ' Untranslated Regions ', ' UTRs ', ' Structure ', ' novel ', ' member ', ' RNA Stability ', ' Code ', ' Coding System ', ' Modeling ', ' Neural Network Simulation ', ' Perceptrons ', ' Neural Network Models ', ' Connectionist Models ', ' Property ', ' DNA Library ', ' DNA bank ', ' Genomics ', ' voice recognition ', ' protein expression ', ' mRNA Stability ', ' Address ', ' Data ', ' Randomized ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Regulatory Element ', ' Resolution ', ' Computational Technique ', ' Expression Library ', ' Genetic Algorithm ', ' Genetic Programming ', ' Transcript ', ' Validation ', ' imaging ', ' Image ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' designing ', ' design ', ' application in practice ', ' practical application ', ' comparative ', ' screening ', ' ribosome footprint profiling ', ' Ribo-seq ', ' ribosome profiling ', ' experimental research ', ' experiment ', ' experimental study ', ' polysome profiling ', ' ']",NHGRI,UNIVERSITY OF WASHINGTON,R01,2018,444578,WA-07,0.025164868455063327
"Optimizing Genetic Testing for Deafness for Clinical Diagnostics Project Summary  Hearing loss is the most common sensory deficit in humans. It is diagnosed in 1 in 500 newborns and affects half of all octogenarians. Although causality is multifactorial, in developed countries a large fraction of hearing loss is genetic and non-syndromic, i.e. not associated with other phenotypes.  During the prior granting period, we implemented and integrated comprehensive genetic testing as a cornerstone in the evaluation of the deaf and hard-of-hearing person. The American College of Medical Genetics has recognized the merit of this approach, and in 2014 included comprehensive genetic testing for the evaluation of deafness in their newest treatment guidelines. In the largest study to date to corroborate this decision, we found an underlying genetic cause for hearing loss in 440 (39%) of 1119 sequentially accrued patients chosen without exclusion criteria. Pathogenic variants were present in 49 genes and included missense variants (49%), copy number changes (18%), indels (18%), nonsense variants (8%), splice-site alterations (6%) and promoter variants (<1%), making comprehensive genetic testing the single best test to order in the diagnosis of hearing loss after an audiogram.  In this competitive renewal, we will build on these accomplishments by completing the following aims:  Specific Aim 1: To optimize phenotype-genotype integration in the analysis of hereditary hearing loss  by refining the use of hierarchical surface clustering and audioprofile surface analysis to determine  which types of genetic hearing loss are associated with clinically meaningful sub-clusters  Specific Aim 2: To validate and integrate physics-based protein modeling as a tool within the Deafness  Variation Database to predict variant effect and the molecular and patient phenotype  Specific Aim 3: To identify genetic modifiers of specific deafness-causing genes predicted by  hierarchical surface clustering and validated by physics-based potential free-energy modeling  The successful completion of this grant will improve the clinical care of persons with hearing loss by enhancing phenome-genome integration and by making variant interpretation more robust. Knowledge gained from this proposal will also lay the foundation for refined studies focused on the identification of genetic modifiers  both positive and negative  associated with complex phenotypes such as noise- induced and age-related hearing loss. This competitive renewal addresses the increasingly daunting challenge of variant interpretation. We will seamlessly integrate AudioGene into the OtoSCOPE pipeline, explore hierarchical surfaces clustering at all loci, enhance the utility of the Deafness Variation Database by adding physics-based potential free-energy modeling, and using these tools, identify genetic modifiers of select types of genetic hearing loss. The completion of these aims will lay the foundation for more refined studies focused on the identification of genetic modifiers  both positive and negative  associated with complex hearing loss phenotypes including noise-induced and age-related hearing loss.",Optimizing Genetic Testing for Deafness for Clinical Diagnostics,9748023,R01DC012049,"['Adoption ', ' Affect ', ' Algorithms ', ' Audiometry ', ' Audiometric Test ', ' Audiogram ', ' Biology ', ' Classification ', ' Systematics ', ' Clinical Trials ', ' Communities ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Cystic Fibrosis ', ' Mucoviscidosis ', ' Deafness ', ' Decision Making ', ' Decision Trees ', ' Developing Countries ', ' Under-Developed Nations ', ' Under-Developed Countries ', ' Third-World Nations ', ' Third-World Countries ', ' Less-Developed Nations ', ' Less-Developed Countries ', ' Developing Nations ', ' Diagnosis ', ' Duchenne muscular dystrophy ', ' pseudohypertrophic muscular paralysis ', ' pseudohypertrophic adult muscular dystrophy ', ' progressive muscular dystrophy of childhood ', ' mild X-linked recessive muscular dystrophy ', ' classic X-linked recessive muscular dystrophy ', ' childhood pseudohypertrophic muscular dystrophy ', ' benign X-linked recessive muscular dystrophy ', ' X-linked recessive muscular dystrophy ', ' X-linked muscular dystrophy ', ' X-linked dilated cardiomyopathy ', ' Pseudohypertrophic Muscular Dystrophy ', ' Ellis-van Creveld (EvC) syndrome ', ' Duchenne-Griesinger syndrome ', ' Duchenne ', ' Duchene ', ' Foundations ', ' gene therapy ', ' genetic therapy ', ' gene-based therapy ', ' Genetic Intervention ', ' Gene Transfer Clinical ', ' DNA Therapy ', ' Genes ', ' Medical Genetics ', ' Clinical genetics ', ' Genome ', ' Genotype ', ' Grant ', ' Health Personnel ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health workforce ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Hearing ', ' sound perception ', ' hearing perception ', ' Human ', ' Modern Man ', ' Newborn Infant ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Methods ', ' Persons ', ' Noise ', ' Octogenarian ', ' Patients ', ' Phenotype ', ' Physics ', ' Presbycusis ', ' age related hearing loss ', ' Presbyacusis ', ' Proteins ', ' Research ', ' RNA Splicing ', ' Splicing ', ' medical schools ', ' school of medicine ', ' medical college ', ' Technology ', ' Testing ', ' falls ', ' Case Study ', ' case report ', ' Healthcare ', ' health care ', ' promoter ', ' promotor ', ' Guidelines ', ' base ', ' evaluation/testing ', ' Otoscopes ', ' improved ', ' Site ', ' Area ', ' Surface ', ' Clinical ', ' Variation ', ' Variant ', ' Evaluation ', ' prognostic ', ' data base ', ' Data Bases ', ' Databases ', ' Industrialized Nations ', ' Industrialized Countries ', ' Developed Nations ', ' Developed Countries ', ' Therapeutic ', ' Cochlear implant procedure ', ' Cochlear Prosthesis Implantation ', ' Cochlear Implantation ', ' Genetic ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Inherited ', ' Hereditary ', ' Complex ', ' Sensory ', ' Techniques ', ' Hearing Impaired Persons ', ' Persons With Hearing Impairments ', ' Hard of Hearing Persons ', ' Deaf ', ' American ', ' genetic disorder diagnosis ', ' genetic diagnosis ', ' cohort ', ' Free Energy ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Reporting ', ' Modeling ', ' Genomics ', ' Pathogenicity ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' hearing impairment ', ' Hypoacusis ', ' Hypoacuses ', ' Hearing Loss ', ' Address ', ' Data ', ' Research Infrastructure ', ' Infrastructure ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' research clinical testing ', ' enroll ', ' Enrollment ', ' Exclusion Criteria ', ' Molecular ', ' clinical phenotype ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' software systems ', ' designing ', ' design ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Heritability ', ' clinical significance ', ' clinically significant ', ' clinical care ', ' phenome ', ' clinical decision-making ', ' Massively Parallel Sequencing ', ' Massively Parallel DNA Sequencing ', ' Massive Parallel Sequencing ', ' personalized genetics ', ' precision genetics ', ' clinical diagnostics ', ' preservation ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' clinical implementation ', ' treatment guidelines ', ' ']",NIDCD,UNIVERSITY OF IOWA,R01,2018,53375,IA-02,0.06534042336241784
"Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies Almost all proteins function through interacting with other proteins. Previous studies have shown that the vast majority of damaging single amino acid mutations in proteins disrupt only a subset of specific protein-protein interactions, and that mutations in the same protein that disrupt different interactions tend to cause clinically distinct disorders. Therefore, it is of great importance to determine interaction-specific disruptions caused by each mutation. Furthermore, rapid advances in sequencing technologies have enabled the identification of tens of millions of single nucleotide variants (SNVs) in the human population, driving an urgent need to understand the impact of each SNV on the human interactome network. Unfortunately, there is currently no method that is capable of predicting the specific impact of a large fraction of these SNVs on individual protein-protein interactions. To address this issue, we propose to leverage our massively-parallel site-directed mutagenesis pipeline, Clone-seq, to generate clones for ~6,000 coding SNVs in the human population: ~4,000 from gnomAD and ~2,000 to be submitted by the international human genetics community. We will then experimentally examine the impact on protein stability and individual protein-protein interactions for every variant using high-throughput DUAL-FLUO and InPOINT (integrating PCA, LUMIER, Y2H, and wNAPPA) assays. This proposal brings together three groups with complementary expertise in high-throughput interactome experiments and network analysis from the Yu lab, in genomic and population genetic studies from the Clark lab, and in comprehensive biophysical and structural modeling of mutations impact on binding free energy of protein interactions from the Alexov lab. Out of the ~6,000 SNVs, we expect to identify ~1,200 disruptive SNVs and ~4,000 different SNV-interaction pairs where the SNV disrupt that specific interaction. The data produced by our project will increase the available experimental information by >140 in number of human proteins and >500 in number of interactions, allowing us for the first time to comprehensively assess the relationships between the impact of SNVs on interactions and their various population genetic attributes (including, but not limited to, allele frequency and flanking haplotype, inter-population differentiation, local rate of recombination, allele age, modes of selection). Finally, we will establish a computational-experimental- integrated iterative learning scheme to build a multi-layer random-forest-based framework, SIMPACT, which can accurately predict specific impacts on all individual protein-protein interactions for all missense SNVs. Our proposed work will fuel hypothesis-driven research, will significantly improve our functional understanding of variants, and will likely fundamentally change the experimental design and data interpretation for whole genome/exome studies going forward. The dramatic increase of DNA variants discovered through advances in sequencing technologies has been inadequately translated into therapeutic successes. Although many of these variants are related to human disorders, the overwhelming number of non-functional variants makes the assessment of functional significance a steep challenge. In this study, we aim to develop a high-throughput pipeline to quickly clone and directly test a large number of coding variants for their impact on the human interactome network and use the results to build a machine learning pipeline to predict functional impact of all coding variants, in anticipation that both our experimental data and computational pipeline will lead to broad clinical and therapeutic applications.",Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies,9420242,R01GM125639,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Amino Acids ', ' aminoacid ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Cells ', ' Cell Body ', ' Communities ', ' Crystallization ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Experimental Designs ', ' Gene Frequency ', ' allelic frequency ', ' Allele Frequency ', ' Genes ', ' Population Genetics ', ' Genome ', ' Haplotypes ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Learning ', ' Methods ', ' Structural Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Proteins ', ' Genetic Recombination ', ' Recombination ', ' DNA Recombination ', ' Research ', ' Resources ', ' Research Resources ', ' Technology ', ' Testing ', ' Time ', ' Translating ', ' Work ', ' Measures ', ' Site-Directed Mutagenesis ', ' Targeted Modification ', ' Targeted DNA Modification ', ' Site-Specific Mutagenesis ', ' forest ', ' base ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Biochemical ', ' Training ', ' Individual ', ' data base ', ' Data Bases ', ' Databases ', ' Measurement ', ' Letters ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' System ', ' interest ', ' mutant ', ' success ', ' Free Energy ', ' Structure ', ' Code ', ' Coding System ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Property ', ' protein protein interaction ', ' Proteomics ', ' Genomics ', ' Binding ', ' Molecular Interaction ', ' Address ', ' Data ', ' Homology Modeling ', ' International ', ' Resolution ', ' Scheme ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' Output ', ' Population ', ' Coupling ', ' biological research ', ' molecular phenotype ', ' exomes ', ' exome ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' screening ', ' biophysical modeling ', ' biophysical model ', ' biophysical methods ', ' biophysical methodology ', ' biophysical approaches ', ' biophysical techniques ', ' Genetic study ', ' internet portal ', ' web portal ', ' full genome ', ' entire genome ', ' whole genome ', ' experimental research ', ' experiment ', ' experimental study ', ' human interactome ', ' ']",NIGMS,CORNELL UNIVERSITY,R01,2018,577782,NY-23,0.09529597184915907
"Deep learning methods to predict the function of genetic variants in orofacial clefts Project Summary  Orofacial clefts (OFCs) comprise a significant fraction of human birth defects in all populations (ranging between 1/500 to 1/2500 live births) and represent a major public health challenge. Individuals born with OFCs require surgical, nutritional, dental, speech, medical and behavioral interventions, imposing a substantial economic and personal burden. There has been convincing evidence that non-syndromic OFCs represent human complex disorders with a multifactorial etiology including genetic risk factors, environmental exposures, and their complex interactions. So far, there have been ~10 genome-wide association studies (GWAS) conducted for non-syndromic CL/P (NSCL/P) and >15 genomic loci reported with compelling statistical support, including genes such as IRF6, PAX7, and ABCA4 and the 8q24 locus. In addition, next-generation sequencing (NGS) as well as exome array have been conducted with extra depth of genotyping that enable detection of rare variants associated with OFCs. However, gaps exist in how to interpret these variants and how to identify novel variants from the large volume of data, with high expectations for new methods and new models for second- analysis of the genome-wide data. In this proposal, we propose two complementary aims to carry out deep and second-analysis of genome-wide data for OFCs. In Aim 1, we propose a deep learning method to build in silico models that can predict the effect of genetic variants in the context of rich craniofacial epigenomic features. With substantial fine map of sequence patterns, ad hoc motifs will be revealed and variants that disturb these motifs will provide mechanistic insights on OFCs. In Aim 2, we shift our focus to the gene level and propose a network assisted method to discover sensibly combined genes in spatial and temporal points that are critical to orofacial development. We target on all forms of OFCs, with particular interest in NSCL/P. To guarantee the success of this proposal, we form a multi-disciplinary team and local computational infrastructure equipped with GPUs for the implementation of both aims. Our aims are non-overlapping; rather, they are integrated and strongly focused on our fundamental question of interest: how genetic variants function to cause OFCs. The successful completion of our proposal will lead to deep understanding of genetic components in OFCs. Project Narrative Orofacial clefts (OFCs) comprise a significant fraction of human birth defects in all populations and represent a major public health challenge. Substantial progress has been made to identify genes and variants for OFCs through recent genome-wide association studies and next- generation sequencing projects. In this proposal, we aim to develop computational methods to comprehensively fine map and interpret the effects of these genetics variants, which will eventually lead to understanding of the mechanisms and new therapies for OFCs.",Deep learning methods to predict the function of genetic variants in orofacial clefts,9508953,R03DE027711,"['Congenital Abnormality ', ' Congenital Malformation ', ' Congenital Deformity ', ' Congenital Defects ', ' Congenital Anatomical Abnormality ', ' Congenital Anatomic Abnormality ', ' Birth Defects ', ' Algorithms ', ' Behavior Therapy ', ' behavioral intervention ', ' behavior intervention ', ' Conditioning Therapy ', ' Behavioral Treatment ', ' Behavioral Therapy ', ' Behavioral Modification ', ' Behavioral Conditioning Therapy ', ' Behavior Treatment ', ' Behavior Modification ', ' Behavior Conditioning Therapy ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Cleft Lip ', ' hare lip ', ' Harelip ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Economics ', ' Environment ', ' Environmental Exposure ', ' Explosion ', ' Gene Expression ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Human ', ' Modern Man ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Maps ', ' Methods ', ' Phenotype ', ' Play ', ' Proteins ', ' Public Health ', ' Research ', ' Resources ', ' Research Resources ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Role ', ' social role ', ' Computer software ', ' Software ', ' Speech ', ' Time ', ' Tissues ', ' Body Tissues ', ' Measures ', ' Mediating ', ' base ', ' Site ', ' Variation ', ' Variant ', ' Medical ', ' Training ', ' Dental ', ' insight ', ' Individual ', ' Sample Size ', ' Biological Function ', ' Biological Process ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' DNA Methylation ', ' Computational Biology ', ' computer biology ', ' Complex ', ' Pattern ', ' Live Birth ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' interest ', ' craniofacial ', ' craniofacies ', ' success ', ' trait ', ' expectation ', ' novel ', ' Reporting ', ' Cleft lip with or without cleft palate ', ' cl/p ', ' genetic risk factor ', ' inherited factor ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' RNA Binding ', ' RNA bound ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' PAX7 gene ', ' Paired Domain Gene 7 ', ' Paired Box Homeotic Gene 7 ', ' Paired Box Gene 7 ', ' PAX7 ', ' HUP1 ', ' Data ', ' Detection ', ' 8q24 ', ' Genetic Risk ', ' Validation ', ' nutritious ', ' Nutritional ', ' Molecular ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' epigenomics ', ' orofacial ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' multidisciplinary ', ' sequence learning ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' novel therapeutics ', ' spatiotemporal ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' genome-wide analysis ', ' genomewide ', ' genome scale ', ' genome-wide ', ' computational infrastructure ', ' computer infrastructure ', ' exomes ', ' exome ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' rare allele ', ' rare variant ', ' FaceBase ', ' craniofacial development ', ' orofacial clefting ', ' orofacial cleft ', ' Genetic study ', ' learning method ', ' learning activity ', ' learning strategy ', ' orofacial development ', ' Expression Profiling ', ' deep learning ', ' ']",NIDCR,UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON,R03,2018,154000,TX-09,0.15030277519418533
"Discovery of pathogenic germline variants in pediatric cancers using genomics. Project Summary/Abstract Genomic alterations drive cancer development in pediatric and adult patients, but pediatric cancers display a relative scarcity of somatic variants. This observation coupled with the earlier age of onset in familial cancer syndromes suggests that germline variants contribute to the development of many pediatric cancers. Many known pathogenic germline variants exhibit biological features such as loss of heterozygosity and rarity within the general population; certain germline cancer-causing variants also cause cancer when acquired somatically. Identifying pathogenic germline variants from whole exome sequence (WES) data would clarify the pathogenesis of pediatric cancers, and might support improved treatments for cancer subtypes with poor prognosis such as relapsed acute lymphoblastic leukemia (ALL), high-grade glioma (glioma), and ependymoma. The long-term goal of this research is to understand the role of germline variants in pediatric cancer development using genomic data. The objective of this application is to develop a computational biology tool that identifies pathogenic germline variants from WES data, and to apply this tool to analyze germline variants in relapse ALL, glioma, and ependymoma. This application's central hypothesis is that pathogenic germline variants have biological and cohort-specific features that distinguish them from benign variants, such that a machine learning pipeline trained on these features can predict pathogenic germline variants. Aim 1 will call germline variants in WES data from 1) pediatric patients with known cancer-causing germline variants and 2) control patients without cancer; patients in data set 1) are randomly divided into a training and test set. A bioinformatics pipeline will call variants, add annotation, and filter out low quality variants. Aim 2 will use the training set to train and optimize a machine-learning algorithm to predict high confidence germline driver variants. Aim 3 will apply the final pipeline to validation sets of pediatric relapsed ALL, glioma, and ependymoma samples. These aims will generate a computational pipeline that predicts pathogenicity of germline variants using a pediatric cancer cohort, enabling improved understanding of the contribution of germline variants to multiple pediatric cancers. Project Narrative Improved understanding how certain germline DNA variants (those DNA changes that are inherited or occur early in development) promote cancer might lead to better treatments for pediatric cancers. However, identifying which germline variants cause cancer is challenging without genetic information from family members. To address this, this research proposal develops a computational tool that learns from germline variants known to cause cancer and then predicts cancer-causing variants from pediatric cancer patient DNA sequences in the absence of family information; these predicted variants will undergo computational and experimental testing, and may clarify how pediatric cancers like relapsed acute lymphoblastic leukemia, glioma, and ependymoma develop.",Discovery of pathogenic germline variants in pediatric cancers using genomics.,9547342,F31CA210607,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Affect ', ' Age ', ' ages ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Control Groups ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Ependymoma ', ' WHO Grade II Ependymal Tumor ', ' WHO Grade II Ependymal Neoplasm ', ' Exhibits ', ' Family ', ' Genes ', ' Glioma ', ' neuroglia tumor ', ' neuroglia neoplasm ', ' glial-derived tumor ', ' Neuroglial Tumor ', ' Neuroglial Neoplasm ', ' Glial Tumor ', ' Glial Neoplasm ', ' Glial Cell Tumors ', ' Goals ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Acute Lymphocytic Leukemia ', ' acute lymphomatic leukemia ', ' acute lymphogenous leukemia ', ' acute lymphatic leukemia ', ' Precursor Lymphoblastic Leukemia ', ' Precursor Cell Lymphoblastic Leukemia ', ' Acute Lymphoid Leukemia ', ' Acute Lymphoblastic Leukemia ', ' ALL - Acute Lymphocytic Leukemia ', ' Leukemia, Lymphocytic, Acute, L1 ', ' infant ALL ', ' Pediatric Acute Lymphoid Leukemia ', ' Pediatric Acute Lymphogenous Leukemia ', ' Pediatric Acute Lymphocytic Leukemia ', ' Pediatric Acute Lymphoblastic Leukemia ', ' Pediatric ALL ', ' Lymphoblastic Leukemia, Acute, L1 ', ' L1 Lymphocytic Leukemia ', ' Childhood Acute Lymphoid Leukemia ', ' Childhood Acute Lymphogenous Leukemia ', ' Childhood Acute Lymphocytic Leukemia ', ' Childhood Acute Lymphoblastic Leukemia ', ' Childhood ALL ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' outcome forecast ', ' Prognosis ', ' Relapse ', ' Research ', ' Research Proposals ', ' Role ', ' social role ', ' Syndrome ', ' Testing ', ' Tumor Suppressor Genes ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' Family member ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Benign ', ' Variation ', ' Variant ', ' Biological ', ' Age of Onset ', ' Training ', ' pediatric ', ' Childhood ', ' data base ', ' Data Bases ', ' Databases ', ' pediatric malignancy ', ' pediatric cancer ', ' children with cancer ', ' childhood malignancy ', ' child with cancer ', ' cancer in children ', ' cancer in a child ', ' Malignant childhood cancer ', ' Malignant Pediatric Tumor ', ' Malignant Pediatric Neoplasm ', ' Malignant Childhood Tumor ', ' Childhood Cancers ', ' Malignant Childhood Neoplasm ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' computer biology ', ' Inherited ', ' Hereditary ', ' Techniques ', ' Loss of Heterozygosity ', ' Allelic Loss ', ' Penetrance ', ' Somatic Mutation ', ' neoplastic cell ', ' Tumor Cell ', ' Performance ', ' cohort ', ' General Population ', ' General Public ', ' Pathogenesis ', ' Cancer Relapse ', ' Modeling ', ' Sampling ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' tumorigenesis ', ' Oncogenesis ', ' Hereditary Malignant Neoplasm ', ' familial cancer ', ' Hereditary Cancer ', ' Familiar Malignant Neoplasm ', ' Pediatric Neoplasm ', ' Pediatric Tumor ', ' Childhood Tumor ', ' Childhood Neoplasm ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Validation ', ' Characteristics ', ' developmental ', ' Development ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' computational tools ', ' computerized tools ', ' Population ', ' Coupled ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' Susceptibility Gene ', ' Oncogenic ', ' functional loss ', ' tumor ', ' effective treatment ', ' effective therapy ', ' exomes ', ' exome ', ' Pediatric Cancer Treatment ', ' Childhood Cancer Treatment ', ' child patients ', ' pediatric patients ', ' genetic information ', ' tumor-specific DNA ', ' tumor cell DNA ', ' tumor DNA ', ' cancer sub-types ', ' cancer subtypes ', ' genomic data ', ' ']",NCI,COLUMBIA UNIVERSITY HEALTH SCIENCES,F31,2018,36532,NY-13,0.18637022043195645
"Quantum-inspired generative machine learning over large datasets to infer new pleiotropic effects of genetic variants in multiple neuropsyciatric diseases Abstract In this supplement, we propose developing new computational approaches for psychiatric genetics, building on emergent strengths of deep learning and quantum computing. These approaches, utilizing very large external medical and genetic datasets, will allow automatic extension of the existing annotations of human genetic variants and of protein expression markers in brain to numerous under-studied neuropsychiatric diseases. Narratives Request for a supplemental funding to RO1MH110905 (2/2-Measuring translational dynamics and the proteome to identify potential brain biomarkers for psychiatric disease).",Quantum-inspired generative machine learning over large datasets to infer new pleiotropic effects of genetic variants in multiple neuropsyciatric diseases,9631714,R01MH110905,"['Algorithms ', ' Mental disorders ', ' psychological disorder ', ' psychiatric illness ', ' mental illness ', ' Psychiatric Disorder ', ' Psychiatric Disease ', ' Mental health disorders ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Disease ', ' Disorder ', ' Medical Genetics ', ' Clinical genetics ', ' Human Genetics ', ' link protein ', ' cartilage link protein ', ' Measures ', ' psychogenetics ', ' psychiatric genetics ', ' Data Set ', ' Dataset ', ' Funding ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' Proteome ', ' protein expression ', ' Data ', ' Electronic Health Record ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' quantum ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' quantum error correcting codes ', ' quantum computation ', ' quantum coding ', ' quantum computing ', ' neuropsychiatric disease ', ' neuropsychiatric disorder ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' deep learning ', ' ']",NIMH,UNIVERSITY OF CHICAGO,R01,2018,144180,IL-01,0.09109693982333371
"UNDERSTANDING THE FUNCTIONAL IMPACTS OF GENETIC VARIANTS IN MENTAL DISORDERS     DESCRIPTION (provided by applicant): In the US, 46% are afflicted with a mental illness at some point of life. The management and treatment of mental disorders pose significant economical and social burden to the society. Many rare and common genetic variants, including SNPs and CNVs, are reported to be associated with mental disorders, yet more remain to be discovered. However, despite the large amount of high-throughput genomics data, there is a lack of integrative methods to systematically prioritize variants that confer susceptibility to mental disorders; additionally, despite the presence of many candidate variants for mental disorders, their disease-contributory mechanism remains elusive, so appropriate functional follow-up experiments cannot be designed. Altogether, these problems resulted in a large gap between the copious amount of data about genetic variation and our understanding of their functional impacts on mental diseases, which ultimately delays the development of targeted therapeutic approaches. To address these problems, we propose to develop a suite of novel bioinformatics approaches: (1) NeuroComplex, an information integration approach that leverages phenotype information and multiple sources of prior biological knowledge to rank genes by their likelihood of contributing to specific phenotypic presentations. (2) integrated MEntal-disorder GEnome Score (iMEGES), which leverages a two-layer strategy to predict the impacts of variants in personal genomes on mental disorders. The first layer uses machine learning algorithm to build variant deleteriousness scores for coding, non-coding and structural variants; the second layer integrates variant scores and NeuroComplex to assign pathogenicity scores. (3) a hierarchical model called CombOmics that incorporates cross-omics information to characterizes how variants confers disease risk, in order to help formulate hypothesis of pathogenicity and facilitate the design of functional follow-up experiments. (4) we will develop user-friendly software tools and web applications that implement all the aforementioned bioinformatics approaches, and continuously release and maintain these tools to ensure the maximum benefits to the scientific community. PUBLIC HEALTH RELEVANCE: We will develop novel informatics approaches to understand how genetic variation impacts various mental disorders, such as schizophrenia and autism. These tools help clarify the genetic cause of mental diseases, characterize individual disease risks and develop individualized treatment strategies.",UNDERSTANDING THE FUNCTIONAL IMPACTS OF GENETIC VARIANTS IN MENTAL DISORDERS,9645863,R01MH108728,"['Algorithms ', ' Autistic Disorder ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Mental disorders ', ' psychological disorder ', ' psychiatric illness ', ' mental illness ', ' Psychiatric Disorder ', ' Psychiatric Disease ', ' Mental health disorders ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Family ', ' Gene Expression ', ' Genes ', ' Genome ', ' Methods ', ' Patients ', ' Phenotype ', ' Psychiatry ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Societies ', ' Computer software ', ' Software ', ' Software Tools ', ' Computer Software Tools ', ' Surveys ', ' Survey Instrument ', ' Testing ', ' Genetic Variation ', ' Genetic Diversity ', ' Generations ', ' Research Methodology ', ' Research Methods ', ' Uncertainty ', ' doubt ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' Susceptibility ', ' Predisposition ', ' mental ', ' Psyche structure ', ' Individual ', ' Patient Selection ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Life ', ' Source ', ' Techniques ', ' System ', ' Benchmarking ', ' Best Practice Analysis ', ' Performance ', ' success ', ' user friendly software ', ' user friendly computer software ', ' cohort ', ' Informatics ', ' skills ', ' novel ', ' disorder risk ', ' disease risk ', ' Disease model ', ' disorder model ', ' Reporting ', ' social ', ' Gene Proteins ', ' Protein Gene Products ', ' Code ', ' Coding System ', ' Modeling ', ' Sampling ', ' response ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Address ', ' Data ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Ontology ', ' Validation ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' Text ', ' developmental ', ' Development ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' Genetic Annotation ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' user-friendly ', ' prototype ', ' public health relevance ', ' treatment strategy ', ' Bayesian tracking algorithms ', ' Bayesian statistical models ', ' Bayesian spatial models ', ' Bayesian spatial image models ', ' Bayesian spatial data model ', ' Bayesian nonparametric models ', ' Bayesian network model ', ' Bayesian hierarchical model ', ' Bayesian framework ', ' Bayesian belief updating model ', ' Bayesian belief network ', ' Bayesian adaptive models ', ' Bayesian adaptive designs ', ' Bayesian Modeling ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' individualized medicine ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' targeted treatment ', ' personalized therapeutic ', ' genetic information ', ' web application ', ' web app ', ' genomic data ', ' experimental research ', ' experiment ', ' experimental study ', ' knowledge integration ', ' high dimensionality ', ' personalized predictors ', ' individualized predictions ', ' Individualized Predictors ', ' personalized predictions ', ' ']",NIMH,CHILDREN'S HOSP OF PHILADELPHIA,R01,2018,430000,PA-03,0.04758119544661363
"Integrated Clinical and Transcriptomic Profiling to Characterize Disease Phenotype PROJECT SUMMARY Exome and whole-genome sequencing are becoming increasingly routine approaches in cancer[1], common disease[2]and rare disease diagnosis.[3] Despite their success, our ability to fully interpret the clinical relevance of personal genome variation remains a significant gap[4-6]. Considering this, the most crucial need is more genotype-phenotype data that link genetic variation with disease causation. The objective of this proposal is to improve the clinical interpretation of genetic variation; in particular, by developing integrative approaches that predict the effect of genetic variation on clinical phenotype. This proposal addresses the hypothesis, supported by preliminary data, that combining patient transcriptomic data with genotypic and clinical data (as opposed to each alone) offers a better mechanistic understanding of disease natural history, from initial presentation to progression. The specific aims are designed such that each independently add substantial functional genomic information, over and above previously available patient genetic data, to further resolve the clinical phenotype. Aim 1 establishes a comprehensive and widely-shared dataset of patient transcriptomic (and genetic) variation across multiple cancer, cardiovascular and thrombosis/bleeding phenotypes, in patients with somatically-acquired myeloproliferative neoplasms (MPN) and select other rare heritable blood diseases (HBD). Aim 2 methodically determines differential RNA expression and processing between clinically-relevant subgroups of MPN and HBD patients. Aim 3 brings these elements together  and applies two integrative Bayesian and machine learning approaches, RIVER[24] (RNA-informed variant effect on regulation) and LASSO[25] (Least Absolute Shrinkage and Selection Operator), to resolve the functional and clinical relevance of rare variants; and identify signatures most predictive of disease risk or progression. Completion of these aims will contribute new scientific knowledge on how integrating transcriptomic data improves clinical genomic analyses in other genetic (and rare) diseases. In addition, this project will enable the Principal Investigator to develop expertise in the informatics and data science aspects of genomic medicine that complement her current background in biophysics, biochemistry and translational hematology. Combined with additional informatics training at Stanford University through coursework, seminars, one-on-one advising from project mentors, and interactions with the wider statistics, bioinformatics and genomics communities, this project will prepare the Principal Investigator to launch an independent academic career in genomic medicine. PROJECT NARRATIVE Accurate clinical interpretation of genetic variation in personal genome data is an essential component of personalized medicine approaches and the precise genetic diagnosis toward achieving improved public health. This project will integrate genetic and clinical modifiers with functional genomic information (RNA sequencing) from adequately-powered, disease-relevant cells; and provide direct insight into transcriptional perturbations caused by genetic variation.",Integrated Clinical and Transcriptomic Profiling to Characterize Disease Phenotype,9666548,K08HG010061,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Age Factors ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Biochemistry ', ' Biological Chemistry ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Blood ', ' Blood Reticuloendothelial System ', ' Blood Cells ', ' Peripheral Blood Cell ', ' Blood Platelets ', ' thrombocyte/platelet ', ' Thrombocytes ', ' Platelets Reticuloendothelial System ', ' Platelets ', ' Marrow platelet ', "" Hayem's elementary corpuscle "", "" Deetjeen's body "", "" Bizzozero's corpuscle/cell "", ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cells ', ' Cell Body ', ' Communities ', ' Complement ', ' Complement Proteins ', ' Demographic Factors ', ' Disease ', ' Disorder ', ' Elements ', ' Foundations ', ' Future ', ' Gene Expression ', ' Gene Fusion ', ' Medical Genetics ', ' Clinical genetics ', ' Genome ', ' Genotype ', ' Hematological Disease ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' Hematology ', ' Hemorrhage ', ' blood loss ', ' Bleeding ', ' Laboratories ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Mentors ', ' Mentorship ', ' Methods ', ' Myeloproliferative disease ', ' myeloproliferative neoplasm ', ' Myeloproliferative Tumors ', ' Myeloproliferative Disorders ', ' Myeloid Tumor ', ' Myeloid Neoplasm ', ' Myeloid Malignancy ', ' Myeloid Disease ', ' Patients ', ' Phenotype ', ' Public Health ', ' Reference Standards ', ' Resources ', ' Research Resources ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' statistics ', ' Thrombosis ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Universities ', ' Genetic Variation ', ' Genetic Diversity ', ' Gender ', ' Lasso ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' base ', ' career ', ' Blood Sample ', ' Blood specimen ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Link ', ' Evaluation ', ' Training ', ' insight ', ' data base ', ' Data Bases ', ' Databases ', ' Disease Progression ', ' Genetic Heterogeneity ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Genetic ', ' Rivers ', ' Whole Blood ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Investigation ', ' Severities ', ' System ', ' experience ', ' genetic disorder diagnosis ', ' genetic diagnosis ', ' Performance ', ' Protein Isoforms ', ' Isoforms ', ' success ', ' cohort ', ' knowledge base ', ' knowledgebase ', ' Informatics ', ' disease natural history ', ' Rare Diseases ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' novel ', ' disorder risk ', ' disease risk ', ' Gene Expression Profiling ', ' transcriptional profiling ', ' gene expression assay ', ' gene expression analysis ', ' Transcript Expression Analysis ', ' Transcript Expression Analyses ', ' Gene Expression Pattern Analysis ', ' Gene Expression Monitoring ', ' Regulation ', ' Modeling ', ' Sampling ', ' functional genomics ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Bioinformatics ', ' Bio-Informatics ', ' RNA Processing ', ' Body mass index ', ' Quetelet index ', ' BMI z-score ', ' BMI percentile ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' genome sequencing ', ' Address ', ' Data ', ' Research Training ', ' Subgroup ', ' Clinical Data ', ' Other Genetics ', ' Tissue-Specific Differential Gene Expression ', ' Differential Gene Expression ', ' Tissue-Specific Gene Expression ', ' Validation ', ' Principal Investigator ', ' Process ', ' clinical phenotype ', ' disease phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' data integration ', ' designing ', ' design ', ' Outcome ', ' prospective ', ' Heritability ', ' transcriptomics ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' informatics training ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' disease diagnosis ', ' biorepository ', ' biobank ', ' exomes ', ' exome ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' rare allele ', ' rare variant ', ' Bayesian tracking algorithms ', ' Bayesian statistical models ', ' Bayesian spatial models ', ' Bayesian spatial image models ', ' Bayesian spatial data model ', ' Bayesian nonparametric models ', ' Bayesian network model ', ' Bayesian hierarchical model ', ' Bayesian framework ', ' Bayesian belief updating model ', ' Bayesian belief network ', ' Bayesian adaptive models ', ' Bayesian adaptive designs ', ' Bayesian Modeling ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' variant of unknown significance ', ' Data Scientist ', ' Data Science ', ' global transcription profile ', ' global gene expression ', ' transcriptome ', ' Genomic medicine ', ' stratified patient ', ' patient stratification ', ' phenotypic data ', ' driver mutation ', ' actionable variants ', ' actionable mutation ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' full genome ', ' entire genome ', ' whole genome ', ' genomic data ', ' Disease stratification ', ' rare tumor ', ' rare malignancy ', ' cancers that are rare ', ' rare cancer ', ' ']",NHGRI,STANFORD UNIVERSITY,K08,2018,190941,CA-18,0.06321286340922413
"Statistical Tests for Mapping Genetic Determinants of Complex Traits     DESCRIPTION (provided by applicant): Genotyping and emerging sequencing technologies have enabled comprehensive interrogation of genetic variation across the human genome, thereby facilitating a study's ability to map genetic variants that influence phenotypes of interes. Nevertheless, genome-wide association studies (GWAS) and next-generation sequencing (NGS) projects have uncovered only a limited number of trait-influencing loci. While large increases in sample size will improve power to detect such variation, the ascertainment and sequencing/genotyping of such samples are costly and inefficient. Therefore, it is desirable to increase power to detect such variants without requiring additional sample collection. We propose novel methods for improved gene mapping of common and rare susceptibility variants that move beyond standard strategies typically applied to GWAS and NGS studies of complex traits. The first topic we consider is pleiotropic or cross- phenotype effects of genetic variants. Empirical studies have suggested that pleiotropy is widespread throughout the genome and that leveraging this additional information for gene mapping yields a more powerful analysis than an analysis that ignores such information. In Aim 1, we propose novel statistical methods for genetic analysis of high-dimensional phenotype data using an innovative kernel distance-covariance (KDC) framework that allows for an arbitrary number of phenotypes both continuous and/or categorical in nature, as well as an arbitrary number of genotypes (permitting gene-based testing of both rare and common variants). We will use the KDC framework to implement tests of pleiotropy as well as tests of mediation. The second topic we consider is the mapping of rare susceptibility variants using affected pedigrees, which provide many attractive features for rare-variant testing that case-control studies lack. In Aim 2, we propose a series of powerful statistical methods for rare-variant association testing in affected pedigrees that are based on a framework (recently published in AJHG) for rare-variant association testing in affected sibships. The existing framework compares rare-variant burden in a region by an affected sib pair to the number of regions that pairs shares identical by descent. We have shown the method is more powerful than case-control association testing given fixed sample size and further is robust to population stratification. In this proposal, we will extend the framework to handle affected pedigrees of arbitrary size and structure (rather than just affected sib pairs) and devise a powerful two-stage screening and validation strategy for rare-variant mapping that first compares familial cases in the pedigrees to external controls and then follows up the most interesting findings using an independent test based on our identity-by-descent sharing statistic among the affected relatives used in the first stage. We will apply the methods in Aims 1-2 to relevant data from genetic studies of complex traits in which we are directly involved. We also will implement the methods in public user-friendly software (Aim 3). PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a set of statistical approaches to investigate two important topics in gene- mapping studies of complex human traits. First, we will develop techniques for identifying genes that have pleiotropic effects on phenotypes of possibly high dimension and further assess whether such genes have direct effects on such phenotypes or indirect effects through other possible factors. Second, we will develop tools to facilitate identification of rare polymorphic variation that increase risk for complex disease using data from affected pedigrees of arbitrary size and structure. We will evaluate these methods using simulated data and illustrate their value by applying them to genetic projects of complex traits in which we are actively involved. Application of the proposed methods to these datasets should improve our understanding of the genetic origins of various complex traits.",Statistical Tests for Mapping Genetic Determinants of Complex Traits,9405576,R01GM117946,"['Affect ', ' Case-Control Studies ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Chromosome Mapping ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Disease ', ' Disorder ', ' Family ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Human ', ' Modern Man ', ' Joints ', ' Maps ', ' Methods ', ' genetic pedigree ', ' pedigree structure ', ' Pedigree ', ' Phenotype ', ' Public Health ', ' Publishing ', ' Risk ', ' Siblings ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Computer software ', ' Software ', ' Technology ', ' Testing ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Procedures ', ' specimen collection ', ' sample collection ', ' Variation ', ' Variant ', ' Series ', ' Sample Size ', ' Genetic ', ' Genets ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Dimensions ', ' Complex ', ' Techniques ', ' interest ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' user friendly software ', ' user friendly computer software ', ' trait ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Mediation ', ' Negotiation ', ' Negotiating ', ' Categories ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' genetic analysis ', ' Genetic analyses ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' case control ', ' Genetic Determinism ', ' genetic determinant ', ' genetic association ', ' Applied Genetics ', ' Data ', ' Validation ', ' Molecular ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' cost ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' innovative ', ' innovate ', ' innovation ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' Susceptibility Gene ', ' human disease ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' genome-wide analysis ', ' public health relevance ', ' genomewide ', ' genome scale ', ' genome-wide ', ' flexible ', ' flexibility ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' screening ', ' rare allele ', ' rare variant ', ' Genetic study ', ' identical by descent ', ' IBD inference ', ' IBD analysis ', ' identity by descent ', ' phenotypic data ', ' population stratification ', ' high dimensionality ', ' new sequencing technology ', ' emerging sequencing technology ', ' novel sequencing technology ', ' ']",NIGMS,EMORY UNIVERSITY,R01,2018,297619,GA-05,0.09474421181580026
"EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE     DESCRIPTION (provided by applicant): The eMERGE III Clinical Center proposal from Partners HealthCare leverages a large biobank, clinical data in the electronic medical records (EMR) for >4 million participants from the largest integrated health care provider in New England, advanced bioinformatics expertise and state-of-the-art genetic analysis. We propose three aims. (1) Aim 1. Discovery. We will test the hypothesis that common and rare variants from a custom chip including 50,000 loss of function (LoF) alleles will be associated with cardiovascular, neuropsychiatric and immune-mediated phenotypes derived from the EMR. We are currently genotyping 25,000 Partners HealthCare Biobank subjects with a custom chip that includes LoF alleles from 63,000 exomes that we have analyzed. (2) Aim 2. Penetrance and Pleiotropy. We will test the hypothesis that sequencing a set of established genes or loci will allow us to discover additional variation, and define penetrance and pleiotropy using EMR phenotypes. Rare variants in genes selected by the eMERGE network will be studied for penetrance and pleiotropic outcomes by PheWAS and chart review. In addition, we are poised to perform recall-by-genotype studies because all Biobank participants have provided consent for such callback. (3) Aim 3. Implementation. We will test the hypothesis that physicians will alter their surveillance and treatment of patients based upon voluntary return of actionable variants to provide safe and cost-effective benefits to patients. We will screen our entire Biobank population of 25,000 individuals for pathogenic variants in the LDLR gene, the leading genetic cause of premature coronary artery disease, and conduct an exploratory trial in disclosing this information. Biobank participants with pathogenic variants in LDLR will be offered enrollment into a randomized trial, in which their finding will be CLIA-confirmed, and in one arm, this result will be communicated to their physicians through the EMR. Over one year, we will collect the following outcomes through participant surveys and EMR queries: physician visits, laboratory testing, changes in medication prescriptions, LDL levels, medical costs and the number of family members screened and treated as a result of the intervention. We will collaborate with the entire eMERGE III Network to incorporate what we learn from this pilot trial into large-scale implementation protocols for the genes selected by the Network for sequencing. Finally, we will participate in all Network activities to enhance the movement of genetics into clinical practice. PUBLIC HEALTH RELEVANCE: The discovery and clinical use of genetic variants associated with both rare Mendelian and more common complex diseases promises to dramatically change the practice of medicine. Our eMERGE III project will leverage a large Biobank and a rich electronic medical record to define the phenotypic impact of mutations emerging from sequencing and then return results on selected variants to Biobank participants using a clinical trial.",EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE,9493516,U01HG008685,"['Algorithms ', ' Alleles ', ' Allelomorphs ', ' Rheumatoid Arthritis ', ' rheumatic arthritis ', ' Atrophic Arthritis ', ' Asthma ', ' Bronchial Asthma ', ' Biology ', ' Bipolar Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Clinical Trials ', ' Coronary Arteriosclerosis ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary heart disease ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Mental Depression ', ' depression ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Genes ', ' Genotype ', ' Goals ', ' Health Personnel ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health workforce ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Congestive Heart Failure ', ' chronic heart failure ', ' Heart Decompensation ', ' Cardiac Failure Congestive ', ' hypercholesterolemia ', ' Hypercholesteremia ', ' Newborn Infant ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Inflammatory Bowel Diseases ', ' Inflammatory Intestinal Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Bowel Disorder ', ' Laboratories ', ' Learning ', ' Low-Density Lipoproteins ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' LDL Cholesterol Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' Medicine ', ' Mining ', ' Movement ', ' body movement ', ' Multiple Sclerosis ', ' insular sclerosis ', ' Disseminated Sclerosis ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' New England ', ' Northeastern United States ', ' Patients ', ' Pharmacogenetics ', ' Phenotype ', ' Physicians ', ' Public Health ', ' Research ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Stroke ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' Surveys ', ' Survey Instrument ', ' Testing ', ' Computerized Medical Record ', ' Electronic Medical Record ', ' Family member ', ' Healthcare ', ' health care ', ' Mediating ', ' Medical Care Costs ', ' medical costs ', ' HLA-DRB1 ', ' HLA-DRB1 antigen ', ' Custom ', ' base ', ' Area ', ' Clinical ', ' prematurity ', ' premature ', ' Phase ', ' Variation ', ' Variant ', ' Individual ', ' Funding ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Immune ', ' Immunes ', ' Complex ', ' Stream ', ' Protocols documentation ', ' Protocol ', ' Source ', ' Penetrance ', ' Visit ', ' experience ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' Informatics ', ' TYK2 ', ' novel ', ' Participant ', ' genetic analysis ', ' Genetic analyses ', ' neuropsychiatry ', ' neuropsychiatric ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' Attention deficit hyperactivity disorder ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' CTLA4 gene ', ' Cytotoxic T-Lymphocyte-Associated Serine Esterase-4 Gene ', ' Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene ', ' Cytotoxic T-Lymphocyte Protein 4 Gene ', ' CTLA4 ', ' CTLA-4 Gene ', ' CD152 Gene ', ' CD152 Antigen Gene ', ' DRD2 gene ', ' Dopamine Receptor D2 Gene ', ' DRD2 ', ' D2R Gene ', ' D2R ', ' D2DR Gene ', ' D2DR ', ' D(2) Dopamine Receptor Gene ', ' TNFRSF1A gene ', ' tumor necrosis factor  receptor ', ' tumor necrosis factor receptor 1A ', ' tumor necrosis factor alpha receptor ', ' Tumor Necrosis Factor Receptor 55 ', ' Tumor Necrosis Factor Receptor 1 ', ' TNF receptor ', ' TNFalpha receptor ', ' TNFRSF1A Receptor ', ' TNFRSF1A ', ' TNFR60 ', ' TNFR55 ', ' TNFR1 ', ' TNFR-I ', ' TNFR, 60-kD ', ' TNFR, 55-kD ', ' TNFR p60 ', ' TNFAR ', ' TNF- receptor ', ' TNF-sR55 ', ' TNF Receptor p55 ', ' CD120a Antigens ', ' CD 120a Antigen ', ' LDLR gene ', ' TCF7L2 gene ', ' Transcription Factor 7-Like 2 ', ' TCF7L2 ', ' TCF4 ', ' TCF-4 ', ' T-Cell-Specific Transcription Factor 4 ', ' Consent ', ' Cost Effectiveness Analysis ', ' cost-effectiveness analysis ', ' cost-effective analysis ', ' cost efficient analysis ', ' cost effectiveness analyses ', ' cost effective analysis ', ' Cost Effective Analyses ', ' Data ', ' Population Attributable Risks ', ' attributable fraction ', ' Callback ', ' Clinical Data ', ' enroll ', ' Enrollment ', ' pilot trial ', ' implementation research ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Outcome ', ' cost-effective ', ' cost effective ', ' Population ', ' loss of function ', ' public health relevance ', ' clinical care ', ' clinical practice ', ' biorepository ', ' biobank ', ' exomes ', ' exome ', ' Randomization trial ', ' randomized trial ', ' arm ', ' rare allele ', ' rare variant ', ' genetic information ', ' clinical sequencing ', ' clinically actionable ', ' support tools ', ' Genomic medicine ', ' marker panel ', ' biomarker panel ', ' driver mutation ', ' actionable variants ', ' actionable mutation ', ' neuropsychiatric disease ', ' neuropsychiatric disorder ', ' eMERGE Network ', ' eMERGE Consortium ', ' Electronic Medical Records and Genomics Network ', ' ']",NHGRI,BRIGHAM AND WOMEN'S HOSPITAL,U01,2018,953224,MA-07,0.12018567818483675
"Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies SUMMARY Almost all proteins function through interacting with other proteins. Previous studies have shown that the vast majority of damaging single amino acid mutations in proteins disrupt only a subset of specific protein-protein interactions, and that mutations in the same protein that disrupt different interactions tend to cause clinically distinct disorders. Therefore, it is of great importance to determine interaction-specific disruptions caused by each mutation. Furthermore, rapid advances in sequencing technologies have enabled the identification of tens of millions of single nucleotide variants (SNVs) in the human population, driving an urgent need to understand the impact of each SNV on the human interactome network. Unfortunately, there is currently no method that is capable of predicting the specific impact of a large fraction of these SNVs on individual protein-protein interactions. To address this issue, we propose to leverage our massively-parallel site-directed mutagenesis pipeline, Clone-seq, to generate clones for ~6,000 coding SNVs in the human population: ~4,000 from gnomAD and ~2,000 to be submitted by the international human genetics community. We will then experimentally examine the impact on protein stability and individual protein-protein interactions for every variant using high-throughput DUAL-FLUO and InPOINT (integrating PCA, LUMIER, Y2H, and wNAPPA) assays. This proposal brings together three groups with complementary expertise in high-throughput interactome experiments and network analysis from the Yu lab, in genomic and population genetic studies from the Clark lab, and in comprehensive biophysical and structural modeling of mutations impact on binding free energy of protein interactions from the Alexov lab. Out of the ~6,000 SNVs, we expect to identify ~1,200 disruptive SNVs and ~4,000 different SNV-interaction pairs where the SNV disrupt that specific interaction. The data produced by our project will increase the available experimental information by >140 in number of human proteins and >500 in number of interactions, allowing us for the first time to comprehensively assess the relationships between the impact of SNVs on interactions and their various population genetic attributes (including, but not limited to, allele frequency and flanking haplotype, inter-population differentiation, local rate of recombination, allele age, modes of selection). Finally, we will establish a computational-experimental- integrated iterative learning scheme to build a multi-layer random-forest-based framework, SIMPACT, which can accurately predict specific impacts on all individual protein-protein interactions for all missense SNVs. Our proposed work will fuel hypothesis-driven research, will significantly improve our functional understanding of variants, and will likely fundamentally change the experimental design and data interpretation for whole genome/exome studies going forward. NARRATIVE The dramatic increase of DNA variants discovered through advances in sequencing technologies has been inadequately translated into therapeutic successes. Although many of these variants are related to human disorders, the overwhelming number of non-functional variants makes the assessment of functional significance a steep challenge. In this study, we aim to develop a high-throughput pipeline to quickly clone and directly test a large number of coding variants for their impact on the human interactome network and use the results to build a machine learning pipeline to predict functional impact of all coding variants, in anticipation that both our experimental data and computational pipeline will lead to broad clinical and therapeutic applications.",Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies,9702305,R01GM125639,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Amino Acids ', ' aminoacid ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Cells ', ' Cell Body ', ' Communities ', ' Crystallization ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Experimental Designs ', ' Gene Frequency ', ' allelic frequency ', ' Allele Frequency ', ' Genes ', ' Population Genetics ', ' Genome ', ' Haplotypes ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Learning ', ' Methods ', ' Structural Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Proteins ', ' Genetic Recombination ', ' Recombination ', ' DNA Recombination ', ' Research ', ' Resources ', ' Research Resources ', ' Technology ', ' Testing ', ' Time ', ' Translating ', ' Work ', ' Measures ', ' Site-Directed Mutagenesis ', ' Targeted Modification ', ' Targeted DNA Modification ', ' Site-Specific Mutagenesis ', ' forest ', ' base ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Biochemical ', ' Training ', ' Individual ', ' data base ', ' Data Bases ', ' Databases ', ' Measurement ', ' Letters ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' System ', ' interest ', ' mutant ', ' success ', ' Free Energy ', ' Structure ', ' Code ', ' Coding System ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Property ', ' protein protein interaction ', ' Proteomics ', ' Genomics ', ' Binding ', ' Molecular Interaction ', ' Address ', ' Data ', ' Homology Modeling ', ' International ', ' Resolution ', ' Scheme ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' Output ', ' Population ', ' Coupling ', ' biological research ', ' molecular phenotype ', ' exomes ', ' exome ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' screening ', ' biophysical modeling ', ' biophysical model ', ' biophysical methods ', ' biophysical methodology ', ' biophysical approaches ', ' biophysical techniques ', ' Genetic study ', ' internet portal ', ' web portal ', ' full genome ', ' entire genome ', ' whole genome ', ' experimental research ', ' experiment ', ' experimental study ', ' human interactome ', ' ']",NIGMS,CORNELL UNIVERSITY,R01,2018,99500,NY-23,0.09529597184915907
"Biomedical Data Translator Technical Feasibility Assessment and Architecture Design Our Vision: We propose DeepLink, a versatile data translator that integrate multi-scale, heterogeneous, and multi-source biomedical and clinical data. The primary goal of DeepLink is to enable meaningful bidirectional translation between clinical and molecular science by closing the interoperability gap between models and knowledge at different scales. The translator will enhance clinical science with molecular insights from basic and translational research (e.g. genetic variants, protein interactions, pathway functions, and cellular organization), and enable the molecular sciences by connecting biological discoveries with their pathophysiological consequences (e.g. diseases, signs and symptoms, pharmacological effects, physiological systems). Fundamental differences in the language and semantics used to describe the models and knowledge between the clinical and molecular domains results in an interoperability gap. DeepLink will systematically and comprehensively close this gap. We will begin with the latest technology in semantic knowledge graphs to support an extensible architecture for dynamic data federation and knowledge harmonization. We will design a system for multi-scale model integration that is ontology-based and will combine model execution with prior, curated biomedical knowledge. Our design strategy will be iterative and participatory and anchored by 10 major milestones. In a series of demonstrations of DeepLinks functions, we will address one of the major challenges facing translational science: reproducibility of biomedical research findings that are based on evolving molecular datasets. Reproducibility of analyses and replication of results are central to scientific advancement. Many landmark studies have used data that are constantly being updated, curated, and pared down over time. Our series of demonstrations projects are designed to prototype the technology required for a scalable and robust translator as well as the techniques we will use to close the interoperability gap for a specific use case. The demonstration project will, itself, will be a significant and novel contribution to science. DeepLink will be able to answer questions that are currently enigmatic. Examples include: - From clinicians: What is the comparative effectiveness of all the treatments for disease Y given a patient's genetic/metabolic/proteomic profile? What are the functional variants in cell type X that are associated with differential treatment outcomes? What metabolite perturbations in cell type Y are associated with different subtypes of disease X? - From basic science researchers: What is known about disease Y across all model organisms (even those not designed to model Y)? What are all the clinical phenotypes that result from a change in function in protein X? Which biological pathways are affected by a pathogenic variant of disease Y? What patient data are available to evaluate a molecularlyderived clinical hypothesis? Challenges and Our Approaches: DeepLink will close the interoperability gap that currently prohibits molecular discoveries from leading to clinical innovations. DeepLink will be technologically driven, addressing the challenges associated with large, heterogeneous, semantically ambiguous, continuously changing, partially overlapping, and contextually dependent data by using (1) scalable, distributed, and versioned graph stores; (2) semantic technologies such as ontologies and Linked Data; (3) network analysis quality control methods; (4) machine-learning focused data fusion methods; (5) context-aware text mining, entity recognition and relation extraction; (6) multi-scale knowledge discovery using patient and molecular data; and (7) presentation of actionable knowledge to clinicians and basic scientists via user-friendly interfaces. ",Biomedical Data Translator Technical Feasibility Assessment and Architecture Design,9635840,OT3TR002027,"['Affect ', ' Architecture ', ' Engineering / Architecture ', ' Awareness ', ' Biomedical Research ', ' Disease ', ' Disorder ', ' Goals ', ' Language ', ' Methods ', ' Patients ', ' Pharmacology ', ' Proteins ', ' Quality Control ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Science ', ' Semantics ', ' Signs and Symptoms ', ' Diagnostic Findings ', ' Technology ', ' Time ', ' Translations ', ' Vision ', ' visual function ', ' Sight ', ' Treatment outcome ', ' Data Set ', ' Dataset ', ' base ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Physiologic ', ' Physiological ', ' Series ', ' Link ', ' insight ', ' Metabolic ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Source ', ' cell type ', ' Techniques ', ' System ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' molecular domain ', ' novel ', ' Graph ', ' Basic Science ', ' Basic Research ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Proteomics ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Pathogenicity ', ' text searching ', ' text mining ', ' literature searching ', ' literature mining ', ' discovery mining ', ' Address ', ' Data ', ' Reproducibility ', ' Clinical Data ', ' Clinical Sciences ', ' Ontology ', ' translation research ', ' Translational Science ', ' Translational Research ', ' Update ', ' Molecular ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' multiscale modeling ', ' multi-scale modeling ', ' designing ', ' design ', ' innovative ', ' innovate ', ' innovation ', ' interoperability ', ' user-friendly ', ' comparative effectiveness ', ' prototype ', ' Knowledge Discovery ', ' ']",NCATS,COLUMBIA UNIVERSITY HEALTH SCIENCES,OT3,2018,854309,NY-13,0.0633714498116252
"Whole Genome Sequencing in Irish Multiplex Schizophrenia Families Project Summary: Although affected members of multiplex schizophrenia pedigrees have substantially elevated recurrence risk compared to singleton cases, the mean polygenic risk scores between these groups do not differ, suggesting that one source of this higher familial recurrence risk is rare, higher impact variation. We will collect whole genome sequence (WGS) from 600 affected members of multiplex schizophrenia pedigrees to identify rare variation shared by affected individuals within and between pedigrees potentially accounting for the increased recurrence risk, and reducing the `variant space' under consideration. After QC and calling in our existing pipeline, a) familial sequence variants in the exome will be directly analyzed in 2000 Irish cases and 2000 Irish controls with 30X exome sequence data in production currently, and b) variants outside the exome will be imputed into 3600 Irish singleton schizophrenia or bipolar disorder cases and 3000 Irish population controls with GWAS framework data; 3781 additional UK10K controls with 10X WGS are available to increase analysis power. This imputed dataset will be analyzed using recently developed methods for kernel-based tests of variation aggregated over a defined interval (such as a gene) that avoid the inflation of type-1 error. We use multiple sources of genomic information to develop weights for each position in the genome (indexing the prior probability that a change at the site has functional consequence) and each variant detected (indexing the probability that observed changes have functional consequence), and we propose to improve the existing genomic information sources for this weighting in a number of ways. In aim 3, prioritized variants from aim 2a/2b will be directly genotyped in the case/control samples by custom microarray; individual genes or genesets showing enrichment of variation in cases (if any are observed) will be resequenced in the case/control sample. In Aim 4, the directly assessed genotypic and sequence data from aim 3 will be analyzed using standard methods to identify individual associated variants, and variant-enriched genes, genesets or other functional sequences. We seek to unambiguously identify 1) individual variants that are significantly more common in cases, or 2) individual genes or other functional sequences or 3) gene- or functional sequence sets enriched for variation in cases to provide critical information about the brain systems perturbed in schizophrenia, and the mechanisms by which such alleles increase risk. Project Narrative Rare sequence variation has been implicated in many human complex traits, incuding schizophrenia, and has been studied in unrelated cases and controls and parent:offspring trios, but remains unstudied in multiplex families. Sequencing the genomes of such families will allow conprehensive identification of variation in protein coding genes, non-coding expressed loci, regulatory sequences, and evolutionarily conserved regions, as well as detection of structural variation, and testing these alleles in a large case/control series of the same ethnic and geographic origin offers significant advantages over prior study designs, and has the potential to identify individual alleles, variant enriched genes, variant enriched non-genic sequences, and/or variant enriched genesets contributing to SCH risk in the Irish population. Such variants offer great potential for understanding the functional impact of risk alleles and improving mechanistic understanding of schizophrenia and related disorders.",Whole Genome Sequencing in Irish Multiplex Schizophrenia Families,9555069,R01MH114593,"['Accounting ', ' Affect ', ' Alleles ', ' Allelomorphs ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Bipolar Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Face ', ' facial ', ' faces ', ' Family ', ' Genes ', ' Genome ', ' Genotype ', ' Geography ', ' Goals ', ' Human ', ' Modern Man ', ' indexing ', ' Ireland ', ' Irish Free State ', ' Eire ', ' Linkage Disequilibrium ', ' Methods ', ' Nucleotides ', ' Parents ', ' genetic pedigree ', ' pedigree structure ', ' Pedigree ', ' Population Control ', ' Probability ', ' Production ', ' Proteins ', ' Psychotic Disorders ', ' psychotic illness ', ' Psychoses ', ' Recurrence ', ' Recurrent ', ' Research Design ', ' study design ', ' Study Type ', ' Resources ', ' Research Resources ', ' Risk ', ' Risk Factors ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Genetic Variation ', ' Genetic Diversity ', ' Weight ', ' Measures ', ' Data Set ', ' Dataset ', ' Custom ', ' base ', ' improved ', ' specimen collection ', ' sample collection ', ' Site ', ' Phase ', ' Variation ', ' Variant ', ' Series ', ' Individual ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Dimensions ', ' Complex ', ' Source ', ' System ', ' trait ', ' member ', ' offspring ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Sampling ', ' case control ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' genome sequencing ', ' LGALS3BP gene ', ' MAC-2-BP ', ' 90K ', ' Data ', ' Detection ', ' Principal Investigator ', ' Process ', ' work group ', ' working group ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' effective treatment ', ' effective therapy ', ' genomewide ', ' genome scale ', ' genome-wide ', ' exomes ', ' exome ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' power analysis ', ' full genome ', ' entire genome ', ' whole genome ', ' genomic data ', ' ']",NIMH,VIRGINIA COMMONWEALTH UNIVERSITY,R01,2018,457798,VA-04,0.16502677022568615
"Biomedical Computing and Informatics Strategies for Infectious Disease Research     DESCRIPTION (provided by applicant): An important goal of infectious disease research is to develop genetic predictors of susceptibility. Our success in this endeavor will depend critically on the informatics methods and software that are available for making sense of high-dimensional genetic and genomic data. The goal of this research program is to develop, evaluate, distribute and support new and novel biomedical computing algorithms and open-source software for identifying combinations of genetic predictors of clinically important infectious disease outcomes. This application will target the growing body of rare genetic variants identified by high-throughput DNA sequencing. Our clinical application will focus on the prediction of antiretroviral response in clinical trials for HIV/AIDS. We propose here a highly innovative Hierarchical Rare Variant Collapsing Machine (HRVCM) algorithm for identifying and collapsing combinations of rare variants across gene regions (AIM 1). We will then integrate these new collapsed HRVCM variables into our popular Multifactor Dimensionality Reduction (MDR) method that will assess them in combination with common single-nucleotide polymorphisms (SNPs) from genome-wide association studies or GWAS (AIM 2). Our novel HRVCM-MDR approach will, for the first time, make it possible to assess non-additive interactions among sets of rare and common variants simultaneously in genetic studies of infectious diseases. We will apply these new and novel methods to approximately 13 million rare and common variants from nearly 3000 subjects that participated in an AIDS Clinical Trials Group (ACTG) study to evaluate risk for virologic failure with efavirenz-containing antiretroviral therapy (ART) regimens (AIM 3). Finally, we will release all methods as open source to the biomedical research community through our freely available MDR software package (AIM 4). PUBLIC HEALTH RELEVANCE: The overall goal of this application is to develop innovative new computational methods for the genetic analysis of infectious diseases. We will focus on the development of methods that are able to detect synergistic effects of multiple genetic variants regardless of whether they are rare of common in human populations. We will apply these methods to the study of HIV/AIDS vaccination response.",Biomedical Computing and Informatics Strategies for Infectious Disease Research,9430380,R01AI116794,"['Algorithms ', ' Biomedical Research ', ' Clinical Trials ', ' Communicable Diseases ', ' Infectious Disorder ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Communities ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Statistical Data Interpretation ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Disease susceptibility ', ' liability to disease ', ' Diathesis ', ' Gene Frequency ', ' allelic frequency ', ' Allele Frequency ', ' Genes ', ' Genome ', ' Goals ', ' Human ', ' Modern Man ', ' Methods ', ' Methodology ', ' Genetic Models ', ' Research ', ' Risk ', ' Computer software ', ' Software ', ' Time ', ' Vaccination ', ' Genetic Variation ', ' Genetic Diversity ', ' virology ', ' Measures ', ' base ', ' method development ', ' Variation ', ' Variant ', ' Susceptibility ', ' Predisposition ', ' Failure ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Dimensions ', ' gene interaction ', ' success ', ' Anti-Retroviral Agents ', ' antiretroviral ', ' anti-retroviral ', ' Antiretroviral Agents ', ' Informatics ', ' efavirenz ', ' simulation ', ' Disease Outcome ', ' novel ', ' Graph ', ' AIDS/HIV problem ', ' HIV/AIDS problem ', ' HIV/AIDS ', ' AIDS/HIV ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' response ', ' Bioinformatics ', ' Bio-Informatics ', ' AIDS clinical trial group ', ' acquired immunodeficiency syndrome clinical trial group ', ' acquired immunodeficiency syndrome (AIDS) clinical trial group ', ' ACTG ', ' AACTG - adult AIDS clinical trial group ', ' AACTG ', ' genetic association ', ' Biomedical Computing ', ' biomedical computation ', ' Data ', ' Detection ', ' Infectious Diseases Research ', ' Infectious Diseases / Laboratory ', ' genomic region ', ' Genomic Segment ', ' antiretroviral treatment ', ' anti-retroviral treatment ', ' anti-retroviral therapy ', ' antiretroviral therapy ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' biomed informatics ', ' biomedical informatics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' innovative ', ' innovate ', ' innovation ', ' clinical applicability ', ' clinical application ', ' open source ', ' public health relevance ', ' genomewide ', ' genome scale ', ' genome-wide ', ' Regimen ', ' rare allele ', ' rare variant ', ' High-Throughput DNA Sequencing ', ' Analysis of Algorithms ', ' Analyses of Algorithms ', ' Algorithmic Analyses ', ' Algorithmic Analysis ', ' clinical predictors ', ' genetic predictors ', ' Genetic study ', ' genomic data ', ' high dimensionality ', ' ']",NIAID,UNIVERSITY OF PENNSYLVANIA,R01,2018,874977,PA-03,0.10185899198932535
"Leveraging Tissue-Specific Regulatory Grammar to Interpret Human Evolution and Non-coding Variation Project Summary  It is now possible to readily identify sequence variants that have been subject to natural selection in human populations. Adaptive variants have been shown to underlie diversity in both disease risk and morphology across human populations, suggesting that the lens of evolution remains a powerful tool for understanding human biology, yet one that is currently underutilized. One challenge to realizing this potential is that over 99% of human genetic variation is non-coding, as are most signals of selection and variants associated with human phenotypic traits. Mutations modifying transcription factor (TF) binding sites in non- coding, cis-regulatory regions are hypothesized to be more amenable to driving phenotypic evolution than coding changes. These cis-regulatory regions are major determinants of tissue-specific gene expression and variation within enhancers has been indicated to play role in selection and disease. However, enhancer `regulatory grammar'  the complex pattern of sequences that interact with TFs to control gene expression, is poorly understood. The challenge of linking a regulatory variant under selection to an adaptive phenotype is similar to that facing disease association studies: the targeted gene, cell type, and biological process are often unknown, hindering further investigation.  Machine learning algorithms automate the discovery of patterns, making them well-suited to uncover sequence constraints and the combinatorial TF binding patterns of enhancers without relying on limited motif databases. I will optimize support vector machine classifiers to elucidate regulatory grammar from over 100 cell types and tissues. These models will be used to predict the impact of sequence variants on cis-regulatory sites, expanding the utility of the NHGRI's ENCODE and Roadmap projects. I will then apply these tissue- specific predictions to signals of selection and/or disease from the NHGRI's 1000 Genomes Project and its genome-wide association studies catalog. By describing the regulatory impact of signals of selection, I will globally describe patterns of functional adaptation across populations, identifying genes, and gene networks targeted by selection and/or disease. I will functionally characterize variants using massively parallel reporter assays and genome editing to give deeper insight into specific cases of evolution relevant for human health.   This project seeks to develop tools and resources to describe the structure and function of sequence variation in the human genome. This proposal seeks to vastly increase the number of elucidated cases of human evolution, and specifically characterize those adaptive variants associated with disease. We will share the functional regulatory predictions for the use in interpreting a broad range of genomic datasets. This work has broad implications, from interpreting genetic variants in populations and understanding functional targets of evolution, to prioritizing non-coding mutations for precision genomic medicine and beyond. Project Narrative While thousands of genomic regions have been linked to human evolution and diseases, many of the genetic variants responsible are non-coding and thus difficult to interpret. I propose to describe the tissue-specific effects of regulatory variants using machine learning algorithms, and then integrate these functional predictions with signals of selection and/or disease association in order to pinpoint genetic variants important for human evolution and health.",Leveraging Tissue-Specific Regulatory Grammar to Interpret Human Evolution and Non-coding Variation,9406681,F32HG009226,"['Algorithms ', ' Automobile Driving ', ' driving ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Chromatin ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Evolution ', ' Gene Expression ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Logic ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Phenotype ', ' Play ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Tissues ', ' Body Tissues ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Enhancers ', ' Experimental Models ', ' Mediating ', ' Natural Selections ', ' Data Set ', ' Dataset ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Link ', ' Training ', ' insight ', ' data base ', ' Data Bases ', ' Databases ', ' Gene Targeting ', ' Biological Function ', ' Biological Process ', ' Genetic ', ' Morphology ', ' Reporter ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Mechanics ', ' mechanical ', ' Investigation ', ' Complex ', ' human tissue ', ' cell type ', ' Pattern ', ' Techniques ', ' interest ', ' trait ', ' Structure ', ' Human Biology ', ' disorder risk ', ' disease risk ', ' Code ', ' Coding System ', ' Modeling ', ' functional genomics ', ' genome database ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Binding ', ' Molecular Interaction ', ' Data ', ' genomic region ', ' Genomic Segment ', ' Tissue-Specific Differential Gene Expression ', ' Differential Gene Expression ', ' Tissue-Specific Gene Expression ', ' trend ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Outcome ', ' Population ', ' combinatorial ', ' lenses ', ' lens ', ' genomewide ', ' genome scale ', ' genome-wide ', ' epigenome ', ' CRISPR/Cas system ', ' CRISPR ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' genomic editing ', ' genome editing ', ' functional adaptation ', ' precision genomic medicine ', ' genomic data ', ' web-based tool ', ' ']",NHGRI,HARVARD UNIVERSITY,F32,2018,57066,MA-05,0.08756717362608825
"Functional characterization of genetic and post-transcriptional variation using machine learning methods The goal of this research proposal is to develop new in-silico approaches for accurate functional annotation of genetic and post-transcriptional variants. The rapid growth of Next-Generation Sequencing (NGS) and high- throughput -omics data have brought us one step closer towards mechanistic understanding of the complex genetic disease, such as cancer, neurological disorders, diabetes, and others at the molecular level. In particular, these data revealed that complex diseases commonly manifest changes at the genetic and post- transcriptional levels. Bot of these types of changes often affect structure and function of the corresponding genes and their products. Understanding the functional implications of the genetic and post-transcriptional variation is an important task as it can provide critical insights into the molecular mechanisms underlying the disease. Here, we propose to leverage novel machine learning paradigms to design computational methods for predicting the effect of genetic and alternative splicing variants on the macromolecular interactions. Macromolecular interactions underlie many cellular functions in a healthy organism. The disease-induced changes in the genes, such as single nucleotide variations (SNVs) and alternative splicing variations (ASVs) have been recently reported to cause the protein-protein interaction network rewiring. Unfortunately, the experimental high-throughput techniques that characterize the large-scale effects of SNVs or ASVs on PPIs are expensive, time-consuming, and far from being comprehensive. The current in-silico methods either suffer from the limited applicability, or are less accurate when compared with the experimental methods. To overcome these challenges, we will use two recent machine learning paradigms, learning under privileged information (LUPI) and semi-supervised learning. If successful, we expect for the proposed methods to provide the critical advancement in the two main challenges of the current computational approaches, the limited coverage and lower than the experimental accuracy. The methods will be freely available to the community as the stand-alone tools as well as web- servers. The goal of this proposal is to build computational tools that discover the links  between the disease-associated mutations as well as alternatively spliced protein isoforms  and the protein-protein interactions mediated by the disease proteins. The tools use advanced  machine learning methods to find such links in a fast and inexpensive way. These tools  will be useful in elucidating the molecular mechanisms implicated in the complex genetic disorders.",Functional characterization of genetic and post-transcriptional variation using machine learning methods,9601437,R21LM012772,"['Affect ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Communities ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Gene Expression ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Learning ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' nervous system disorder ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' Nucleotides ', ' Organism ', ' living system ', ' Proteins ', ' Publishing ', ' Research Proposals ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA Splicing ', ' Splicing ', ' Role ', ' social role ', ' Supervision ', ' Time ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Work ', ' forest ', ' Mediating ', ' Data Set ', ' Dataset ', ' Variation ', ' Variant ', ' Link ', ' Training ', ' insight ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' gene function ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Adopted ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Techniques ', ' One-Step dentin bonding system ', ' One Step ', ' Protein Isoforms ', ' Isoforms ', ' Structure ', ' novel ', ' Reporting ', ' protein protein interaction ', ' Data ', ' Homology Modeling ', ' Mutate ', ' RNA-Protein Interaction ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Molecular ', ' Genetic Annotation ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' computational tools ', ' computerized tools ', ' rapid growth ', ' designing ', ' design ', ' transcriptomics ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' learning method ', ' learning activity ', ' learning strategy ', ' gene product ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' human interactome ', ' ']",NLM,WORCESTER POLYTECHNIC INSTITUTE,R21,2018,159669,MA-02,0.04788228541402422
"Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases     DESCRIPTION (provided by applicant) Over the past 10 years human genetics studies made unprecedented numbers of discoveries relating genome variation to common diseases. While it is unquestionably true that we have learned substantially from the discoveries made to date, we must also acknowledge that with respect to the identification and characterization of the genome variation affecting risk of common human diseases - those accounting for the overwhelming majority of public health care expenditures - our discoveries have not generated nearly the knowledge of disease etiology that we would have expected given the sheer number of these discoveries. The combination of these observations coupled with the dramatic reduction in the cost of sequencing is driving the case for moving to whole genome sequencing studies for common disease. We have focused our application on three critical challenges for methods development and analysis of whole genome sequence data. While there has been substantial progress in methods development for analysis of exome sequencing, with gene-based tests that are relatively robust to the direction of effects of rare coding variants as well as the proportionof the gene's rare variants contributing to phenotype, it is clear that methods integrating the analysis of common and rare variation as well as functional genomics data will be essential for appropriate analysis of whole genome sequence data. Thus, we propose in Specific Aim 1 to develop novel methods, software and analysis pipelines for integrated analysis of common and rare variants for the analysis of whole genome sequence on 50,000- 100,000 individuals for any given common disease, and in Specific Aim 2 to develop and apply novel approaches for prioritizing results from these large-scale sequencing studies using BioVU, the 200,000 member biobank at Vanderbilt that is associated with 30 years of high quality electronic health records, and in Specific Aim 3 to develop queriable results databases and a comprehensive web portal to serve results of our studies on the sequence data for both the internal sequencing community and for the broader scientific community. PUBLIC HEALTH RELEVANCE Large-scale whole genome sequencing studies are being carried out to understand the genetic architecture of human complex diseases. It remains challenging to decipher the genetic mechanisms of disease etiology. In this application we aim to develop a suite of statistical and computational methods to identify genes and variants associated with complex disease and use BioVU, a DNA BioBank linked to electronic health records, to validate and investigate genetic architecture of multiple complex diseases.","Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases",9483341,U01HG009086,"['Accounting ', ' Affect ', ' Automobile Driving ', ' driving ', ' Communities ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Health Expenditures ', ' healthcare expenditure ', ' health-care expenditures ', ' health care expenditure ', ' Face ', ' facial ', ' faces ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Genome ', ' Government ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Methods ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Phenotype ', ' Public Health ', ' Research ', ' Resources ', ' Research Resources ', ' Risk ', ' Science ', ' Computer software ', ' Software ', ' Technology ', ' Time ', ' Tissues ', ' Body Tissues ', ' Generations ', ' Data Set ', ' Dataset ', ' base ', ' method development ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' data base ', ' Data Bases ', ' Databases ', ' Policies ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetically predisposed ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Complex ', ' experience ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' success ', ' expectation ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' member ', ' Reporting ', ' Code ', ' Coding System ', ' Statistical Methods ', ' functional genomics ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' genome sequencing ', ' Data ', ' Large-Scale Sequencing ', ' Validation ', ' Electronic Health Record ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' disease phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' cost ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Coupled ', ' human disease ', ' public health relevance ', ' biorepository ', ' biobank ', ' exomes ', ' exome ', ' exome-seq ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' Genetic study ', ' internet portal ', ' web portal ', ' human genomics ', ' full genome ', ' entire genome ', ' whole genome ', ' genomic data ', ' experimental research ', ' experiment ', ' experimental study ', ' genomic science ', ' genome sciences ', ' genetic architecture ', ' ']",NHGRI,VANDERBILT UNIVERSITY,U01,2018,864186,TN-05,0.12227602667964475
"Uncovering the Genetic Mechanisms Behind Joint-Specific Osteoarthritis Project Summary/Abstract In the United States, the joint disease osteoarthritis (OA) debilitates over one-third of people over sixty-five years old and causes hundreds of thousands of knee replacements annually. Despite its high prevalence, little is known about the molecular mechanisms that regulate knee formation and OA risk and how one inherits risk at specific joints (e.g., knee versus hip). Recent GWAS have identified at least seventeen loci that significantly associate with knee OA risk. However, the casual variants for these loci have not been identified because their association signals span large genomic intervals harboring uninvestigated non-coding regulatory regions. Of these, common variants in the Growth Differentiation Factor Five gene (GDF5), a critical regulator of joint development, reproducibly associate with knee OA risk in human populations. GDF5 OA variants reside on a high frequency 130 kb haplotype possessing numerous mutations that each may be causal for OA risk, but interestingly, no protein coding mutations have been uncovered that explain the associations. In a complementary study, we discovered ten GDF5 regulatory elements (e.g., promoters, enhancers) spanning this interval and revealed that they function with tremendous joint specificity (e.g., knee vs. hip). These enhancers were initially tested at incipient stages of GDF5 expression in mouse embryos, but we also know that GDF5 contributes to the differentiation of knee structures (ligaments, tendons, menisci, articular surfaces) well after this stage of development. Our research will bring together knee OA risk variants in patient populations and our knowledge of how GDF5 is controlled at the DNA level. We first aim to assess the functional contributions of joint-specific GDF5 enhancers to pre-natal knee development and adult joint homeostasis using CRISPR-Cas9 editing to excise these elements in vitro in human cells and in vivo in the mouse. Strikingly, our pilot analyses also revealed that a subset of these GDF5 enhancers possesses common and rare human variants in strong linkage disequilibrium with the highest associated OA variants in the interval. Our second aim is to further explore the association between genetic variants in the locus and OA knee shape using data acquired from the complete Osteoarthritis Initiative MR database on adult knees. Our preliminary data reveal that several variants associated with OA knee shape reside in several functional enhancers that control expression of GDF5 in the knee. Finally, our third aim is to functionally test these human regulatory variants for their impact on enhancer activity, knee formation, and OA risk by using transfection studies and CRISPR-Cas9 in human cartilage cells and in the mouse model. Completion of these studies will reveal functional variants in GDF5 that underlie its role in knee shape and OA risk. Project Narrative The Growth Differentiation Factor Five (GDF5) gene is the most reproducibly detected gene region in candidate and genome-wide association studies focusing on knee osteoarthritis risk. The proposed research focuses on (1) assessing the specific functions of key GDF5 regulatory sequences in knee development and cartilage maintenance in mice and humans, (2) the association of genetic variants in GDF5 locus with osteoarthritis knee shape, and (3) the impacts that human GDF5 risk mutations have on chondrocyte and joint biology.",Uncovering the Genetic Mechanisms Behind Joint-Specific Osteoarthritis,9448210,R01AR070139,"['genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Prevalence ', ' five years of age ', ' five year old ', ' age 5 years ', ' 5 years of age ', ' 5 year old ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' Susceptibility Gene ', ' murine model ', ' mouse model ', ' spatiotemporal ', ' patient population ', ' in vitro activity ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' risk variant ', ' Geometry ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' CRISPR/Cas technology ', ' full genome ', ' entire genome ', ' whole genome ', ' experimental research ', ' experiment ', ' experimental study ', ' Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Affect ', ' Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Architecture ', ' Engineering / Architecture ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Cartilage ', ' Cartilaginous Tissue ', ' Cells ', ' Cell Body ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Elements ', ' Embryo ', ' Embryonic ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Haplotypes ', ' Hip region structure ', ' Hip ', ' Coxa ', ' Homeostasis ', ' Physiological Homeostasis ', ' Autoregulation ', ' Human ', ' Modern Man ', ' In Vitro ', ' arthropathies ', ' joint disorder ', ' arthropathy ', ' arthropathic ', ' Joint Diseases ', ' Joints ', ' Knee ', ' Knee joint ', ' Ligaments ', ' Linkage Disequilibrium ', ' Maintenance ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Degenerative polyarthritis ', ' osteoarthritic ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Patients ', ' Pregnancy ', ' Gestation ', ' Proteins ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Research ', ' Risk ', ' Role ', ' social role ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Specificity ', ' Tendon structure ', ' Tendons ', ' Testing ', ' Transfection ', ' United States ', ' Veins ', ' Work ', ' Enhancers ', ' knee replacement arthroplasty ', ' total knee arthroplasty ', ' Total Knee Replacement ', ' Knee replacement ', ' Knee joint replacement operation ', ' Knee arthroplasty ', ' promoter ', ' promotor ', ' Data Set ', ' Dataset ', ' joint replacement ', ' joint arthroplasty ', ' Joint Prosthesis Implantation ', ' Arthroplasty ', ' Replacement Arthroplasty ', ' Surface ', ' Variation ', ' Variant ', ' Susceptibility ', ' Predisposition ', ' Meniscus ', ' Meniscus structure of joint ', ' cartilage cell ', ' Chondrocytes ', ' disability ', ' Individual ', ' data base ', ' Data Bases ', ' Databases ', ' Genetic ', ' Morphology ', ' Shapes ', ' Reporter ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Life ', ' Knee Osteoarthritis ', ' Dimensions ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Pattern ', ' Structure ', ' prenatal ', ' unborn ', ' novel ', ' disorder risk ', ' disease risk ', ' Reporting ', ' Code ', ' Coding System ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' genetic association ', ' Defect ', ' Data ', ' Differentiation and Growth ', ' High Prevalence ', ' Regulatory Element ', ' in vivo ', ' Molecular ', ' developmental ', ' Development ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' ']",NIAMS,HARVARD UNIVERSITY,R01,2018,699831,MA-05,0.11986487891546534
"Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases     DESCRIPTION (provided by applicant): The NHGRI Genome Sequencing Program (GSP) will identify genomic variants relevant to health and disease by genome sequencing over 225,000 participants across a multitude of diseases. The GSP will also serve as a pilot for the Precision Medicine Initiative that aims to enroll and sequence more than a million people representative of U.S. ethnic diversity. Here, we propose a GSP analysis center focused on Multi- and Trans- ethnic Mapping of Mendelian and Complex Diseases. There is a growing recognition of the substantial scientific advantages, as well as public health importance, of conducting biomedical research across ethnically diverse cohorts. We propose to develop scalable methods that incorporate ancestry to optimize medical genomic study design and improve power for uncovering the role of common and rare variants in disease. Achieving this goal requires expertise across diverse domains of knowledge including: medical and population genomics, algorithm development for complex disease mapping, and expertise in management of large-scale databases. Here, we have assembled a world-class team of medical and population geneticists, computer scientists, statisticians and clinicians, with leading expertise in the development of novel and scalable strategies for characterizing sequence variants and their role in disease. Importantly, our group has been at the forefront of development of resources, study designs and methods to enable genomic research in U.S. minority populations. Our project has three main objectives. First, we will develop an Automated Scalable Ancestry Pipeline (ASAP) for common disease mapping in diverse populations. ASAP will improve the computational efficiency of existing state-of-the-art methods for ancestry inference and develop important extensions to linear mixed models (LMMs) and other mapping strategies leveraging local and global ancestry. We will also develop methods to refine phenotypes and identify common controls for disease studies and define endpoints. Secondly, we will develop tools and resources for trans- and multi-population rare variant discovery that incorporate patterns of local and sub-continental ancestry. We will also develop machine-learning tools for variant annotation that leverage ancestral information, patterns of sequence evolution, and protein structure in a unified framework. Furthermore, we will incorporate population-specific patterns of cellular phenotypes to improve functional prediction algorithms for non-coding and coding variants. Lastly, we will disseminate our results through web-based resource that empower the biomedical research community. We will augment existing resources including ClinGen by annotating and characterizing pathogenic variants across diverse populations. We will develop a secure web-server that allows sharing of summary statistics and analysis pipelines to enable discovery, fine-mapping and functional prediction of genetic variants. Our team has ample experience with NIH-funded consortia and is dedicated to meeting the overall GSP project goals through collaborative work with NHGRI leadership and other funded investigators. PUBLIC HEALTH RELEVANCE The goal of our project is to accelerate the discovery of DNA variation relevant to health and disease by analyzing data from over 225,000 ethnically and racially diverse patients that will undergo genome sequencing. Of particular importance is ensuring we have powerful statistical methods for analyzing data from underserved groups including U.S. minority populations. Achieving this goal requires expertise across many domains of knowledge including: medical and population genomics, algorithm development for disease mapping, and expertise in large-scale databases.",Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases,9462637,U01HG009080,"['Algorithms ', ' Architecture ', ' Engineering / Architecture ', ' Biomedical Research ', ' Chronic Disease ', ' chronic disorder ', ' Chronic Illness ', ' Communities ', ' Computers ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Evolution ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Leadership ', ' Methods ', ' Methodology ', ' Methylation ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Patients ', ' Phenotype ', ' Privatization ', ' Public Health ', ' Research ', ' Research Design ', ' study design ', ' Study Type ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Risk ', ' Role ', ' social role ', ' Shoulder ', ' statistics ', ' Target Populations ', ' Testing ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' United States ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Population Heterogeneity ', ' population diversity ', ' heterogeneous population ', ' diverse populations ', ' Data Set ', ' Dataset ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' programs ', ' Scientist ', ' Investigation ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' meetings ', ' experience ', ' cohort ', ' simulation ', ' novel ', ' Participant ', ' Code ', ' Coding System ', ' Statistical Methods ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' disorder control ', ' disease control ', ' Pathogenicity ', ' genome sequencing ', ' protein structure ', ' Data ', ' Resolution ', ' Resource Development ', ' enroll ', ' Enrollment ', ' developmental ', ' Development ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' patient privacy ', ' Minority ', ' Population ', ' innovative ', ' innovate ', ' innovation ', ' large-scale data base ', ' large-scale database ', ' tool development ', ' public health relevance ', ' phenome ', ' Secure ', ' rare allele ', ' rare variant ', ' Precision Medicine Initiative ', ' genomic tools ', ' GTEx ', ' Genotype-Tissue Expression Project ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' ethnically diverse ', ' ethnic diversity ', ' racially diverse ', ' racial diversity ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' web-based resource ', ' web resource ', ' online compendium ', ' on-line resource ', ' on-line compendium ', ' internet resource ', ' online resource ', ' web-based tool ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2018,921743,CA-18,0.16988658568500095
"Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea ABSTRACT  Obstructive sleep apnea (OSA) is recognized as an extremely common disorder that results in excessive daytime sleepiness and an increased risk of automobile crashes. It is also an independent risk factor for insulin resistance, hypertension, cardiovascular events, increased cancer rates and cancer mortality, and accelerates the progression of neurodegenerative disorders. OSA is a systemic disorder and the cyclical intermittent hypoxia that occurs during sleep affects every organ system. OSA is heritable, with first degree relatives of individuals with OSA having a two-fold increased risk of the disorder. Although this has been known for over two decades, there are very limited data on gene variants conferring risk or protection for OSA. This is likely the result of underpowered studies and GENETIC HETEROGENEITY. There are multiple pathways to OSA. Obesity is a major risk factor, as are craniofacial dimensions. The relative risk of these different risk factors varies by ethnic group. There are also neuronal mechanisms and other physiological risk factors. This proposal seeks to directly address the issue of genetic heterogeneity using a very large sample of patients and state-of- the-art analysis techniques. Towards this end, we have assembled by far the largest sample of well characterized and genotyped patients with OSA. This is the result of collaboration with key sites in the eMERGE Network [Geisinger, Vanderbilt, Mayo Clinic, Northwestern], Kaiser Permanente Southern California, and the University of Pennsylvania. We propose to carry out a robust genome-wide association studies (GWAS) using an electronic health record (EHR) derived case definition and quantitative trait analysis of OSA severity. We will use novel machine learning approaches to specifically address genetic heterogeneity. The GWAS approach will be complimented by a PheWAS strategy as another approach to identifying common variants and related clinical phenotypes. Specifically, we will look for variants that associate with OSA and other clinical diagnoses in the EHR. It is likely that gene variants for OSA will have pleiotropic effects. Gene variants identified from GWAS and/or PheWAS will be further assessed. First, we will use available whole exome sequencing data to see if there are relevant rare variants in these genes, as well as to perform exploratory discovery analyses to look for novel rare variation. The functional role of the genes identified will be studied by functional network analysis. Finally, we will assess associations with quantitative data on intermediate traits identified by high throughput craniofacial and intra-oral photography. These data are currently available within the Sleep Apnea Global Interdisciplinary Consortium (SAGIC). Future directions will assess the function of the genes identified in model systems and the clinical utility of utilizing variants as part of risk stratification for OSA. PROJECT NARRATIVE  Obstructive sleep apnea (OSA) is a common disorder with multiple adverse consequences. It is known that OSA has a genetic basis, but to date no convincing gene variants have been identified. This study uses state of the art approaches to identifying relevant genes based on a very large sample of patients with OSA obtained from multiple institutions in the United States. It is by far the largest study ever proposed for identifying genes for this common sleep disorder.",Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea,9478321,R01HL134015,"['Affect ', ' Algorithms ', ' Automobiles ', ' Bladder ', ' urinary bladder ', ' Bladder Urinary System ', ' California ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Ethnic group ', ' ethnicity group ', ' Fatty acid glycerol esters ', ' Fats ', ' Foundations ', ' Future ', ' Genes ', ' Genotype ', ' Heterogeneity ', ' Hypertension ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Insulin Resistance ', ' insulin resistant ', ' Learning ', ' men ', "" men's "", ' Methodology ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' mortality ', ' Neurons ', ' neuronal ', ' Neurocyte ', ' Neural Cell ', ' Nerve Unit ', ' Nerve Cells ', ' Obesity ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Patients ', ' Pennsylvania ', ' Periodicity ', ' Rhythmicity ', ' Cyclicity ', ' Phenotype ', ' Photography ', ' Play ', ' Public Health ', ' Research ', ' Resources ', ' Research Resources ', ' Risk ', ' Risk Factors ', ' Role ', ' social role ', ' Sleep ', ' Sleep Apnea Syndromes ', ' sleep-related breathing disorder ', ' Sleep-Disordered Breathing ', ' Sleep Hypopnea ', ' Sleep Apnea ', ' Thinness ', ' Leanness ', ' Tissues ', ' Body Tissues ', ' United States ', ' Universities ', ' Woman ', ' Measures ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' soft tissue ', ' Individual ', ' Oxygen Deficiency ', ' Hypoxic ', ' Hypoxia ', ' Relative Risks ', ' Genetic Heterogeneity ', ' Collaborations ', ' Genetic ', ' gene function ', ' clinical Diagnosis ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Dimensions ', ' Severities ', ' Complex ', ' Event ', ' Clinic ', ' Techniques ', ' System ', ' body system ', ' Organ System ', ' Obstructive Sleep Apnea ', ' Syndrome, Sleep Apnea, Obstructive ', ' Severity of illness ', ' disease severity ', ' Neurodegenerative Disorders ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' craniofacial ', ' craniofacies ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' cohort ', ' trait ', ' Structure ', ' novel ', ' Participant ', ' disorder risk ', ' disease risk ', ' Excessive Daytime Sleepiness ', ' Excessive daytime somnolence ', ' Code ', ' Coding System ', ' cardiovascular risk factor ', ' cardiovascular risk ', ' Sleep Disorders ', ' sleep problem ', ' Pathway Analysis ', ' Network Analysis ', ' Sampling ', ' case control ', ' Genomics ', ' Institution ', ' genetic association ', ' Address ', ' Data ', ' Collection ', ' 1st degree relative ', ' First Degree Relative ', ' Process ', ' Electronic Health Record ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Vehicular crash ', ' Vehicular collision ', ' Motor vehicle crash ', ' Motor vehicle collision ', ' Car crash ', ' Car collision ', ' Automobile crash ', ' Automobile collision ', ' Vehicle crash ', ' innovative ', ' innovate ', ' innovation ', ' Heritability ', ' discover genes ', ' gene discovery ', ' high risk ', ' genomewide ', ' genome scale ', ' genome-wide ', ' phenome ', ' exomes ', ' exome ', ' adverse consequence ', ' adverse outcome ', ' exome-seq ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' precision-based medicine ', ' precision medicine ', ' learning method ', ' learning activity ', ' learning strategy ', ' genotyped patients ', ' genomic data ', ' Risk stratification ', ' secondary analysis ', ' eMERGE Network ', ' eMERGE Consortium ', ' Electronic Medical Records and Genomics Network ', ' craniofacial tissue ', ' ']",NHLBI,UNIVERSITY OF PENNSYLVANIA,R01,2018,692794,PA-03,-0.01804975114259039
"Interrogating regulatory variants by multiplexed genome editing A major result from recent genome wide association studies (GWAS) is that the majority of genetic variants driving common human diseases lie in regulatory, rather than protein-coding, regions. Massive efforts to map epigenomic features such as localization of histone modifications (HMs) and transcription factors (TFs) have paved the way toward understanding the regulatory genome. However, dissecting the impact of an individual non-coding variant remains an unsolved challenge.  A variety of computational methods have been proposed, such as quantitative trait loci (QTL) studies and machine learning techniques. However, these methods still do not provide conclusive information about causality of any specific non-coding mutation and lack gold-standard experimental results for evaluation. Several techniques are used to experimentally test the impact of individual regulatory variants. For example, massively parallel reporter assays (MPRA) synthesize thousands of oligonucleotides encoding mutated versions of putative regulatory elements placed in plasmids upstream of reporter genes. However, a major limitation is that tested sequences are outside of their endogenous chromosomal locus, and hence do not necessarily provide physiological relevance.  CRISPR enables targeted editing of genomic DNA. Indeed, CRISPR is widely used, but studies of individual point mutations have been primarily on a small scale and are usually limited to a handful of variants or to a single gene. The major throughput challenge in studying a specific variant using genome editing is in tying genotype to phenotype. Introducing individual mutations exhibits low efficiency, and thus there is a need for enrichment of the genotype or phenotype of interest prior to assessing the impact of a mutation on a phenotype, such as gene expression. Current enrichment methods either disrupt the physiological context or are low throughput. Recent efforts overcame these challenges using pooled editing to analyze thousands of mutations simultaneously, but were limited to variants in protein coding regions.  This proposal aims to develop a novel technique merging multiplexed genome editing of putative regulatory variants followed by chromatin immunoprecipitation sequencing (ChIP-seq) to simultaneously measure the impact of hundreds of non-coding variants on regulatory potential in their native genomic context. The key insight of the proposed approach is that mutations impacting epigenomic features can be measured both in genomic DNA and in phenotypic readouts such as ChIP-seq of TFs or HMs, avoiding the need for a selection step to connect genotypes with phenotypes. Aim 1 develops the pooled editing technique on a pilot set of previously validated regulatory variants. Aim 2 scales this approach to interrogate thousands of mutations at once. Aim 3 integrates experimental predictions with state of the art machine learning methods to evaluate and optimize computational methods for regulatory variant effect prediction. Recent studies have demonstrated that the majority of genetic changes in the population contributing to common human diseases, such as schizophrenia, heart disease, and diabetes, lie in regions of the genome that do not code for proteins, but rather regulate the expression of genes. Despite massive efforts to map regulatory regions across dozens of human cell types, it is still difficult to predict the effect of an individual non-coding mutation. This project develops a high-throughput genome editing technique to simultaneously measure the impact of hundreds of non-coding mutations on regulatory potential in their native genomic context, with the ultimate goal of interpreting genetic changes leading to human disease.",Interrogating regulatory variants by multiplexed genome editing,9761568,R21HG010070,"['Affect ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Cell Body ', ' Cells ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Deoxyribonucleic Acid ', ' DNA ', ' Exhibits ', ' Gene Expression ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Gold ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' liver carcinoma ', ' Liver Cells Carcinoma ', ' Hepatoma ', ' Hepatocellular cancer ', ' Hepatocellular Carcinoma ', ' Hepatocarcinoma ', ' Primary carcinoma of the liver cells ', ' Modern Man ', ' Human ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' oligos ', ' Oligo ', ' Oligonucleotides ', ' Phenotype ', ' Plasmids ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research Resources ', ' Resources ', ' mRNA ', ' Messenger RNA ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' Testing ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Measures ', ' Protein Coding Region ', ' ORFs ', ' Open Reading Frames ', ' Enhancers ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' improved ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' Reporter Genes ', ' Evaluation ', ' Hepatocyte ', ' Liver Cells ', ' Hepatic Parenchymal Cell ', ' Hepatic Cells ', ' insight ', ' Individual ', ' Reporter ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' cell type ', ' Techniques ', ' interest ', ' Quantitative Trait Loci ', ' QTL ', ' novel ', ' Sorting - Cell Movement ', ' sorting ', ' Cell Fraction ', ' Code ', ' Coding System ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Allelic Imbalance ', ' Genomics ', ' histone modification ', ' Molecular Interaction ', ' Binding ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Address ', ' Mutate ', ' Regulatory Element ', ' mRNA Expression ', ' Malignant Epithelial Cell ', ' Carcinoma Cell ', ' Molecular ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' epigenomics ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' human disease ', ' molecular phenotype ', ' ChIP-seq ', ' chromatin immunoprecipitation-sequencing ', ' ChIP Sequencing ', ' Genomic DNA ', ' gDNA ', ' genome editing ', ' genomic editing ', ' HepG2 ', ' HepG2 cell line ', ' Hep G2 ', ' HNF4A gene ', ' Transcription Factor 14, Hepatic Nuclear Factor ', ' TCF14 ', ' Hepatocyte Nuclear Factor, 4 ', ' Hepatocyte Nuclear Factor 4-Alpha ', ' HNF4A ', ' HNF4-Alpha ', ' HNF4 ', ' learning strategy ', ' learning method ', ' learning activity ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' ']",NHGRI,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R21,2019,236250,CA-52,0.0003235263490157797
"A predictive model of mRNA stability and translation for variant interpretation and mRNA therapeutics The leading and trailing untranslated regions (UTRs) of an mRNA, along with the coding sequence (CDS), control protein production by modulating translation and mRNA stability. However, although we have identified a vast number of regulatory features in these regions, we are still far from being able to predict, for example, whether and how a sequence variant affects the levels of protein being made. Here, we propose to combine high-throughput experimental characterization of protein expression in synthetic libraries with machine learning to create predictive models of translation and mRNA stability, addressing an urgent need. Recent progress in machine vision, voice recognition and other fields of computer science has been driven by the availability of enormous data sets on which to train models. Machine learning approaches have also had remarkable impact in biology, but biological data sets often are comparatively small, limiting the quality of models that can be learned. For example, there are only around 20,000 genes in the human genome, a restrictively small set of examples for training a predictive model that captures the full extent of the genomes regulatory code. In this proposal, we aim to overcome this data size limitation by training predictive models of protein expression on data from millions of synthetic constructs -- a data set several orders of magnitude larger than the number of genes in the genome. Specifically, we will create libraries of in vitro transcribed mRNA with targeted variation in the UTRs and CDS and will assay protein expression of each library member by performing high-throughput polysome profiling, ribosome profiling, and mRNA stability assays. We will then use neural network approaches to learn predictive models of the relationship between mRNA sequence and levels of protein production. We will apply our models to three applications of practical importance: first, we expect to uncover novel biology, for example identifying regulatory sequence elements and interactions between them. Second, we will validate our models through the de novo design and experimental testing of sequences that result in higher levels or protein production than any of the millions of randomly generated members of the original library or than the endogenous UTR sequences currently used in biotechnology. Such stable and highly translating mRNA constructs would be of particular value for the field or mRNA therapeutics. Third, we will predict the functional consequences of genetic variation in UTRs on protein production and we will validate these predictions experimentally. We are far from understanding which genetic variants compromise gene regulatory function in ways that may contribute to disease, making such a comprehensive and quantitative analysis of variants valuable. This research project aims to use machine learning to build predictive models of translation and mRNA stability. Models are trained on data obtained by measuring protein production for millions of synthetic RNA constructs. Models will then be applied for understanding the consequences of genetic variation in humans and for the design of mRNA therapeutics.",A predictive model of mRNA stability and translation for variant interpretation and mRNA therapeutics,9712954,R01HG009892,"['Affect ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Biotechnology ', ' Biotech ', ' Disorder ', ' Disease ', ' Elements ', ' Engineering ', ' Gene Expression ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Modern Man ', ' Human ', ' Human Engineering ', ' Human Genetics ', ' In Vitro ', ' Learning ', ' Libraries ', ' Methods ', ' Polysomes ', ' Polyribosomes ', ' Production ', ' Proteins ', ' Ribosomes ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' Splicing ', ' RNA Splicing ', ' mRNA ', ' Messenger RNA ', ' social role ', ' Role ', ' Testing ', ' 4-thio-uridine ', ' 4-Thiouridine ', ' Thiouridine ', ' Time ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Translating ', ' mRNA Translation ', ' Genetic Translation ', ' Translations ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Measures ', ' RNA-Binding Proteins ', ' Dataset ', ' Data Set ', ' base ', ' Site ', ' Variant ', ' Variation ', ' Biological ', ' Training ', ' Research Project Grants ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Source ', ' Techniques ', ' Performance ', ' stable cell line ', ' synthetic construct ', ' synthetic DNA ', ' computer science ', "" 5' Untranslated Regions "", ' mRNA Leader Sequences ', "" 5'UTR "", "" 3' Untranslated Regions "", "" 3'UTR "", ' Untranslated Regions ', ' UTRs ', ' Structure ', ' novel ', ' member ', ' RNA Stability ', ' Code ', ' Coding System ', ' Modeling ', ' Neural Network Simulation ', ' Perceptrons ', ' Neural Network Models ', ' Connectionist Models ', ' Property ', ' DNA Library ', ' DNA bank ', ' Genomics ', ' voice recognition ', ' protein expression ', ' mRNA Stability ', ' Address ', ' Data ', ' Randomized ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Regulatory Element ', ' Resolution ', ' Computational Technique ', ' Expression Library ', ' Genetic Programming ', ' Genetic Algorithm ', ' Transcript ', ' Validation ', ' Image ', ' imaging ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' design ', ' designing ', ' practical application ', ' application in practice ', ' comparative ', ' screening ', ' ribosome profiling ', ' ribosome footprint profiling ', ' Ribo-seq ', ' experimental study ', ' experimental research ', ' experiment ', ' polysome profiling ', ' neural network ', ' convolutional neural network ', ' convolutional neural nets ', ' ConvNet ', ' machine vision ', ' ']",NHGRI,UNIVERSITY OF WASHINGTON,R01,2019,459955,WA-07,0.025164868455063327
"Linking human enhancers to predictive models of mRNA abundance PROJECT SUMMARY/ABSTRACT A central challenge in understanding the genetic origins of disease is the inability to isolate which regions of the genome are functionally responsible for the aberrant expression of genes. To date, nearly 85% of identified disease-causing mutations lie within protein-coding exons (i.e. the exome), which comprises 2% of the human genome. Yet an estimated 50-75% of Mendelian disorders, and an even greater proportion of non-Mendelian (i.e. polygenic) diseases, have unexplained genetic etiologies which are suspected to involve genetic variants in the remaining 98% of the human non-coding genome. Over the past 5 years, new genome-scale technologies have uncovered the existence of ~400,000 enhancer-like regions. Mutations in these regions are suspected to be a major source of the misregulation of gene expression levels, which can in turn manifest in disease. Nevertheless, the vast majority of these regions have never been directly tested for their ability to activate transcription, nor have they been definitively linked to the regulation of target genes. The K99 training phase of this award entails the development of a new generation of massively parallel reporter assay (MPRA) technologies that can interrogate the functional activity of 10,000-100,000 enhancers with high precision and reproducibility, an order of magnitude more than is currently possible (Aim 1). Coordinated with this effort will be the quantitative modeling of biological determinants that are predictive of enhancer activity (Aim 2). Complementing Aims 1 and 2 is the development of models designed to infer enhancer-promoter regulatory interactions. Towards this goal, self-attentive models, derived from the field of computational linguistics, will be trained to learn how the epigenetic marks and transcription factor binding events associated with distal enhancers contribute to gene expression levels in a diversity of cell types (Aim 3). As this work transitions into the R00 independent phase of the award, deep convolutional neural networks will be trained to learn how underlying DNA sequences encode epigenetic and transcription factor binding information. This would thereby generate a mathematical function which links DNA sequence directly to gene expression levels, which would help to predict how specific genetic variants in distal enhancers might perturb the mRNA levels of target genes. These predictions will help to informat single nucleotide resolutionwhich genetic variants identified by genome-wide association studies are causally linked to disease (Aim 4). Collectively, these aims will give insight into the cis-regulatory logic encoded in DNA that specifies mRNA abundance. The methods developed herein will lay a quantitative framework with which to evaluate enhancer function, prioritize which genetic variants are likely to be associated with disease, and shed light onto the elusive functions of the non-coding regions of the human genome. PROJECT NARRATIVE The goals of this project are to develop a technology that can measure the activity of >10,000 enhancers in parallel, and to devise quantitative models that describe the impact of enhancers on gene expression levels. Achieving these goals will give insight into the cis-regulatory logic encoded in DNA that specifies mRNA abundance. We anticipate that these methods will shed light upon the elusive functions of non-coding regions in the human genome, and help to dissect the molecular origins of diverse genetic diseases.",Linking human enhancers to predictive models of mRNA abundance,9804719,K99HG010662,"['Attention ', ' Award ', ' Base Sequence ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Complement Proteins ', ' Complement ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Dissection ', ' Deoxyribonucleic Acid ', ' DNA ', ' Exons ', ' Gene Expression ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Histones ', ' Modern Man ', ' Human ', ' Language ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Photoradiation ', ' Light ', ' Logic ', ' Math ', ' Mathematics ', ' Mentors ', ' Methods ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' DNA Molecular Biology ', ' Molecular Biology ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Neighborhoods ', ' Nucleotides ', ' Probability ', ' Proteins ', ' mRNA ', ' Messenger RNA ', ' Technology ', ' Testing ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Work ', ' Generations ', ' Measures ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Enhancers ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' improved ', ' Distal ', ' Specific qualifier value ', ' Specified ', ' Phase ', ' Variant ', ' Variation ', ' Biological ', ' Medical ', ' Link ', ' Training ', ' insight ', ' Measurement ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetically predisposed ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Reporter ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Dependence ', ' Event ', ' Source ', ' cell type ', ' Code ', ' Coding System ', ' Regulation ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' model design ', ' model development ', ' Molecular Interaction ', ' Binding ', ' Address ', ' Data ', ' Reproducibility ', ' Resolution ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Molecular ', ' Development ', ' developmental ', ' disease phenotype ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' reconstruction ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' next generation ', ' Outcome ', ' Coupled ', ' disease-causing mutation ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' ChIP-seq ', ' chromatin immunoprecipitation-sequencing ', ' ChIP Sequencing ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' Computational Linguistics ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' experimental study ', ' experimental research ', ' experiment ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' convolutional neural network ', ' convolutional neural nets ', ' ConvNet ', ' ']",NHGRI,UNIVERSITY OF WASHINGTON,K99,2019,1,WA-07,0.02139389557347799
"Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases     DESCRIPTION (provided by applicant) Over the past 10 years human genetics studies made unprecedented numbers of discoveries relating genome variation to common diseases. While it is unquestionably true that we have learned substantially from the discoveries made to date, we must also acknowledge that with respect to the identification and characterization of the genome variation affecting risk of common human diseases - those accounting for the overwhelming majority of public health care expenditures - our discoveries have not generated nearly the knowledge of disease etiology that we would have expected given the sheer number of these discoveries. The combination of these observations coupled with the dramatic reduction in the cost of sequencing is driving the case for moving to whole genome sequencing studies for common disease. We have focused our application on three critical challenges for methods development and analysis of whole genome sequence data. While there has been substantial progress in methods development for analysis of exome sequencing, with gene-based tests that are relatively robust to the direction of effects of rare coding variants as well as the proportionof the gene's rare variants contributing to phenotype, it is clear that methods integrating the analysis of common and rare variation as well as functional genomics data will be essential for appropriate analysis of whole genome sequence data. Thus, we propose in Specific Aim 1 to develop novel methods, software and analysis pipelines for integrated analysis of common and rare variants for the analysis of whole genome sequence on 50,000- 100,000 individuals for any given common disease, and in Specific Aim 2 to develop and apply novel approaches for prioritizing results from these large-scale sequencing studies using BioVU, the 200,000 member biobank at Vanderbilt that is associated with 30 years of high quality electronic health records, and in Specific Aim 3 to develop queriable results databases and a comprehensive web portal to serve results of our studies on the sequence data for both the internal sequencing community and for the broader scientific community. PUBLIC HEALTH RELEVANCE Large-scale whole genome sequencing studies are being carried out to understand the genetic architecture of human complex diseases. It remains challenging to decipher the genetic mechanisms of disease etiology. In this application we aim to develop a suite of statistical and computational methods to identify genes and variants associated with complex disease and use BioVU, a DNA BioBank linked to electronic health records, to validate and investigate genetic architecture of multiple complex diseases.","Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases",9693289,U01HG009086,"['Accounting ', ' Affect ', ' Automobile Driving ', ' driving ', ' Communities ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' healthcare expenditure ', ' health care expenditure ', ' Health Expenditures ', ' facial ', ' faces ', ' Face ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' Government ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Phenotype ', ' Public Health ', ' Research ', ' Research Resources ', ' Resources ', ' Risk ', ' Science ', ' Software ', ' Computer software ', ' Technology ', ' Time ', ' Body Tissues ', ' Tissues ', ' Generations ', ' Dataset ', ' Data Set ', ' base ', ' method development ', ' improved ', ' Variant ', ' Variation ', ' Link ', ' insight ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Policies ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetically predisposed ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Complex ', ' experience ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' success ', ' expectation ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' member ', ' Reporting ', ' Code ', ' Coding System ', ' Statistical Methods ', ' functional genomics ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' genome sequencing ', ' Data ', ' Large-Scale Sequencing ', ' Validation ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' National Human Genome Research Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' disease phenotype ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' cost ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' design ', ' designing ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Coupled ', ' human disease ', ' public health relevance ', ' biobank ', ' biorepository ', ' exome ', ' exomes ', ' exome sequencing ', ' exome-seq ', ' rare variant ', ' rare allele ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' Genetic study ', ' web portal ', ' internet portal ', ' human genomics ', ' whole genome ', ' full genome ', ' entire genome ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' experimental study ', ' experimental research ', ' experiment ', ' genome sciences ', ' genomic science ', ' genetic architecture ', ' analysis pipeline ', ' ']",NHGRI,VANDERBILT UNIVERSITY,U01,2019,864186,TN-05,0.12227602667964475
"Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases     DESCRIPTION (provided by applicant): The NHGRI Genome Sequencing Program (GSP) will identify genomic variants relevant to health and disease by genome sequencing over 225,000 participants across a multitude of diseases. The GSP will also serve as a pilot for the Precision Medicine Initiative that aims to enroll and sequence more than a million people representative of U.S. ethnic diversity. Here, we propose a GSP analysis center focused on Multi- and Trans- ethnic Mapping of Mendelian and Complex Diseases. There is a growing recognition of the substantial scientific advantages, as well as public health importance, of conducting biomedical research across ethnically diverse cohorts. We propose to develop scalable methods that incorporate ancestry to optimize medical genomic study design and improve power for uncovering the role of common and rare variants in disease. Achieving this goal requires expertise across diverse domains of knowledge including: medical and population genomics, algorithm development for complex disease mapping, and expertise in management of large-scale databases. Here, we have assembled a world-class team of medical and population geneticists, computer scientists, statisticians and clinicians, with leading expertise in the development of novel and scalable strategies for characterizing sequence variants and their role in disease. Importantly, our group has been at the forefront of development of resources, study designs and methods to enable genomic research in U.S. minority populations. Our project has three main objectives. First, we will develop an Automated Scalable Ancestry Pipeline (ASAP) for common disease mapping in diverse populations. ASAP will improve the computational efficiency of existing state-of-the-art methods for ancestry inference and develop important extensions to linear mixed models (LMMs) and other mapping strategies leveraging local and global ancestry. We will also develop methods to refine phenotypes and identify common controls for disease studies and define endpoints. Secondly, we will develop tools and resources for trans- and multi-population rare variant discovery that incorporate patterns of local and sub-continental ancestry. We will also develop machine-learning tools for variant annotation that leverage ancestral information, patterns of sequence evolution, and protein structure in a unified framework. Furthermore, we will incorporate population-specific patterns of cellular phenotypes to improve functional prediction algorithms for non-coding and coding variants. Lastly, we will disseminate our results through web-based resource that empower the biomedical research community. We will augment existing resources including ClinGen by annotating and characterizing pathogenic variants across diverse populations. We will develop a secure web-server that allows sharing of summary statistics and analysis pipelines to enable discovery, fine-mapping and functional prediction of genetic variants. Our team has ample experience with NIH-funded consortia and is dedicated to meeting the overall GSP project goals through collaborative work with NHGRI leadership and other funded investigators. PUBLIC HEALTH RELEVANCE The goal of our project is to accelerate the discovery of DNA variation relevant to health and disease by analyzing data from over 225,000 ethnically and racially diverse patients that will undergo genome sequencing. Of particular importance is ensuring we have powerful statistical methods for analyzing data from underserved groups including U.S. minority populations. Achieving this goal requires expertise across many domains of knowledge including: medical and population genomics, algorithm development for disease mapping, and expertise in large-scale databases.",Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases,9995640,U01HG009080,"['Algorithms ', ' Architecture ', ' Engineering / Architecture ', ' Biomedical Research ', ' chronic disorder ', ' Chronic Illness ', ' Chronic Disease ', ' Communities ', ' Computers ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Leadership ', ' Methods ', ' Methodology ', ' Methylation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' Privatization ', ' Public Health ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Risk ', ' social role ', ' Role ', ' Shoulder ', ' statistics ', ' Target Populations ', ' Testing ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' United States ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' population diversity ', ' heterogeneous population ', ' diverse populations ', ' Population Heterogeneity ', ' Dataset ', ' Data Set ', ' improved ', ' Clinical ', ' Variant ', ' Variation ', ' Medical ', ' Ensure ', ' Funding ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' programs ', ' Scientist ', ' Investigation ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' meetings ', ' experience ', ' cohort ', ' simulation ', ' novel ', ' Participant ', ' Code ', ' Coding System ', ' Statistical Methods ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' disorder control ', ' disease control ', ' Pathogenicity ', ' genome sequencing ', ' protein structure ', ' Data ', ' Resolution ', ' Resource Development ', ' Enrollment ', ' enroll ', ' Development ', ' developmental ', ' National Human Genome Research Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' patient privacy ', ' Minority ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' large-scale database ', ' large-scale data base ', ' tool development ', ' public health relevance ', ' phenome ', ' Secure ', ' rare variant ', ' rare allele ', ' Precision Medicine Initiative ', ' genomic tools ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' ethnic diversity ', ' ethnically diverse ', ' racial diversity ', ' racially diverse ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' Structural Protein ', ' online resource ', ' web-based resource ', ' web resource ', ' online compendium ', ' on-line resource ', ' on-line compendium ', ' internet resource ', ' web-based tool ', ' preservation ', ' analysis pipeline ', ' web server ', ' ']",NHGRI,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,U01,2019,728322,NY-13,0.16988658568500095
"Deep learning methods to predict the function of genetic variants in orofacial clefts Project Summary  Orofacial clefts (OFCs) comprise a significant fraction of human birth defects in all populations (ranging between 1/500 to 1/2500 live births) and represent a major public health challenge. Individuals born with OFCs require surgical, nutritional, dental, speech, medical and behavioral interventions, imposing a substantial economic and personal burden. There has been convincing evidence that non-syndromic OFCs represent human complex disorders with a multifactorial etiology including genetic risk factors, environmental exposures, and their complex interactions. So far, there have been ~10 genome-wide association studies (GWAS) conducted for non-syndromic CL/P (NSCL/P) and >15 genomic loci reported with compelling statistical support, including genes such as IRF6, PAX7, and ABCA4 and the 8q24 locus. In addition, next-generation sequencing (NGS) as well as exome array have been conducted with extra depth of genotyping that enable detection of rare variants associated with OFCs. However, gaps exist in how to interpret these variants and how to identify novel variants from the large volume of data, with high expectations for new methods and new models for second- analysis of the genome-wide data. In this proposal, we propose two complementary aims to carry out deep and second-analysis of genome-wide data for OFCs. In Aim 1, we propose a deep learning method to build in silico models that can predict the effect of genetic variants in the context of rich craniofacial epigenomic features. With substantial fine map of sequence patterns, ad hoc motifs will be revealed and variants that disturb these motifs will provide mechanistic insights on OFCs. In Aim 2, we shift our focus to the gene level and propose a network assisted method to discover sensibly combined genes in spatial and temporal points that are critical to orofacial development. We target on all forms of OFCs, with particular interest in NSCL/P. To guarantee the success of this proposal, we form a multi-disciplinary team and local computational infrastructure equipped with GPUs for the implementation of both aims. Our aims are non-overlapping; rather, they are integrated and strongly focused on our fundamental question of interest: how genetic variants function to cause OFCs. The successful completion of our proposal will lead to deep understanding of genetic components in OFCs. Project Narrative Orofacial clefts (OFCs) comprise a significant fraction of human birth defects in all populations and represent a major public health challenge. Substantial progress has been made to identify genes and variants for OFCs through recent genome-wide association studies and next- generation sequencing projects. In this proposal, we aim to develop computational methods to comprehensively fine map and interpret the effects of these genetics variants, which will eventually lead to understanding of the mechanisms and new therapies for OFCs.",Deep learning methods to predict the function of genetic variants in orofacial clefts,9764346,R03DE027711,"['Congenital Abnormality ', ' Congenital Malformation ', ' Congenital Deformity ', ' Congenital Defects ', ' Congenital Anatomical Abnormality ', ' Congenital Anatomic Abnormality ', ' Birth Defects ', ' Algorithms ', ' Behavior Therapy ', ' behavioral intervention ', ' behavior intervention ', ' Conditioning Therapy ', ' Behavioral Treatment ', ' Behavioral Therapy ', ' Behavioral Modification ', ' Behavioral Conditioning Therapy ', ' Behavior Treatment ', ' Behavior Modification ', ' Behavior Conditioning Therapy ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' hare lip ', ' Harelip ', ' Cleft Lip ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Economics ', ' Environment ', ' Environmental Exposure ', ' Explosion ', ' Gene Expression ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Modern Man ', ' Human ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Maps ', ' Methods ', ' Phenotype ', ' Play ', ' Proteins ', ' Public Health ', ' Research ', ' Research Resources ', ' Resources ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' social role ', ' Role ', ' Software ', ' Computer software ', ' Speech ', ' Time ', ' Body Tissues ', ' Tissues ', ' Measures ', ' Mediating ', ' base ', ' Site ', ' Variant ', ' Variation ', ' Medical ', ' Training ', ' Dental ', ' insight ', ' Individual ', ' Sample Size ', ' Biological Process ', ' Biological Function ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' DNA Methylation ', ' Computational Biology ', ' computer biology ', ' Complex ', ' Pattern ', ' Live Birth ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' interest ', ' craniofacial ', ' craniofacies ', ' success ', ' trait ', ' expectation ', ' novel ', ' Reporting ', ' Cleft lip with or without cleft palate ', ' cleft of the lip and/or palate ', ' cl/p ', ' genetic risk factor ', ' inherited factor ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' RNA Binding ', ' RNA bound ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' PAX7 gene ', ' Paired Domain Gene 7 ', ' Paired Box Homeotic Gene 7 ', ' Paired Box Gene 7 ', ' PAX7 ', ' HUP1 ', ' Data ', ' Detection ', ' 8q24 ', ' Genetic Risk ', ' Validation ', ' Nutritional ', ' nutritious ', ' Molecular ', ' Development ', ' developmental ', ' Pathway interactions ', ' pathway ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' epigenomics ', ' orofacial ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Population ', ' multidisciplinary ', ' sequence learning ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' spatiotemporal ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' genome-wide ', ' genomewide ', ' genome scale ', ' computer infrastructure ', ' computational infrastructure ', ' exome ', ' exomes ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' rare variant ', ' rare allele ', ' FaceBase ', ' craniofacial development ', ' orofacial cleft ', ' orofacial clefting ', ' Genetic study ', ' learning strategy ', ' learning method ', ' learning activity ', ' orofacial development ', ' Expression Profiling ', ' deep learning ', ' multidimensional data ', ' high dimensional data ', ' ']",NIDCR,UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON,R03,2019,154000,TX-09,0.15030277519418533
"Biomedical Data Translator Technical Feasibility Assessment and Architecture Design Our Vision: We propose DeepLink, a versatile data translator that integrate multi-scale, heterogeneous, and multi-source biomedical and clinical data. The primary goal of DeepLink is to enable meaningful bidirectional translation between clinical and molecular science by closing the interoperability gap between models and knowledge at different scales. The translator will enhance clinical science with molecular insights from basic and translational research (e.g. genetic variants, protein interactions, pathway functions, and cellular organization), and enable the molecular sciences by connecting biological discoveries with their pathophysiological consequences (e.g. diseases, signs and symptoms, pharmacological effects, physiological systems). Fundamental differences in the language and semantics used to describe the models and knowledge between the clinical and molecular domains results in an interoperability gap. DeepLink will systematically and comprehensively close this gap. We will begin with the latest technology in semantic knowledge graphs to support an extensible architecture for dynamic data federation and knowledge harmonization. We will design a system for multi-scale model integration that is ontology-based and will combine model execution with prior, curated biomedical knowledge. Our design strategy will be iterative and participatory and anchored by 10 major milestones. In a series of demonstrations of DeepLinks functions, we will address one of the major challenges facing translational science: reproducibility of biomedical research findings that are based on evolving molecular datasets. Reproducibility of analyses and replication of results are central to scientific advancement. Many landmark studies have used data that are constantly being updated, curated, and pared down over time. Our series of demonstrations projects are designed to prototype the technology required for a scalable and robust translator as well as the techniques we will use to close the interoperability gap for a specific use case. The demonstration project will, itself, will be a significant and novel contribution to science. DeepLink will be able to answer questions that are currently enigmatic. Examples include: - From clinicians: What is the comparative effectiveness of all the treatments for disease Y given a patient's genetic/metabolic/proteomic profile? What are the functional variants in cell type X that are associated with differential treatment outcomes? What metabolite perturbations in cell type Y are associated with different subtypes of disease X? - From basic science researchers: What is known about disease Y across all model organisms (even those not designed to model Y)? What are all the clinical phenotypes that result from a change in function in protein X? Which biological pathways are affected by a pathogenic variant of disease Y? What patient data are available to evaluate a molecularlyderived clinical hypothesis? Challenges and Our Approaches: DeepLink will close the interoperability gap that currently prohibits molecular discoveries from leading to clinical innovations. DeepLink will be technologically driven, addressing the challenges associated with large, heterogeneous, semantically ambiguous, continuously changing, partially overlapping, and contextually dependent data by using (1) scalable, distributed, and versioned graph stores; (2) semantic technologies such as ontologies and Linked Data; (3) network analysis quality control methods; (4) machine-learning focused data fusion methods; (5) context-aware text mining, entity recognition and relation extraction; (6) multi-scale knowledge discovery using patient and molecular data; and (7) presentation of actionable knowledge to clinicians and basic scientists via user-friendly interfaces. ",Biomedical Data Translator Technical Feasibility Assessment and Architecture Design,9855180,OT3TR002027,"['Affect ', ' Architecture ', ' Engineering / Architecture ', ' Awareness ', ' Biomedical Research ', ' Disorder ', ' Disease ', ' Goals ', ' Language ', ' Methods ', ' Patients ', ' Pharmacology ', ' Proteins ', ' Quality Control ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Science ', ' Semantics ', ' Diagnostic Findings ', ' Signs and Symptoms ', ' Technology ', ' Time ', ' Translations ', ' visual function ', ' Sight ', ' Vision ', ' Treatment outcome ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Variant ', ' Variation ', ' Biological ', ' Physiological ', ' Physiologic ', ' Series ', ' Link ', ' insight ', ' Metabolic ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Source ', ' cell type ', ' Techniques ', ' System ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' molecular domain ', ' novel ', ' Graph ', ' Basic Science ', ' Basic Research ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Proteomics ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Pathogenicity ', ' text mining ', ' literature searching ', ' literature mining ', ' discovery mining ', ' text searching ', ' Address ', ' Data ', ' Reproducibility ', ' Clinical Data ', ' Clinical Sciences ', ' Ontology ', ' Translational Research ', ' translation research ', ' Translational Science ', ' Update ', ' Molecular ', ' Pathway interactions ', ' pathway ', ' clinical phenotype ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' multi-scale modeling ', ' multiscale modeling ', ' design ', ' designing ', ' innovation ', ' innovative ', ' innovate ', ' interoperability ', ' user-friendly ', ' comparative effectiveness ', ' prototype ', ' Knowledge Discovery ', ' ']",NCATS,COLUMBIA UNIVERSITY HEALTH SCIENCES,OT3,2019,702655,NY-13,0.0633714498116252
"Mosaicism in focal cortical dysplasias spectrum seen in neuropsychiatric disease Abstract/Summary  Our parent grant U01-MH108898 entitled Mosaicism in focal cortical dysplasias spectrum seen in neuropsychiatric disease has a focus on understanding the mechanisms of dysplasia of the cerebral cortex, and the contribution of brain somatic mosaicism to this process. Mosaicism is the occurrence of two (or more) genomes in an individual who is derived from a single zygote. Members of the NIMH-supported Brain Somatic Mosaicism Network (BSMN) are characterizing mosaic variation in other neuropsychiatric disorders with a common goal of assessing the role of somatic mosaic variation across diseases including BPD, schizophrenia, autism spectrum disorder, Tourette syndrome, and dysplasias. We propose three capstone projects to map the full spectrum of somatic variation in human brain and characterize the contributions of mosaic variants to neuropsychiatric disease risk. These capstones can advance the mission of the BSMN, to both achieve greater power of discovery of somatic mutations by combining and harmonizing deep coverage whole genome sequencing data that have been generated across nodes, as well as placing the variants identified through the study of brain somatic mosaicism (BSM) in the context of neurodevelopment and disease. To integrate this multi- dimensional data from the BSMN, as well as other consortia, administrative supplements are requested to continue, in the final two years of the award, three capstone projects, as well as to contribute to the Data Coordinating Center (DCC) and data analytic core (DAC). We expect these Capstone Projects to increase the profile of the BSMN by creating an unprecedented data resource of somatic mosaicism variants across development and diseases widely available to the scientific community. The enhanced power provided by the combined analyses of the BSMN will provide foundational knowledge that will guide future work, and lead to new insight into brain somatic mosaicism. The specific aims are (1) for Capstone 2, to assess the somatic mutational landscape in the human brain, by an unprecedented, comprehensive mapping of brain mosaicism in a single person; (2) for Capstone 3, to exploit deeply sequenced bulk short-read WGS to detect somatic structural variation by refining and employing a novel machine-learning classifier approach named CHONK that was developed in our lab. Project Narrative This project assesses the natural mosaic variation in the human brain using unprecedented depth on comprehensive sampling to analyze the mosaicism within a single individual. We will further extend our analysis of mosaic variation to structural variants by employing a novel, machine-learning based, classifier. 1",Mosaicism in focal cortical dysplasias spectrum seen in neuropsychiatric disease,9905189,U01MH108898,"['Award ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Brain Mapping ', ' Cell Body ', ' Cells ', ' Cerebral cortex ', ' Communities ', ' Disorder ', ' Disease ', ' Foundations ', ' Future ', ' Genome ', ' Goals ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Photoradiation ', ' Light ', ' Maps ', ' Mission ', ' mosaic disorders ', ' Mosaicism ', ' Names ', ' NIMH ', ' National Institute of Mental Health ', ' social role ', ' Role ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' Single Person ', ' Maritally Unattached ', ' Unmarried person ', ' Time ', ' tic de Guinon ', ' maladie des tics ', "" Tourette's Syndrome "", "" Tourette's Disorder "", "" Tourette's Disease "", "" Tourette's "", ' Tourette Syndrome ', ' Tic Disorder, Combined Vocal and Multiple Motor ', "" Guinon's disease "", "" Gilles de la Tourette's Disease "", ' Gilles de la Tourette syndrome ', ' Work ', ' Fertilized Ovum ', ' Fertilized Egg ', ' zygote ', ' base ', ' Lateral ', ' Dorsal ', ' Medial ', ' Variant ', ' Variation ', ' Microglia ', ' perivascular glial cell ', ' microgliocyte ', ' microglial cell ', ' mesoglia ', ' gitter cell ', ' Hortega cell ', ' insight ', ' Individual ', ' Cell Lineage ', ' Dysplasia ', ' dyscrasia ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Cortical Dysplasia ', ' brain tissue ', ' Somatic Mutation ', ' neurodevelopment ', ' Neural Development ', ' Structure ', ' novel ', ' member ', ' disorder risk ', ' disease risk ', ' Sampling ', ' genome sequencing ', ' autism spectrum disorder ', ' autistic spectrum disorder ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autistic Disorder ', ' Autism ', ' Administrative Supplement ', ' Data ', ' Process ', ' Development ', ' developmental ', ' Data Coordinating Center ', ' Data Coordination Center ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' parent grant ', ' Data Analytics ', ' neuropsychiatric disorder ', ' neuropsychiatric disease ', ' whole genome ', ' full genome ', ' entire genome ', ' data resource ', ' multidimensional data ', ' high dimensional data ', ' ']",NIMH,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",U01,2019,248888,CA-52,0.05976342706227756
"TOOLS FOR NORMALIZING AND INTERPRETING THE CLINICAL ACTIONABILITY OF GENOMIC VARIANTS PROJECT SUMMARY/ABSTRACT The availability of high-throughput, low-cost sequencing has transformed the landscape of biomedical research by dramatically expanding our capacity to interrogate the sequence of the human genome. Consequently, there has been an explosion of biomedical literature describing the role of specific genomic variants and their impact on human diseases. These advances are bringing sequencing into the clinic to shape clinical practice from the patients genomic content, a paradigm colloquially referred to as genomic or precision medicine. There remain many obstacles to fully realizing our potential in the era of precision medicine. Among them is a recognized need for robust, well-engineered systems that provide knowledge about genomic variants and their role in disease. Ideally, such systems would provide a comprehensive summary of all knowledge that is relevant to the patients unique genomic content. An early bottleneck to realizing precision medicine was that, despite the substantial literature and several established knowledgebases that define interactions between drugs and genes, querying across them was extremely challenging. In response to this need, the Drug-Gene Interaction database (DGIdb, dgidb.org) was developed. Through a combination of automated processing and manual curation, drug-gene interaction information was collected, structured, and connected (normalized) from these diverse sources of data and entered into a database with a user-friendly search interface and an application programming interface (API). However, linking drug and drug-gene interaction concepts across resources remains an extremely challenging task, and aggregated drug-gene interactions are also challenging to represent in a way that highlights the utility of the collected knowledge for precision medicine efforts. This proposal seeks to improve our ability to normalize and interpret drug-gene interactions corresponding to patient genomic variants. We will achieve this goal through two specific aims. First, the DGIdb normalization routines will be improved through incorporation of new content and features. Among these, the DGIdb will support collections of drugs, including combination therapies and drug classes. Also, the DGIdb will have new community submission and curation features, allowing users to incorporate new knowledge into the database. Second, the Variant Interpretation Aggregator database (VIAdb) will be created to normalize knowledge across several disparate sources focused on the clinical interpretations of genomic variants. The VIAdb will operate as a stand-alone web tool and API and will behave as a source of relevant interpretations to DGIdb. Finally, we will develop techniques for automated identification of drug-gene interactions and variant interpretation consensus to assist community curation efforts. If successful, this research will improve breadth and consistency of variant interpretations and drug-gene interactions for precision medicine efforts. PROJECT NARRATIVE This research will improve our ability to interpret genomic variations in human patients in support of precision medicine efforts. Specifically, it will provide web-based tools for identifying potential therapies that specifically target the patients individual genes or variants, and an assessment of the clinical actionability of those drugs.",TOOLS FOR NORMALIZING AND INTERPRETING THE CLINICAL ACTIONABILITY OF GENOMIC VARIANTS,9744231,K99HG010157,"['Biomedical Research ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Client ', ' Clinical Trials ', ' Concurrent Studies ', ' Cohort Studies ', ' multi-modal treatment ', ' multi-modal therapy ', ' combined treatment ', ' combined modality treatment ', ' combination therapy ', ' Multimodal Treatment ', ' Multimodal Therapy ', ' Combined Modality Therapy ', ' Communities ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Engineering ', ' Explosion ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Literature ', ' Manuals ', ' Methods ', ' Patients ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Suggestion ', ' Work ', ' Imagery ', ' Visualization ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' Phase ', ' Variant ', ' Variation ', ' Link ', ' Databases ', ' data base ', ' Data Bases ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Shapes ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Knowledge ', ' programs ', ' Level of Evidence ', ' Side ', ' Clinic ', ' Source ', ' Techniques ', ' System ', ' Services ', ' gene interaction ', ' cohort ', ' knowledge base ', ' knowledgebase ', ' Structure ', ' novel ', ' Reporting ', ' response ', ' Genomics ', ' drug discovery ', ' drug resource ', ' Data ', ' Resource Development ', ' The Vanderbilt-Ingram Cancer Center at the Vanderbilt University ', ' VICC ', ' Collection ', ' Development ', ' developmental ', ' cost ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' data modeling ', ' modeling of the data ', ' model the data ', ' model of data ', ' design ', ' designing ', ' Clinical assessments ', ' cancer type ', ' user-friendly ', ' web interface ', ' open source ', ' human disease ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' tumor ', ' molecular marker ', ' molecular biomarker ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' clinical practice ', ' precision medicine ', ' precision-based medicine ', ' genomic variation ', ' clinically actionable ', ' application programming interface ', ' learning strategy ', ' learning method ', ' learning activity ', ' Genomic medicine ', ' individual patient ', ' profiles in patients ', ' patient profile ', ' web app ', ' web application ', ' therapeutic biomarker ', ' therapeutic marker ', ' web-based tool ', ' ']",NHGRI,WASHINGTON UNIVERSITY,K99,2019,115001,MO-01,0.1338129295815199
"Inferring Molecular Mechanisms of Complex Disease by Integrating Patterns of Epistasis with Functional Genomic Networks The goal of this proposal is to develop computational methods that will identify genes driving epistasis between quantitative trait loci. Genetic association studies in both humans and model organisms have been increasingly able to detect interactions among genetic variants that influence disease risk and pathogenesis. However, identifying which genes are represented by individual variants is a major challenge. Many variants influencing disease are situated between genes, and even those that are in genes may be representing an effect from a neighboring gene. In model organism studies the situation is even more problematic. In breeding experiments, genetic associations with phenotypes typically encompass large regions of DNA with many genes, and experimental follow-up to identify the genes responsible for the association is resource-intensive. To address this problem, we are developing computational tools to prioritize putative gene interactions in interacting genomic regions for biological follow-up. We use machine learning classifiers trained on functional gene-gene interaction networks and combinatorial optimization to identify likely candidate gene-gene interactions responsible for epistatic interactions between genomic regions. Our methods sift through enormous spaces of candidate interactions, retaining only those whose functional interactions identify as plausible for supporting the epistatic interaction. These tools hold promise to dramatically limit the resource-intensity of biological follow up of putative epistasis and to clarify the genetic architecture of complex disease. Genetic studies in humans and model organisms are critical to understanding how genes interact to influence disease. Standard association studies, however, do not identify individual genes, but rather large genetic regions containing many genes, and determining individual genes responsible for phenotypic effects requires resource-intensive biological follow-up experiments. We are developing computational methods to prioritize genes in these regions for biological follow-up, with the ultimate goal of speeding the discovery of novel roles of genes in disease.",Inferring Molecular Mechanisms of Complex Disease by Integrating Patterns of Epistasis with Functional Genomic Networks,9712956,R21LM012615,"['Algorithms ', ' Automobile Driving ', ' driving ', ' Bacteria ', ' Breeding ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Engineering ', ' genetic epistases ', ' gene x gene interaction ', ' epistatic relationship ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Genetic Epistasis ', ' Future ', ' Genes ', ' Goals ', ' Gold ', ' chronic kidney disease ', ' Chronic Renal Failure ', ' Chronic Renal Disease ', ' Chronic Kidney Failure ', ' Methods ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' Phenotype ', ' Play ', ' Proteins ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' progressive systemic sclerosis ', ' Systemic Sclerosis ', ' Systemic Scleroderma ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Training Support ', ' Work ', ' Yeasts ', ' Dataset ', ' Data Set ', ' Variant ', ' Variation ', ' Biological ', ' Training ', ' Individual ', ' Letters ', ' Genetic ', ' gene function ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Source ', ' Pattern ', ' System ', ' interest ', ' gene interaction ', ' mutant ', ' Quantitative Trait Loci ', ' QTL ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' trait ', ' Base Pairing ', ' Speed ', ' novel ', ' disorder risk ', ' disease risk ', ' Pathogenesis ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' functional genomics ', ' Genomics ', ' genetic association ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Address ', ' Copy Number Polymorphism ', ' copy number variation ', ' copy number variant ', ' Data ', ' The Jackson Laboratory ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Genomic Segment ', ' genomic region ', ' Lower Organism ', ' Ontology ', ' Molecular ', ' Knock-out ', ' Knockout ', ' Modification ', ' follow-up ', ' followup ', ' followed up ', ' follow up ', ' active followup ', ' Active Follow-up ', ' Development ', ' developmental ', ' Pathway interactions ', ' pathway ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' computerized tools ', ' computational tools ', ' combinatorial ', ' human disease ', ' mouse model ', ' murine model ', "" Alzheimer's disease model "", ' alzheimer model ', ' AD model ', ' systemic autoimmune disease ', ' systemic autoimmune disorder ', ' Combinatorial Optimization ', ' Genetic study ', ' learning strategy ', ' learning method ', ' learning activity ', ' genomic biomarker ', ' genomic marker ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' experimental study ', ' experimental research ', ' experiment ', ' human model ', ' genetic architecture ', ' supervised learning ', ' supervised machine learning ', ' multidimensional data ', ' high dimensional data ', ' learning algorithm ', ' ']",NLM,JACKSON LABORATORY,R21,2019,223200,ME-02,0.06680903808895139
"Common Fund Data Supplement: Integration of KOMP2 (IMPC) and PHAROS into MARRVEL 2.0 for machine learning-assisted rare variant prioritization Project Summary  This application is being submitted in response to NOT-RM-19-009 as a supplement to the parent award U54NS093793.  The Common Fund supports a number of resources that can significantly enhance gene and variant prioritization for study in the Model Organisms Screening Center of the Undiagnosed Diseases Network and beyond. To facilitate the use of these resources, we propose to create a tool that can be easily accessed by clinical geneticists and model organism scientists alike.  MARRVEL (Model organism Aggregated Resources for Rare Variant ExpLoration) was created two years ago because important data that is necessary for rare variant analysis for personalized medicine is spread throughout the internet in tens of different locations. To improve efficiency and streamline access to these data sources, we created a web-tool that allows users to query tens of data sources at once, including GTEx, and links to IMPC, the display portal for KOMP2.  In this proposal, our goal is to develop version 2 of MARRVEL to promote the use of Common Fund resources in the rare disease research community for manual and automated data analysis. This goal will be accomplished by developing MARRVEL 2.0 by integrating KOMP2 (IMPC) and PHAROS data and using the aggregated dataset to develop a machine-assisted gene and variant prioritization for diagnosis and animal model generation.  Our goals align with those of the NIH Common Fund to increase the utility of resources for broader use in the biomedical community. Project Narrative  We aim to promote the use of Common Fund resources and facilitate the diagnosis of rare diseases and the subsequent generation of animal models for the Undiagnosed Diseases Network and beyond. This goal will be accomplished by developing the web resource, MARRVEL 2.0.",Common Fund Data Supplement: Integration of KOMP2 (IMPC) and PHAROS into MARRVEL 2.0 for machine learning-assisted rare variant prioritization,9984757,U54NS093793,"['Affect ', ' Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' Award ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Display ', ' Data Sources ', ' Diagnosis ', ' Disorder ', ' Disease ', ' fruit fly ', ' Drosophila ', ' Drosophila genus ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Intelligent systems ', ' Expert Systems ', ' Family ', ' Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Health Care Systems ', ' Healthcare Systems ', ' Human Genetics ', ' Manuals ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Parents ', ' Phenotype ', ' Proteins ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Science ', ' Suggestion ', ' Testing ', ' Time ', ' Yeasts ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' Zebrafish ', ' Generations ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Clinical ', ' Variant ', ' Variation ', ' Medical ', ' Link ', ' Training ', ' Discipline ', ' Individual ', ' Funding ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Collaborations ', ' Therapeutic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Investigation ', ' System ', ' Location ', ' Country ', ' interest ', ' Visit ', ' genetic disorder diagnosis ', ' genetic diagnosis ', ' human data ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' Rare Diseases ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' Disease model ', ' disorder model ', ' Modeling ', ' response ', ' Pathogenicity ', ' Symptoms ', ' Data ', ' Therapeutic Studies ', ' Therapy Research ', ' Process ', ' Development ', ' developmental ', ' fly ', ' Flies ', ' feeding ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' model organisms databases ', ' design ', ' designing ', ' screening ', ' Drug Targeting ', ' rare variant ', ' rare allele ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' learning community ', ' data wrangling ', ' phenotypic data ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' online resource ', ' web-based resource ', ' web resource ', ' online compendium ', ' on-line resource ', ' on-line compendium ', ' internet resource ', ' experimental study ', ' experimental research ', ' experiment ', ' web-based tool ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' machine learning algorithm ', ' supervised learning ', ' supervised machine learning ', ' rare genetic disorder ', ' rare genetic disease ', ' ']",NINDS,BAYLOR COLLEGE OF MEDICINE,U54,2019,320000,TX-09,0.12841218723027525
"Micropublications for Automating Genome Sequence Variant Interpretation from Medical Literature PROJECT SUMMARY Accurate and efficient interpretation of genomic variants for clinical decision making is predicated on ready access to useful information in the medical literature. The sheer number of potentially relevant articles that must be examined during this curation process poses a major challenge in ensuring the accuracy and reproducibility of clinical variant interpretation as it is time-consuming and the results highly user-dependent. To this end, we have developed the Mastermind Genomic Search Engine - a commercial database that automatically organizes disease, gene and variant information from the medical literature by systematically indexing millions of scientific articles. In direct comparison to manually developed databases of genetic variants, we have achieved greater than 97% concordance and accurately identified >50% more variants with an average of 3-fold more references demonstrating the effectiveness of our automated approach. Currently, Mastermind is used by over 1800 variant scientists in 25 different countries to more quickly curate literature for genetic variants in clinical settings. In response to feedback from ClinGen curators and others, the present proposal seeks to create a framework to facilitate literature curation and clinical variant interpretation activities within Mastermind by 1) prioritizing relevant references and external database entries containing content meaningful to variant classification guidelines, 2) assembling this information into a micropublication text format with codified data fields including population frequencies, computational predictions, reference citations and relevant sentence fragments with conclusive content, 3) allowing users to manually review, alter and augment pre-populated entries and 4) providing a platform to share and continuously update this information with other variant scientists in the Mastermind community and elsewhere. Developing tools that allow for collaborative curation in real-time at the point of interaction with source material (i.e. individual articles) will mitigate reproducibility challenges plaguing other large-scale crowd-sourced projects. In contrast to genetic variant databases of user submitted classification information and associated data, the present proposal seeks to create enhanced curation tools to fill such variant databases with more accurate and reproducible data and in a way that would promote dramatic scaling of variant curation activities including those undertaken by groups like ClinVar. To test this approach, we will work with industry partners engaged in variant curation activities to 1) determine the requisite data fields, 2) integrate external database information, 3) test the accuracy and relevance of results and the overall efficacy of the approach using hundreds of manually curated genetic variants, and 4) solicit and incorporate feedback from our development partners to iterate and refine the software features for the greatest effect. Within the $4B genome sequencing software market, there is significant commercial potential and scientific merit in bringing more automated techniques of data analysis to large-scale genome sequencing variant interpretation as described in this proposal. [Word count  447; Line count - 30] PROJECT NARRATIVE Successful completion of the present project will contribute to the public health mission of the NIH by promoting more widespread adoption of genome sequencing by making the interpretation of genome variant data more accurate, reproducible and cost-effective in clinical and research laboratories. The community of users that can benefit from this work include geneticists, oncologists, pathologists, researchers and patients. [Two sentences]",Micropublications for Automating Genome Sequence Variant Interpretation from Medical Literature,9776985,R43HG010446,"['Adoption ', ' Algorithms ', ' Authorship ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Consultations ', ' Aggregated Data ', ' Data Aggregation ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Feedback ', ' Future ', ' Genome ', ' Goals ', ' Gold ', ' indexing ', ' Laboratory Research ', ' Photoradiation ', ' Light ', ' Literature ', ' Manuals ', ' Methods ', ' Mission ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Public Health ', ' Publishing ', ' Recommendation ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Semantics ', ' Software ', ' Computer software ', ' Testing ', ' Time ', ' Work ', ' Dataset ', ' Data Set ', ' Blinded ', ' Guidelines ', ' Clinical ', ' Phase ', ' Variant ', ' Variation ', ' Medical ', ' Ensure ', ' Training ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Oncologist ', ' Collaborations ', ' Published Comment ', ' Viewpoint ', ' Editorial Comment ', ' Commentary ', ' Comment ', ' Pathologist ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Frequencies ', ' Clinic ', ' Source ', ' Techniques ', ' Country ', ' literature citation ', ' success ', ' information classification ', ' novel ', ' peer ', ' Categories ', ' response ', ' Genetic Databases ', ' Genetic Information Databases ', ' Genetic Databanks ', ' Genetic Data Bases ', ' Genetic Data Banks ', ' Genomics ', ' Pathogenicity ', ' PubMed ', ' Effectiveness ', ' genome sequencing ', ' Address ', ' Data ', ' Population Database ', ' Reproducibility ', ' Update ', ' Process ', ' Modification ', ' Text ', ' Development ', ' developmental ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' design ', ' designing ', ' cost effective ', ' Population ', ' Consumption ', ' standardize guidelines ', ' genome-wide ', ' genomewide ', ' genome scale ', ' industry partner ', ' industry partnership ', ' industrial partnership ', ' clinical practice ', ' clinical decision-making ', ' crowdsourcing ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' search engine ', ' preservation ', ' ']",NHGRI,"GENOMENON, INC.",R43,2019,152946,MI-12,0.2111729979822328
"Integrated Clinical and Transcriptomic Profiling to Characterize Disease Phenotype PROJECT SUMMARY Exome and whole-genome sequencing are becoming increasingly routine approaches in cancer[1], common disease[2]and rare disease diagnosis.[3] Despite their success, our ability to fully interpret the clinical relevance of personal genome variation remains a significant gap[4-6]. Considering this, the most crucial need is more genotype-phenotype data that link genetic variation with disease causation. The objective of this proposal is to improve the clinical interpretation of genetic variation; in particular, by developing integrative approaches that predict the effect of genetic variation on clinical phenotype. This proposal addresses the hypothesis, supported by preliminary data, that combining patient transcriptomic data with genotypic and clinical data (as opposed to each alone) offers a better mechanistic understanding of disease natural history, from initial presentation to progression. The specific aims are designed such that each independently add substantial functional genomic information, over and above previously available patient genetic data, to further resolve the clinical phenotype. Aim 1 establishes a comprehensive and widely-shared dataset of patient transcriptomic (and genetic) variation across multiple cancer, cardiovascular and thrombosis/bleeding phenotypes, in patients with somatically-acquired myeloproliferative neoplasms (MPN) and select other rare heritable blood diseases (HBD). Aim 2 methodically determines differential RNA expression and processing between clinically-relevant subgroups of MPN and HBD patients. Aim 3 brings these elements together  and applies two integrative Bayesian and machine learning approaches, RIVER[24] (RNA-informed variant effect on regulation) and LASSO[25] (Least Absolute Shrinkage and Selection Operator), to resolve the functional and clinical relevance of rare variants; and identify signatures most predictive of disease risk or progression. Completion of these aims will contribute new scientific knowledge on how integrating transcriptomic data improves clinical genomic analyses in other genetic (and rare) diseases. In addition, this project will enable the Principal Investigator to develop expertise in the informatics and data science aspects of genomic medicine that complement her current background in biophysics, biochemistry and translational hematology. Combined with additional informatics training at Stanford University through coursework, seminars, one-on-one advising from project mentors, and interactions with the wider statistics, bioinformatics and genomics communities, this project will prepare the Principal Investigator to launch an independent academic career in genomic medicine. PROJECT NARRATIVE Accurate clinical interpretation of genetic variation in personal genome data is an essential component of personalized medicine approaches and the precise genetic diagnosis toward achieving improved public health. This project will integrate genetic and clinical modifiers with functional genomic information (RNA sequencing) from adequately-powered, disease-relevant cells; and provide direct insight into transcriptional perturbations caused by genetic variation.",Integrated Clinical and Transcriptomic Profiling to Characterize Disease Phenotype,9786811,K08HG010061,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Age Factors ', ' Alleles ', ' Allelomorphs ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Biochemistry ', ' Biological Chemistry ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Blood ', ' Blood Reticuloendothelial System ', ' Blood Cells ', ' Peripheral Blood Cell ', ' Blood Platelets ', ' Thrombocytes ', ' Platelets ', ' Marrow platelet ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cell Body ', ' Cells ', ' Communities ', ' Complement Proteins ', ' Complement ', ' Demographic Factors ', ' Disorder ', ' Disease ', ' Elements ', ' Foundations ', ' Future ', ' Gene Expression ', ' Gene Fusion ', ' Clinical genetics ', ' Medical Genetics ', ' Genome ', ' Genotype ', ' blood disorder ', ' Hematological Disorder ', ' Hematologic Diseases ', ' Blood Diseases ', ' Hematological Disease ', ' Hematology ', ' blood loss ', ' Bleeding ', ' Hemorrhage ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Mentors ', ' Mentorship ', ' Methods ', ' myeloproliferative neoplasm ', ' Myeloproliferative Tumors ', ' Myeloproliferative Disorders ', ' Myeloid Tumor ', ' Myeloid Neoplasm ', ' Myeloid Malignancy ', ' Myeloid Disease ', ' Myeloproliferative disease ', ' Patients ', ' Phenotype ', ' Public Health ', ' Reference Standards ', ' Research Resources ', ' Resources ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' statistics ', ' thrombotic disorder ', ' thrombotic disease ', ' Thrombosis ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Universities ', ' Genetic Diversity ', ' Genetic Variation ', ' Gender ', ' Lasso ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' career ', ' Blood specimen ', ' Blood Sample ', ' improved ', ' Clinical ', ' Variant ', ' Variation ', ' Link ', ' Evaluation ', ' Training ', ' insight ', ' Databases ', ' data base ', ' Data Bases ', ' Disease Progression ', ' Genetic Heterogeneity ', ' Functional disorder ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Genetic ', ' Rivers ', ' Whole Blood ', ' Knowledge ', ' Investigation ', ' Severities ', ' System ', ' experience ', ' genetic disorder diagnosis ', ' genetic diagnosis ', ' Performance ', ' Protein Isoforms ', ' Isoforms ', ' success ', ' cohort ', ' knowledge base ', ' knowledgebase ', ' Informatics ', ' disease natural history ', ' Rare Diseases ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' novel ', ' disorder risk ', ' disease risk ', ' Gene Expression Profiling ', ' transcriptional profiling ', ' gene expression assay ', ' gene expression analysis ', ' Transcript Expression Analysis ', ' Transcript Expression Analyses ', ' Gene Expression Pattern Analysis ', ' Gene Expression Monitoring ', ' Regulation ', ' Modeling ', ' Sampling ', ' functional genomics ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Bioinformatics ', ' Bio-Informatics ', ' RNA Processing ', ' Quetelet index ', ' BMI z-score ', ' BMI percentile ', ' Body mass index ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' genome sequencing ', ' Address ', ' Data ', ' Research Training ', ' Subgroup ', ' Clinical Data ', ' Other Genetics ', ' Tissue-Specific Gene Expression ', ' Tissue-Specific Differential Gene Expression ', ' Differential Gene Expression ', ' Validation ', ' Principal Investigator ', ' Process ', ' clinical phenotype ', ' disease phenotype ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' data integration ', ' design ', ' designing ', ' Outcome ', ' prospective ', ' Heritability ', ' transcriptomics ', ' clinically relevant ', ' clinical relevance ', ' multidisciplinary ', ' informatics training ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' disease diagnosis ', ' biobank ', ' biorepository ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' rare variant ', ' rare allele ', ' Bayesian Modeling ', ' Bayesian tracking algorithms ', ' Bayesian statistical models ', ' Bayesian spatial models ', ' Bayesian spatial image models ', ' Bayesian spatial data model ', ' Bayesian nonparametric models ', ' Bayesian network model ', ' Bayesian hierarchical model ', ' Bayesian framework ', ' Bayesian belief updating model ', ' Bayesian belief network ', ' Bayesian adaptive models ', ' Bayesian adaptive designs ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' variant of unknown significance ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' Data Science ', ' transcriptome ', ' global transcription profile ', ' global gene expression ', ' Genomic medicine ', ' patient stratification ', ' stratified patient ', ' phenotypic data ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' whole genome ', ' full genome ', ' entire genome ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Disease stratification ', ' rare cancer ', ' rare tumor ', ' rare malignancy ', ' cancers that are rare ', ' Bayesian learning ', ' Bayesian machine learning ', ' regression algorithm ', ' ']",NHGRI,STANFORD UNIVERSITY,K08,2019,190941,CA-18,0.06321286340922413
"Comprehensive Characterization of Adaptive Regulatory Variation Linked to Human Disease Project Summary/ Abstract  Over the past decade there has been a rapid expansion of genome-wide association studies (GWAS), as well as the development of large-scale consortia like the UKBioBank and the All of Us project. While the number of genetic associations to human traits and disease is soaring, tools to characterize and interpret these variants are lacking. One challenge to realizing the potential of genomics is that over 99% of human genetic variation is non-coding, regulatory sequences. However, regulatory grammar  the complex pattern of sequences that interact with transcription factors to control gene expression, is poorly understood. A repertoire of well-characterized causal variants is needed to build generalizable models with which to unlock insights into the genetic basis of human health and history.  Natural selection is a powerful driver of human genetic variation. As our species has encountered new climates, dramatic alterations in diet, and novel pathogens, these selective pressures have left hundreds of signatures of adaptation in our genomes, reflected in our species diversity of disease risk and morphology. For selection to have acted positively on them, these adaptive alleles must exhibit relatively strong phenotypic effects, and they continue to contribute to modern traits and disease (e.g. height or sickle cell anemia). Salient examples of human adaptation include immunity, metabolism, and morphology, all of which have extensive, unresolved GWAS signals. This renders the lens of recent evolution a powerful, but underutilized, tool for identifying alleles that contribute to phenotypic variation in modern association studies.  This proposal aims to expand the repertoire of well-characterized GWAS signals, by A) using evolution to prioritize adaptive variants, and B) applying novel, high-throughput experimental and computational tools to comprehensively decipher the functions of regulatory variants. These approaches will identify much needed causal variants, devise paradigms for their study, and inform future predictive models to characterize them. During the mentored phase of the K99, I will first develop methods to colocalize signals of selection and GWAS, and then use Variant Effect Predictions (VEP) to predict their function. I will then employ high-through methods such as a the massively parallel reporter assay and CRISPR non-coding screen to functionally characterize them directly. From the adaptive GWAS alleles our screens identify, we will make in-vivo system to more deeply characterize them during the Independent R00 phase. During this time I will deploy a variety of genomic tools such as ChIP, ChIA-PET, and RNA-seq to understand the adaptive variants molecular etiology. I will use the empirical data fro these studies, and the MPRA/HCR-FlowFISH screens to build more accurate VEP models. ! Project Narrative While thousands of genomic regions have been linked to human evolution and diseases, many of the genetic variants responsible are non-coding and thus difficult to interpret. I propose to identify adaptive human alleles underlying genome wide association studies and comprehensively characterize them using novel computational and experimental tools. I will then make in-vivo models of these to test their function and effects on fitness, improving future predictions of how genetic variants impact human evolution and health.",Comprehensive Characterization of Adaptive Regulatory Variation Linked to Human Disease,9805238,K99HG010669,"['Alleles ', ' Allelomorphs ', ' Sickle Cell Anemia ', ' sicklemia ', ' sickle disease ', ' sickle cell disease ', ' Hemoglobin sickle cell disorder ', ' Hemoglobin sickle cell disease ', ' Hemoglobin S Disease ', ' HbSS disease ', ' Hb SS disease ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cell Body ', ' Cells ', ' climatic ', ' Meteorological Climate ', ' Climate ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' DNase ', ' DNA Nucleases ', ' Deoxyribonucleases ', ' dietary ', ' Diet ', ' Disorder ', ' Disease ', ' Evolution ', ' Exhibits ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Health ', ' Histones ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Immunity ', ' Lassa Fever ', ' Linkage Disequilibrium ', ' Mentors ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Metabolism ', ' Methods ', ' Modernization ', ' Phenotype ', ' pressure ', ' Research ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Time ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Genetic Diversity ', ' Genetic Variation ', ' Measures ', ' Natural Selections ', ' improved ', ' Left ', ' Phase ', ' Variant ', ' Variation ', ' Link ', ' Training ', ' insight ', ' African ', ' Databases ', ' data base ', ' Data Bases ', ' Gene Targeting ', ' Genetic ', ' Morphology ', ' Reporter ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Scanning ', ' cell type ', ' Pattern ', ' Techniques ', ' System ', ' Height ', ' trait ', ' novel ', ' disorder risk ', ' disease risk ', ' Reporting ', ' Modeling ', ' Neural Network Simulation ', ' Perceptrons ', ' Neural Network Models ', ' Connectionist Models ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' genetic association ', ' CCRL2 gene ', ' HCR ', ' Chemokine (C-C Motif) Receptor-Like 2 Gene ', ' CRAM-B ', ' CRAM-A ', ' CKRX ', ' CCRL2 ', ' fitness ', ' Data ', ' Regulatory Element ', ' in vivo ', ' in vivo Model ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Genomic Segment ', ' genomic region ', ' Preparation ', ' Molecular ', ' Development ', ' developmental ', ' National Human Genome Research Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' computerized tools ', ' computational tools ', ' pathogen ', ' Population ', ' Cell model ', ' Cellular model ', ' human disease ', ' mouse model ', ' murine model ', ' lens ', ' lenses ', ' biobank ', ' biorepository ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' genome editing ', ' genomic editing ', ' genomic tools ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' CRISPR interference ', ' CRISPRi ', ' Chromatin Interaction Analysis by Paired-End Tag Sequencing ', ' Chromosome Interaction Analysis with Paired-End Tags ', ' ChIA-PET ', ' CRISPR screen ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR/Cas9 screen ', ' CRISPR-based screen ', ' CRISPR editing screen ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NHGRI,"BROAD INSTITUTE, INC.",K99,2019,124916,MA-07,0.10475877760314724
"EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE     DESCRIPTION (provided by applicant): The eMERGE III Clinical Center proposal from Partners HealthCare leverages a large biobank, clinical data in the electronic medical records (EMR) for >4 million participants from the largest integrated health care provider in New England, advanced bioinformatics expertise and state-of-the-art genetic analysis. We propose three aims. (1) Aim 1. Discovery. We will test the hypothesis that common and rare variants from a custom chip including 50,000 loss of function (LoF) alleles will be associated with cardiovascular, neuropsychiatric and immune-mediated phenotypes derived from the EMR. We are currently genotyping 25,000 Partners HealthCare Biobank subjects with a custom chip that includes LoF alleles from 63,000 exomes that we have analyzed. (2) Aim 2. Penetrance and Pleiotropy. We will test the hypothesis that sequencing a set of established genes or loci will allow us to discover additional variation, and define penetrance and pleiotropy using EMR phenotypes. Rare variants in genes selected by the eMERGE network will be studied for penetrance and pleiotropic outcomes by PheWAS and chart review. In addition, we are poised to perform recall-by-genotype studies because all Biobank participants have provided consent for such callback. (3) Aim 3. Implementation. We will test the hypothesis that physicians will alter their surveillance and treatment of patients based upon voluntary return of actionable variants to provide safe and cost-effective benefits to patients. We will screen our entire Biobank population of 25,000 individuals for pathogenic variants in the LDLR gene, the leading genetic cause of premature coronary artery disease, and conduct an exploratory trial in disclosing this information. Biobank participants with pathogenic variants in LDLR will be offered enrollment into a randomized trial, in which their finding will be CLIA-confirmed, and in one arm, this result will be communicated to their physicians through the EMR. Over one year, we will collect the following outcomes through participant surveys and EMR queries: physician visits, laboratory testing, changes in medication prescriptions, LDL levels, medical costs and the number of family members screened and treated as a result of the intervention. We will collaborate with the entire eMERGE III Network to incorporate what we learn from this pilot trial into large-scale implementation protocols for the genes selected by the Network for sequencing. Finally, we will participate in all Network activities to enhance the movement of genetics into clinical practice. PUBLIC HEALTH RELEVANCE: The discovery and clinical use of genetic variants associated with both rare Mendelian and more common complex diseases promises to dramatically change the practice of medicine. Our eMERGE III project will leverage a large Biobank and a rich electronic medical record to define the phenotypic impact of mutations emerging from sequencing and then return results on selected variants to Biobank participants using a clinical trial.",EMERGE PHASE III CLINICAL CENTER AT PARTNERS HEALTHCARE,9882457,U01HG008685,"['Algorithms ', ' Alleles ', ' Allelomorphs ', ' Rheumatoid Arthritis ', ' rheumatic arthritis ', ' Atrophic Arthritis ', ' Asthma ', ' Bronchial Asthma ', ' Biology ', ' Bipolar Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Clinical Trials ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary Arteriosclerosis ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Coronary heart disease ', ' depression ', ' Mental Depression ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Genes ', ' Genotype ', ' Goals ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health workforce ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' chronic heart failure ', ' Heart Decompensation ', ' Cardiac Failure Congestive ', ' Congestive Heart Failure ', ' Hypercholesteremia ', ' hypercholesterolemia ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Newborn Infant ', ' Inflammatory Intestinal Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Bowel Disorder ', ' Inflammatory Bowel Diseases ', ' Laboratories ', ' Learning ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' Low-Density Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' LDL Cholesterol Lipoproteins ', ' Medicine ', ' Mining ', ' body movement ', ' Movement ', ' insular sclerosis ', ' Disseminated Sclerosis ', ' Multiple Sclerosis ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Northeastern United States ', ' New England ', ' Patients ', ' Pharmacogenetics ', ' Phenotype ', ' Physicians ', ' Public Health ', ' Research ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' Stroke ', ' Survey Instrument ', ' Surveys ', ' Testing ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' Family member ', ' health care ', ' Healthcare ', ' Mediating ', ' medical costs ', ' Medical Care Costs ', ' HLA-DRB1 antigen ', ' HLA-DRB1 ', ' Custom ', ' base ', ' Area ', ' Clinical ', ' premature ', ' prematurity ', ' Phase ', ' Variant ', ' Variation ', ' Individual ', ' Funding ', ' Genetic ', ' Immune ', ' Immunes ', ' Complex ', ' Stream ', ' Protocols documentation ', ' Protocol ', ' Source ', ' Penetrance ', ' Visit ', ' experience ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' Informatics ', ' TYK2 ', ' novel ', ' Participant ', ' genetic analysis ', ' Genetic analyses ', ' neuropsychiatry ', ' neuropsychiatric ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Attention deficit hyperactivity disorder ', ' CTLA4 gene ', ' cytotoxic T-lymphocyte antigen 4 ', ' Cytotoxic T-Lymphocyte-Associated Serine Esterase-4 Gene ', ' Cytotoxic T-Lymphocyte-Associated Serine Esterase-4 ', ' Cytotoxic T-Lymphocyte-Associated Protein 4 ', ' Cytotoxic T-Lymphocyte-Associated Antigen 4 Gene ', ' Cytotoxic T-Lymphocyte-Associated Antigen 4 ', ' Cytotoxic T-Lymphocyte Protein 4 Gene ', ' Cytotoxic T-Lymphocyte Protein 4 ', ' CTLA4-TM ', ' CTLA4 Protein ', ' CTLA4 ', ' CTLA-4 antigen ', ' CTLA-4 Gene ', ' CTLA 4 ', ' CD152 Gene ', ' CD152 Antigen Gene ', ' CD152 Antigen ', ' CD152 ', ' DRD2 gene ', ' Dopamine Receptor D2 Gene ', ' DRD2 ', ' D2R Gene ', ' D2R ', ' D2DR Gene ', ' D2DR ', ' D(2) Dopamine Receptor Gene ', ' TNFRSF1A gene ', ' tumor necrosis factor  receptor ', ' tumor necrosis factor receptor 1A ', ' tumor necrosis factor alpha receptor ', ' Tumor Necrosis Factor Receptor 55 ', ' Tumor Necrosis Factor Receptor 1 ', ' TNF receptor ', ' TNFalpha receptor ', ' TNFRSF1A Receptor ', ' TNFRSF1A ', ' TNFR60 ', ' TNFR55 ', ' TNFR1 ', ' TNFR-I ', ' TNFR, 60-kD ', ' TNFR, 55-kD ', ' TNFR p60 ', ' TNFAR ', ' TNF- receptor ', ' TNF-sR55 ', ' TNF Receptor p55 ', ' CD120a Antigens ', ' CD 120a Antigen ', ' LDLR gene ', ' TCF7L2 gene ', ' Transcription Factor 7-Like 2 ', ' TCF7L2 ', ' TCF4 ', ' TCF-4 ', ' T-Cell-Specific Transcription Factor 4 ', ' Consent ', ' Cost Effectiveness Analysis ', ' cost-effective analysis ', ' cost efficient analysis ', ' Data ', ' Population Attributable Risks ', ' attributable fraction ', ' Callback ', ' Clinical Data ', ' Enrollment ', ' enroll ', ' pilot trial ', ' implementation research ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' design ', ' designing ', ' Outcome ', ' cost effective ', ' Population ', ' loss of function ', ' public health relevance ', ' clinical care ', ' clinical practice ', ' biobank ', ' biorepository ', ' exome ', ' exomes ', ' randomized trial ', ' Randomization trial ', ' arm ', ' rare variant ', ' rare allele ', ' genetic information ', ' clinical sequencing ', ' clinically actionable ', ' support tools ', ' Genomic medicine ', ' biomarker panel ', ' marker panel ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' neuropsychiatric disorder ', ' neuropsychiatric disease ', ' Electronic Medical Records and Genomics Network ', ' eMERGE Network ', ' eMERGE Consortium ', ' machine learning algorithm ', ' ']",NHGRI,BRIGHAM AND WOMEN'S HOSPITAL,U01,2019,800708,MA-07,0.12018567818483675
"NEIGHBORHOOD Consortium for POAG Genetics Primary open-angle glaucoma (POAG) is an intraocular pressure (IOP) related, progressive optic neuropathy that ultimately leads to blindness. Permanent visual field loss from POAG is a condition of public health significance worldwide. The etiology of POAG is poorly understood and primary prevention is not possible. Current treatments can slow but do not cure this progressive neuropathy. The overall goal of our research is to elucidate the pathogenesis of POAG allowing for implementation of effective screening and prevention strategies and development of novel therapies. POAG has significant heritability and recent genome-wide association studies, including our NEIGHBORHOOD GWAS, have identified 30 POAG loci defined by common genomic variants. However, in addition to common variants the complex POAG genetic architecture is likely to also include contributions from rare coding variants as has been discovered for other complex traits. Large-scale studies of rare coding variation and glaucoma have not yet been done. Of the current POAG loci, the majority appear to contribute to disease through elevation of IOP. However, approximately one third of U.S. glaucoma cases are normal tension (NTG), charaterized by progressive optic nerve degeneration despite normal IOP. Our prior NTG GWAS identified two loci: 8q22, a loci not found in POAG GWASs and CDKN2BAS, a locus known to effect ganglion cell vulnerability. There results suggest that genes associated with NTG can influence susceptiblity to optic nerve degeneration, and that identification of these optic-nerve-related loci is more likely using NTG cases and controls for GWAS, rather than POAG overall. For the next funding period we propose the following specific aims: 1) complete a larger-scale well-powered NTG GWAS to discover novel loci; 2) assess contributions of rare coding variants to NTG and high-tension POAG (HTG) using whole exome sequencing; 3) explore potential protective effects of dietary factors and medications on cases with high-risk variants in POAG loci related to lipid metabolism and to mitochondrial function; and 4) support additional clinical data collection for the NEIGHBORHOOD. Primary open angle glaucoma (POAG) causes permanent loss of vision and is a condition of public health significance worldwide, affecting millions of people. The etiology of POAG is poorly understood and effective means of primary prevention and curative therapies are not available. In this proposal, our collaborative consortium will complete genetic studies to identify risk factors for POAG and the normal tension subgroup with the ultimate goals of developing effective screening and prevention strategies and novel therapies targeted to the molecular events responsible for the disease.",NEIGHBORHOOD Consortium for POAG Genetics,9819220,R01EY022305,"['Affect ', ' Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' Data Collection ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Future ', ' Genes ', ' Genotype ', ' glaucomatous ', ' Glaucoma ', ' Goals ', ' Haplotypes ', ' Modern Man ', ' Human ', ' intra-ocular pressure ', ' Ocular Tension ', ' Intraocular Pressure ', ' Physiologic Intraocular Pressure ', ' Lipids ', ' mitochondrial ', ' Mitochondria ', ' neuronal degeneration ', ' neurological degeneration ', ' neurodegenerative ', ' neurodegeneration ', ' neural degeneration ', ' Neuron Degeneration ', ' Nerve Degeneration ', ' Second Cranial Nerve ', ' Cranial Nerve II ', ' Optic Nerve ', ' second cranial nerve disorder ', ' Second Cranial Nerve Diseases ', ' Optic Neuropathy ', ' Optic Nerve Diseases ', ' Neural-Optical Lesion ', ' Cranial Nerve II Disorder ', ' Cranial Nerve II Diseases ', ' optic nerve disorder ', ' Patients ', ' Phenotype ', ' Primary Prevention ', ' Public Health ', ' Research ', ' Research Resources ', ' Resources ', ' retinal ganglion ', ' Retinal Ganglion Cells ', ' Risk ', ' Risk Factors ', ' Testing ', ' eye field ', ' Visual Fields ', ' Vitamin B ', ' Neurobion ', ' Vitamin B Complex ', ' Dataset ', ' Data Set ', ' Variant ', ' Variation ', ' Biological ', ' ganglion cell ', ' gangliocyte ', ' Databases ', ' data base ', ' Data Bases ', ' Funding ', ' Biological Process ', ' Biological Function ', ' Collaborations ', ' Genetic ', ' Primary Open Angle Glaucoma ', ' POAG ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Frequencies ', ' Complex ', ' Event ', ' Neuropathy ', ' neuropathic ', ' Blindness ', ' visual loss ', ' vision loss ', ' lipid metabolism ', ' fat metabolism ', ' cohort ', ' trait ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Prevention strategy ', ' Preventive strategy ', ' Preventative strategy ', ' Pathogenesis ', ' Fundus ', ' Code ', ' Coding System ', ' Sampling ', ' case control ', ' ATP binding cassette transporter 1 ', ' cholesterol-efflux regulatory protein ', ' HDLDT1 ', ' ABCA1 protein ', ' ABCA1 ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' CAV1 gene ', ' VIP21 Gene ', ' Caveolin-1 Gene ', ' CAV1 ', ' CAV Gene ', ' Beta Isoform Gene Caveolin 1 ', ' Alpha Isoform Gene Caveolin 1 ', ' 22kD Gene Caveolin 1 Caveolae Protein ', ' 22-kD Gene Caveolae Protein ', ' Health system ', ' Data ', ' Dietary Factors ', ' Subgroup ', ' Clinical Data ', ' Collection ', ' Genetic Risk ', ' Molecular ', ' Process ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' Pathway interactions ', ' pathway ', ' clinical phenotype ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Prevention therapy ', ' protective effect ', ' Heritability ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' therapeutic target ', ' high risk ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' exome sequencing ', ' exome-seq ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' screening ', ' genetic information ', ' Genetic study ', ' curative treatments ', ' curative therapy ', ' curative therapeutic ', ' curative intervention ', ' protective factors ', ' genetic architecture ', ' ']",NEI,MASSACHUSETTS EYE AND EAR INFIRMARY,R01,2019,872775,MA-08,0.041215605070107734
"Integrating epigenomics with DNA breathing dynamics for human non-coding disease variants ABSTRACT Genome-wide association studies (GWAS) and whole genome sequencing of complex diseases have revealed a plethora of disease risk variants, most of which lie in noncoding regions of DNA without easily interpretable function. A main functional mechanism of noncoding variants is to alter chromatin accessibility to transcription factors (TFs), thereby influencing gene expression. Predicting the effects of noncoding variants on TF binding and gene expression on a large scale is thus important but remains challenging. Available computational tools for predicting regulatory variants largely rely on TF-binding motif models and/or local chromatin modification features. Here, we aim to develop a novel computational framework to address two major limitations of these methods. First, given that known disease causal noncoding variants often reside outside of TF binding motifs, how can we improve the prediction of TF binding variants outside of motifs? For this, we plan to integrate TF ChIP-seq data with features that are important for TF binding but have not been considered in previous methods, in particular the DNA breathing dynamics (AIM1). DNA breathing reflects local transient opening of the DNA double helix due to thermal fluctuations. We have shown that genetic variants can affect nearby (up to a few hundred base pairs) DNA breathing dynamics that affect TF binding. Using TF ChIP-seq data, we will train models that predict specific TF binding variants in or outside TF motifs, incorporating DNA breathing dynamics with other features such as DNA shapes and cooperative TF binding. Secondly, given that chromatin features only show modest (<2-fold) enrichment of genetic variants associated with complex diseases or traits, how can we improve the prediction of regulatory variants? For this, we will build a computation model, considering the allele-specific chromatin accessibility (ASCA; i.e., two alleles of a heterozygous individual show read imbalance in chromatin accessibility assays) as a functional readout of a regulatory variant (AIM2). We have shown that neuronal ASCA SNPs are highly enriched for those implicated by schizophrenia (SZ) GWAS. Using neuronal ASCA data, we will train models that predict variants with regulatory effects, taking advantage of our TF-specific classifiers (from AIM1). As a proof of concept, the models will be applied to a large SZ GWAS dataset to predict putative causal regulatory variants. We will validate the effects of the predicted top-ranking regulatory SZ variants on gene expression in a well-powered hiPSC sample by combining multiplex CRISPR-based SNP editing and single-cell RNA-seq analysis (AIM3). For SNPs showing the strongest regulatory effects, we will further use CRISPR editing to verify the SNP effect on gene expression and disease-relevant neuronal phenotypes. Accurately predicting TF-affecting noncoding variants will enable better understanding of the large number of noncoding variants implicated in complex disorders and help formulate testable biological hypotheses, ultimately facilitating the development of targeted therapeutics. NARRATIVE We will develop novel computational methods and a cost-effective functional validation approach to systematically infer the effect of disease-associated noncoding variants on transcription factor binding and gene expression. Identifying the functional noncoding variants that are associated with disease risk will help illuminate causal molecular mechanisms, facilitating the clinical translation of genetic findings into disease risk prediction and treatment.",Integrating epigenomics with DNA breathing dynamics for human non-coding disease variants,9670347,R01MH116281,"['Adenine ', ' Vitamin B4 ', ' 1H-Purin-6-amine ', ' Affect ', ' Alleles ', ' Allelomorphs ', ' Breathing ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' Systematics ', ' Classification ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' DNA-Binding Proteins ', ' balance function ', ' balance ', ' Equilibrium ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Modern Man ', ' Human ', ' Methods ', ' neuronal ', ' Neurocyte ', ' Neural Cell ', ' Nerve Unit ', ' Nerve Cells ', ' Neurons ', ' Phenotype ', ' Rest ', ' Risk ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' Computer Software Tools ', ' Software Tools ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' mRNA Translation ', ' Genetic Translation ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Variant ', ' Variation ', ' Biological ', ' Training ', ' Individual ', ' Shapes ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' trait ', ' Base Pairing ', ' Structure ', ' novel ', ' disorder risk ', ' disease risk ', ' Modeling ', ' Sampling ', ' Property ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' DNA Binding ', ' DNA bound ', ' DNA Binding Interaction ', ' chromatin modification ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Data ', ' Validation ', ' Molecular ', ' Development ', ' developmental ', ' Neurodevelopmental Disorder ', ' Neurological Development Disorder ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' epigenomics ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' computer framework ', ' computational framework ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' computerized tools ', ' computational tools ', ' cost effective ', ' open source ', ' induced pluripotent stem cell ', ' iPSCs ', ' iPSC ', ' iPS ', ' genome-wide ', ' genomewide ', ' genome scale ', ' ChIP-seq ', ' chromatin immunoprecipitation-sequencing ', ' ChIP Sequencing ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' ATAC-seq ', ' ATACseq ', ' whole genome ', ' full genome ', ' entire genome ', ' predictive tools ', ' clinical translation ', ' single-cell RNA sequencing ', ' single cell RNA-seq ', ' scRNA-seq ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NIMH,NORTHSHORE UNIVERSITY HEALTHSYSTEM,R01,2019,672622,IL-09,0.11398567039393037
"Uncovering the Genetic Mechanisms Behind Joint-Specific Osteoarthritis Project Summary/Abstract In the United States, the joint disease osteoarthritis (OA) debilitates over one-third of people over sixty-five years old and causes hundreds of thousands of knee replacements annually. Despite its high prevalence, little is known about the molecular mechanisms that regulate knee formation and OA risk and how one inherits risk at specific joints (e.g., knee versus hip). Recent GWAS have identified at least seventeen loci that significantly associate with knee OA risk. However, the casual variants for these loci have not been identified because their association signals span large genomic intervals harboring uninvestigated non-coding regulatory regions. Of these, common variants in the Growth Differentiation Factor Five gene (GDF5), a critical regulator of joint development, reproducibly associate with knee OA risk in human populations. GDF5 OA variants reside on a high frequency 130 kb haplotype possessing numerous mutations that each may be causal for OA risk, but interestingly, no protein coding mutations have been uncovered that explain the associations. In a complementary study, we discovered ten GDF5 regulatory elements (e.g., promoters, enhancers) spanning this interval and revealed that they function with tremendous joint specificity (e.g., knee vs. hip). These enhancers were initially tested at incipient stages of GDF5 expression in mouse embryos, but we also know that GDF5 contributes to the differentiation of knee structures (ligaments, tendons, menisci, articular surfaces) well after this stage of development. Our research will bring together knee OA risk variants in patient populations and our knowledge of how GDF5 is controlled at the DNA level. We first aim to assess the functional contributions of joint-specific GDF5 enhancers to pre-natal knee development and adult joint homeostasis using CRISPR-Cas9 editing to excise these elements in vitro in human cells and in vivo in the mouse. Strikingly, our pilot analyses also revealed that a subset of these GDF5 enhancers possesses common and rare human variants in strong linkage disequilibrium with the highest associated OA variants in the interval. Our second aim is to further explore the association between genetic variants in the locus and OA knee shape using data acquired from the complete Osteoarthritis Initiative MR database on adult knees. Our preliminary data reveal that several variants associated with OA knee shape reside in several functional enhancers that control expression of GDF5 in the knee. Finally, our third aim is to functionally test these human regulatory variants for their impact on enhancer activity, knee formation, and OA risk by using transfection studies and CRISPR-Cas9 in human cartilage cells and in the mouse model. Completion of these studies will reveal functional variants in GDF5 that underlie its role in knee shape and OA risk. Project Narrative The Growth Differentiation Factor Five (GDF5) gene is the most reproducibly detected gene region in candidate and genome-wide association studies focusing on knee osteoarthritis risk. The proposed research focuses on (1) assessing the specific functions of key GDF5 regulatory sequences in knee development and cartilage maintenance in mice and humans, (2) the association of genetic variants in GDF5 locus with osteoarthritis knee shape, and (3) the impacts that human GDF5 risk mutations have on chondrocyte and joint biology.",Uncovering the Genetic Mechanisms Behind Joint-Specific Osteoarthritis,9675210,R01AR070139,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Affect ', ' Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Anatomy ', ' Anatomy Qualifier ', ' Anatomical Sciences ', ' Anatomic structures ', ' Anatomic Structures and Systems ', ' Anatomic Structure, System, or Substance ', ' Anatomic Sites ', ' Anatomic ', ' Architecture ', ' Engineering / Architecture ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Cartilaginous Tissue ', ' Cartilage ', ' Cell Body ', ' Cells ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Elements ', ' Embryonic ', ' Embryo ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Haplotypes ', ' Hip ', ' Coxa ', ' Hip region structure ', ' Physiological Homeostasis ', ' Autoregulation ', ' Homeostasis ', ' Modern Man ', ' Human ', ' In Vitro ', ' joint disorder ', ' arthropathy ', ' arthropathic ', ' Joint Diseases ', ' arthropathies ', ' Joints ', ' Knee ', ' Knee joint ', ' Ligaments ', ' Linkage Disequilibrium ', ' Maintenance ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' osteoarthritic ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Degenerative polyarthritis ', ' Patients ', ' Gestation ', ' Pregnancy ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Risk ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Specificity ', ' Tendons ', ' Tendon structure ', ' Testing ', ' Transfection ', ' United States ', ' Veins ', ' Work ', ' Enhancers ', ' total knee arthroplasty ', ' Total Knee Replacement ', ' Knee replacement ', ' Knee joint replacement operation ', ' Knee arthroplasty ', ' knee replacement arthroplasty ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' Replacement Arthroplasty ', ' joint replacement ', ' joint arthroplasty ', ' Joint Prosthesis Implantation ', ' Arthroplasty ', ' Surface ', ' Variant ', ' Variation ', ' Predisposition ', ' Susceptibility ', ' Meniscus structure of joint ', ' Meniscus ', ' cartilage cell ', ' Chondrocytes ', ' disability ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Genetic ', ' Morphology ', ' Shapes ', ' Reporter ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Life ', ' Knee Osteoarthritis ', ' knee joint osteoarthritis ', ' knee joint OA ', ' knee OA ', ' Dimensions ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Pattern ', ' Structure ', ' prenatal ', ' unborn ', ' novel ', ' disorder risk ', ' disease risk ', ' Reporting ', ' Code ', ' Coding System ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' genetic association ', ' Defect ', ' Data ', ' Differentiation and Growth ', ' High Prevalence ', ' Regulatory Element ', ' in vivo ', ' Molecular ', ' Development ', ' developmental ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Population ', ' Prevalence ', ' 5 year old ', ' five years of age ', ' five year old ', ' age 5 years ', ' 5 years of age ', ' Susceptibility Gene ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' mouse model ', ' murine model ', ' spatiotemporal ', ' patient population ', ' in vitro activity ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' Geometry ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' whole genome ', ' full genome ', ' entire genome ', ' experimental study ', ' experimental research ', ' experiment ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NIAMS,HARVARD UNIVERSITY,R01,2019,836792,MA-05,0.11986487891546534
"Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies Almost all proteins function through interacting with other proteins. Previous studies have shown that the vast majority of damaging single amino acid mutations in proteins disrupt only a subset of specific protein-protein interactions, and that mutations in the same protein that disrupt different interactions tend to cause clinically distinct disorders. Therefore, it is of great importance to determine interaction-specific disruptions caused by each mutation. Furthermore, rapid advances in sequencing technologies have enabled the identification of tens of millions of single nucleotide variants (SNVs) in the human population, driving an urgent need to understand the impact of each SNV on the human interactome network. Unfortunately, there is currently no method that is capable of predicting the specific impact of a large fraction of these SNVs on individual protein-protein interactions. To address this issue, we propose to leverage our massively-parallel site-directed mutagenesis pipeline, Clone-seq, to generate clones for ~6,000 coding SNVs in the human population: ~4,000 from gnomAD and ~2,000 to be submitted by the international human genetics community. We will then experimentally examine the impact on protein stability and individual protein-protein interactions for every variant using high-throughput DUAL-FLUO and InPOINT (integrating PCA, LUMIER, Y2H, and wNAPPA) assays. This proposal brings together three groups with complementary expertise in high-throughput interactome experiments and network analysis from the Yu lab, in genomic and population genetic studies from the Clark lab, and in comprehensive biophysical and structural modeling of mutations impact on binding free energy of protein interactions from the Alexov lab. Out of the ~6,000 SNVs, we expect to identify ~1,200 disruptive SNVs and ~4,000 different SNV-interaction pairs where the SNV disrupt that specific interaction. The data produced by our project will increase the available experimental information by >140 in number of human proteins and >500 in number of interactions, allowing us for the first time to comprehensively assess the relationships between the impact of SNVs on interactions and their various population genetic attributes (including, but not limited to, allele frequency and flanking haplotype, inter-population differentiation, local rate of recombination, allele age, modes of selection). Finally, we will establish a computational-experimental- integrated iterative learning scheme to build a multi-layer random-forest-based framework, SIMPACT, which can accurately predict specific impacts on all individual protein-protein interactions for all missense SNVs. Our proposed work will fuel hypothesis-driven research, will significantly improve our functional understanding of variants, and will likely fundamentally change the experimental design and data interpretation for whole genome/exome studies going forward. The dramatic increase of DNA variants discovered through advances in sequencing technologies has been inadequately translated into therapeutic successes. Although many of these variants are related to human disorders, the overwhelming number of non-functional variants makes the assessment of functional significance a steep challenge. In this study, we aim to develop a high-throughput pipeline to quickly clone and directly test a large number of coding variants for their impact on the human interactome network and use the results to build a machine learning pipeline to predict functional impact of all coding variants, in anticipation that both our experimental data and computational pipeline will lead to broad clinical and therapeutic applications.",Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies,9629970,R01GM125639,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Amino Acids ', ' aminoacid ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Cell Body ', ' Cells ', ' Communities ', ' Crystallization ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Experimental Designs ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Population Genetics ', ' Genome ', ' Haplotypes ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Learning ', ' Methods ', ' Structural Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Proteins ', ' Recombination ', ' DNA Recombination ', ' Genetic Recombination ', ' Research ', ' Research Resources ', ' Resources ', ' Technology ', ' Testing ', ' Time ', ' Translating ', ' Work ', ' Measures ', ' Targeted Modification ', ' Targeted DNA Modification ', ' Site-Specific Mutagenesis ', ' Site-Directed Mutagenesis ', ' base ', ' improved ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Training ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Measurement ', ' Letters ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' System ', ' interest ', ' mutant ', ' success ', ' Free Energy ', ' Structure ', ' Code ', ' Coding System ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Property ', ' protein protein interaction ', ' Proteomics ', ' Genomics ', ' Molecular Interaction ', ' Binding ', ' Address ', ' Data ', ' Homology Modeling ', ' International ', ' Resolution ', ' Scheme ', ' Molecular ', ' protein function ', ' Development ', ' developmental ', ' Output ', ' Population ', ' Coupling ', ' biological research ', ' molecular phenotype ', ' exome ', ' exomes ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' screening ', ' biophysical model ', ' biophysical modeling ', ' biophysical techniques ', ' biophysical methods ', ' biophysical methodology ', ' biophysical approaches ', ' Genetic study ', ' web portal ', ' internet portal ', ' whole genome ', ' full genome ', ' entire genome ', ' experimental study ', ' experimental research ', ' experiment ', ' human interactome ', ' random forest ', ' ']",NIGMS,CORNELL UNIVERSITY,R01,2019,563248,NY-23,0.09529597184915907
"Integrate gene expression data to characterize the contribution of rare genetic risk factors to structural birth defects Project Summary  We aim to maximize discovery of new risk genes and elucidate the genetic architecture of structural birth defects. To achieve that, we propose cross-disease genetic analysis of both protein-coding and noncoding variants and integration of gene expression data to prioritize candidate risk genes.  Better understanding of the genetic basis of structural birth defects will lead to new insights into human developmental biology and will provide targets for medical intervention and treatment. Recent large-scale genome and exome sequencing studies of birth defects have identified new risk genes, especially through the analysis of de novo variants in protein coding regions. However, we are still far from complete understanding of the genetic causes of birth defects. Estimates are that there are 400- 800 risk genes of large effect size for birth defects such as congenital heart disease, and the vast majority of these genes are unknown. This is primarily due to the lack of statistical power. While increasing sample size is essential and is part of the core deliverables of the Gabriella Miller Kids First (GMKF) programs, we also need to develop and apply new analytical methods that improve power and maximize the utility of the available genetic data by using other types of data and biological knowledge. In addition, in most prior studies, the analysis of rare genetic variation has been focused on small variants in the coding regions or large copy number variants (CNV). The data and methods to interrogate the contribution of rare noncoding variants is rudimentary, limiting our understanding of genetic architecture of these diseases. In this study, we propose two aims to address these questions by leverage GMKF cross-disease whole genome sequencing data sets: Specific Aim 1. Elucidate genetic architecture by cross-disease analysis of rare coding and non-coding variants. Specific Aim 2. Integrate gene expression with genome sequencing data to improve discovery and biological interpretation of risk genes of structural birth defects.  The proposed study will maximize the genetic discovery potential of the GMKF WGS data sets for birth defects and improve our understanding of the pleiotropic effects and tissue specificity of risk genes and variants. The analytical approaches developed in this study will be applicable to genetic data of birth defects and developmental disorders from future GMKF cohorts and other programs. Project Narrative We propose to analyze whole genome sequencing data from the Gabriella Miller Kids First cohorts using new computational approaches that maximize the risk gene discovery and improve interpretation of candidate genes. Our research will enhance the utility of Kids First program generated data and improve our understanding of the genetics of birth defects.",Integrate gene expression data to characterize the contribution of rare genetic risk factors to structural birth defects,9727073,R03HL147197,"['Genes ', ' Structural Genes ', ' Modern Man ', ' Human ', ' Human Development ', ' Methods ', ' Multiple Births ', ' Multiple Birth Offspring ', ' Proteins ', ' Research ', ' social role ', ' Role ', ' Specificity ', ' Body Tissues ', ' Tissues ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Genetic Diversity ', ' Genetic Variation ', ' Protein Coding Region ', ' ORFs ', ' Open Reading Frames ', ' Dataset ', ' Data Set ', ' congenital heart malformation ', ' congenital heart disease ', ' congenital heart anomaly ', ' congenital heart abnormality ', ' congenital cardiac malformation ', ' congenital cardiac disorder ', ' congenital cardiac disease ', ' congenital cardiac abnormality ', ' congenital heart disorder ', ' analytical method ', ' base ', ' dosage ', ' Organ ', ' improved ', ' Variant ', ' Variation ', ' Biological ', ' Medical ', ' Ensure ', ' insight ', ' Congenital diaphragmatic hernia ', ' Sample Size ', ' Funding ', ' Collaborations ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' programs ', ' cell type ', ' Pattern ', ' body system ', ' Organ System ', ' interest ', ' brain cell ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' cohort ', ' novel ', ' genetic analysis ', ' Genetic analyses ', ' Code ', ' Coding System ', ' genetic risk factor ', ' inherited factor ', ' functional genomics ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' developmental disease ', ' developmental disorder ', ' Bioinformatics ', ' Bio-Informatics ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Address ', ' autism spectrum disorder ', ' autistic spectrum disorder ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autistic Disorder ', ' Autism ', ' Copy Number Polymorphism ', ' copy number variation ', ' copy number variant ', ' Data ', ' Gene Structure ', ' Gene Structure/Organization ', ' Gene Organization ', ' Genetic Risk ', ' Molecular ', ' Esophageal ', ' Development ', ' developmental ', ' Neurodevelopmental Disorder ', ' Neurological Development Disorder ', ' Pathway interactions ', ' pathway ', ' Gene Expression Profile ', ' transcriptional signature ', ' gene expression signature ', ' gene expression pattern ', ' Expression Signature ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' gene discovery ', ' discover genes ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' exome sequencing ', ' exome-seq ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' Structural Congenital Anomalies ', ' congenital structural malformation ', ' Structural Birth Defect ', ' rare variant ', ' rare allele ', ' learning strategy ', ' learning method ', ' learning activity ', ' whole genome ', ' full genome ', ' entire genome ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' single-cell RNA sequencing ', ' single cell RNA-seq ', ' scRNA-seq ', ' genetic architecture ', ' Congenital Abnormality ', ' Congenital Malformation ', ' Congenital Deformity ', ' Congenital Defects ', ' Congenital Anatomical Abnormality ', ' Congenital Anatomic Abnormality ', ' Birth Defects ', ' Award ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Developmental Biology ', ' Disorder ', ' Disease ', ' Future ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' ']",NHLBI,COLUMBIA UNIVERSITY HEALTH SCIENCES,R03,2019,157574,NY-13,0.11017471739313058
"Whole Genome Sequencing in Irish Multiplex Schizophrenia Families Project Summary: Although affected members of multiplex schizophrenia pedigrees have substantially elevated recurrence risk compared to singleton cases, the mean polygenic risk scores between these groups do not differ, suggesting that one source of this higher familial recurrence risk is rare, higher impact variation. We will collect whole genome sequence (WGS) from 600 affected members of multiplex schizophrenia pedigrees to identify rare variation shared by affected individuals within and between pedigrees potentially accounting for the increased recurrence risk, and reducing the `variant space' under consideration. After QC and calling in our existing pipeline, a) familial sequence variants in the exome will be directly analyzed in 2000 Irish cases and 2000 Irish controls with 30X exome sequence data in production currently, and b) variants outside the exome will be imputed into 3600 Irish singleton schizophrenia or bipolar disorder cases and 3000 Irish population controls with GWAS framework data; 3781 additional UK10K controls with 10X WGS are available to increase analysis power. This imputed dataset will be analyzed using recently developed methods for kernel-based tests of variation aggregated over a defined interval (such as a gene) that avoid the inflation of type-1 error. We use multiple sources of genomic information to develop weights for each position in the genome (indexing the prior probability that a change at the site has functional consequence) and each variant detected (indexing the probability that observed changes have functional consequence), and we propose to improve the existing genomic information sources for this weighting in a number of ways. In aim 3, prioritized variants from aim 2a/2b will be directly genotyped in the case/control samples by custom microarray; individual genes or genesets showing enrichment of variation in cases (if any are observed) will be resequenced in the case/control sample. In Aim 4, the directly assessed genotypic and sequence data from aim 3 will be analyzed using standard methods to identify individual associated variants, and variant-enriched genes, genesets or other functional sequences. We seek to unambiguously identify 1) individual variants that are significantly more common in cases, or 2) individual genes or other functional sequences or 3) gene- or functional sequence sets enriched for variation in cases to provide critical information about the brain systems perturbed in schizophrenia, and the mechanisms by which such alleles increase risk. Project Narrative Rare sequence variation has been implicated in many human complex traits, incuding schizophrenia, and has been studied in unrelated cases and controls and parent:offspring trios, but remains unstudied in multiplex families. Sequencing the genomes of such families will allow conprehensive identification of variation in protein coding genes, non-coding expressed loci, regulatory sequences, and evolutionarily conserved regions, as well as detection of structural variation, and testing these alleles in a large case/control series of the same ethnic and geographic origin offers significant advantages over prior study designs, and has the potential to identify individual alleles, variant enriched genes, variant enriched non-genic sequences, and/or variant enriched genesets contributing to SCH risk in the Irish population. Such variants offer great potential for understanding the functional impact of risk alleles and improving mechanistic understanding of schizophrenia and related disorders.",Whole Genome Sequencing in Irish Multiplex Schizophrenia Families,9749268,R01MH114593,"['Accounting ', ' Affect ', ' Alleles ', ' Allelomorphs ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Bipolar Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Diagnosis ', ' Disorder ', ' Disease ', ' facial ', ' faces ', ' Face ', ' Family ', ' Genes ', ' Genome ', ' Genotype ', ' Geography ', ' Goals ', ' Modern Man ', ' Human ', ' indexing ', ' Irish Free State ', ' Eire ', ' Ireland ', ' Linkage Disequilibrium ', ' Methods ', ' Nucleotides ', ' Parents ', ' pedigree structure ', ' Pedigree ', ' genetic pedigree ', ' Population Control ', ' Probability ', ' Production ', ' Proteins ', ' psychotic illness ', ' Psychoses ', ' Psychotic Disorders ', ' Recurrent ', ' Recurrence ', ' study design ', ' Study Type ', ' Research Design ', ' Research Resources ', ' Resources ', ' Risk ', ' Risk Factors ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Genetic Diversity ', ' Genetic Variation ', ' Weight ', ' Measures ', ' Dataset ', ' Data Set ', ' Custom ', ' base ', ' improved ', ' sample collection ', ' specimen collection ', ' Site ', ' Phase ', ' Variant ', ' Variation ', ' Series ', ' Individual ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Dimensions ', ' Complex ', ' Source ', ' System ', ' trait ', ' Structure ', ' member ', ' offspring ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Sampling ', ' case control ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' genome sequencing ', ' LGALS3BP gene ', ' MAC-2-BP ', ' 90K ', ' Data ', ' Detection ', ' Principal Investigator ', ' Process ', ' working group ', ' work group ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' design ', ' designing ', ' Population ', ' effective therapy ', ' effective treatment ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' power analysis ', ' whole genome ', ' full genome ', ' entire genome ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' ']",NIMH,VIRGINIA COMMONWEALTH UNIVERSITY,R01,2019,430191,VA-04,0.16502677022568615
"Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases     DESCRIPTION (provided by applicant): The NHGRI Genome Sequencing Program (GSP) will identify genomic variants relevant to health and disease by genome sequencing over 225,000 participants across a multitude of diseases. The GSP will also serve as a pilot for the Precision Medicine Initiative that aims to enroll and sequence more than a million people representative of U.S. ethnic diversity. Here, we propose a GSP analysis center focused on Multi- and Trans- ethnic Mapping of Mendelian and Complex Diseases. There is a growing recognition of the substantial scientific advantages, as well as public health importance, of conducting biomedical research across ethnically diverse cohorts. We propose to develop scalable methods that incorporate ancestry to optimize medical genomic study design and improve power for uncovering the role of common and rare variants in disease. Achieving this goal requires expertise across diverse domains of knowledge including: medical and population genomics, algorithm development for complex disease mapping, and expertise in management of large-scale databases. Here, we have assembled a world-class team of medical and population geneticists, computer scientists, statisticians and clinicians, with leading expertise in the development of novel and scalable strategies for characterizing sequence variants and their role in disease. Importantly, our group has been at the forefront of development of resources, study designs and methods to enable genomic research in U.S. minority populations. Our project has three main objectives. First, we will develop an Automated Scalable Ancestry Pipeline (ASAP) for common disease mapping in diverse populations. ASAP will improve the computational efficiency of existing state-of-the-art methods for ancestry inference and develop important extensions to linear mixed models (LMMs) and other mapping strategies leveraging local and global ancestry. We will also develop methods to refine phenotypes and identify common controls for disease studies and define endpoints. Secondly, we will develop tools and resources for trans- and multi-population rare variant discovery that incorporate patterns of local and sub-continental ancestry. We will also develop machine-learning tools for variant annotation that leverage ancestral information, patterns of sequence evolution, and protein structure in a unified framework. Furthermore, we will incorporate population-specific patterns of cellular phenotypes to improve functional prediction algorithms for non-coding and coding variants. Lastly, we will disseminate our results through web-based resource that empower the biomedical research community. We will augment existing resources including ClinGen by annotating and characterizing pathogenic variants across diverse populations. We will develop a secure web-server that allows sharing of summary statistics and analysis pipelines to enable discovery, fine-mapping and functional prediction of genetic variants. Our team has ample experience with NIH-funded consortia and is dedicated to meeting the overall GSP project goals through collaborative work with NHGRI leadership and other funded investigators. PUBLIC HEALTH RELEVANCE The goal of our project is to accelerate the discovery of DNA variation relevant to health and disease by analyzing data from over 225,000 ethnically and racially diverse patients that will undergo genome sequencing. Of particular importance is ensuring we have powerful statistical methods for analyzing data from underserved groups including U.S. minority populations. Achieving this goal requires expertise across many domains of knowledge including: medical and population genomics, algorithm development for disease mapping, and expertise in large-scale databases.",Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases,9685931,U01HG009080,"['Algorithms ', ' Architecture ', ' Engineering / Architecture ', ' Biomedical Research ', ' chronic disorder ', ' Chronic Illness ', ' Chronic Disease ', ' Communities ', ' Computers ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Leadership ', ' Methods ', ' Methodology ', ' Methylation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' Privatization ', ' Public Health ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Risk ', ' social role ', ' Role ', ' Shoulder ', ' statistics ', ' Target Populations ', ' Testing ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' United States ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' population diversity ', ' heterogeneous population ', ' diverse populations ', ' Population Heterogeneity ', ' Dataset ', ' Data Set ', ' improved ', ' Clinical ', ' Variant ', ' Variation ', ' Medical ', ' Ensure ', ' Funding ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' programs ', ' Scientist ', ' Investigation ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Pattern ', ' meetings ', ' experience ', ' cohort ', ' simulation ', ' novel ', ' Participant ', ' Code ', ' Coding System ', ' Statistical Methods ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' disorder control ', ' disease control ', ' Pathogenicity ', ' genome sequencing ', ' protein structure ', ' Data ', ' Resolution ', ' Resource Development ', ' Enrollment ', ' enroll ', ' Development ', ' developmental ', ' National Human Genome Research Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' patient privacy ', ' Minority ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' large-scale database ', ' large-scale data base ', ' tool development ', ' public health relevance ', ' phenome ', ' Secure ', ' rare variant ', ' rare allele ', ' Precision Medicine Initiative ', ' genomic tools ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' ethnic diversity ', ' ethnically diverse ', ' racial diversity ', ' racially diverse ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' Structural Protein ', ' online resource ', ' web-based resource ', ' web resource ', ' online compendium ', ' on-line resource ', ' on-line compendium ', ' internet resource ', ' web-based tool ', ' preservation ', ' analysis pipeline ', ' web server ', ' ']",NHGRI,STANFORD UNIVERSITY,U01,2019,276777,CA-18,0.16988658568500095
"Optimizing Genetic Testing for Deafness for Clinical Diagnostics Project Summary  Hearing loss is the most common sensory deficit in humans. It is diagnosed in 1 in 500 newborns and affects half of all octogenarians. Although causality is multifactorial, in developed countries a large fraction of hearing loss is genetic and non-syndromic, i.e. not associated with other phenotypes.  During the prior granting period, we implemented and integrated comprehensive genetic testing as a cornerstone in the evaluation of the deaf and hard-of-hearing person. The American College of Medical Genetics has recognized the merit of this approach, and in 2014 included comprehensive genetic testing for the evaluation of deafness in their newest treatment guidelines. In the largest study to date to corroborate this decision, we found an underlying genetic cause for hearing loss in 440 (39%) of 1119 sequentially accrued patients chosen without exclusion criteria. Pathogenic variants were present in 49 genes and included missense variants (49%), copy number changes (18%), indels (18%), nonsense variants (8%), splice-site alterations (6%) and promoter variants (<1%), making comprehensive genetic testing the single best test to order in the diagnosis of hearing loss after an audiogram.  In this competitive renewal, we will build on these accomplishments by completing the following aims:  Specific Aim 1: To optimize phenotype-genotype integration in the analysis of hereditary hearing loss  by refining the use of hierarchical surface clustering and audioprofile surface analysis to determine  which types of genetic hearing loss are associated with clinically meaningful sub-clusters  Specific Aim 2: To validate and integrate physics-based protein modeling as a tool within the Deafness  Variation Database to predict variant effect and the molecular and patient phenotype  Specific Aim 3: To identify genetic modifiers of specific deafness-causing genes predicted by  hierarchical surface clustering and validated by physics-based potential free-energy modeling  The successful completion of this grant will improve the clinical care of persons with hearing loss by enhancing phenome-genome integration and by making variant interpretation more robust. Knowledge gained from this proposal will also lay the foundation for refined studies focused on the identification of genetic modifiers  both positive and negative  associated with complex phenotypes such as noise- induced and age-related hearing loss. This competitive renewal addresses the increasingly daunting challenge of variant interpretation. We will seamlessly integrate AudioGene into the OtoSCOPE pipeline, explore hierarchical surfaces clustering at all loci, enhance the utility of the Deafness Variation Database by adding physics-based potential free-energy modeling, and using these tools, identify genetic modifiers of select types of genetic hearing loss. The completion of these aims will lay the foundation for more refined studies focused on the identification of genetic modifiers  both positive and negative  associated with complex hearing loss phenotypes including noise-induced and age-related hearing loss.",Optimizing Genetic Testing for Deafness for Clinical Diagnostics,9593020,R01DC012049,"['Adoption ', ' Affect ', ' Algorithms ', ' Biology ', ' Systematics ', ' Classification ', ' Clinical Trials ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Mucoviscidosis ', ' Cystic Fibrosis ', ' deafness ', ' Decision Making ', ' Decision Trees ', ' Under-Developed Nations ', ' Under-Developed Countries ', ' Third-World Nations ', ' Third-World Countries ', ' Less-Developed Nations ', ' Less-Developed Countries ', ' Developing Nations ', ' Developing Countries ', ' Diagnosis ', ' pseudohypertrophic muscular paralysis ', ' pseudohypertrophic adult muscular dystrophy ', ' progressive muscular dystrophy of childhood ', ' mild X-linked recessive muscular dystrophy ', ' classic X-linked recessive muscular dystrophy ', ' childhood pseudohypertrophic muscular dystrophy ', ' benign X-linked recessive muscular dystrophy ', ' X-linked recessive muscular dystrophy ', ' X-linked muscular dystrophy ', ' X-linked dilated cardiomyopathy ', ' Pseudohypertrophic Muscular Dystrophy ', ' Ellis-van Creveld (EvC) syndrome ', ' Duchenne-Griesinger syndrome ', ' Duchenne ', ' Duchene ', ' Duchenne muscular dystrophy ', ' Foundations ', ' genomic therapy ', ' genetic therapy ', ' gene-based therapy ', ' Genetic Intervention ', ' Gene Transfer Clinical ', ' DNA Therapy ', ' gene therapy ', ' Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Genome ', ' Genotype ', ' Grant ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health workforce ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' Hearing ', ' hearing\xa0assessment ', ' Audiometry ', ' Audiometric Test ', ' Audiogram ', ' Hearing Tests ', ' Modern Man ', ' Human ', ' newborn children ', ' newborn child ', ' Newborns ', ' 0-4 weeks old ', ' Newborn Infant ', ' Methods ', ' Persons ', ' Noise ', ' Octogenarian ', ' Patients ', ' Phenotype ', ' Physics ', ' aging related hearing loss ', ' aging related hearing impairment ', ' aging related hearing deficits ', ' aging related decline in hearing ', ' aging induced\xa0hearing loss ', ' aging associated hearing loss ', ' age related hearing loss ', ' age related hearing impairment ', ' age related hearing deficits ', ' age related decline in\xa0hearing ', ' age induced\xa0hearing loss ', ' age associated hearing loss ', ' Presbyacusis ', ' Presbycusis ', ' Proteins ', ' Research ', ' Splicing ', ' RNA Splicing ', ' school of medicine ', ' medical college ', ' medical schools ', ' Technology ', ' Testing ', ' falls ', ' case report ', ' Case Study ', ' health care ', ' Healthcare ', ' promotor ', ' promoter ', ' Guidelines ', ' base ', ' evaluation/testing ', ' Otoscopes ', ' improved ', ' Site ', ' Area ', ' Surface ', ' Clinical ', ' Variant ', ' Variation ', ' Evaluation ', ' prognostic ', ' Databases ', ' data base ', ' Data Bases ', ' Developed Countries ', ' Industrialized Nations ', ' Industrialized Countries ', ' Developed Nations ', ' Therapeutic ', ' Cochlear implant procedure ', ' Cochlear Prosthesis Implantation ', ' Cochlear Implantation ', ' Genetic ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Complex ', ' Sensory ', ' Techniques ', ' American ', ' genetic disorder diagnosis ', ' genetic diagnosis ', ' cohort ', ' Free Energy ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Reporting ', ' Modeling ', ' Genomics ', ' Pathogenicity ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' hearing impairment ', ' hearing dysfunction ', ' hearing disability ', ' hearing difficulty ', ' hearing deficit ', ' hearing defect ', ' dysfunctional hearing ', ' Hypoacusis ', ' Hypoacuses ', ' Hearing Loss ', ' Address ', ' Data ', ' research clinical testing ', ' clinical test ', ' Clinical Testing ', ' Clinical Evaluation ', ' Enrollment ', ' enroll ', ' Exclusion Criteria ', ' Molecular ', ' clinical phenotype ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' software systems ', ' design ', ' designing ', ' Treatment Efficacy ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Heritability ', ' clinically significant ', ' clinical significance ', ' clinical care ', ' phenome ', ' clinical decision-making ', ' Massive Parallel Sequencing ', ' Massively Parallel Sequencing ', ' Massively Parallel DNA Sequencing ', ' precision genetics ', ' personalized genetics ', ' clinical diagnostics ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' clinical implementation ', ' treatment guidelines ', ' Infrastructure ', ' deaf ', ' profound hearing loss ', ' deafened ', ' hereditary hearing loss ', ' inherited\xa0hearing loss ', ' inherited hearing impairment ', ' hereditary hearing impairment ', ' genetic hearing loss ', ' genetic hearing impairment ', ' hearing preservation ', ' preserve hearing ', ' hearing threshold ', ' hard of hearing ', ' hearing loss phenotype ', ' ']",NIDCD,UNIVERSITY OF IOWA,R01,2019,480576,IA-02,0.06534042336241784
"Functional characterization of genetic and post-transcriptional variation using machine learning methods The goal of this research proposal is to develop new in-silico approaches for accurate functional annotation of genetic and post-transcriptional variants. The rapid growth of Next-Generation Sequencing (NGS) and high- throughput -omics data have brought us one step closer towards mechanistic understanding of the complex genetic disease, such as cancer, neurological disorders, diabetes, and others at the molecular level. In particular, these data revealed that complex diseases commonly manifest changes at the genetic and post- transcriptional levels. Bot of these types of changes often affect structure and function of the corresponding genes and their products. Understanding the functional implications of the genetic and post-transcriptional variation is an important task as it can provide critical insights into the molecular mechanisms underlying the disease. Here, we propose to leverage novel machine learning paradigms to design computational methods for predicting the effect of genetic and alternative splicing variants on the macromolecular interactions. Macromolecular interactions underlie many cellular functions in a healthy organism. The disease-induced changes in the genes, such as single nucleotide variations (SNVs) and alternative splicing variations (ASVs) have been recently reported to cause the protein-protein interaction network rewiring. Unfortunately, the experimental high-throughput techniques that characterize the large-scale effects of SNVs or ASVs on PPIs are expensive, time-consuming, and far from being comprehensive. The current in-silico methods either suffer from the limited applicability, or are less accurate when compared with the experimental methods. To overcome these challenges, we will use two recent machine learning paradigms, learning under privileged information (LUPI) and semi-supervised learning. If successful, we expect for the proposed methods to provide the critical advancement in the two main challenges of the current computational approaches, the limited coverage and lower than the experimental accuracy. The methods will be freely available to the community as the stand-alone tools as well as web- servers. The goal of this proposal is to build computational tools that discover the links  between the disease-associated mutations as well as alternatively spliced protein isoforms  and the protein-protein interactions mediated by the disease proteins. The tools use advanced  machine learning methods to find such links in a fast and inexpensive way. These tools  will be useful in elucidating the molecular mechanisms implicated in the complex genetic disorders.",Functional characterization of genetic and post-transcriptional variation using machine learning methods,9730612,R21LM012772,"['Affect ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Gene Expression ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Learning ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Nucleotides ', ' living system ', ' Organism ', ' Proteins ', ' Publishing ', ' Research Proposals ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Supervision ', ' Time ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Work ', ' Mediating ', ' Dataset ', ' Data Set ', ' Variant ', ' Variation ', ' Link ', ' Training ', ' insight ', ' Genetic ', ' gene function ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Adopted ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' Techniques ', ' One-Step dentin bonding system ', ' One Step ', ' Protein Isoforms ', ' Isoforms ', ' Structure ', ' novel ', ' Reporting ', ' protein protein interaction ', ' Data ', ' Homology Modeling ', ' Mutate ', ' RNA-Protein Interaction ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Molecular ', ' Genetic Annotation ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' computerized tools ', ' computational tools ', ' rapid growth ', ' design ', ' designing ', ' Consumption ', ' transcriptomics ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' learning strategy ', ' learning method ', ' learning activity ', ' gene product ', ' preservation ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' human interactome ', ' random forest ', ' supervised learning ', ' supervised machine learning ', ' web server ', ' ']",NLM,WORCESTER POLYTECHNIC INSTITUTE,R21,2019,193732,MA-02,0.04788228541402422
"Optimizing imputation for diverse populations in a distributed framework The NHGRI Genome Sequencing Program (GSP) will identify genomic variants relevant to health and disease by genome sequencing over 225,000 participants across a multitude of diseases. The GSP will also serve as a pilot for the Precision Medicine Initiative that aims to enroll and sequence more than a million people representative of U.S. ethnic diversity. Here, we propose a GSP analysis center focused on Multi- and Trans- ethnic Mapping of Mendelian and Complex Diseases. There is a growing recognition of the substantial scientific advantages, as well as public health importance, of conducting biomedical research across ethnically diverse cohorts. We propose to develop scalable methods that incorporate ancestry to optimize medical genomic study design and improve power for uncovering the role of common and rare variants in disease. Achieving this goal requires expertise across diverse domains of knowledge including: medical and population genomics, algorithm development for complex disease mapping, and expertise in management of large-scale databases. Here, we have assembled a world-class team of medical and population geneticists, computer scientists, statisticians and clinicians, with leading expertise in the development of novel and scalable strategies for characterizing sequence variants and their role in disease. Importantly, our group has been at the forefront of development of resources, study designs and methods to enable genomic research in U.S. minority populations. Our project has three main objectives. First, we will develop an Automated Scalable Ancestry Pipeline (ASAP) for common disease mapping in diverse populations. ASAP will improve the computational efficiency of existing state-of-the-art methods for ancestry inference and develop important extensions to linear mixed models (LMMs) and other mapping strategies leveraging local and global ancestry. We will also develop methods to refine phenotypes and identify common controls for disease studies and define endpoints. Secondly, we will develop tools and resources for trans- and multi-population rare variant discovery that incorporate patterns of local and sub-continental ancestry. We will also develop machine-learning tools for variant annotation that leverage ancestral information, patterns of sequence evolution, and protein structure in a unified framework. Furthermore, we will incorporate population-specific patterns of cellular phenotypes to improve functional prediction algorithms for non-coding and coding variants. Lastly, we will disseminate our results through web-based resource that empower the biomedical research community. We will augment existing resources including ClinGen by annotating and characterizing pathogenic variants across diverse populations. We will develop a secure web-server that allows sharing of summary statistics and analysis pipelines to enable discovery, fine-mapping and functional prediction of genetic variants. Our team has ample experience with NIH-funded consortia and is dedicated to meeting the overall GSP project goals through collaborative work with NHGRI leadership and other funded investigators. The goal of our project is to accelerate the discovery of DNA variation relevant to health and disease by analyzing data from over 225,000 ethnically and racially diverse patients that will undergo genome sequencing. Of particular importance is ensuring we have powerful statistical methods for analyzing data from underserved groups including U.S. minority populations. Achieving this goal requires expertise across many domains of knowledge including: medical and population genomics, algorithm development for disease mapping, and expertise in large-scale databases. ",Optimizing imputation for diverse populations in a distributed framework,10016895,U01HG009080,"['Algorithms ', ' Biomedical Research ', ' Communities ', ' Computers ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Goals ', ' Health ', ' Leadership ', ' Methods ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' Public Health ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' statistics ', ' Work ', ' population diversity ', ' heterogeneous population ', ' diverse populations ', ' Population Heterogeneity ', ' improved ', ' Variant ', ' Variation ', ' Medical ', ' Ensure ', ' Funding ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' programs ', ' Scientist ', ' Complex ', ' Pattern ', ' meetings ', ' experience ', ' cohort ', ' novel ', ' Participant ', ' Code ', ' Coding System ', ' Statistical Methods ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' disorder control ', ' disease control ', ' Pathogenicity ', ' genome sequencing ', ' protein structure ', ' Resource Development ', ' Enrollment ', ' enroll ', ' Development ', ' developmental ', ' National Human Genome Research Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Minority ', ' Population ', ' large-scale database ', ' large-scale data base ', ' Secure ', ' rare variant ', ' rare allele ', ' Precision Medicine Initiative ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' ethnic diversity ', ' ethnically diverse ', ' racial diversity ', ' racially diverse ', ' Structural Protein ', ' online resource ', ' web-based resource ', ' web resource ', ' online compendium ', ' on-line resource ', ' on-line compendium ', ' internet resource ', ' analysis pipeline ', ' web server ', ' ']",NHGRI,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,U01,2019,422665,NY-13,0.17236688966551345
"Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies Almost all proteins function through interacting with other proteins. Previous studies have shown that the vast majority of damaging single amino acid mutations in proteins disrupt only a subset of specific protein-protein interactions, and that mutations in the same protein that disrupt different interactions tend to cause clinically distinct disorders. Therefore, it is of great importance to determine interaction-specific disruptions caused by each mutation. Furthermore, rapid advances in sequencing technologies have enabled the identification of tens of millions of single nucleotide variants (SNVs) in the human population, driving an urgent need to understand the impact of each SNV on the human interactome network. Unfortunately, there is currently no method that is capable of predicting the specific impact of a large fraction of these SNVs on individual protein-protein interactions. To address this issue, we propose to leverage our massively-parallel site-directed mutagenesis pipeline, Clone-seq, to generate clones for ~6,000 coding SNVs in the human population: ~4,000 from gnomAD and ~2,000 to be submitted by the international human genetics community. We will then experimentally examine the impact on protein stability and individual protein-protein interactions for every variant using high-throughput DUAL-FLUO and InPOINT (integrating PCA, LUMIER, Y2H, and wNAPPA) assays. This proposal brings together three groups with complementary expertise in high-throughput interactome experiments and network analysis from the Yu lab, in genomic and population genetic studies from the Clark lab, and in comprehensive biophysical and structural modeling of mutations impact on binding free energy of protein interactions from the Alexov lab. Out of the ~6,000 SNVs, we expect to identify ~1,200 disruptive SNVs and ~4,000 different SNV-interaction pairs where the SNV disrupt that specific interaction. The data produced by our project will increase the available experimental information by >140 in number of human proteins and >500 in number of interactions, allowing us for the first time to comprehensively assess the relationships between the impact of SNVs on interactions and their various population genetic attributes (including, but not limited to, allele frequency and flanking haplotype, inter-population differentiation, local rate of recombination, allele age, modes of selection). Finally, we will establish a computational-experimental- integrated iterative learning scheme to build a multi-layer random-forest-based framework, SIMPACT, which can accurately predict specific impacts on all individual protein-protein interactions for all missense SNVs. Our proposed work will fuel hypothesis-driven research, will significantly improve our functional understanding of variants, and will likely fundamentally change the experimental design and data interpretation for whole genome/exome studies going forward. The dramatic increase of DNA variants discovered through advances in sequencing technologies has been inadequately translated into therapeutic successes. Although many of these variants are related to human disorders, the overwhelming number of non-functional variants makes the assessment of functional significance a steep challenge. In this study, we aim to develop a high-throughput pipeline to quickly clone and directly test a large number of coding variants for their impact on the human interactome network and use the results to build a machine learning pipeline to predict functional impact of all coding variants, in anticipation that both our experimental data and computational pipeline will lead to broad clinical and therapeutic applications.",Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies,9988741,R01GM125639,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Amino Acids ', ' aminoacid ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Cell Body ', ' Cells ', ' Communities ', ' Crystallization ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Experimental Designs ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Population Genetics ', ' Genome ', ' Haplotypes ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Learning ', ' Methods ', ' Structural Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Proteins ', ' Recombination ', ' DNA Recombination ', ' Genetic Recombination ', ' Research ', ' Research Resources ', ' Resources ', ' Technology ', ' Testing ', ' Time ', ' Translating ', ' Work ', ' Measures ', ' Targeted Modification ', ' Targeted DNA Modification ', ' Site-Specific Mutagenesis ', ' Site-Directed Mutagenesis ', ' base ', ' improved ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Training ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Measurement ', ' Letters ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' System ', ' interest ', ' mutant ', ' success ', ' Free Energy ', ' Structure ', ' Code ', ' Coding System ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Property ', ' protein protein interaction ', ' Proteomics ', ' Genomics ', ' Molecular Interaction ', ' Binding ', ' Address ', ' Data ', ' Homology Modeling ', ' International ', ' Resolution ', ' Scheme ', ' Molecular ', ' protein function ', ' Development ', ' developmental ', ' Output ', ' Population ', ' Coupling ', ' biological research ', ' molecular phenotype ', ' exome ', ' exomes ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' screening ', ' biophysical model ', ' biophysical modeling ', ' biophysical techniques ', ' biophysical methods ', ' biophysical methodology ', ' biophysical approaches ', ' Genetic study ', ' web portal ', ' internet portal ', ' whole genome ', ' full genome ', ' entire genome ', ' experimental study ', ' experimental research ', ' experiment ', ' human interactome ', ' random forest ', ' ']",NIGMS,CORNELL UNIVERSITY,R01,2019,238632,NY-23,0.09529597184915907
"Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea ABSTRACT  Obstructive sleep apnea (OSA) is recognized as an extremely common disorder that results in excessive daytime sleepiness and an increased risk of automobile crashes. It is also an independent risk factor for insulin resistance, hypertension, cardiovascular events, increased cancer rates and cancer mortality, and accelerates the progression of neurodegenerative disorders. OSA is a systemic disorder and the cyclical intermittent hypoxia that occurs during sleep affects every organ system. OSA is heritable, with first degree relatives of individuals with OSA having a two-fold increased risk of the disorder. Although this has been known for over two decades, there are very limited data on gene variants conferring risk or protection for OSA. This is likely the result of underpowered studies and GENETIC HETEROGENEITY. There are multiple pathways to OSA. Obesity is a major risk factor, as are craniofacial dimensions. The relative risk of these different risk factors varies by ethnic group. There are also neuronal mechanisms and other physiological risk factors. This proposal seeks to directly address the issue of genetic heterogeneity using a very large sample of patients and state-of- the-art analysis techniques. Towards this end, we have assembled by far the largest sample of well characterized and genotyped patients with OSA. This is the result of collaboration with key sites in the eMERGE Network [Geisinger, Vanderbilt, Mayo Clinic, Northwestern], Kaiser Permanente Southern California, and the University of Pennsylvania. We propose to carry out a robust genome-wide association studies (GWAS) using an electronic health record (EHR) derived case definition and quantitative trait analysis of OSA severity. We will use novel machine learning approaches to specifically address genetic heterogeneity. The GWAS approach will be complimented by a PheWAS strategy as another approach to identifying common variants and related clinical phenotypes. Specifically, we will look for variants that associate with OSA and other clinical diagnoses in the EHR. It is likely that gene variants for OSA will have pleiotropic effects. Gene variants identified from GWAS and/or PheWAS will be further assessed. First, we will use available whole exome sequencing data to see if there are relevant rare variants in these genes, as well as to perform exploratory discovery analyses to look for novel rare variation. The functional role of the genes identified will be studied by functional network analysis. Finally, we will assess associations with quantitative data on intermediate traits identified by high throughput craniofacial and intra-oral photography. These data are currently available within the Sleep Apnea Global Interdisciplinary Consortium (SAGIC). Future directions will assess the function of the genes identified in model systems and the clinical utility of utilizing variants as part of risk stratification for OSA. PROJECT NARRATIVE  Obstructive sleep apnea (OSA) is a common disorder with multiple adverse consequences. It is known that OSA has a genetic basis, but to date no convincing gene variants have been identified. This study uses state of the art approaches to identifying relevant genes based on a very large sample of patients with OSA obtained from multiple institutions in the United States. It is by far the largest study ever proposed for identifying genes for this common sleep disorder.",Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea,9975264,R01HL134015,"['Affect ', ' Algorithms ', ' Automobiles ', ' Bladder ', ' urinary bladder ', ' Bladder Urinary System ', ' California ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Diagnosis ', ' Disorder ', ' Disease ', ' ethnicity group ', ' Ethnic group ', ' Fats ', ' Fatty acid glycerol esters ', ' Foundations ', ' Future ', ' Genes ', ' Genotype ', ' Heterogeneity ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Hypertension ', ' insulin resistant ', ' Insulin Resistance ', ' Learning ', "" men's "", ' men ', ' Methodology ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' mortality ', ' neuronal ', ' Neurocyte ', ' Neural Cell ', ' Nerve Unit ', ' Nerve Cells ', ' Neurons ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' Patients ', ' Pennsylvania ', ' Rhythmicity ', ' Cyclicity ', ' Periodicity ', ' Phenotype ', ' Photography ', ' Play ', ' Public Health ', ' Research ', ' Research Resources ', ' Resources ', ' Risk ', ' Risk Factors ', ' social role ', ' Role ', ' Sleep ', ' sleep-related breathing disorder ', ' Sleep-Disordered Breathing ', ' Sleep Hypopnea ', ' Sleep Apnea ', ' Sleep Apnea Syndromes ', ' Leanness ', ' Thinness ', ' Body Tissues ', ' Tissues ', ' United States ', ' Universities ', ' Woman ', ' Measures ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' soft tissue ', ' Individual ', ' Hypoxia ', ' Oxygen Deficiency ', ' Hypoxic ', ' Relative Risks ', ' Genetic Heterogeneity ', ' Collaborations ', ' Genetic ', ' gene function ', ' clinical Diagnosis ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Dimensions ', ' Severities ', ' Complex ', ' Event ', ' Clinic ', ' Techniques ', ' System ', ' body system ', ' Organ System ', ' Obstructive Sleep Apnea ', ' Syndrome, Sleep Apnea, Obstructive ', ' Severity of illness ', ' disease severity ', ' Neurodegenerative Disorders ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' craniofacial ', ' craniofacies ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' cohort ', ' trait ', ' Structure ', ' novel ', ' Participant ', ' disorder risk ', ' disease risk ', ' Excessive Daytime Sleepiness ', ' Excessive daytime somnolence ', ' Code ', ' Coding System ', ' cardiovascular risk factor ', ' cardiovascular risk ', ' Sleep Disorders ', ' sleep problem ', ' sleep dysregulation ', ' sleep dysfunction ', ' Pathway Analysis ', ' Network Analysis ', ' Sampling ', ' case control ', ' Genomics ', ' Institution ', ' genetic association ', ' Address ', ' Data ', ' Collection ', ' First Degree Relative ', ' 1st degree relative ', ' Process ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' Pathway interactions ', ' pathway ', ' clinical phenotype ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Population ', ' Vehicle crash ', ' Vehicular crash ', ' Vehicular collision ', ' Motor vehicle crash ', ' Motor vehicle collision ', ' Car crash ', ' Car collision ', ' Automobile crash ', ' Automobile collision ', ' innovation ', ' innovative ', ' innovate ', ' Heritability ', ' gene discovery ', ' discover genes ', ' high risk ', ' genome-wide ', ' genomewide ', ' genome scale ', ' phenome ', ' exome ', ' exomes ', ' adverse outcome ', ' adverse consequence ', ' exome sequencing ', ' exome-seq ', ' rare variant ', ' rare allele ', ' precision medicine ', ' precision-based medicine ', ' learning strategy ', ' learning method ', ' learning activity ', ' genotyped patients ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Risk stratification ', ' secondary analysis ', ' Electronic Medical Records and Genomics Network ', ' eMERGE Network ', ' eMERGE Consortium ', ' craniofacial tissue ', ' machine learning algorithm ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NHLBI,UNIVERSITY OF PENNSYLVANIA,R01,2019,342266,PA-03,-0.01804975114259039
"Algorithms to identify non-coding mutational burden and disease-relevant pathways PROJECT SUMMARY/ABSTRACT Type 2 diabetes mellitus (T2D) is a disease with complex, polygenic etiology with numerous contributing mechanisms. To devise new therapeutics to combat this epidemic, we need to identify causal genes and variants for T2D and related, cardiometabolic traits implicated by human genetic association. Recently, large- scale DNA biobanks attached to electronic health records have facilitated extensive phenotyping in surprising large sample sizes (>500,000 subjects), importantly in diverse ancestries. These data have enabled a dramatic expansion of the number of bona-fide associations for T2D and related traits. While the increase in statistical power is certainly welcome, new opportunities for how to use these data require new computational methods and analytical pipelines. In this renewal, we focus on three areas for new methods development, which we will create and subsequently deploy to accelerate the genetic dissection for cardiometabolic disease. First, the number of associated loci now available permit the opportunity to learn directly from the data, which non- coding sequences functionally relate to T2D risk. We propose to utilize techniques in machine learning to make predictions for T2D and related causal traits, used to identify and prioritize causal variants and functional elements that are disease-predictive. A second challenge is that the quantity and pace at which this data is being produced is outstripping the rate at which even highly expert quantitative scientists can explore and extract novel insights from the data. To combat this problem, we propose to develop an informatics toolkit with apps to perform compute-intensive, important analyses and visualization with these data, tethered to cloud- based or local computation infrastructure. Finally, one key observation that follows biobank-based data analysis is that, at each physically distinct associated locus, numerous additional conditionally independent associations segregate nearby. This series of alleles can be identified through existing methods, but their use in causal inference approaches (i.e., Mendelian Randomization) has not been extensively explored. Here, we will evaluate their utility and develop statistical pipelines to use this spectrum of variation to perform new causal inference studies. PROJECT NARRATIVE Identification of causal variants and genes underlying type-2 diabetes (T2D) and related cardiometabolic trait associations are key challenge impeding biological understand and therapeutic developments. New, large- scale data sets from DNA biobanks are poised to help overcome these challenges but require the development of new informatics and statistical methods to take full advantage of the data. In this renewal application, we will develop new methods, machine learning applications, informatics tools, and causal inference statistical approaches to identify pinpoint casual variants and genes contributing to T2D and related traits.",Algorithms to identify non-coding mutational burden and disease-relevant pathways,10007107,R56DK101478,"['Adoption ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Communities ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Collection ', ' type two diabetes ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Noninsulin Dependent Diabetes ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Dissection ', ' Deoxyribonucleic Acid ', ' DNA ', ' Elements ', ' Environment ', ' Epidemic ', ' Genes ', ' Genome ', ' Grant ', ' Human Genetics ', ' Learning ', ' Methods ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' Phenotype ', ' Research Resources ', ' Resources ', ' Risk ', ' Risk Factors ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Measures ', ' falls ', ' doubt ', ' Uncertainty ', ' Dataset ', ' Data Set ', ' Imagery ', ' Visualization ', ' base ', ' method development ', ' Site ', ' Area ', ' Variant ', ' Variation ', ' Biological ', ' Physiological ', ' Physiologic ', ' Series ', ' Link ', ' insight ', ' Sample Size ', ' Genetic ', ' Exposure to ', ' instrument ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Scientist ', ' Investigation ', ' Complex ', ' Techniques ', ' Informatics ', ' trait ', ' Base Pairing ', ' novel ', ' Reporting ', ' Code ', ' Coding System ', ' Statistical Methods ', ' Modeling ', ' functional genomics ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' genetic association ', ' Address ', ' Data ', ' Randomized ', ' randomly assigned ', ' randomization ', ' randomisation ', ' Scheme ', ' follow-up ', ' followup ', ' followed up ', ' follow up ', ' active followup ', ' Active Follow-up ', ' Development ', ' developmental ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' Pathway interactions ', ' pathway ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' burden of illness ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' cluster computing ', ' distributed computing ', ' datagrid ', ' data grid ', ' Outcome ', ' Coupled ', ' task analysis ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' therapeutic development ', ' therapeutic agent development ', ' combat ', ' computer infrastructure ', ' computational infrastructure ', ' biobank ', ' biorepository ', ' genome analysis ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' cloud based ', ' power analysis ', ' parallelization ', ' experimental study ', ' experimental research ', ' experiment ', ' cardiometabolism ', ' cardiometabolic ', ' Infrastructure ', ' informatics\xa0tool ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NIDDK,UNIVERSITY OF PENNSYLVANIA,R56,2019,272474,PA-03,0.06587366569339212
"Biomedical Computing and Informatics Strategies for Infectious Disease Research     DESCRIPTION (provided by applicant): An important goal of infectious disease research is to develop genetic predictors of susceptibility. Our success in this endeavor will depend critically on the informatics methods and software that are available for making sense of high-dimensional genetic and genomic data. The goal of this research program is to develop, evaluate, distribute and support new and novel biomedical computing algorithms and open-source software for identifying combinations of genetic predictors of clinically important infectious disease outcomes. This application will target the growing body of rare genetic variants identified by high-throughput DNA sequencing. Our clinical application will focus on the prediction of antiretroviral response in clinical trials for HIV/AIDS. We propose here a highly innovative Hierarchical Rare Variant Collapsing Machine (HRVCM) algorithm for identifying and collapsing combinations of rare variants across gene regions (AIM 1). We will then integrate these new collapsed HRVCM variables into our popular Multifactor Dimensionality Reduction (MDR) method that will assess them in combination with common single-nucleotide polymorphisms (SNPs) from genome-wide association studies or GWAS (AIM 2). Our novel HRVCM-MDR approach will, for the first time, make it possible to assess non-additive interactions among sets of rare and common variants simultaneously in genetic studies of infectious diseases. We will apply these new and novel methods to approximately 13 million rare and common variants from nearly 3000 subjects that participated in an AIDS Clinical Trials Group (ACTG) study to evaluate risk for virologic failure with efavirenz-containing antiretroviral therapy (ART) regimens (AIM 3). Finally, we will release all methods as open source to the biomedical research community through our freely available MDR software package (AIM 4). PUBLIC HEALTH RELEVANCE: The overall goal of this application is to develop innovative new computational methods for the genetic analysis of infectious diseases. We will focus on the development of methods that are able to detect synergistic effects of multiple genetic variants regardless of whether they are rare of common in human populations. We will apply these methods to the study of HIV/AIDS vaccination response.",Biomedical Computing and Informatics Strategies for Infectious Disease Research,9658422,R01AI116794,"['Algorithms ', ' Biomedical Research ', ' Clinical Trials ', ' Infectious Disorder ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Communicable Diseases ', ' Communities ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' liability to disease ', ' Diathesis ', ' Disease susceptibility ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Genome ', ' Goals ', ' Modern Man ', ' Human ', ' Methods ', ' Methodology ', ' Genetic Models ', ' Research ', ' Risk ', ' Software ', ' Computer software ', ' Time ', ' Vaccination ', ' Genetic Diversity ', ' Genetic Variation ', ' virology ', ' Measures ', ' base ', ' method development ', ' Variant ', ' Variation ', ' Predisposition ', ' Susceptibility ', ' Failure ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Dimensions ', ' gene interaction ', ' success ', ' Anti-Retroviral Agents ', ' antiretroviral ', ' anti-retroviral ', ' Antiretroviral Agents ', ' Informatics ', ' efavirenz ', ' simulation ', ' Disease Outcome ', ' novel ', ' Graph ', ' AIDS/HIV problem ', ' HIV/AIDS problem ', ' HIV/AIDS ', ' AIDS/HIV ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' response ', ' Bioinformatics ', ' Bio-Informatics ', ' acquired immunodeficiency syndrome clinical trial group ', ' acquired immunodeficiency syndrome (AIDS) clinical trial group ', ' ACTG ', ' AACTG - adult AIDS clinical trial group ', ' AACTG ', ' AIDS clinical trial group ', ' genetic association ', ' Biomedical Computing ', ' biomedical computation ', ' Data ', ' Detection ', ' Infectious Diseases Research ', ' Infectious Diseases / Laboratory ', ' Genomic Segment ', ' genomic region ', ' antiretroviral therapy ', ' antiretroviral treatment ', ' anti-retroviral treatment ', ' anti-retroviral therapy ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' biomedical informatics ', ' biomed informatics ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' design ', ' designing ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' clinical application ', ' clinical applicability ', ' open source ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' Regimen ', ' rare variant ', ' rare allele ', ' High-Throughput DNA Sequencing ', ' Algorithmic Analysis ', ' Analysis of Algorithms ', ' Analyses of Algorithms ', ' Algorithmic Analyses ', ' clinical predictors ', ' genetic predictors ', ' Genetic study ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' high dimensionality ', ' ']",NIAID,UNIVERSITY OF PENNSYLVANIA,R01,2019,475263,PA-03,0.10185899198932535
"Statistical Tests for Mapping Genetic Determinants of Complex Traits     DESCRIPTION (provided by applicant): Genotyping and emerging sequencing technologies have enabled comprehensive interrogation of genetic variation across the human genome, thereby facilitating a study's ability to map genetic variants that influence phenotypes of interes. Nevertheless, genome-wide association studies (GWAS) and next-generation sequencing (NGS) projects have uncovered only a limited number of trait-influencing loci. While large increases in sample size will improve power to detect such variation, the ascertainment and sequencing/genotyping of such samples are costly and inefficient. Therefore, it is desirable to increase power to detect such variants without requiring additional sample collection. We propose novel methods for improved gene mapping of common and rare susceptibility variants that move beyond standard strategies typically applied to GWAS and NGS studies of complex traits. The first topic we consider is pleiotropic or cross- phenotype effects of genetic variants. Empirical studies have suggested that pleiotropy is widespread throughout the genome and that leveraging this additional information for gene mapping yields a more powerful analysis than an analysis that ignores such information. In Aim 1, we propose novel statistical methods for genetic analysis of high-dimensional phenotype data using an innovative kernel distance-covariance (KDC) framework that allows for an arbitrary number of phenotypes both continuous and/or categorical in nature, as well as an arbitrary number of genotypes (permitting gene-based testing of both rare and common variants). We will use the KDC framework to implement tests of pleiotropy as well as tests of mediation. The second topic we consider is the mapping of rare susceptibility variants using affected pedigrees, which provide many attractive features for rare-variant testing that case-control studies lack. In Aim 2, we propose a series of powerful statistical methods for rare-variant association testing in affected pedigrees that are based on a framework (recently published in AJHG) for rare-variant association testing in affected sibships. The existing framework compares rare-variant burden in a region by an affected sib pair to the number of regions that pairs shares identical by descent. We have shown the method is more powerful than case-control association testing given fixed sample size and further is robust to population stratification. In this proposal, we will extend the framework to handle affected pedigrees of arbitrary size and structure (rather than just affected sib pairs) and devise a powerful two-stage screening and validation strategy for rare-variant mapping that first compares familial cases in the pedigrees to external controls and then follows up the most interesting findings using an independent test based on our identity-by-descent sharing statistic among the affected relatives used in the first stage. We will apply the methods in Aims 1-2 to relevant data from genetic studies of complex traits in which we are directly involved. We also will implement the methods in public user-friendly software (Aim 3). PUBLIC HEALTH RELEVANCE: The goal of this project is to develop a set of statistical approaches to investigate two important topics in gene- mapping studies of complex human traits. First, we will develop techniques for identifying genes that have pleiotropic effects on phenotypes of possibly high dimension and further assess whether such genes have direct effects on such phenotypes or indirect effects through other possible factors. Second, we will develop tools to facilitate identification of rare polymorphic variation that increase risk for complex disease using data from affected pedigrees of arbitrary size and structure. We will evaluate these methods using simulated data and illustrate their value by applying them to genetic projects of complex traits in which we are actively involved. Application of the proposed methods to these datasets should improve our understanding of the genetic origins of various complex traits.",Statistical Tests for Mapping Genetic Determinants of Complex Traits,9616870,R01GM117946,"['Affect ', ' Case-Referrent Studies ', ' Case-Referent Studies ', ' Case-Compeer Studies ', ' Case-Comparison Studies ', ' Case-Base Studies ', ' Case-Control Studies ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Disorder ', ' Disease ', ' Family ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' Modern Man ', ' Human ', ' Joints ', ' Maps ', ' Methods ', ' pedigree structure ', ' Pedigree ', ' genetic pedigree ', ' Phenotype ', ' Public Health ', ' Publishing ', ' Risk ', ' Siblings ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Software ', ' Computer software ', ' Technology ', ' Testing ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Procedures ', ' sample collection ', ' specimen collection ', ' Variant ', ' Variation ', ' Series ', ' Sample Size ', ' Genetic ', ' Genets ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Dimensions ', ' Complex ', ' Techniques ', ' interest ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' user friendly software ', ' user friendly computer software ', ' trait ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Mediation ', ' Negotiation ', ' Negotiating ', ' Categories ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' genetic analysis ', ' Genetic analyses ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' case control ', ' Genetic Determinism ', ' genetic determinant ', ' genetic association ', ' Applied Genetics ', ' Data ', ' Validation ', ' Molecular ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' cost ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' design ', ' designing ', ' innovation ', ' innovative ', ' innovate ', ' Susceptibility Gene ', ' susceptibility variant ', ' susceptibility locus ', ' susceptibility allele ', ' predisposing gene ', ' Predisposition gene ', ' human disease ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' flexibility ', ' flexible ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' screening ', ' rare variant ', ' rare allele ', ' Genetic study ', ' identity by descent ', ' identical by descent ', ' IBD inference ', ' IBD analysis ', ' phenotypic data ', ' population stratification ', ' high dimensionality ', ' novel sequencing technology ', ' new sequencing technology ', ' emerging sequencing technology ', ' ']",NIGMS,EMORY UNIVERSITY,R01,2019,297373,GA-05,0.09474421181580026
"Leveraging Tissue-Specific Regulatory Grammar to Interpret Human Evolution and Non-coding Variation Project Summary  It is now possible to readily identify sequence variants that have been subject to natural selection in human populations. Adaptive variants have been shown to underlie diversity in both disease risk and morphology across human populations, suggesting that the lens of evolution remains a powerful tool for understanding human biology, yet one that is currently underutilized. One challenge to realizing this potential is that over 99% of human genetic variation is non-coding, as are most signals of selection and variants associated with human phenotypic traits. Mutations modifying transcription factor (TF) binding sites in non- coding, cis-regulatory regions are hypothesized to be more amenable to driving phenotypic evolution than coding changes. These cis-regulatory regions are major determinants of tissue-specific gene expression and variation within enhancers has been indicated to play role in selection and disease. However, enhancer `regulatory grammar'  the complex pattern of sequences that interact with TFs to control gene expression, is poorly understood. The challenge of linking a regulatory variant under selection to an adaptive phenotype is similar to that facing disease association studies: the targeted gene, cell type, and biological process are often unknown, hindering further investigation.  Machine learning algorithms automate the discovery of patterns, making them well-suited to uncover sequence constraints and the combinatorial TF binding patterns of enhancers without relying on limited motif databases. I will optimize support vector machine classifiers to elucidate regulatory grammar from over 100 cell types and tissues. These models will be used to predict the impact of sequence variants on cis-regulatory sites, expanding the utility of the NHGRI's ENCODE and Roadmap projects. I will then apply these tissue- specific predictions to signals of selection and/or disease from the NHGRI's 1000 Genomes Project and its genome-wide association studies catalog. By describing the regulatory impact of signals of selection, I will globally describe patterns of functional adaptation across populations, identifying genes, and gene networks targeted by selection and/or disease. I will functionally characterize variants using massively parallel reporter assays and genome editing to give deeper insight into specific cases of evolution relevant for human health.   This project seeks to develop tools and resources to describe the structure and function of sequence variation in the human genome. This proposal seeks to vastly increase the number of elucidated cases of human evolution, and specifically characterize those adaptive variants associated with disease. We will share the functional regulatory predictions for the use in interpreting a broad range of genomic datasets. This work has broad implications, from interpreting genetic variants in populations and understanding functional targets of evolution, to prioritizing non-coding mutations for precision genomic medicine and beyond. Project Narrative While thousands of genomic regions have been linked to human evolution and diseases, many of the genetic variants responsible are non-coding and thus difficult to interpret. I propose to describe the tissue-specific effects of regulatory variants using machine learning algorithms, and then integrate these functional predictions with signals of selection and/or disease association in order to pinpoint genetic variants important for human evolution and health.",Leveraging Tissue-Specific Regulatory Grammar to Interpret Human Evolution and Non-coding Variation,9614325,F32HG009226,"['Automobile Driving ', ' driving ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Gene Expression ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Logic ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Phenotype ', ' Play ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Enhancers ', ' Experimental Models ', ' Mediating ', ' Natural Selections ', ' Site ', ' Variant ', ' Variation ', ' Biological ', ' Biochemical ', ' Link ', ' Training ', ' insight ', ' Databases ', ' data base ', ' Data Bases ', ' Biological Process ', ' Biological Function ', ' Genetic ', ' Morphology ', ' Reporter ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Mechanics ', ' mechanical ', ' Investigation ', ' Complex ', ' human tissue ', ' cell type ', ' Pattern ', ' Techniques ', ' interest ', ' trait ', ' Structure ', ' Human Biology ', ' disorder risk ', ' disease risk ', ' Code ', ' Coding System ', ' Modeling ', ' functional genomics ', ' genome database ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Molecular Interaction ', ' Binding ', ' Data ', ' Genomic Segment ', ' genomic region ', ' Tissue-Specific Gene Expression ', ' Tissue-Specific Differential Gene Expression ', ' Differential Gene Expression ', ' trend ', ' National Human Genome Research Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' disease phenotype ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Outcome ', ' Population ', ' combinatorial ', ' lens ', ' lenses ', ' genome-wide ', ' genomewide ', ' genome scale ', ' epigenome ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' genome editing ', ' genomic editing ', ' functional adaptation ', ' precision genomic medicine ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' web-based tool ', ' machine learning algorithm ', ' ']",NHGRI,HARVARD UNIVERSITY,F32,2019,46114,MA-05,0.08756717362608825
"Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea ABSTRACT  Obstructive sleep apnea (OSA) is recognized as an extremely common disorder that results in excessive daytime sleepiness and an increased risk of automobile crashes. It is also an independent risk factor for insulin resistance, hypertension, cardiovascular events, increased cancer rates and cancer mortality, and accelerates the progression of neurodegenerative disorders. OSA is a systemic disorder and the cyclical intermittent hypoxia that occurs during sleep affects every organ system. OSA is heritable, with first degree relatives of individuals with OSA having a two-fold increased risk of the disorder. Although this has been known for over two decades, there are very limited data on gene variants conferring risk or protection for OSA. This is likely the result of underpowered studies and GENETIC HETEROGENEITY. There are multiple pathways to OSA. Obesity is a major risk factor, as are craniofacial dimensions. The relative risk of these different risk factors varies by ethnic group. There are also neuronal mechanisms and other physiological risk factors. This proposal seeks to directly address the issue of genetic heterogeneity using a very large sample of patients and state-of- the-art analysis techniques. Towards this end, we have assembled by far the largest sample of well characterized and genotyped patients with OSA. This is the result of collaboration with key sites in the eMERGE Network [Geisinger, Vanderbilt, Mayo Clinic, Northwestern], Kaiser Permanente Southern California, and the University of Pennsylvania. We propose to carry out a robust genome-wide association studies (GWAS) using an electronic health record (EHR) derived case definition and quantitative trait analysis of OSA severity. We will use novel machine learning approaches to specifically address genetic heterogeneity. The GWAS approach will be complimented by a PheWAS strategy as another approach to identifying common variants and related clinical phenotypes. Specifically, we will look for variants that associate with OSA and other clinical diagnoses in the EHR. It is likely that gene variants for OSA will have pleiotropic effects. Gene variants identified from GWAS and/or PheWAS will be further assessed. First, we will use available whole exome sequencing data to see if there are relevant rare variants in these genes, as well as to perform exploratory discovery analyses to look for novel rare variation. The functional role of the genes identified will be studied by functional network analysis. Finally, we will assess associations with quantitative data on intermediate traits identified by high throughput craniofacial and intra-oral photography. These data are currently available within the Sleep Apnea Global Interdisciplinary Consortium (SAGIC). Future directions will assess the function of the genes identified in model systems and the clinical utility of utilizing variants as part of risk stratification for OSA. PROJECT NARRATIVE  Obstructive sleep apnea (OSA) is a common disorder with multiple adverse consequences. It is known that OSA has a genetic basis, but to date no convincing gene variants have been identified. This study uses state of the art approaches to identifying relevant genes based on a very large sample of patients with OSA obtained from multiple institutions in the United States. It is by far the largest study ever proposed for identifying genes for this common sleep disorder.",Approaches to Genetic Heterogeneity of Obstructive Sleep Apnea,9692399,R01HL134015,"['Affect ', ' Algorithms ', ' Automobiles ', ' Bladder ', ' urinary bladder ', ' Bladder Urinary System ', ' California ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Diagnosis ', ' Disorder ', ' Disease ', ' ethnicity group ', ' Ethnic group ', ' Fats ', ' Fatty acid glycerol esters ', ' Foundations ', ' Future ', ' Genes ', ' Genotype ', ' Heterogeneity ', ' hypertensive disease ', ' hyperpiesis ', ' hyperpiesia ', ' high blood pressure ', ' Vascular Hypertensive Disorder ', ' Vascular Hypertensive Disease ', ' Hypertension ', ' insulin resistant ', ' Insulin Resistance ', ' Learning ', "" men's "", ' men ', ' Methodology ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' mortality ', ' neuronal ', ' Neurocyte ', ' Neural Cell ', ' Nerve Unit ', ' Nerve Cells ', ' Neurons ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' Patients ', ' Pennsylvania ', ' Rhythmicity ', ' Cyclicity ', ' Periodicity ', ' Phenotype ', ' Photography ', ' Play ', ' Public Health ', ' Research ', ' Research Resources ', ' Resources ', ' Risk ', ' Risk Factors ', ' social role ', ' Role ', ' Sleep ', ' sleep-related breathing disorder ', ' Sleep-Disordered Breathing ', ' Sleep Hypopnea ', ' Sleep Apnea ', ' Sleep Apnea Syndromes ', ' Leanness ', ' Thinness ', ' Body Tissues ', ' Tissues ', ' United States ', ' Universities ', ' Woman ', ' Measures ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' soft tissue ', ' Individual ', ' Hypoxia ', ' Oxygen Deficiency ', ' Hypoxic ', ' Relative Risks ', ' Genetic Heterogeneity ', ' Collaborations ', ' Genetic ', ' gene function ', ' clinical Diagnosis ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Dimensions ', ' Severities ', ' Complex ', ' Event ', ' Clinic ', ' Techniques ', ' System ', ' body system ', ' Organ System ', ' Obstructive Sleep Apnea ', ' Syndrome, Sleep Apnea, Obstructive ', ' Severity of illness ', ' disease severity ', ' Neurodegenerative Disorders ', ' neurodegenerative illness ', ' degenerative neurological diseases ', ' degenerative diseases of motor and sensory neurons ', ' Neurologic Degenerative Conditions ', ' Neurodegenerative Diseases ', ' Neural degenerative Disorders ', ' Neural Degenerative Diseases ', ' Nervous System Degenerative Diseases ', ' Degenerative Neurologic Disorders ', ' Degenerative Neurologic Diseases ', ' craniofacial ', ' craniofacies ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' cohort ', ' trait ', ' Structure ', ' novel ', ' Participant ', ' disorder risk ', ' disease risk ', ' Excessive Daytime Sleepiness ', ' Excessive daytime somnolence ', ' Code ', ' Coding System ', ' cardiovascular risk factor ', ' cardiovascular risk ', ' Sleep Disorders ', ' sleep problem ', ' sleep dysregulation ', ' sleep dysfunction ', ' Pathway Analysis ', ' Network Analysis ', ' Sampling ', ' case control ', ' Genomics ', ' Institution ', ' genetic association ', ' Address ', ' Data ', ' Collection ', ' First Degree Relative ', ' 1st degree relative ', ' Process ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' Pathway interactions ', ' pathway ', ' clinical phenotype ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Population ', ' Vehicle crash ', ' Vehicular crash ', ' Vehicular collision ', ' Motor vehicle crash ', ' Motor vehicle collision ', ' Car crash ', ' Car collision ', ' Automobile crash ', ' Automobile collision ', ' innovation ', ' innovative ', ' innovate ', ' Heritability ', ' gene discovery ', ' discover genes ', ' high risk ', ' genome-wide ', ' genomewide ', ' genome scale ', ' phenome ', ' exome ', ' exomes ', ' adverse outcome ', ' adverse consequence ', ' exome sequencing ', ' exome-seq ', ' rare variant ', ' rare allele ', ' precision medicine ', ' precision-based medicine ', ' learning strategy ', ' learning method ', ' learning activity ', ' genotyped patients ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Risk stratification ', ' secondary analysis ', ' Electronic Medical Records and Genomics Network ', ' eMERGE Network ', ' eMERGE Consortium ', ' craniofacial tissue ', ' machine learning algorithm ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NHLBI,UNIVERSITY OF PENNSYLVANIA,R01,2019,724926,PA-03,-0.01804975114259039
"Direct measurement of gene-environment interactions by high-throughput precision genome editing Abstract  Modern genetics has identified many genetic variants that affect traits such as height, but most phenotypic variation still cannot be explained by these variants alone. Importantly, differences in environment often result in individual variation of traitsincluding disease risk and drug responsefor different genotypes. These relationships are known as genotype by environment (GxE) interactions. For example, the sickle cell allele of hemoglobin S causes sickle cell anemia, but also provides a fitness advantage in the presence of malaria by conferring resistance to infection. However, there are few examples where the exact causal variants are known. Therefore, we need to develop new methodology for identifying more of these GxE interactions, to improve prediction of disease risk and treatment outcomes.  In this study, I will fill in the gap of knowledge in GxE interactions by establishing an experimental framework for identifying hundreds of causal GxE variants in parallel, providing the first comprehensive view of GxE causal variant landscape. Specifically, I will study how thousands of genetic variants between a laboratory yeast strain (BY) and a vineyard strain (RM) lead to their differences in growth upon stress and drug treatments, as one form of GxE interaction. In Aim 1, I will use a novel gene-editing technology that can detect the fitness effects of thousands of variants in one experiment, as shown in a pilot experiment. Using this method, I will be able to map hundreds of casual variants that contribute to growth differences under various conditions, such as carbon source, oxidative stress and drug treatment. In Aim 2, I will measure allele-specific mRNA expression (ASE) from BYxRM F1 hybrids in above-mentioned conditions and associate the mapped causal GxE variants, to identify GxE variants that influence growth rate through gene expression. Then, I will apply a machine learning model to predict causal GxE genes using the molecular features found in this study. By mapping causal GxE variants, linking them to gene expression and predicting causal genes through gene expression, I will establish a complete framework for accelerating the discovery of GxE interactions. Public Health Relevance The recent explosion of precision medicine based on genotype and mutations has enabled personalized treatment of diseases. However, how environmental factors influence the outcome of such treatments is not clear. By establishing a framework to study general principles and underlying molecular mechanisms of these gene-by-environment interactions, we will be able to integrate such knowledge in disease risk prediction and personalized treatment.",Direct measurement of gene-environment interactions by high-throughput precision genome editing,9678678,F31ES030282,"['Accounting ', ' Affect ', ' Alleles ', ' Allelomorphs ', ' Sickle Cell Anemia ', ' sicklemia ', ' sickle disease ', ' sickle cell disease ', ' Hemoglobin sickle cell disorder ', ' Hemoglobin sickle cell disease ', ' Hemoglobin S Disease ', ' HbSS disease ', ' Hb SS disease ', ' Carbon ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' dietary ', ' Diet ', ' Disorder ', ' Disease ', ' drug treatment ', ' Drug Therapy ', ' Pharmacotherapy ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' Environmental Exposure ', ' Explosion ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Health ', ' Hemoglobin S ', ' Sickle Hemoglobin ', ' Modern Man ', ' Human ', ' Somatic Cell Hybrids ', ' Hybrid Cells ', ' Hybrids ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Libraries ', ' Plasmodium Infections ', ' Paludism ', ' Malaria ', ' Maps ', ' Methods ', ' Methodology ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' Modernization ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Phenotype ', ' pilot study ', ' Pilot Projects ', ' Research ', ' S. cerevisiae ', ' S cerevisiae ', "" Brewer's Yeast "", "" Baker's Yeast "", ' Saccharomyces cerevisiae ', ' Stress ', ' Technology ', ' Time ', ' Work ', ' Yeasts ', ' Measures ', ' Racial Segregation ', ' segregation ', ' Lactose Galactohydrolase ', ' Lactase Enzyme ', ' Lactase ', ' Treatment outcome ', ' promotor ', ' promoter ', ' career ', ' improved ', ' Variant ', ' Variation ', ' Link ', ' Training ', ' Sickle Cell ', ' sickle red blood cell ', ' sickle erythrocyte ', ' sickle RBC ', ' Individual ', ' Measurement ', ' Oxidative Stress ', ' Genetic ', ' Exposure to ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Source ', ' Techniques ', ' System ', ' Height ', ' Resistance to infection ', ' infection resistance ', ' gene environment interaction ', ' environment effect on gene ', ' GxE interaction ', ' Gene x Environment Interaction ', ' Quantitative Trait Loci ', ' QTL ', ' trait ', ' skills ', ' novel ', ' Human Cell Line ', ' disorder risk ', ' disease risk ', ' Disease model ', ' disorder model ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Modeling ', ' response ', ' Genomics ', ' Polygenic Traits ', ' Polygenic Inheritances ', ' Polygenic Characters ', ' Meiotic Recombination ', ' Address ', ' fitness ', ' Resolution ', ' mRNA Expression ', ' Molecular ', ' Pathway interactions ', ' pathway ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Outcome ', ' pathogen ', ' Heritability ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' precision medicine ', ' precision-based medicine ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' Genetic study ', ' genome editing ', ' genomic editing ', ' experimental study ', ' experimental research ', ' experiment ', ' precise genome editing ', ' individual variation ', ' individual variability ', ' individual heterogeneity ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NIEHS,STANFORD UNIVERSITY,F31,2019,29016,CA-18,0.15825858458705416
"Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies Almost all proteins function through interacting with other proteins. Previous studies have shown that the vast majority of damaging single amino acid mutations in proteins disrupt only a subset of specific protein-protein interactions, and that mutations in the same protein that disrupt different interactions tend to cause clinically distinct disorders. Therefore, it is of great importance to determine interaction-specific disruptions caused by each mutation. Furthermore, rapid advances in sequencing technologies have enabled the identification of tens of millions of single nucleotide variants (SNVs) in the human population, driving an urgent need to understand the impact of each SNV on the human interactome network. Unfortunately, there is currently no method that is capable of predicting the specific impact of a large fraction of these SNVs on individual protein-protein interactions. To address this issue, we propose to leverage our massively-parallel site-directed mutagenesis pipeline, Clone-seq, to generate clones for ~6,000 coding SNVs in the human population: ~4,000 from gnomAD and ~2,000 to be submitted by the international human genetics community. We will then experimentally examine the impact on protein stability and individual protein-protein interactions for every variant using high-throughput DUAL-FLUO and InPOINT (integrating PCA, LUMIER, Y2H, and wNAPPA) assays. This proposal brings together three groups with complementary expertise in high-throughput interactome experiments and network analysis from the Yu lab, in genomic and population genetic studies from the Clark lab, and in comprehensive biophysical and structural modeling of mutations impact on binding free energy of protein interactions from the Alexov lab. Out of the ~6,000 SNVs, we expect to identify ~1,200 disruptive SNVs and ~4,000 different SNV-interaction pairs where the SNV disrupt that specific interaction. The data produced by our project will increase the available experimental information by >140 in number of human proteins and >500 in number of interactions, allowing us for the first time to comprehensively assess the relationships between the impact of SNVs on interactions and their various population genetic attributes (including, but not limited to, allele frequency and flanking haplotype, inter-population differentiation, local rate of recombination, allele age, modes of selection). Finally, we will establish a computational-experimental- integrated iterative learning scheme to build a multi-layer random-forest-based framework, SIMPACT, which can accurately predict specific impacts on all individual protein-protein interactions for all missense SNVs. Our proposed work will fuel hypothesis-driven research, will significantly improve our functional understanding of variants, and will likely fundamentally change the experimental design and data interpretation for whole genome/exome studies going forward. The dramatic increase of DNA variants discovered through advances in sequencing technologies has been inadequately translated into therapeutic successes. Although many of these variants are related to human disorders, the overwhelming number of non-functional variants makes the assessment of functional significance a steep challenge. In this study, we aim to develop a high-throughput pipeline to quickly clone and directly test a large number of coding variants for their impact on the human interactome network and use the results to build a machine learning pipeline to predict functional impact of all coding variants, in anticipation that both our experimental data and computational pipeline will lead to broad clinical and therapeutic applications.",Quantifying molecular consequences of human missense variants with large-scale interactome perturbation studies,9872026,R01GM125639,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Amino Acids ', ' aminoacid ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Cells ', ' Cell Body ', ' Communities ', ' Crystallization ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Experimental Designs ', ' Gene Frequency ', ' Allele Frequency ', ' allelic frequency ', ' Genes ', ' Population Genetics ', ' Genome ', ' Haplotypes ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Learning ', ' Methods ', ' Structural Models ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Phenotype ', ' Proteins ', ' Publishing ', ' Genetic Recombination ', ' DNA Recombination ', ' Recombination ', ' Research ', ' Resources ', ' Research Resources ', ' Technology ', ' Testing ', ' Time ', ' Translating ', ' Work ', ' Measures ', ' Site-Directed Mutagenesis ', ' Site-Specific Mutagenesis ', ' Targeted DNA Modification ', ' Targeted Modification ', ' base ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Biochemical ', ' Training ', ' Individual ', ' Data Bases ', ' data base ', ' Databases ', ' Measurement ', ' Letters ', ' Therapeutic ', ' machine learned ', ' Machine Learning ', ' System ', ' interest ', ' mutant ', ' success ', ' Free Energy ', ' Structure ', ' Single Base Polymorphism ', ' single nucleotide variant ', ' Single Nucleotide Polymorphism ', ' Coding System ', ' Code ', ' Network Analysis ', ' Pathway Analysis ', ' Modeling ', ' Property ', ' protein protein interaction ', ' Proteomics ', ' Genomics ', ' Molecular Interaction ', ' Binding ', ' Address ', ' Data ', ' Homology Modeling ', ' International ', ' Resolution ', ' Scheme ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' Output ', ' Population ', ' Coupling ', ' biological research ', ' molecular phenotype ', ' exomes ', ' exome ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' screening ', ' biophysical model ', ' biophysical approaches ', ' biophysical methodology ', ' biophysical methods ', ' biophysical techniques ', ' Genetic study ', ' internet portal ', ' on-line portal ', ' online portal ', ' web-based portal ', ' web portal ', ' entire genome ', ' full genome ', ' whole genome ', ' experiment ', ' experimental research ', ' experimental study ', ' human interactome ', ' random forest ', ' data pipeline ', ' computational pipelines ', ' ']",NIGMS,CORNELL UNIVERSITY,R01,2020,563248,NY-23,0.09529597184915907
"Integrate gene expression data to characterize the contribution of rare genetic risk factors to structural birth defects Project Summary  We aim to maximize discovery of new risk genes and elucidate the genetic architecture of structural birth defects. To achieve that, we propose cross-disease genetic analysis of both protein-coding and noncoding variants and integration of gene expression data to prioritize candidate risk genes.  Better understanding of the genetic basis of structural birth defects will lead to new insights into human developmental biology and will provide targets for medical intervention and treatment. Recent large-scale genome and exome sequencing studies of birth defects have identified new risk genes, especially through the analysis of de novo variants in protein coding regions. However, we are still far from complete understanding of the genetic causes of birth defects. Estimates are that there are 400- 800 risk genes of large effect size for birth defects such as congenital heart disease, and the vast majority of these genes are unknown. This is primarily due to the lack of statistical power. While increasing sample size is essential and is part of the core deliverables of the Gabriella Miller Kids First (GMKF) programs, we also need to develop and apply new analytical methods that improve power and maximize the utility of the available genetic data by using other types of data and biological knowledge. In addition, in most prior studies, the analysis of rare genetic variation has been focused on small variants in the coding regions or large copy number variants (CNV). The data and methods to interrogate the contribution of rare noncoding variants is rudimentary, limiting our understanding of genetic architecture of these diseases. In this study, we propose two aims to address these questions by leverage GMKF cross-disease whole genome sequencing data sets: Specific Aim 1. Elucidate genetic architecture by cross-disease analysis of rare coding and non-coding variants. Specific Aim 2. Integrate gene expression with genome sequencing data to improve discovery and biological interpretation of risk genes of structural birth defects.  The proposed study will maximize the genetic discovery potential of the GMKF WGS data sets for birth defects and improve our understanding of the pleiotropic effects and tissue specificity of risk genes and variants. The analytical approaches developed in this study will be applicable to genetic data of birth defects and developmental disorders from future GMKF cohorts and other programs. Project Narrative We propose to analyze whole genome sequencing data from the Gabriella Miller Kids First cohorts using new computational approaches that maximize the risk gene discovery and improve interpretation of candidate genes. Our research will enhance the utility of Kids First program generated data and improve our understanding of the genetics of birth defects.",Integrate gene expression data to characterize the contribution of rare genetic risk factors to structural birth defects,9882319,R03HL147197,"['Congenital Abnormality ', ' Birth Defects ', ' Congenital Anatomic Abnormality ', ' Congenital Anatomical Abnormality ', ' Congenital Defects ', ' Congenital Deformity ', ' Congenital Malformation ', ' Award ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Developmental Biology ', ' Disease ', ' Disorder ', ' Esophagus ', ' Future ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Human ', ' Modern Man ', ' Human Development ', ' Methods ', ' Multiple Birth Offspring ', ' Multiple Births ', ' Proteins ', ' Research ', ' Role ', ' social role ', ' Specificity ', ' Tissues ', ' Body Tissues ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Genetic Variation ', ' Genetic Diversity ', ' Open Reading Frames ', ' ORFs ', ' Protein Coding Region ', ' Dataset ', ' Data Set ', ' congenital cardiac abnormality ', ' congenital cardiac disease ', ' congenital cardiac disorder ', ' congenital cardiac malformation ', ' congenital heart abnormality ', ' congenital heart anomaly ', ' congenital heart disease ', ' congenital heart malformation ', ' congenital heart disorder ', ' analytical method ', ' base ', ' dosage ', ' Organ ', ' improved ', ' Variation ', ' Variant ', ' Biological ', ' Medical ', ' Ensure ', ' insight ', ' Congenital diaphragmatic hernia ', ' Sample Size ', ' Funding ', ' Collaborations ', ' Genetic ', ' Knowledge ', ' programs ', ' cell type ', ' Pattern ', ' Organ System ', ' body system ', ' interest ', ' brain cell ', ' pleiotropic effect ', ' pleiotropy ', ' pleiotropism ', ' cohort ', ' novel ', ' Genetic analyses ', ' genetic analysis ', ' Coding System ', ' Code ', ' inherited factor ', ' genetic risk factor ', ' functional genomics ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' developmental disorder ', ' developmental disease ', ' genome sequencing ', ' Candidate Gene ', ' Candidate Disease Gene ', ' Address ', ' Autism ', ' Autistic Disorder ', ' Early Infantile Autism ', ' Infantile Autism ', "" Kanner's Syndrome "", ' autistic spectrum disorder ', ' autism spectrum disorder ', ' copy number variant ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Genetic Risk ', ' Molecular ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' pathway ', ' Pathway interactions ', ' Expression Signature ', ' gene expression pattern ', ' gene expression signature ', ' transcriptional signature ', ' Gene Expression Profile ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' discover genes ', ' gene discovery ', ' genome scale ', ' genomewide ', ' genome-wide ', ' exomes ', ' exome ', ' exome-seq ', ' exome sequencing ', ' Risk-associated variant ', ' risk allele ', ' risk gene ', ' risk genotype ', ' risk loci ', ' risk locus ', ' risk variant ', ' Structural Birth Defect ', ' congenital structural malformation ', ' Structural Congenital Anomalies ', ' rare allele ', ' rare variant ', ' entire genome ', ' full genome ', ' whole genome ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' scRNA-seq ', ' single cell RNA-seq ', ' single cell RNAseq ', ' single-cell RNA sequencing ', ' genetic architecture ', ' bio-informatics pipeline ', ' bioinformatics pipeline ', ' de novo variant ', ' de novo mutation ', ' machine learning method ', ' ']",NHLBI,COLUMBIA UNIVERSITY HEALTH SCIENCES,R03,2020,157441,NY-13,0.11017471739313058
"Tools for Normalizing and Interpreting the Clinical Actionability of Genomic Variants PROJECT SUMMARY/ABSTRACT The availability of high-throughput, low-cost sequencing has transformed the landscape of biomedical research by dramatically expanding our capacity to interrogate the sequence of the human genome. Consequently, there has been an explosion of biomedical literature describing the role of specific genomic variants and their impact on human diseases. These advances are bringing sequencing into the clinic to shape clinical practice from the patients genomic content, a paradigm colloquially referred to as genomic or precision medicine. There remain many obstacles to fully realizing our potential in the era of precision medicine. Among them is a recognized need for robust, well-engineered systems that provide knowledge about genomic variants and their role in disease. Ideally, such systems would provide a comprehensive summary of all knowledge that is relevant to the patients unique genomic content. An early bottleneck to realizing precision medicine was that, despite the substantial literature and several established knowledgebases that define interactions between drugs and genes, querying across them was extremely challenging. In response to this need, the Drug-Gene Interaction database (DGIdb, dgidb.org) was developed. Through a combination of automated processing and manual curation, drug-gene interaction information was collected, structured, and connected (normalized) from these diverse sources of data and entered into a database with a user-friendly search interface and an application programming interface (API). However, linking drug and drug-gene interaction concepts across resources remains an extremely challenging task, and aggregated drug-gene interactions are also challenging to represent in a way that highlights the utility of the collected knowledge for precision medicine efforts. This proposal seeks to improve our ability to normalize and interpret drug-gene interactions corresponding to patient genomic variants. We will achieve this goal through two specific aims. First, the DGIdb normalization routines will be improved through incorporation of new content and features. Among these, the DGIdb will support collections of drugs, including combination therapies and drug classes. Also, the DGIdb will have new community submission and curation features, allowing users to incorporate new knowledge into the database. Second, the Variant Interpretation Aggregator database (VIAdb) will be created to normalize knowledge across several disparate sources focused on the clinical interpretations of genomic variants. The VIAdb will operate as a stand-alone web tool and API and will behave as a source of relevant interpretations to DGIdb. Finally, we will develop techniques for automated identification of drug-gene interactions and variant interpretation consensus to assist community curation efforts. If successful, this research will improve breadth and consistency of variant interpretations and drug-gene interactions for precision medicine efforts. PROJECT NARRATIVE This research will improve our ability to interpret genomic variations in human patients in support of precision medicine efforts. Specifically, it will provide web-based tools for identifying potential therapies that specifically target the patients individual genes or variants, and an assessment of the clinical actionability of those drugs.",Tools for Normalizing and Interpreting the Clinical Actionability of Genomic Variants,10212005,K99HG010157,"['drug resource ', ' Data ', ' Resource Development ', ' VICC ', ' The Vanderbilt-Ingram Cancer Center at the Vanderbilt University ', ' Collection ', ' developmental ', ' Development ', ' cost ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' model of data ', ' model the data ', ' modeling of the data ', ' data modeling ', ' designing ', ' design ', ' Clinical assessments ', ' cancer type ', ' user-friendly ', ' web interface ', ' open source ', ' human disease ', ' new drug treatments ', ' new drugs ', ' new therapeutics ', ' new therapy ', ' next generation therapeutics ', ' novel drug treatments ', ' novel drugs ', ' novel therapy ', ' novel therapeutics ', ' tumor ', ' molecular biomarker ', ' molecular marker ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' clinical practice ', ' precision-based medicine ', ' precision medicine ', ' genomic variation ', ' clinically actionable ', ' application program interface ', ' application programming interface ', ' learning activity ', ' learning method ', ' learning strategy ', ' Genomic medicine ', ' individual patient ', ' patient profile ', ' profiles in patients ', ' web application ', ' web app ', ' therapeutic marker ', ' therapeutic biomarker ', ' web-based tool ', ' Visualization ', ' Biomedical Research ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Client ', ' Clinical Trials ', ' Cohort Studies ', ' Concurrent Studies ', ' Combined Modality Therapy ', ' Multimodal Therapy ', ' Multimodal Treatment ', ' combination therapy ', ' combined modality treatment ', ' combined treatment ', ' multi-modal therapy ', ' multi-modal treatment ', ' Communities ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Engineering ', ' Explosion ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Recording of previous events ', ' History ', ' Human ', ' Modern Man ', ' Literature ', ' Manuals ', ' Methods ', ' Patients ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Suggestion ', ' Work ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Link ', ' Data Bases ', ' data base ', ' Databases ', ' WWW ', ' web ', ' world wide web ', ' Internet ', ' Shapes ', ' tool ', ' machine learned ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' programs ', ' Level of Evidence ', ' Side ', ' Clinic ', ' Source ', ' Techniques ', ' System ', ' Services ', ' gene interaction ', ' cohort ', ' knowledgebase ', ' knowledge base ', ' Structure ', ' novel ', ' Reporting ', ' response ', ' Genomics ', ' drug discovery ', ' ']",NHGRI,RESEARCH INST NATIONWIDE CHILDREN'S HOSP,K99,2020,92118,OH-03,0.1338129295815199
"Biomedical Computing and Informatics Strategies for Infectious Disease Research     DESCRIPTION (provided by applicant): An important goal of infectious disease research is to develop genetic predictors of susceptibility. Our success in this endeavor will depend critically on the informatics methods and software that are available for making sense of high-dimensional genetic and genomic data. The goal of this research program is to develop, evaluate, distribute and support new and novel biomedical computing algorithms and open-source software for identifying combinations of genetic predictors of clinically important infectious disease outcomes. This application will target the growing body of rare genetic variants identified by high-throughput DNA sequencing. Our clinical application will focus on the prediction of antiretroviral response in clinical trials for HIV/AIDS. We propose here a highly innovative Hierarchical Rare Variant Collapsing Machine (HRVCM) algorithm for identifying and collapsing combinations of rare variants across gene regions (AIM 1). We will then integrate these new collapsed HRVCM variables into our popular Multifactor Dimensionality Reduction (MDR) method that will assess them in combination with common single-nucleotide polymorphisms (SNPs) from genome-wide association studies or GWAS (AIM 2). Our novel HRVCM-MDR approach will, for the first time, make it possible to assess non-additive interactions among sets of rare and common variants simultaneously in genetic studies of infectious diseases. We will apply these new and novel methods to approximately 13 million rare and common variants from nearly 3000 subjects that participated in an AIDS Clinical Trials Group (ACTG) study to evaluate risk for virologic failure with efavirenz-containing antiretroviral therapy (ART) regimens (AIM 3). Finally, we will release all methods as open source to the biomedical research community through our freely available MDR software package (AIM 4). PUBLIC HEALTH RELEVANCE: The overall goal of this application is to develop innovative new computational methods for the genetic analysis of infectious diseases. We will focus on the development of methods that are able to detect synergistic effects of multiple genetic variants regardless of whether they are rare of common in human populations. We will apply these methods to the study of HIV/AIDS vaccination response.",Biomedical Computing and Informatics Strategies for Infectious Disease Research,9869806,R01AI116794,"['Algorithms ', ' Biomedical Research ', ' Clinical Trials ', ' Communicable Diseases ', ' Infectious Disease Pathway ', ' Infectious Diseases ', ' Infectious Disorder ', ' Communities ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Statistical Data Interpretation ', ' Statistical Data Analyses ', ' Statistical Data Analysis ', ' statistical analysis ', ' Disease susceptibility ', ' Diathesis ', ' liability to disease ', ' Gene Frequency ', ' Allele Frequency ', ' allelic frequency ', ' Genes ', ' Genome ', ' Goals ', ' Human ', ' Modern Man ', ' Methods ', ' Methodology ', ' Genetic Models ', ' Research ', ' Risk ', ' Computer software ', ' Software ', ' Time ', ' Vaccination ', ' Genetic Variation ', ' Genetic Diversity ', ' virology ', ' Measures ', ' base ', ' method development ', ' Variation ', ' Variant ', ' Susceptibility ', ' Predisposition ', ' Failure ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' programs ', ' Dimensions ', ' gene interaction ', ' success ', ' Antiretroviral Agents ', ' anti-retroviral ', ' antiretroviral ', ' Anti-Retroviral Agents ', ' Informatics ', ' efavirenz ', ' simulation ', ' Disease Outcome ', ' novel ', ' Graph ', ' AIDS/HIV ', ' HIV/AIDS ', ' HIV/AIDS problem ', ' AIDS/HIV problem ', ' Single Base Polymorphism ', ' single nucleotide variant ', ' Single Nucleotide Polymorphism ', ' Genetic analyses ', ' genetic analysis ', ' Modeling ', ' response ', ' Bio-Informatics ', ' Bioinformatics ', ' AACTG ', ' ACTG ', ' acquired immunodeficiency syndrome clinical trial group ', ' AIDS clinical trial group ', ' genetic association ', ' biomedical computation ', ' Biomedical Computing ', ' Data ', ' Detection ', ' Infectious Diseases / Laboratory ', ' Infectious Diseases Research ', ' genomic region ', ' Genomic Segment ', ' anti-retroviral therapy ', ' anti-retroviral treatment ', ' antiretroviral treatment ', ' antiretroviral therapy ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' biomed informatics ', ' biomedical informatics ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' innovate ', ' innovative ', ' innovation ', ' clinical applicability ', ' clinical application ', ' open source ', ' public health relevance ', ' genome scale ', ' genomewide ', ' genome-wide ', ' Regimen ', ' rare allele ', ' rare variant ', ' High-Throughput DNA Sequencing ', ' Algorithmic Analyses ', ' Analyses of Algorithms ', ' Analysis of Algorithms ', ' Algorithmic Analysis ', ' clinical predictors ', ' genetic predictors ', ' Genetic study ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' high dimensionality ', ' ']",NIAID,UNIVERSITY OF PENNSYLVANIA,R01,2020,463248,PA-03,0.10185899198932535
"A predictive model of mRNA stability and translation for variant interpretation and mRNA therapeutics The leading and trailing untranslated regions (UTRs) of an mRNA, along with the coding sequence (CDS), control protein production by modulating translation and mRNA stability. However, although we have identified a vast number of regulatory features in these regions, we are still far from being able to predict, for example, whether and how a sequence variant affects the levels of protein being made. Here, we propose to combine high-throughput experimental characterization of protein expression in synthetic libraries with machine learning to create predictive models of translation and mRNA stability, addressing an urgent need. Recent progress in machine vision, voice recognition and other fields of computer science has been driven by the availability of enormous data sets on which to train models. Machine learning approaches have also had remarkable impact in biology, but biological data sets often are comparatively small, limiting the quality of models that can be learned. For example, there are only around 20,000 genes in the human genome, a restrictively small set of examples for training a predictive model that captures the full extent of the genomes regulatory code. In this proposal, we aim to overcome this data size limitation by training predictive models of protein expression on data from millions of synthetic constructs -- a data set several orders of magnitude larger than the number of genes in the genome. Specifically, we will create libraries of in vitro transcribed mRNA with targeted variation in the UTRs and CDS and will assay protein expression of each library member by performing high-throughput polysome profiling, ribosome profiling, and mRNA stability assays. We will then use neural network approaches to learn predictive models of the relationship between mRNA sequence and levels of protein production. We will apply our models to three applications of practical importance: first, we expect to uncover novel biology, for example identifying regulatory sequence elements and interactions between them. Second, we will validate our models through the de novo design and experimental testing of sequences that result in higher levels or protein production than any of the millions of randomly generated members of the original library or than the endogenous UTR sequences currently used in biotechnology. Such stable and highly translating mRNA constructs would be of particular value for the field or mRNA therapeutics. Third, we will predict the functional consequences of genetic variation in UTRs on protein production and we will validate these predictions experimentally. We are far from understanding which genetic variants compromise gene regulatory function in ways that may contribute to disease, making such a comprehensive and quantitative analysis of variants valuable. This research project aims to use machine learning to build predictive models of translation and mRNA stability. Models are trained on data obtained by measuring protein production for millions of synthetic RNA constructs. Models will then be applied for understanding the consequences of genetic variation in humans and for the design of mRNA therapeutics.",A predictive model of mRNA stability and translation for variant interpretation and mRNA therapeutics,9894822,R01HG009892,"['synthetic DNA ', ' synthetic construct ', ' computer science ', "" 5'UTR "", ' mRNA Leader Sequences ', "" 5' Untranslated Regions "", "" 3'UTR "", "" 3' Untranslated Regions "", ' UTRs ', ' Untranslated Regions ', ' Structure ', ' novel ', ' member ', ' RNA Stability ', ' Coding System ', ' Code ', ' Modeling ', ' Connectionist Models ', ' Neural Network Models ', ' Perceptrons ', ' Neural Network Simulation ', ' Property ', ' DNA bank ', ' DNA Library ', ' Genomics ', ' voice recognition ', ' protein expression ', ' mRNA Stability ', ' Address ', ' Data ', ' randomisation ', ' randomization ', ' randomly assigned ', ' Randomized ', ' Regulatory Element ', ' Resolution ', ' Computational Technique ', ' Expression Library ', ' Genetic Algorithm ', ' Genetic Programming ', ' Transcript ', ' Validation ', ' imaging ', ' Image ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' designing ', ' design ', ' application in practice ', ' practical application ', ' comparative ', ' screening ', ' Ribo-seq ', ' ribosome footprint profiling ', ' ribosome profiling ', ' experiment ', ' experimental research ', ' experimental study ', ' polysome profiling ', ' neural network ', ' ConvNet ', ' convolutional network ', ' convolutional neural nets ', ' convolutional neural network ', ' machine vision ', ' statistical learning ', ' Affect ', ' Alternative Splicing ', ' Alternate Splicing ', ' Alternative RNA Splicing ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Biotechnology ', ' Biotech ', ' Disease ', ' Disorder ', ' Elements ', ' Engineering ', ' Gene Expression ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Human ', ' Modern Man ', ' Human Engineering ', ' Human Genetics ', ' In Vitro ', ' Learning ', ' Libraries ', ' Methods ', ' Polyribosomes ', ' Polysomes ', ' Production ', ' Proteins ', ' Ribosomes ', ' RNA ', ' Non-Polyadenylated RNA ', ' RNA Gene Products ', ' Ribonucleic Acid ', ' RNA Splicing ', ' Splicing ', ' Messenger RNA ', ' mRNA ', ' Role ', ' social role ', ' Testing ', ' Thiouridine ', ' 4-Thiouridine ', ' 4-thio-uridine ', ' Time ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Translating ', ' Genetic Translation ', ' mRNA Translation ', ' Translations ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Measures ', ' RNA-Binding Proteins ', ' Dataset ', ' Data Set ', ' base ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' R-Series Research Projects ', ' R01 Mechanism ', ' R01 Program ', ' Research Grants ', ' Research Projects ', ' Research Project Grants ', ' Therapeutic ', ' machine learned ', ' Machine Learning ', ' Source ', ' Techniques ', ' Performance ', ' stable cell line ', ' ']",NHGRI,UNIVERSITY OF WASHINGTON,R01,2020,473065,WA-07,0.025164868455063327
"Diversity Supplement for Prioritization of Splicing-Altering Genetic Variants in Alzheimer's disease Project Summary The goal of this project is to develop computational pipelines that allow in silico prediction of functional genetic variants that disrupt pre-mRNA splicing and related pathways in Alzheimer's disease (AD). Recently, tremendous success has been achieved in constructing a catalog of genetic variants in AD genomes of various patient cohorts. The next great challenge is to identify causal variants and elucidate their potential function relevant to disease processes. To this end, research efforts have been directed to studying variants located in protein-coding, promoter, and splice site regions due to their apparent impacts on gene expression. However, many of the newly identified disease-associated variants reside in other non-coding regions, such as introns, that may confer regulatory function to the related gene. The mechanisms of these variants have been hard to decipher. It is expected that many of them may function at the post-transcriptional level, thus affecting mRNA expression. In human, a myriad of processes mediate RNA expression at the post-transcriptional stage, one of which being splicing. Splicing is an essential step of mammalian gene expression and alternative splicing affects most human genes. Recent literature reported that RNA splicing is a primary link between GVs and disease. In general, it was estimated that 15-60% of point mutations that result in human genetic diseases disrupt splicing, highlighting the importance of this regulatory step. In AD, aberrant splicing has been detected in many functionally critical genes, some of which are modulated by GVs. Despite the importance, how to accurately identify functional genetic variants in splicing regulation remains a key question in the field. To address this question, the large collection of RNA-Seq and genotyping data sets collected from AD and control subjects represent an invaluable resource. We will develop and apply novel methodologies to make full use of these data sets, complemented by further bioinformatic prediction and experimental validations. This work will allow a previously unattained level of understanding of genetic variants in splicing regulation and provide new means to tackle the imperative task of functional annotations of genetic variants in AD. Project Narrative Alternative splicing can significantly alter gene expression and contribute to Alzheimer's disease (AD) mechanisms. The proposed research aims to develop computational pipelines, aided by experimental validation, to predict functional genetic mutations or polymorphisms that cause splicing changes in AD. This work will provide mechanistic basis for how genetic variations may contribute to AD, such that future interventions can target specific genes therapeutically.",Diversity Supplement for Prioritization of Splicing-Altering Genetic Variants in Alzheimer's disease,10211993,R01AG056476,"['Affect ', ' Alternative Splicing ', ' Alternate Splicing ', ' Alternative RNA Splicing ', "" Alzheimer's Disease "", ' AD dementia ', ' Alzheimer ', ' Alzheimer Type Dementia ', ' Alzheimer disease ', ' Alzheimer sclerosis ', ' Alzheimer syndrome ', "" Alzheimer's "", "" Alzheimer's disease dementia "", ' Alzheimers Dementia ', ' Alzheimers disease ', ' Primary Senile Degenerative Dementia ', ' dementia of the Alzheimer type ', ' primary degenerative dementia ', ' senile dementia of the Alzheimer type ', ' Award ', ' Biology ', ' Complement ', ' Complement Proteins ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Disease ', ' Disorder ', ' Education ', ' Educational aspects ', ' Fellowship ', ' Foundations ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Introns ', ' Intervening Sequences ', ' Literature ', ' Mentorship ', ' Methods ', ' Methodology ', ' Michigan ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' mRNA Precursor ', ' Pre-mRNA ', ' RNA, Messenger, Precursors ', ' premRNA ', ' Parents ', ' Patients ', ' Genetic Polymorphism ', ' polymorphism ', ' Proteins ', ' Research ', ' Resources ', ' Research Resources ', ' RNA ', ' Non-Polyadenylated RNA ', ' RNA Gene Products ', ' Ribonucleic Acid ', ' RNA Splicing ', ' Splicing ', ' Rotation ', ' statistics ', ' Training Activity ', ' training module ', ' Training Support ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Universities ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' RNA-Binding Proteins ', ' Hispanic Populations ', ' Latino Population ', ' Spanish Origin ', ' hispanic community ', ' Hispanics ', ' Mediating ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' base ', ' method development ', ' Site ', ' Area ', ' Solid ', ' Variation ', ' Variant ', ' Link ', ' Ensure ', ' Training ', ' Research Activity ', ' Development Plans ', ' R-Series Research Projects ', ' R01 Mechanism ', ' R01 Program ', ' Research Grants ', ' Research Projects ', ' Research Project Grants ', ' Therapeutic ', ' machine learned ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Postdoc ', ' Research Associate ', ' post-doc ', ' post-doctoral ', ' Postdoctoral Fellow ', ' success ', ' cohort ', ' novel ', ' member ', ' Reporting ', ' RNA Stability ', ' Genetic analyses ', ' genetic analysis ', ' Coding System ', ' Code ', ' Regulation ', ' career development ', ' RNA analysis ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' disease control ', ' disorder control ', ' Bio-Informatics ', ' Bioinformatics ', ' Effectiveness ', ' Address ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Ph.D. ', ' PhD ', ' Doctor of Philosophy ', ' Research Training ', ' mRNA Expression ', ' Collection ', ' Validation ', ' Process ', ' pathway ', ' Pathway interactions ', ' Genetic Annotation ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' parent grant ', ' undergraduate ', ' undergraduate student ', ' Ph D student ', ' Ph D. student ', ' Ph. D. student ', ' Ph.D student ', ' Ph.D. student ', ' PhD student ', ' PhD. student ', ' doctoral student ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' learning activity ', ' learning method ', ' learning strategy ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' deep learning ', ' autoencoding neural network ', ' autoencoder ', ' causal allele ', ' causal gene ', ' causal mutation ', ' causative mutation ', ' causative variant ', ' causal variant ', ' in silico ', ' computational pipelines ', ' statistical and machine learning ', ' machine learning method ', "" Alzheimer's patient "", "" Alzheimer's disease patient "", ' ']",NIA,UNIVERSITY OF CALIFORNIA LOS ANGELES,R01,2020,60567,CA-33,0.00811530428620764
"Leveraging Common Fund data for feature selection in Kids First studies. Project Abstract This project will pilot a process for identifying multi-variant interactions contributing structural birth defect and childhood cancer disorders. This study will focus on analysis of oral-facial clefts, congenital diaphragmatic hernia, and congenital heart defects from whole-genome sequencing (WGS) data from family cohorts taken from Gabriella Miller Kids First Pediatric Research Project (KF).  Typically, tests to link disorders to genome-wide complex multivariate associations are computationally prohibitive. Thus, a first step to making such analyses more reasonable is to limit the number of variables (genes, variants) being tested together. We can reduce the number of possible tests by restricting what data should be tested. This study will seek to reduce the data for testing by utilizing biological knowledge from other two Common Fund datasets: the Knockout Mouse Phenotyping Program (KOMP2), and the Genotype-Tissue Expression (GTEx) project. KOMP2 has generated extensive information on mouse knockout developmental phenotypes relevant for matching gene and phenotypes in KF WGS studies. GTEx can be merged with KF loci and relevant tissue-to-phenotype relationships. Thus, using features from other Common Fund data and annotations, we can generate selected subsets of KF variants and genes as feature-reduced KF data.  A comprehensive machine learning (ML) analysis pipeline will then be utilized for the identification of candidate risk factors and characterization of complex patterns of association between these feature-reduced KF data. In addition to performing the more traditional univariate association analyses of genotype vs. phenotype, this pipeline will also identify complex associations including (1) context-dependent genetic effects resulting from non-additive multi-variant interactions, i.e. epistasis, and (2) subgroup-specific associations, i.e. by phenotype and genotypic heterogeneity, where different etiological paths lead to the same/similar phenotypes in the selected KF subject group. This pipeline will include feature selection, modeling, and interpretation of multi-variant interactions.  The outcomes of this study will include (1) pipelines for integrating Common Fund data into Kids First datasets, (2) integrated KF-KOMP2-GTEx datasets including cross-species integration, (3) ML pipelines for multi-variant interaction analyses of phenotype vs genotype in selected, reduced-feature KF data, and (4) results from the aforementioned pipelines for multi-variant interactions for later hypothesis testing. Project Abstract This project will pilot a process for identifying interactions between genetic variants that contribute to structural birth defect and childhood cancer disorders by combining data from the Gabriella Miller Kids First Pediatric Research Project with biological knowledge from other two Common Fund datasets: the Knockout Mouse Phenotyping Program (KOMP2), and the Genotype-Tissue Expression (GTEx) project. By selective use of this merged data within machine-learning pipelines, we will produce novel genetic analysis methods for studying complex variant interactions that may contribute to these childhood disorders.",Leveraging Common Fund data for feature selection in Kids First studies.,10112014,R03OD030600,"['Anatomy ', ' Anatomic ', ' Anatomic Sites ', ' Anatomic structures ', ' Anatomical Sciences ', ' Biology ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Child ', ' 0-11 years old ', ' Child Youth ', ' Children (0-21) ', ' children ', "" childrens' "", ' youngster ', ' Cohort Studies ', ' Concurrent Studies ', ' Disease ', ' Disorder ', ' Genetic Epistasis ', ' Epistasis ', ' Epistatic Deviation ', ' Interaction Deviation ', ' epistatic relationship ', ' gene x gene interaction ', ' genetic epistases ', ' Face ', ' faces ', ' facial ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Grant ', ' Heart ', ' Congenital Heart Defects ', ' Congenital Cardiac Defects ', ' congenital cardiac anomalies ', ' Heterogeneity ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Methods ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Phenotype ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Risk ', ' Risk Factors ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Work ', ' Dataset ', ' Data Set ', ' analytical method ', ' base ', ' Variation ', ' Variant ', ' Biological ', ' KO mice ', ' Knock-out Mice ', ' Null Mouse ', ' Knockout Mice ', ' Link ', ' pediatric ', ' Childhood ', ' insight ', ' Congenital diaphragmatic hernia ', ' Individual ', ' Recovery ', ' Data Bases ', ' data base ', ' Databases ', ' Funding ', ' R-Series Research Projects ', ' R01 Mechanism ', ' R01 Program ', ' Research Grants ', ' Research Projects ', ' Research Project Grants ', ' Childhood Cancers ', ' Malignant Childhood Tumor ', ' Malignant Pediatric Neoplasm ', ' Malignant Pediatric Tumor ', ' Malignant childhood cancer ', ' cancer in a child ', ' cancer in children ', ' child with cancer ', ' childhood malignancy ', ' children with cancer ', ' pediatric cancer ', ' pediatric malignancy ', ' Malignant Childhood Neoplasm ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' programs ', ' Complex ', ' Oral ', ' Source ', ' Pattern ', ' Outcome Study ', ' interest ', ' Services ', ' gene interaction ', ' Performance ', ' QTL ', ' Quantitative Trait Loci ', ' cohort ', ' knockout gene ', ' novel ', ' Agreement ', ' Graph ', ' Genetic analyses ', ' genetic analysis ', ' Modeling ', ' performance tests ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' genome sequencing ', ' Data ', ' randomisation ', ' randomization ', ' randomly assigned ', ' Randomized ', ' Subgroup ', ' Ontology ', ' Pediatric Research ', ' Knockout ', ' Knock-out ', ' Process ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' meta data ', ' Metadata ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' data integration ', ' Population ', ' genome scale ', ' genomewide ', ' genome-wide ', ' candidate identification ', ' dbGaP ', ' database of Genotypes and Phenotypes ', ' Drug Targeting ', ' Structural Birth Defect ', ' congenital structural malformation ', ' Structural Congenital Anomalies ', ' rare allele ', ' rare variant ', ' Cardiac Abnormalities ', ' Cardiac Malformation ', ' Cardiac defect ', ' Heart Malformation ', ' heart defect ', ' Heart Abnormalities ', ' phenotypic data ', ' GTEx ', ' Genotype-Tissue Expression Project ', ' entire genome ', ' full genome ', ' whole genome ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' data resource ', ' analysis pipeline ', ' large scale data sets ', ' large scale datasets ', ' large scale data ', ' complex data  ', ' statistical and machine learning ', ' feature selection ', ' gene locus ', ' genetic locus ', ' genomic locus ', ' ']",OD,CHILDREN'S HOSP OF PHILADELPHIA,R03,2020,363306,PA-03,0.0730460105240889
"Integrated Clinical and Transcriptomic Profiling to Characterize Disease Phenotype PROJECT SUMMARY Exome and whole-genome sequencing are becoming increasingly routine approaches in cancer[1], common disease[2]and rare disease diagnosis.[3] Despite their success, our ability to fully interpret the clinical relevance of personal genome variation remains a significant gap[4-6]. Considering this, the most crucial need is more genotype-phenotype data that link genetic variation with disease causation. The objective of this proposal is to improve the clinical interpretation of genetic variation; in particular, by developing integrative approaches that predict the effect of genetic variation on clinical phenotype. This proposal addresses the hypothesis, supported by preliminary data, that combining patient transcriptomic data with genotypic and clinical data (as opposed to each alone) offers a better mechanistic understanding of disease natural history, from initial presentation to progression. The specific aims are designed such that each independently add substantial functional genomic information, over and above previously available patient genetic data, to further resolve the clinical phenotype. Aim 1 establishes a comprehensive and widely-shared dataset of patient transcriptomic (and genetic) variation across multiple cancer, cardiovascular and thrombosis/bleeding phenotypes, in patients with somatically-acquired myeloproliferative neoplasms (MPN) and select other rare heritable blood diseases (HBD). Aim 2 methodically determines differential RNA expression and processing between clinically-relevant subgroups of MPN and HBD patients. Aim 3 brings these elements together  and applies two integrative Bayesian and machine learning approaches, RIVER[24] (RNA-informed variant effect on regulation) and LASSO[25] (Least Absolute Shrinkage and Selection Operator), to resolve the functional and clinical relevance of rare variants; and identify signatures most predictive of disease risk or progression. Completion of these aims will contribute new scientific knowledge on how integrating transcriptomic data improves clinical genomic analyses in other genetic (and rare) diseases. In addition, this project will enable the Principal Investigator to develop expertise in the informatics and data science aspects of genomic medicine that complement her current background in biophysics, biochemistry and translational hematology. Combined with additional informatics training at Stanford University through coursework, seminars, one-on-one advising from project mentors, and interactions with the wider statistics, bioinformatics and genomics communities, this project will prepare the Principal Investigator to launch an independent academic career in genomic medicine. PROJECT NARRATIVE Accurate clinical interpretation of genetic variation in personal genome data is an essential component of personalized medicine approaches and the precise genetic diagnosis toward achieving improved public health. This project will integrate genetic and clinical modifiers with functional genomic information (RNA sequencing) from adequately-powered, disease-relevant cells; and provide direct insight into transcriptional perturbations caused by genetic variation.",Integrated Clinical and Transcriptomic Profiling to Characterize Disease Phenotype,9948713,K08HG010061,"['Adult ', ' 21+ years old ', ' Adult Human ', ' adulthood ', ' Age Factors ', ' Alleles ', ' Allelomorphs ', ' Alternative Splicing ', ' Alternate Splicing ', ' Alternative RNA Splicing ', ' Biochemistry ', ' Biological Chemistry ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Blood ', ' Blood Reticuloendothelial System ', ' Blood Cells ', ' Peripheral Blood Cell ', ' Blood Platelets ', ' Marrow platelet ', ' Platelets ', ' Thrombocytes ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cardiovascular system ', ' Cardiovascular ', ' Cardiovascular Body System ', ' Cardiovascular Organ System ', ' Heart Vascular ', ' circulatory system ', ' Cells ', ' Cell Body ', ' Communities ', ' Complement ', ' Complement Proteins ', ' Demographic Factors ', ' Disease ', ' Disorder ', ' Elements ', ' Foundations ', ' Future ', ' Gene Expression ', ' Gene Fusion ', ' Medical Genetics ', ' Clinical genetics ', ' Genome ', ' Genotype ', ' Hematological Disease ', ' Blood Diseases ', ' Hematologic Diseases ', ' Hematological Disorder ', ' blood disorder ', ' Hematology ', ' Hemorrhage ', ' Bleeding ', ' blood loss ', ' Laboratories ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Mentors ', ' Mentorship ', ' Methods ', ' Myeloproliferative disease ', ' Myeloid Disease ', ' Myeloid Malignancy ', ' Myeloid Neoplasm ', ' Myeloid Tumor ', ' Myeloproliferative Disorders ', ' Myeloproliferative Tumors ', ' myeloproliferative neoplasm ', ' Patients ', ' Phenotype ', ' Public Health ', ' Reference Standards ', ' Resources ', ' Research Resources ', ' RNA ', ' Non-Polyadenylated RNA ', ' RNA Gene Products ', ' Ribonucleic Acid ', ' statistics ', ' Thrombosis ', ' thrombotic disease ', ' thrombotic disorder ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Universities ', ' Genetic Variation ', ' Genetic Diversity ', ' Gender ', ' Lasso ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' career ', ' Blood Sample ', ' Blood specimen ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Link ', ' Evaluation ', ' Training ', ' insight ', ' Data Bases ', ' data base ', ' Databases ', ' Disease Progression ', ' Genetic Heterogeneity ', ' Dysfunction ', ' Physiopathology ', ' pathophysiology ', ' Functional disorder ', ' Genetic ', ' Rivers ', ' Whole Blood ', ' Knowledge ', ' Investigation ', ' Severities ', ' System ', ' experience ', ' genetic diagnosis ', ' genetic disorder diagnosis ', ' Performance ', ' Isoforms ', ' Protein Isoforms ', ' success ', ' cohort ', ' knowledgebase ', ' knowledge base ', ' Informatics ', ' disease natural history ', ' Orphan Disease ', ' Rare Disorder ', ' orphan disorder ', ' Rare Diseases ', ' novel ', ' disease risk ', ' disorder risk ', ' Gene Expression Monitoring ', ' Gene Expression Pattern Analysis ', ' Transcript Expression Analyses ', ' Transcript Expression Analysis ', ' gene expression analysis ', ' gene expression assay ', ' transcriptional profiling ', ' Gene Expression Profiling ', ' Regulation ', ' Modeling ', ' Sampling ', ' functional genomics ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' RNA Processing ', ' BMI percentile ', ' BMI z-score ', ' Quetelet index ', ' Body mass index ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' genome sequencing ', ' Address ', ' Data ', ' Research Training ', ' Subgroup ', ' Clinical Data ', ' Other Genetics ', ' Differential Gene Expression ', ' Tissue-Specific Differential Gene Expression ', ' Tissue-Specific Gene Expression ', ' Validation ', ' Principal Investigator ', ' Process ', ' clinical phenotype ', ' disease phenotype ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' data integration ', ' designing ', ' design ', ' Outcome ', ' prospective ', ' Heritability ', ' transcriptomics ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' informatics training ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' disease diagnosis ', ' biorepository ', ' biobank ', ' exomes ', ' exome ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' rare allele ', ' rare variant ', ' Bayesian adaptive designs ', ' Bayesian adaptive models ', ' Bayesian belief network ', ' Bayesian belief updating model ', ' Bayesian framework ', ' Bayesian hierarchical model ', ' Bayesian network model ', ' Bayesian nonparametric models ', ' Bayesian spatial data model ', ' Bayesian spatial image models ', ' Bayesian spatial models ', ' Bayesian statistical models ', ' Bayesian tracking algorithms ', ' Bayesian Modeling ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' unclassified variant ', ' variant of uncertain clinical significance ', ' variant of uncertain significance ', ' variant of undetermined significance ', ' variant of unknown significance ', ' Data Science ', ' global gene expression ', ' global transcription profile ', ' transcriptome ', ' Genomic medicine ', ' stratified patient ', ' patient stratification ', ' phenotypic data ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' entire genome ', ' full genome ', ' whole genome ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' Disease stratification ', ' cancers that are rare ', ' rare malignancy ', ' rare tumor ', ' rare cancer ', ' Bayesian machine learning ', ' Bayesian learning ', ' regression algorithm ', ' driver mutation ', ' ']",NHGRI,STANFORD UNIVERSITY,K08,2020,190941,CA-18,0.06321286340922413
"Comprehensive Characterization of Missense Mutants in Factor IX SUMMARY Deficiencies in coagulation factor IX (FIX) cause the bleeding disorder hemophilia B, while high levels of FIX pose a risk for thrombosis. Thus, genetic variation in the F9 gene encoding FIX can impact bleeding by decreasing FIX expression or activity, or can impact thrombosis by increasing FIX expression or activity. However, when a new DNA variant is discovered in the F9 gene, we typically lack the evidence needed to confidently determine if the variant alters the function of the encoded FIX protein and, if so, how severely. For example, in the national hemophilia genotyping project MyLifeOurFuture, the majority of F9 missense variants (i.e. DNA changes predicted to change a FIX amino acid) discovered in patients with hemophilia B had insufficient evidence to be classified as pathogenic. Functional studies, where a FIX variants stability, activity or other properties are evaluated in vitro, can provide strong evidence to inform interpretation of F9 variants. However, traditional functional studies are time- and resource-intensive, so testing the hundreds of F9 variant we have observed so far would be impractical. Evaluating the thousands of possible FIX missense variants we could observe as more individuals are sequenced would be impossible. Instead, we propose a new approach to express and characterize nearly every possible missense variant in the FIX protein to advance our understanding of FIX biology, improve the interpretation of genetic variation in the F9 gene, and advance hemophilia care and treatments. To accomplish this goal, we will employ deep mutational scanning, a method we developed for measuring the effects of massive numbers of missense variants of a protein simultaneously. Here, we will display a library of nearly all possible FIX missense variants tethered to the surface of cultured human cells. We propose to exploit this FIX surface display library in two aims: 1) Quantifying the effect of nearly every possible F9 missense variant on FIX expression and secretion, and 2) Quantifying the effect of nearly every possible F9 missense variant on specific FIX functions including Gla-domain gamma-carboxylation and activation of FIX by factor XIa (FXIa). These aims will reveal how nearly all possible missense variants in FIX impact expression, secretion, gamma- carboxylation, and activation by FXIa. In aim 3, we will use these large-scale functional data to dissect the mechanism by which F9 pathogenic variants disrupt FIX function. We will also use machine learning, leveraging the functional data along with other features to predict pathogenicity for each missense variant in FIX. Taken together, the functional data we generate, the analyses we propose, and tools we build will transform the characterization of F9 variants. They will also serve as a resource to better understand FIX biology, improve the clinical translation of F9 genetic information, and inform new treatments. NARRATIVE DNA changes that affect the F9 gene that makes coagulation factor IX (FIX) can reduce FIX levels and cause the bleeding disorder hemophilia B, or increase the amount of active FIX and increase the risk of thrombosis. Although hundreds of variants have been detected in the F9 gene, there is often insufficient information to know how any one specific change will affect the protein, if that change will cause disease, or how severe disease will likely be. We will use new technologies to study the consequences of every possible amino acide change in FIX, with the goal of developing the information needed to understand the significance of new genetic changes as they are discovered in the future and to improve the care and treatment of patients.",Comprehensive Characterization of Missense Mutants in Factor IX,9946710,R01HL152066,"['Affect ', ' Amino Acids ', ' aminoacid ', ' Antibodies ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Blood Coagulation Disorders ', ' Coagulation Disorder ', ' Coagulopathy ', ' bleeding disorder ', ' clotting disorder ', ' Cells ', ' Cell Body ', ' Hemophilia B ', ' Christmas Disease ', ' Factor IX Deficiency ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Factor IX ', ' Autoprothrombin II ', ' Blood Coagulation Factor IX ', ' Christmas Factor ', ' Coagulation Factor IX ', ' EC 3.4.21.22 ', ' Factor IX Complex ', ' Factor IX Fraction ', ' Plasma Thromboplastin Component ', ' antihemophilic factor B ', ' thromboplastinogen B ', ' Factor XIa ', ' Activated Blood Coagulation Factor XI ', ' Activated Factor XI ', ' Coagulation Factor XIa ', ' Contact Activation Product ', ' Fluorescence ', ' Fluorescent Antibody Technique ', "" Coon's Technic "", "" Coon's Technique "", ' Fluorescent Antibody Technic ', ' Fluorescent Antinuclear Antibody Test ', ' Immunofluorescence Technic ', ' Immunofluorescence Technique ', ' fluorescent antibody ', ' Future ', ' Genotype ', ' Goals ', ' Hemophilia A ', ' Factor VIII Deficiency ', ' Hemophilia ', ' Hemorrhage ', ' Bleeding ', ' blood loss ', ' Hemostatic function ', ' Hemostasis ', ' Human ', ' Modern Man ', ' In Vitro ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Libraries ', ' Methods ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Peptides ', ' Production ', ' Proteins ', ' Research ', ' Resources ', ' Research Resources ', ' Risk ', ' Technology ', ' Testing ', ' Thrombosis ', ' thrombotic disease ', ' thrombotic disorder ', ' Time ', ' Translating ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Measures ', ' Factor Analyses ', ' Factor Analysis ', ' Dataset ', ' Data Set ', ' Caring ', ' DNA Sequence ', ' Comprehension ', ' base ', ' carboxylation ', ' Label ', ' improved ', ' Surface ', ' Variation ', ' Variant ', ' Individual ', ' tool ', ' machine learned ', ' Machine Learning ', ' Clinic ', ' System ', ' mutant ', ' Structure ', ' novel technologies ', ' new technology ', ' Cell surface ', ' sorting ', ' Sorting - Cell Movement ', ' Modeling ', ' Property ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' Clotting ', ' Coagulation ', ' Coagulation Process ', ' F9 gene ', ' Data ', ' Mammalian Cell ', ' Validation ', ' Molecular ', ' developmental ', ' Development ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' new approaches ', ' novel approaches ', ' novel strategy ', ' novel strategies ', ' new drug treatments ', ' new drugs ', ' new therapeutics ', ' new therapy ', ' next generation therapeutics ', ' novel drug treatments ', ' novel drugs ', ' novel therapy ', ' novel therapeutics ', ' gain of function ', ' High-Throughput DNA Sequencing ', ' genetic information ', ' Genetic study ', ' mutation scanning ', ' mutation screening ', ' experiment ', ' experimental research ', ' experimental study ', ' clinical translation ', ' ']",NHLBI,BLOODWORKS,R01,2020,418577,WA-07,0.20821203968321292
"Integrative approaches to identification and interpretation of genes underlying psychiatric disorders Psychiatric disorders contribute substantially to the disease burden in the United States and worldwide. There is strong evidence for a genetic contribution to many psychiatric illnesses. In recent years, with the advancement of high throughput genomic technologies and the availability of large samples, remarkable success has been made in risk gene discovery for major psychiatric disorders [e.g., schizophrenia (SCZ), bipolar disorder (BD) and major depressive disorder (MDD)] through genome-wide association studies (GWAS). However, due to the high complexity of the human genome, few causal genes or variants have been identified within GWAS risk loci, thus, to date, limiting the potential of translating these genetic findings into biological mechanisms. There is now a great need to pinpoint causal genes/variants at the known GWAS risk loci and to understand their causal mechanisms, as well as to discover novel genes from novel risk loci. There is also growing evidence that risk variants from GWAS tend to be located in regulatory DNA regions in disease-relevant tissues or cell types, suggesting that risk variants may act through regulation of gene expression. Studies leveraging diverse functional genomic resources may benefit psychiatric risk gene discovery and result in better prediction of their biological relevance. This proposal aims to employ highly integrative approaches to identify causal genes and regulatory noncoding variants underlying SCZ, BD, and MDD. Our specific aims are: 1) Integrate GWAS with brain methylome for risk gene discovery, by leveraging a dense high-resolution reference panel of DNAm from whole genome bisulfite sequencing of DNA from three different brain regions (frontal cortex, hippocampus, and caudate) and an enlarged array-based reference panel; 2) Apply a deep learning approach to predicting disease-relevant regulatory variants, by employing features from disease-relevant gene regulatory networks and functional genomic annotations within brain tissues and neural cell types; and 3) Map prioritized genes and variants to specific brain cell types and brain function. We have assembled an outstanding multidisciplinary team with expertise in psychiatric genetics, bioinformatics, machine learning, and neuroimaging. Our goal is to apply multidisciplinary and cutting-edge analytical strategies to help address the challenges arising in the post-GWAS era. The identification and characterization of risk genes and noncoding regulatory variants would help improve our understanding of the biological mechanisms that underlie psychiatric illnesses, moving us closer to designing effective prevention and treatment for these disorders. Project Narrative: This proposal takes integrative approaches to prioritizing genes and noncoding variants underlying psychiatric disorders through better leveraging functional genomic resources to predict their biological relevance. The identification and characterization of potential causal genes would help improve our understanding of the biological mechanisms underlying psychiatric disorders, moving us closer to designing effective prevention and treatment.",Integrative approaches to identification and interpretation of genes underlying psychiatric disorders,10049302,R01MH121394,"['Affect ', ' Mental disorders ', ' Mental health disorders ', ' Psychiatric Disease ', ' Psychiatric Disorder ', ' mental illness ', ' psychiatric illness ', ' psychological disorder ', ' Bipolar Disorder ', ' Bipolar Affective Psychosis ', ' Manic-Depressive Psychosis ', ' bipolar affective disorder ', ' bipolar disease ', ' bipolar illness ', ' manic depressive disorder ', ' manic depressive illness ', ' Brain ', ' Brain Nervous System ', ' Encephalon ', ' Cell Nucleus ', ' Nucleus ', ' Cells ', ' Cell Body ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' frontal lobe ', ' frontal cortex ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Hippocampus (Brain) ', ' Ammon Horn ', ' Cornu Ammonis ', ' Hippocampus ', ' hippocampal ', ' Maps ', ' Short-Term Memory ', ' Immediate Memory ', ' Shortterm Memory ', ' working memory ', ' Methylation ', ' Neurons ', ' Nerve Cells ', ' Nerve Unit ', ' Neural Cell ', ' Neurocyte ', ' neuronal ', ' Psychotic Disorders ', ' Psychoses ', ' psychotic illness ', ' Resources ', ' Research Resources ', ' RNA Splicing ', ' Splicing ', ' Schizophrenia ', ' Schizophrenic Disorders ', ' dementia praecox ', ' schizophrenic ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' statistics ', ' Technology ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Translating ', ' United States ', ' Weight ', ' Work ', ' Enhancers ', ' promotor ', ' promoter ', ' psychiatric genetics ', ' psychogenetics ', ' Prefrontal Cortex ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Link ', ' insight ', ' Gene Targeting ', ' Sample Size ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' DNA Methylation ', ' cognitive function ', ' postnatal ', ' cell type ', ' brain tissue ', ' Affective Disorders ', ' Mood Disorders ', ' brain cell ', ' success ', ' trait ', "" 5'UTR "", ' mRNA Leader Sequences ', "" 5' Untranslated Regions "", "" 3'UTR "", "" 3' Untranslated Regions "", ' neuro-imaging ', ' neuroimaging ', ' novel ', ' Prevention ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' functional genomics ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' Transcription Regulation ', ' Transcriptional Control ', ' Transcriptional Regulation ', ' clinical depression ', ' major depression ', ' major depression disorder ', ' Major Depressive Disorder ', ' Brain region ', ' genetic association ', ' Address ', ' Data ', ' randomisation ', ' randomization ', ' randomly assigned ', ' Randomized ', ' Resolution ', ' Genetic Risk ', ' Scheme ', ' Differential Gene Expression ', ' Tissue-Specific Differential Gene Expression ', ' Tissue-Specific Gene Expression ', ' developmental ', ' Development ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' burden of disease ', ' disease burden ', ' years of life lost to disability ', ' years of life lost to disease ', ' burden of illness ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' designing ', ' design ', ' innovate ', ' innovative ', ' innovation ', ' Heritability ', ' multidisciplinary ', ' discover genes ', ' gene discovery ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' Risk-associated variant ', ' risk allele ', ' risk gene ', ' risk genotype ', ' risk loci ', ' risk locus ', ' risk variant ', ' methylome ', ' BS-seq ', ' Bisulfite-based sequencing ', ' bisulfite-seq ', ' bisulfite sequencing ', ' entire genome ', ' full genome ', ' whole genome ', ' data resource ', ' DNA seq ', ' DNAseq ', ' DNA sequencing ', ' deep learning based neural network ', ' deep learning neural network ', ' deep neural net ', ' deep neural network ', ' deep learning ', ' supervised machine learning ', ' supervised learning ', ' causal allele ', ' causal gene ', ' causal mutation ', ' causative mutation ', ' causative variant ', ' causal variant ', ' psychiatric genomics ', ' polygenic risk score ', ' ']",NIMH,"LIEBER INSTITUTE, INC.",R01,2020,647274,MD-07,0.05285225119141758
"Uncovering the Genetic Mechanisms Behind Joint-Specific Osteoarthritis Project Summary/Abstract In the United States, the joint disease osteoarthritis (OA) debilitates over one-third of people over sixty-five years old and causes hundreds of thousands of knee replacements annually. Despite its high prevalence, little is known about the molecular mechanisms that regulate knee formation and OA risk and how one inherits risk at specific joints (e.g., knee versus hip). Recent GWAS have identified at least seventeen loci that significantly associate with knee OA risk. However, the casual variants for these loci have not been identified because their association signals span large genomic intervals harboring uninvestigated non-coding regulatory regions. Of these, common variants in the Growth Differentiation Factor Five gene (GDF5), a critical regulator of joint development, reproducibly associate with knee OA risk in human populations. GDF5 OA variants reside on a high frequency 130 kb haplotype possessing numerous mutations that each may be causal for OA risk, but interestingly, no protein coding mutations have been uncovered that explain the associations. In a complementary study, we discovered ten GDF5 regulatory elements (e.g., promoters, enhancers) spanning this interval and revealed that they function with tremendous joint specificity (e.g., knee vs. hip). These enhancers were initially tested at incipient stages of GDF5 expression in mouse embryos, but we also know that GDF5 contributes to the differentiation of knee structures (ligaments, tendons, menisci, articular surfaces) well after this stage of development. Our research will bring together knee OA risk variants in patient populations and our knowledge of how GDF5 is controlled at the DNA level. We first aim to assess the functional contributions of joint-specific GDF5 enhancers to pre-natal knee development and adult joint homeostasis using CRISPR-Cas9 editing to excise these elements in vitro in human cells and in vivo in the mouse. Strikingly, our pilot analyses also revealed that a subset of these GDF5 enhancers possesses common and rare human variants in strong linkage disequilibrium with the highest associated OA variants in the interval. Our second aim is to further explore the association between genetic variants in the locus and OA knee shape using data acquired from the complete Osteoarthritis Initiative MR database on adult knees. Our preliminary data reveal that several variants associated with OA knee shape reside in several functional enhancers that control expression of GDF5 in the knee. Finally, our third aim is to functionally test these human regulatory variants for their impact on enhancer activity, knee formation, and OA risk by using transfection studies and CRISPR-Cas9 in human cartilage cells and in the mouse model. Completion of these studies will reveal functional variants in GDF5 that underlie its role in knee shape and OA risk. Project Narrative The Growth Differentiation Factor Five (GDF5) gene is the most reproducibly detected gene region in candidate and genome-wide association studies focusing on knee osteoarthritis risk. The proposed research focuses on (1) assessing the specific functions of key GDF5 regulatory sequences in knee development and cartilage maintenance in mice and humans, (2) the association of genetic variants in GDF5 locus with osteoarthritis knee shape, and (3) the impacts that human GDF5 risk mutations have on chondrocyte and joint biology.",Uncovering the Genetic Mechanisms Behind Joint-Specific Osteoarthritis,9951002,R01AR070139,"['Adult ', ' 21+ years old ', ' Adult Human ', ' adulthood ', ' Affect ', ' Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Anatomy ', ' Anatomic ', ' Anatomic Sites ', ' Anatomic structures ', ' Anatomical Sciences ', ' Architecture ', ' Engineering / Architecture ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Cartilage ', ' Cartilaginous Tissue ', ' Cells ', ' Cell Body ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Elements ', ' Embryo ', ' Embryonic ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Haplotypes ', ' Hip region structure ', ' Coxa ', ' Hip ', ' Homeostasis ', ' Autoregulation ', ' Physiological Homeostasis ', ' Human ', ' Modern Man ', ' In Vitro ', ' arthropathies ', ' Joint Diseases ', ' arthropathic ', ' arthropathy ', ' joint disorder ', ' Joints ', ' Knee ', ' Knee joint ', ' Ligaments ', ' Linkage Disequilibrium ', ' Maintenance ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Degenerative polyarthritis ', ' Degenerative Arthritis ', ' Osteoarthritis ', ' Osteoarthrosis ', ' degenerative joint disease ', ' hypertrophic arthritis ', ' osteoarthritic ', ' Patients ', ' Pregnancy ', ' Gestation ', ' Proteins ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Research ', ' Risk ', ' Role ', ' social role ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Specificity ', ' Tendon structure ', ' Tendons ', ' Testing ', ' Transfection ', ' United States ', ' Veins ', ' Work ', ' Enhancers ', ' Knee arthroplasty ', ' Knee joint replacement operation ', ' Knee replacement ', ' Total Knee Replacement ', ' total knee arthroplasty ', ' knee replacement arthroplasty ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' Arthroplasty ', ' Joint Prosthesis Implantation ', ' joint arthroplasty ', ' joint replacement ', ' Replacement Arthroplasty ', ' Surface ', ' Variation ', ' Variant ', ' Susceptibility ', ' Predisposition ', ' Meniscus ', ' Meniscus structure of joint ', ' cartilage cell ', ' Chondrocytes ', ' disability ', ' Individual ', ' Data Bases ', ' data base ', ' Databases ', ' Genetic ', ' Morphology ', ' Shapes ', ' Reporter ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Life ', ' knee OA ', ' knee joint OA ', ' knee joint osteoarthritis ', ' Knee Osteoarthritis ', ' Dimensions ', ' Frequencies ', ' Hereditary ', ' Inherited ', ' Pattern ', ' Structure ', ' unborn ', ' prenatal ', ' novel ', ' disease risk ', ' disorder risk ', ' Reporting ', ' Coding System ', ' Code ', ' Modeling ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' genetic association ', ' Defect ', ' Data ', ' Differentiation and Growth ', ' High Prevalence ', ' Regulatory Element ', ' in vivo ', ' Molecular ', ' developmental ', ' Development ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' Population ', ' Prevalence ', ' 5 years of age ', ' age 5 years ', ' five year old ', ' five years of age ', ' 5 year old ', ' Predisposition gene ', ' predisposing gene ', ' susceptibility allele ', ' susceptibility locus ', ' susceptibility variant ', ' Susceptibility Gene ', ' murine model ', ' mouse model ', ' spatiotemporal ', ' patient population ', ' in vitro activity ', ' Risk-associated variant ', ' risk allele ', ' risk gene ', ' risk genotype ', ' risk loci ', ' risk locus ', ' risk variant ', ' Geometry ', ' CRISPR method ', ' CRISPR methodology ', ' CRISPR technique ', ' CRISPR technology ', ' CRISPR-CAS-9 ', ' CRISPR-based method ', ' CRISPR-based technique ', ' CRISPR-based technology ', ' CRISPR-based tool ', ' CRISPR/Cas method ', ' CRISPR/Cas9 ', ' CRISPR/Cas9 technology ', ' Cas nuclease technology ', ' Clustered Regularly Interspaced Short Palindromic Repeats method ', ' Clustered Regularly Interspaced Short Palindromic Repeats methodology ', ' Clustered Regularly Interspaced Short Palindromic Repeats technique ', ' Clustered Regularly Interspaced Short Palindromic Repeats technology ', ' CRISPR/Cas technology ', ' entire genome ', ' full genome ', ' whole genome ', ' experiment ', ' experimental research ', ' experimental study ', ' causal allele ', ' causal gene ', ' causal mutation ', ' causative mutation ', ' causative variant ', ' causal variant ', ' gene locus ', ' genetic locus ', ' genomic locus ', ' ']",NIAMS,HARVARD UNIVERSITY,R01,2020,597506,MA-05,0.11986487891546534
"Novel statistical methods and tools to integrate multiple endophenotypes and functional annotation data to study the roles of rare variants in complex human diseases using sequencing data Project Summary In the past fifteen years, great efforts have been made to understand the genetic architecture of complex human diseases through genome-wide association studies. Although many genome-wide significant variants have been identified, the heritability or variance explained by these variants remains very small, suggesting substantial missing heritability that may yet be explained by common genetic variants with smaller effect sizes and/or rare and low frequency variants, which calls for the development and application of novel statistical methods to whole genome/exome sequencing data collected from deeply phenotyped cohorts. In this project, we will develop methods that leverage multiple correlated endophenotypes and further integrate functional annotation data to identify novel rare variants for complex traits. We will develop a set of new computational and analytical tools that are practically useful and broadly applicable to general sequencing studies, and the applications of our methods will likely identity novel rare variant associations and shed new lights on the genetics of cardiometabolic diseases. In Aim 1, we propose to develop novel statistical methods to integrate multiple endophenotypes to study the impact of rare variants on complex human diseases. Our methods will fill in the gap between the current practice of association studies and the practical needs of integrating endophenotypes for improved understanding and diagnosis of clinical outcomes. In Aim 2, we will extend the methods to meta-analyses across studies. In Aim 3, we will develop a novel kernel machine learning approach to integrating various functional information to annotate the whole genome region, and further integrate them to develop a dynamic whole-genome scan test to detect rare variant associations with multiple endophenotypes. We will leverage the NHLBI TOPMed whole genome sequencing (WGS) data and the UK Biobank whole exome sequencing (WES) data, and integrate the functional annotation data to identify and dissect the role of rare variants on the cardiometabolic traits (Aim 4). Our proposed work is cost-effective as it leverages the existing WGS/WES samples and functional annotation data while providing methods and tools that are broadly applicable to other studies, and builds on a strong team of scientists with proven track record in statistical genetics, large-scale genetic studies, and cardiometabolic traits. We expect our methods will lead to the discoveries of many more rare and low frequency variants for these traits. These results will offer new insights to help design more effective treatment and prevention strategies. All our proposed methods will be disseminated to the public through well-tested and publicly available software (Aim 5). Project Narrative We will develop statistical methods and computational software to analyze whole genome/exome sequencing data by integrating multiple phenotypes and functional annotations to identify novel genes associated with cardiometabolic diseases and allow researchers to better disentangle the impacts of rare variants on these complex human diseases. It will also facilitate the translation of basic research findings into clinical studies.",Novel statistical methods and tools to integrate multiple endophenotypes and functional annotation data to study the roles of rare variants in complex human diseases using sequencing data,9972090,R01GM134005,"['Cardiovascular Diseases ', ' cardiovascular disorder ', ' Clinical Research ', ' Clinical Study ', ' Disease ', ' Disorder ', ' Genes ', ' Human ', ' Modern Man ', ' Metabolic Diseases ', ' Metabolic Disorder ', ' Thesaurismosis ', ' metabolism disorder ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Phenotype ', ' Play ', ' Public Health ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Role ', ' social role ', ' Computer software ', ' Software ', ' Software Tools ', ' Computer Software Tools ', ' Testing ', ' Time ', ' Translations ', ' Work ', ' Measures ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Biological ', ' insight ', ' ER Positive ', ' ER+ ', ' Estrogen receptor positive ', ' Genetic ', ' clinical Diagnosis ', ' tool ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' programs ', ' Scientist ', ' Frequencies ', ' Complex ', ' Source ', ' experience ', ' cohort ', ' trait ', ' novel ', ' Preventative strategy ', ' Preventive strategy ', ' Prevention strategy ', ' Basic Research ', ' Basic Science ', ' Statistical Methods ', ' Modeling ', ' Sampling ', ' Meta-Analysis ', ' genome sequencing ', ' Address ', ' Data ', ' genome-wide scan ', ' genomewide scan ', ' whole-genome scan ', ' Genome Scan ', ' Large-Scale Sequencing ', ' developmental ', ' Development ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' website ', ' web site ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' Outcome ', ' cost effective ', ' Heritability ', ' analytical tool ', ' endophenotype ', ' human disease ', ' treatment strategy ', ' effective treatment ', ' effective therapy ', ' genome scale ', ' genomewide ', ' genome-wide ', ' disease diagnosis ', ' biorepository ', ' biobank ', ' exome-seq ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' Genetic study ', ' entire genome ', ' full genome ', ' whole genome ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' cardiometabolic ', ' cardiometabolism ', ' genetic architecture ', ' ']",NIGMS,YALE UNIVERSITY,R01,2020,328257,CT-03,0.16483582594992613
"TOOLS FOR NORMALIZING AND INTERPRETING THE CLINICAL ACTIONABILITY OF GENOMIC VARIANTS PROJECT SUMMARY/ABSTRACT The availability of high-throughput, low-cost sequencing has transformed the landscape of biomedical research by dramatically expanding our capacity to interrogate the sequence of the human genome. Consequently, there has been an explosion of biomedical literature describing the role of specific genomic variants and their impact on human diseases. These advances are bringing sequencing into the clinic to shape clinical practice from the patients genomic content, a paradigm colloquially referred to as genomic or precision medicine. There remain many obstacles to fully realizing our potential in the era of precision medicine. Among them is a recognized need for robust, well-engineered systems that provide knowledge about genomic variants and their role in disease. Ideally, such systems would provide a comprehensive summary of all knowledge that is relevant to the patients unique genomic content. An early bottleneck to realizing precision medicine was that, despite the substantial literature and several established knowledgebases that define interactions between drugs and genes, querying across them was extremely challenging. In response to this need, the Drug-Gene Interaction database (DGIdb, dgidb.org) was developed. Through a combination of automated processing and manual curation, drug-gene interaction information was collected, structured, and connected (normalized) from these diverse sources of data and entered into a database with a user-friendly search interface and an application programming interface (API). However, linking drug and drug-gene interaction concepts across resources remains an extremely challenging task, and aggregated drug-gene interactions are also challenging to represent in a way that highlights the utility of the collected knowledge for precision medicine efforts. This proposal seeks to improve our ability to normalize and interpret drug-gene interactions corresponding to patient genomic variants. We will achieve this goal through two specific aims. First, the DGIdb normalization routines will be improved through incorporation of new content and features. Among these, the DGIdb will support collections of drugs, including combination therapies and drug classes. Also, the DGIdb will have new community submission and curation features, allowing users to incorporate new knowledge into the database. Second, the Variant Interpretation Aggregator database (VIAdb) will be created to normalize knowledge across several disparate sources focused on the clinical interpretations of genomic variants. The VIAdb will operate as a stand-alone web tool and API and will behave as a source of relevant interpretations to DGIdb. Finally, we will develop techniques for automated identification of drug-gene interactions and variant interpretation consensus to assist community curation efforts. If successful, this research will improve breadth and consistency of variant interpretations and drug-gene interactions for precision medicine efforts. PROJECT NARRATIVE This research will improve our ability to interpret genomic variations in human patients in support of precision medicine efforts. Specifically, it will provide web-based tools for identifying potential therapies that specifically target the patients individual genes or variants, and an assessment of the clinical actionability of those drugs.",TOOLS FOR NORMALIZING AND INTERPRETING THE CLINICAL ACTIONABILITY OF GENOMIC VARIANTS,9938666,K99HG010157,"['Biomedical Research ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Client ', ' Clinical Trials ', ' Cohort Studies ', ' Concurrent Studies ', ' Combined Modality Therapy ', ' Multimodal Therapy ', ' Multimodal Treatment ', ' combination therapy ', ' combined modality treatment ', ' combined treatment ', ' multi-modal therapy ', ' multi-modal treatment ', ' Communities ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Engineering ', ' Explosion ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Recording of previous events ', ' History ', ' Human ', ' Modern Man ', ' Literature ', ' Manuals ', ' Methods ', ' Patients ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Suggestion ', ' Work ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Link ', ' Data Bases ', ' data base ', ' Databases ', ' WWW ', ' web ', ' world wide web ', ' Internet ', ' Shapes ', ' tool ', ' machine learned ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' programs ', ' Level of Evidence ', ' Side ', ' Clinic ', ' Source ', ' Techniques ', ' System ', ' Services ', ' gene interaction ', ' cohort ', ' knowledgebase ', ' knowledge base ', ' Structure ', ' novel ', ' Reporting ', ' response ', ' Genomics ', ' drug discovery ', ' drug resource ', ' Data ', ' Resource Development ', ' VICC ', ' The Vanderbilt-Ingram Cancer Center at the Vanderbilt University ', ' Collection ', ' developmental ', ' Development ', ' cost ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' model of data ', ' model the data ', ' modeling of the data ', ' data modeling ', ' designing ', ' design ', ' Clinical assessments ', ' cancer type ', ' user-friendly ', ' web interface ', ' open source ', ' human disease ', ' new drug treatments ', ' new drugs ', ' new therapeutics ', ' new therapy ', ' next generation therapeutics ', ' novel drug treatments ', ' novel drugs ', ' novel therapy ', ' novel therapeutics ', ' tumor ', ' molecular biomarker ', ' molecular marker ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' clinical practice ', ' precision-based medicine ', ' precision medicine ', ' genomic variation ', ' clinically actionable ', ' application program interface ', ' application programming interface ', ' learning activity ', ' learning method ', ' learning strategy ', ' Genomic medicine ', ' individual patient ', ' patient profile ', ' profiles in patients ', ' web application ', ' web app ', ' therapeutic marker ', ' therapeutic biomarker ', ' web-based tool ', ' Visualization ', ' ']",NHGRI,WASHINGTON UNIVERSITY,K99,2020,18900,MO-01,0.1338129295815199
"Leveraging biological pathways, gene networks, and functional annotations to understand the genetic architecture of diseases and complex traits Project Summary  Over the past decade, data generated from genome-wide association studies (GWAS) have been used to analyze heritability of human diseases and complex traits to improve understanding of genetic architecture, including identifying the genetic variants associated with diseases and their effect sizes. These heritability enrichment analyses have revealed underlying biological mechanisms such as regulatory elements involved in disease pathways. This research proposes statistical methods and analysis to formally assess the contribution of biological pathways, gene networks, and re-prioritized functional annotations to the genetic architecture of 94 human diseases and complex traits. Better understanding of disease architecture will improve genome-wide associations and fine mapping and provides robust inference of disease etiology and mechanisms.  The first aim is to determine the contribution of disease-associated gene pathways to disease heritability. It is well known that an abnormality in individual genes rarely causes a human disease. Large-scale pathway analysis will elucidate disease pathways by constructing functional annotations and applying an existing polygenic method to partition heritability. Furthermore, pathway analyses on candidate genes identified via whole-exome sequencing (WES) data will inform new biological inference. The resulting set of enriched pathway-trait pairs will further help with independent validation of previously reported associations and for novel associations enriched for trait heritability.  The second aim is to determine the contribution of gene network to disease heritability across 94 diseases, focusing on hub genes defined by a broad set of network connectivity metrics. The contribution of gene network to disease heritability has been only partially answered, limited to few network connectivity metrics across 42 diseases. Comprehensive analysis of gene sets informed by published gene networks will inform a new direction of integrating gene networks to infer biological mechanisms of human diseases. In addition, visualization method for large-scale gene networks will greatly enhance research translation, serving as a useful resource for studying gene-gene interactions for potential drugs and therapeutic targets.  The third aim is to de-noise and re-prioritize Mendelian annotations to infer candidate genes. Despite considerable process on prioritizing rare variants impacting Mendelian diseases, little is known about the utility of these Mendelian pathogenicity scores for common disease. I will conduct heritability enrichment analyses to answer informativeness of Mendelian disease pathogenicity scores for common disease. To further improve their informativeness, I propose a machine learning variant reprioritization framework. Ultimately, this project will produce (1) a detailed understanding of disease-associated biological pathways to disease heritability, (2) a set of functional annotations informed by gene networks significantly enriched for disease heritability, and (3) a new method to prioritize variants and identifying candidate genes based on diverse genomic features. Project Narrative Understanding human genetic variations, from single-nucleotide polymorphisms (SNPs) to mutations, offers a great potential in uncovering underlying disease mechanisms by identifying new disease-associated genes and in discovering potential drug targets and therapeutics. This proposed studies aim to understand the role of these genetic variations in trait heritability, leveraging disease-associated biological pathways, gene networks, and functional annotations. The developed method to prioritize variants and genes will answer the contribution of gene pathways, gene sets informed by gene networks, and Mendelian pathogenicity scores to disease heritability.","Leveraging biological pathways, gene networks, and functional annotations to understand the genetic architecture of diseases and complex traits",9990520,F31HG010818,"['Architecture ', ' Engineering / Architecture ', ' Statistical Data Interpretation ', ' Statistical Data Analyses ', ' Statistical Data Analysis ', ' statistical analysis ', ' Decision Trees ', ' Disease ', ' Disorder ', ' Genes ', ' Goals ', ' Human Genetics ', ' Methods ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Publishing ', ' Research ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Computer software ', ' Software ', ' Tissues ', ' Body Tissues ', ' Genetic Variation ', ' Genetic Diversity ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Biological ', ' Link ', ' Training ', ' insight ', ' Individual ', ' Biological Function ', ' Biological Process ', ' machine learned ', ' Machine Learning ', ' Complex ', ' gene interaction ', ' trait ', ' novel ', ' disease risk ', ' disorder risk ', ' Reporting ', ' Single Base Polymorphism ', ' single nucleotide variant ', ' Single Nucleotide Polymorphism ', ' Coding System ', ' Code ', ' Statistical Methods ', ' Network Analysis ', ' Pathway Analysis ', ' Sampling ', ' Property ', ' protein protein interaction ', ' Genomics ', ' Pathogenicity ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Candidate Gene ', ' Candidate Disease Gene ', ' fitness ', ' Data ', ' Disease Pathway ', ' Regulatory Element ', ' Translational Science ', ' translation research ', ' Translational Research ', ' Validation ', ' Process ', ' pathway ', ' Pathway interactions ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' Heritability ', ' user-friendly ', ' open source ', ' human disease ', ' therapeutic target ', ' exome-seq ', ' exome sequencing ', ' Drug Targeting ', ' rare allele ', ' rare variant ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' Mendelian disease ', ' Mendelian genetic disorder ', ' monogenic disease ', ' monogenic disorder ', ' single-gene disease ', ' single-gene disorder ', ' Mendelian disorder ', ' entire genome ', ' full genome ', ' whole genome ', ' genetic architecture ', ' de-noising ', ' denoising ', ' supervised machine learning ', ' supervised learning ', ' Visualization ', ' ']",NHGRI,MASSACHUSETTS INSTITUTE OF TECHNOLOGY,F31,2020,45520,MA-07,0.0799953039145725
"Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases     DESCRIPTION (provided by applicant) Over the past 10 years human genetics studies made unprecedented numbers of discoveries relating genome variation to common diseases. While it is unquestionably true that we have learned substantially from the discoveries made to date, we must also acknowledge that with respect to the identification and characterization of the genome variation affecting risk of common human diseases - those accounting for the overwhelming majority of public health care expenditures - our discoveries have not generated nearly the knowledge of disease etiology that we would have expected given the sheer number of these discoveries. The combination of these observations coupled with the dramatic reduction in the cost of sequencing is driving the case for moving to whole genome sequencing studies for common disease. We have focused our application on three critical challenges for methods development and analysis of whole genome sequence data. While there has been substantial progress in methods development for analysis of exome sequencing, with gene-based tests that are relatively robust to the direction of effects of rare coding variants as well as the proportionof the gene's rare variants contributing to phenotype, it is clear that methods integrating the analysis of common and rare variation as well as functional genomics data will be essential for appropriate analysis of whole genome sequence data. Thus, we propose in Specific Aim 1 to develop novel methods, software and analysis pipelines for integrated analysis of common and rare variants for the analysis of whole genome sequence on 50,000- 100,000 individuals for any given common disease, and in Specific Aim 2 to develop and apply novel approaches for prioritizing results from these large-scale sequencing studies using BioVU, the 200,000 member biobank at Vanderbilt that is associated with 30 years of high quality electronic health records, and in Specific Aim 3 to develop queriable results databases and a comprehensive web portal to serve results of our studies on the sequence data for both the internal sequencing community and for the broader scientific community. PUBLIC HEALTH RELEVANCE Large-scale whole genome sequencing studies are being carried out to understand the genetic architecture of human complex diseases. It remains challenging to decipher the genetic mechanisms of disease etiology. In this application we aim to develop a suite of statistical and computational methods to identify genes and variants associated with complex disease and use BioVU, a DNA BioBank linked to electronic health records, to validate and investigate genetic architecture of multiple complex diseases.","Analysis, Validation and Resource Creation for Genome Sequencing of Complex Diseases",10116927,U01HG009086,"['Accounting ', ' Affect ', ' Automobile Driving ', ' driving ', ' Communities ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Health Expenditures ', ' health care expenditure ', ' healthcare expenditure ', ' Face ', ' faces ', ' facial ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Government ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Phenotype ', ' Public Health ', ' Research ', ' Resources ', ' Research Resources ', ' Risk ', ' Science ', ' Computer software ', ' Software ', ' Technology ', ' Time ', ' Tissues ', ' Body Tissues ', ' Generations ', ' Dataset ', ' Data Set ', ' base ', ' method development ', ' improved ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Data Bases ', ' data base ', ' Databases ', ' Policies ', ' Genetic ', ' Genetic Predisposition ', ' Genetic Susceptibility ', ' Inherited Predisposition ', ' Inherited Susceptibility ', ' genetic etiology ', ' genetic mechanism of disease ', ' genetic vulnerability ', ' genetically predisposed ', ' Genetic Predisposition to Disease ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Complex ', ' experience ', ' pleiotropic effect ', ' pleiotropy ', ' pleiotropism ', ' success ', ' expectation ', ' novel ', ' member ', ' Reporting ', ' Coding System ', ' Code ', ' Statistical Methods ', ' functional genomics ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' genome sequencing ', ' Data ', ' Large-Scale Sequencing ', ' Validation ', ' electronic health care record ', ' electronic healthcare record ', ' Electronic Health Record ', ' NHGRI ', ' National Center for Human Genome Research ', ' National Human Genome Research Institute ', ' disease phenotype ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' cost ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' designing ', ' design ', ' new approaches ', ' novel approaches ', ' novel strategy ', ' novel strategies ', ' Coupled ', ' human disease ', ' public health relevance ', ' biorepository ', ' biobank ', ' exomes ', ' exome ', ' exome-seq ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' Genetic study ', ' internet portal ', ' on-line portal ', ' online portal ', ' web-based portal ', ' web portal ', ' human genomics ', ' entire genome ', ' full genome ', ' whole genome ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' experiment ', ' experimental research ', ' experimental study ', ' genomic science ', ' genome sciences ', ' genetic architecture ', ' analysis pipeline ', ' gene testing ', ' gene-based testing ', ' genetic testing ', ' ']",NHGRI,VANDERBILT UNIVERSITY,U01,2020,864183,TN-05,0.12227602667964475
"Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening ABSTRACT A simple method to comprehensively discover, characterize and identify structural variants arising from normal metabolic processes, as well as cell manipulations, would have great utility for gene editing, oncology, and rare disease research, among other applications. De Novo Directional Genomic Hybridization (dGH) has been developed to efficiently screen thousands of cells for the presence of simple, complex, and heterogenous structural variants. In this project, Automated, High-Throughput Identification of Genetic Structural Variants for Gene Editing and Undiagnosed Genetic Diseases Screening, we propose K-Band dGH, an expanded dGH method. K-Band dGH is an in-situ hybridization method that utilizes high-density chromatid paints with bands of distinct spectra. A normal chromosome has a definitive pattern of bands, spectra and probe density. Structural variants are detected and identified via changes to the signal pattern. The proposed K-Band dGH method will provide the means for de novo discovery of balanced allelic translocations involving breakpoints at the same loci, inversions, and sister chromatid recombination and exchange events that are invisible to existing methods such as sequencing and aCGH. K-Band dGH will additionally characterize deletions, duplications, translocations, aneuploidy, polyploidy and more complex rearrangements. Structural variations cause a wide range of disorders, from rare diseases to cancers, and can be precise and definitive biomarkers. Also, because variations arise from the mis-repair of DNA double-strand breaks, unintended structural damage is an inevitable and potentially high-risk byproduct of genome editing. The potential of genome editing approaches such as CRISPR-Cas9 in the treatment of diseases is widely recognized and the realization of the promise of such therapeutic approaches will rely on accurate confirmation of the presence and absence of potentially risky structural variants. For these reasons, comprehensive detection and characterization of structural variations is a necessary step toward understanding, diagnosing and ultimately precisely treating genetic diseases. From a homogeneous or heterogenous population of cells, and in a single experiment, K-Band dGH will identify cells with a structurally normal phenotype, detect all classes of structural variants, and locate the breakpoints of all simple and complex structural variants in each cell. With a limit of detection below 5Kb, K-Band dGH is an ideal method for determining the outcomes of gene editing, discovering the causes of undiagnosed rare diseases, profiling genomic structural instability and variability, and discovering and validating previously unknown structural genetic drivers of disease. PROJECT NARRATIVE Modern genomics, driven by the demands of personalized medicine, needs higher throughput, higher integrity, and improved resolution to enable the discovery of new disease drivers and in the development of safer gene therapies. Rapid, accurate, efficient characterization of structural variants and their associated risks is critical to the discovery of potential therapeutic avenues for undiagnosed and rare diseases, and to the development of engineered cellular therapies, including stem cells, CAR-T and other gene therapies leveraging gene-editing tools such as CRISPR. K-Band dGH, proposed in Automated, High-Throughput Identification of Genetic Structural Variants for Gene Editing and Undiagnosed Genetic Diseases Screening, will enable single-cell, single-experiment identification of clinically important structural variants that cannot be discovered or identified by NGS or other available methods with broad applicability in genome engineering R&D, target discovery and personalized therapy development.","Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening",10080433,R44HG011442,"['Algorithms ', ' Alleles ', ' Allelomorphs ', ' Aneuploidy ', ' Aneuploid ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biomedical Research ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Cells ', ' Cell Body ', ' Chromatids ', ' Chromosomes ', ' Color ', ' Diagnosis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' DNA Repair ', ' DNA Damage Repair ', ' Unscheduled DNA Synthesis ', ' Fingerprint ', ' gene therapy ', ' DNA Therapy ', ' Gene Transfer Clinical ', ' Genetic Intervention ', ' gene-based therapy ', ' genetic therapy ', ' genomic therapy ', ' Genes ', ' Goals ', ' Government ', ' Human ', ' Modern Man ', ' Maps ', ' Marketing ', ' Metabolism ', ' Intermediary Metabolism ', ' Metabolic Processes ', ' Methods ', ' Modernization ', ' Paint ', ' Phenotype ', ' Polyploidy ', ' Polyploid ', ' Genetic Recombination ', ' DNA Recombination ', ' Recombination ', ' Research ', ' research and development ', ' Development and Research ', ' R & D ', ' R&D ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Risk ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' stem cells ', ' Progenitor Cells ', ' Technology ', ' Testing ', ' Work ', ' Measures ', ' DNA Sequence ', ' in situ Hybridization Genetics ', ' in situ Hybridization Staining Method ', ' In Situ Hybridization ', ' base ', ' density ', ' improved ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Solid ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Medical ', ' Individual ', ' Measurement ', ' Funding ', ' Oncology Cancer ', ' Oncology ', ' cell mediated therapies ', ' cell-based therapy ', ' cellular therapy ', ' Cell Therapy ', ' Therapeutic ', ' Exposure to ', ' Reciprocal Translocation ', ' tool ', ' Genomic Hybridizations ', ' Knowledge ', ' Complex ', ' Event ', ' Pattern ', ' System ', ' Location ', ' Comparative Genome Hybridization ', ' aCGH ', ' array CGH ', ' comparative genomic hybridization ', ' genotoxicity ', ' fluorophore ', ' Orphan Disease ', ' Rare Disorder ', ' orphan disorder ', ' Rare Diseases ', ' Structure ', ' technological innovation ', ' Chromosomal Organization ', ' Chromosomal Structure ', ' Chromosome Organization ', ' Chromosome Structures ', ' Radiation ', ' Sampling ', ' cell engineering ', ' cellular engineering ', ' Genomics ', ' Genetic Structures ', ' Bio-Informatics ', ' Bioinformatics ', ' Double Strand Break Repair ', ' structural genomics ', ' Pharmaceutical Agent ', ' Pharmaceuticals ', ' Pharmacological Substance ', ' Pharmacologic Substance ', ' DNA Double Strand Break ', ' Data ', ' Detection ', ' Resolution ', ' Chromosomal Rearrangement ', ' Pattern Recognition ', ' Sister Chromatid ', ' SBIR ', ' Small Business Innovation Research ', ' Small Business Innovation Research Grant ', ' Validation ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' reconstruction ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' Clinical assessments ', ' Outcome ', ' Genome engineering ', ' Population ', ' Prevalence ', ' gene therapeutics ', ' gene-based therapeutic ', ' gene-based therapeutics ', ' genes therapeutic ', ' genes therapeutics ', ' therapeutic gene ', ' clinical relevance ', ' clinically relevant ', ' therapeutic target ', ' develop therapy ', ' intervention development ', ' treatment development ', ' therapy development ', ' commercial application ', ' high risk ', ' new drug target ', ' new druggable target ', ' new pharmacotherapy target ', ' new therapy target ', ' novel drug target ', ' novel druggable target ', ' novel pharmacotherapy target ', ' novel therapeutic target ', ' novel therapy target ', ' new therapeutic target ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' screening ', ' CRISPR ', ' CRISPR/Cas system ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' genomic editing ', ' genome editing ', ' genomic profiles ', ' CRISPR method ', ' CRISPR methodology ', ' CRISPR technique ', ' CRISPR technology ', ' CRISPR-CAS-9 ', ' CRISPR-based method ', ' CRISPR-based technique ', ' CRISPR-based technology ', ' CRISPR-based tool ', ' CRISPR/Cas method ', ' CRISPR/Cas9 ', ' CRISPR/Cas9 technology ', ' Cas nuclease technology ', ' Clustered Regularly Interspaced Short Palindromic Repeats method ', ' Clustered Regularly Interspaced Short Palindromic Repeats methodology ', ' Clustered Regularly Interspaced Short Palindromic Repeats technique ', ' Clustered Regularly Interspaced Short Palindromic Repeats technology ', ' CRISPR/Cas technology ', ' entire genome ', ' full genome ', ' whole genome ', ' CRISPR editing screen ', ' CRISPR-based screen ', ' CRISPR/Cas9 screen ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR screen ', ' experiment ', ' experimental research ', ' experimental study ', ' CRISPR based therapeutics ', ' CRISPR/Cas therapeutics ', ' CRISPR/Cas9 therapeutics ', ' CRISPR/Cas9 therapy ', ' Cas9 based therapeutics ', ' Clustered Regularly Interspaced Short Palindromic Repeats based therapeutics ', ' Clustered Regularly Interspaced Short Palindromic Repeats therapeutics ', ' CRISPR therapeutics ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' automated image analysis ', ' smart algorithm ', ' intelligent algorithm ', ' ']",NHGRI,"KROMATID, INC.",R44,2020,1088162,CO-04,0.1717723094988597
"Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases     DESCRIPTION (provided by applicant): The NHGRI Genome Sequencing Program (GSP) will identify genomic variants relevant to health and disease by genome sequencing over 225,000 participants across a multitude of diseases. The GSP will also serve as a pilot for the Precision Medicine Initiative that aims to enroll and sequence more than a million people representative of U.S. ethnic diversity. Here, we propose a GSP analysis center focused on Multi- and Trans- ethnic Mapping of Mendelian and Complex Diseases. There is a growing recognition of the substantial scientific advantages, as well as public health importance, of conducting biomedical research across ethnically diverse cohorts. We propose to develop scalable methods that incorporate ancestry to optimize medical genomic study design and improve power for uncovering the role of common and rare variants in disease. Achieving this goal requires expertise across diverse domains of knowledge including: medical and population genomics, algorithm development for complex disease mapping, and expertise in management of large-scale databases. Here, we have assembled a world-class team of medical and population geneticists, computer scientists, statisticians and clinicians, with leading expertise in the development of novel and scalable strategies for characterizing sequence variants and their role in disease. Importantly, our group has been at the forefront of development of resources, study designs and methods to enable genomic research in U.S. minority populations. Our project has three main objectives. First, we will develop an Automated Scalable Ancestry Pipeline (ASAP) for common disease mapping in diverse populations. ASAP will improve the computational efficiency of existing state-of-the-art methods for ancestry inference and develop important extensions to linear mixed models (LMMs) and other mapping strategies leveraging local and global ancestry. We will also develop methods to refine phenotypes and identify common controls for disease studies and define endpoints. Secondly, we will develop tools and resources for trans- and multi-population rare variant discovery that incorporate patterns of local and sub-continental ancestry. We will also develop machine-learning tools for variant annotation that leverage ancestral information, patterns of sequence evolution, and protein structure in a unified framework. Furthermore, we will incorporate population-specific patterns of cellular phenotypes to improve functional prediction algorithms for non-coding and coding variants. Lastly, we will disseminate our results through web-based resource that empower the biomedical research community. We will augment existing resources including ClinGen by annotating and characterizing pathogenic variants across diverse populations. We will develop a secure web-server that allows sharing of summary statistics and analysis pipelines to enable discovery, fine-mapping and functional prediction of genetic variants. Our team has ample experience with NIH-funded consortia and is dedicated to meeting the overall GSP project goals through collaborative work with NHGRI leadership and other funded investigators. PUBLIC HEALTH RELEVANCE The goal of our project is to accelerate the discovery of DNA variation relevant to health and disease by analyzing data from over 225,000 ethnically and racially diverse patients that will undergo genome sequencing. Of particular importance is ensuring we have powerful statistical methods for analyzing data from underserved groups including U.S. minority populations. Achieving this goal requires expertise across many domains of knowledge including: medical and population genomics, algorithm development for disease mapping, and expertise in large-scale databases.",Center for Multi- and Trans-ethnic Mapping of Mendelian and Complex Diseases,10126204,U01HG009080,"['Architecture ', ' Engineering / Architecture ', ' Biomedical Research ', ' Chronic Disease ', ' Chronic Illness ', ' chronic disorder ', ' Communities ', ' Computers ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Evolution ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Leadership ', ' Methods ', ' Methodology ', ' Methylation ', ' Molecular Conformation ', ' Molecular Configuration ', ' Molecular Stereochemistry ', ' conformation ', ' conformational state ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Patients ', ' Phenotype ', ' Privatization ', ' Public Health ', ' Research ', ' Research Design ', ' Study Type ', ' study design ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Shoulder ', ' statistics ', ' Target Populations ', ' Testing ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' United States ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' diverse populations ', ' heterogeneous population ', ' population diversity ', ' Population Heterogeneity ', ' Dataset ', ' Data Set ', ' improved ', ' Clinical ', ' Variation ', ' Variant ', ' Medical ', ' Ensure ', ' Funding ', ' Genetic ', ' tool ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' programs ', ' Scientist ', ' Investigation ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Pattern ', ' meetings ', ' experience ', ' cohort ', ' simulation ', ' novel ', ' Participant ', ' Coding System ', ' Code ', ' Statistical Methods ', ' Modeling ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' disease control ', ' disorder control ', ' Pathogenicity ', ' genome sequencing ', ' protein structures ', ' proteins structure ', ' protein structure ', ' Data ', ' Resolution ', ' Resource Development ', ' enroll ', ' Enrollment ', ' developmental ', ' Development ', ' NHGRI ', ' National Center for Human Genome Research ', ' National Human Genome Research Institute ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' patient privacy ', ' Minority ', ' Population ', ' innovate ', ' innovative ', ' innovation ', ' large-scale data base ', ' large-scale database ', ' tool development ', ' public health relevance ', ' phenome ', ' Secure ', ' Risk-associated variant ', ' risk allele ', ' risk gene ', ' risk genotype ', ' risk loci ', ' risk locus ', ' risk variant ', ' rare allele ', ' rare variant ', ' Precision Medicine Initiative ', ' genomic tools ', ' GTEx ', ' Genotype-Tissue Expression Project ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' ethnically diverse ', ' ethnic diversity ', ' racially diverse ', ' racial diversity ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' internet resource ', ' on-line compendium ', ' on-line resource ', ' online compendium ', ' web resource ', ' web-based resource ', ' online resource ', ' web-based tool ', ' preservation ', ' analysis pipeline ', ' web server ', ' algorithm development ', ' protective variant ', ' protective allele ', ' ']",NHGRI,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,U01,2020,962530,NY-13,0.16988658568500095
"Integrating epigenomics with DNA breathing dynamics for human non-coding disease variants ABSTRACT Genome-wide association studies (GWAS) and whole genome sequencing of complex diseases have revealed a plethora of disease risk variants, most of which lie in noncoding regions of DNA without easily interpretable function. A main functional mechanism of noncoding variants is to alter chromatin accessibility to transcription factors (TFs), thereby influencing gene expression. Predicting the effects of noncoding variants on TF binding and gene expression on a large scale is thus important but remains challenging. Available computational tools for predicting regulatory variants largely rely on TF-binding motif models and/or local chromatin modification features. Here, we aim to develop a novel computational framework to address two major limitations of these methods. First, given that known disease causal noncoding variants often reside outside of TF binding motifs, how can we improve the prediction of TF binding variants outside of motifs? For this, we plan to integrate TF ChIP-seq data with features that are important for TF binding but have not been considered in previous methods, in particular the DNA breathing dynamics (AIM1). DNA breathing reflects local transient opening of the DNA double helix due to thermal fluctuations. We have shown that genetic variants can affect nearby (up to a few hundred base pairs) DNA breathing dynamics that affect TF binding. Using TF ChIP-seq data, we will train models that predict specific TF binding variants in or outside TF motifs, incorporating DNA breathing dynamics with other features such as DNA shapes and cooperative TF binding. Secondly, given that chromatin features only show modest (<2-fold) enrichment of genetic variants associated with complex diseases or traits, how can we improve the prediction of regulatory variants? For this, we will build a computation model, considering the allele-specific chromatin accessibility (ASCA; i.e., two alleles of a heterozygous individual show read imbalance in chromatin accessibility assays) as a functional readout of a regulatory variant (AIM2). We have shown that neuronal ASCA SNPs are highly enriched for those implicated by schizophrenia (SZ) GWAS. Using neuronal ASCA data, we will train models that predict variants with regulatory effects, taking advantage of our TF-specific classifiers (from AIM1). As a proof of concept, the models will be applied to a large SZ GWAS dataset to predict putative causal regulatory variants. We will validate the effects of the predicted top-ranking regulatory SZ variants on gene expression in a well-powered hiPSC sample by combining multiplex CRISPR-based SNP editing and single-cell RNA-seq analysis (AIM3). For SNPs showing the strongest regulatory effects, we will further use CRISPR editing to verify the SNP effect on gene expression and disease-relevant neuronal phenotypes. Accurately predicting TF-affecting noncoding variants will enable better understanding of the large number of noncoding variants implicated in complex disorders and help formulate testable biological hypotheses, ultimately facilitating the development of targeted therapeutics. NARRATIVE We will develop novel computational methods and a cost-effective functional validation approach to systematically infer the effect of disease-associated noncoding variants on transcription factor binding and gene expression. Identifying the functional noncoding variants that are associated with disease risk will help illuminate causal molecular mechanisms, facilitating the clinical translation of genetic findings into disease risk prediction and treatment.",Integrating epigenomics with DNA breathing dynamics for human non-coding disease variants,9908170,R01MH116281,"['Adenine ', ' 1H-Purin-6-amine ', ' Vitamin B4 ', ' Affect ', ' Alleles ', ' Allelomorphs ', ' Breathing ', ' Respiratory Aspiration ', ' Respiratory Inspiration ', ' inspiration ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Brain ', ' Brain Nervous System ', ' Encephalon ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Chromatin ', ' Classification ', ' Systematics ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' DNA-Binding Proteins ', ' Equilibrium ', ' balance ', ' balance function ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Human ', ' Modern Man ', ' Methods ', ' Neurons ', ' Nerve Cells ', ' Nerve Unit ', ' Neural Cell ', ' Neurocyte ', ' neuronal ', ' Phenotype ', ' Rest ', ' Risk ', ' Schizophrenia ', ' Schizophrenic Disorders ', ' dementia praecox ', ' schizophrenic ', ' Software Tools ', ' Computer Software Tools ', ' Tissues ', ' Body Tissues ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Genetic Translation ', ' mRNA Translation ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' Individual ', ' Shapes ', ' machine learned ', ' Machine Learning ', ' Complex ', ' trait ', ' Base Pairing ', ' Structure ', ' novel ', ' disease risk ', ' disorder risk ', ' Modeling ', ' Sampling ', ' Property ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' DNA Binding Interaction ', ' DNA bound ', ' DNA Binding ', ' chromatin modification ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Data ', ' Validation ', ' Molecular ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' epigenomics ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' computational framework ', ' computer framework ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' computational tools ', ' computerized tools ', ' cost effective ', ' open source ', ' iPS ', ' iPSC ', ' iPSCs ', ' induced pluripotent stem cell ', ' genome scale ', ' genomewide ', ' genome-wide ', ' ChIP Sequencing ', ' chromatin immunoprecipitation-sequencing ', ' ChIP-seq ', ' Risk-associated variant ', ' risk allele ', ' risk gene ', ' risk genotype ', ' risk loci ', ' risk locus ', ' risk variant ', ' CRISPR ', ' CRISPR/Cas system ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' ATACseq ', ' ATAC-seq ', ' entire genome ', ' full genome ', ' whole genome ', ' predictive tools ', ' clinical translation ', ' scRNA-seq ', ' single cell RNA-seq ', ' single cell RNAseq ', ' single-cell RNA sequencing ', ' causal allele ', ' causal gene ', ' causal mutation ', ' causative mutation ', ' causative variant ', ' causal variant ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' support vector machine ', ' ']",NIMH,NORTHSHORE UNIVERSITY HEALTHSYSTEM,R01,2020,592430,IL-09,0.11398567039393037
"Single cell atlas as a roadmap for interpreting human genetic variation in complex disease Project Summary Genome wide association studies (GWAS) have successfully identified thousands of loci likely affecting human health. To translate these findings into therapeutic targets and disease treatments, we need to understand the cellular context and underlying biological mechanisms through which each disease associated variant disrupts function. Large scale, information rich datasets are being generated across multiple modalities including transcriptomics from single cell RNA-seq studies, traits and phenotypes from the UK Biobank and germline genetic variation from exome sequencing studies. Here, we propose to develop methods to integrate these amazing resources towards understanding the identifying biological and cellular mechanisms that are leading to disease. The objectives will be accomplished with the following specific aims: 1) Integrate population scale biological datasets including UK Biobank and single cell transcriptomics data to construct gene modules with the goal to recapitulate biological pathways. 2) Develop a statistical framework to measure mutational burden across each of the cell type specific gene modules. Together, this research proposal will increase the power in interpreting human genetic variation and help better understand the mechanism through which they act. These methods are being developed around an IBD dataset and will derive substantial molecular information about the mechanisms driving IBD. The lessons and methodological advances from this work will be directly applicable in many complex disease contexts. Project Narrative Genome wide association studies are highly successful identifying thousands of disease-associated loci but fall short at 1) pinpointing the biological mechanisms through which the variants effect disease and 2) capturing the effects of rare variants which may be having larger effect on disease outcomes. This research proposal details plans to integrate high-throughput single cell transcriptomics, population scale biobank datasets and exome sequencing from large disease cohorts to learn a prior on which genes are likely working together in which cell types and consequently improve the statistical power in interpreting rare human genetic variation. Our work will create foundational methods that can be applied broadly across many disease contexts.",Single cell atlas as a roadmap for interpreting human genetic variation in complex disease,10068981,F32HG011434,"['Affect ', ' Asthma ', ' Bronchial Asthma ', ' Atlases ', ' Automobile Driving ', ' driving ', ' Cell physiology ', ' Cell Function ', ' Cell Process ', ' Cellular Function ', ' Cellular Physiology ', ' Cellular Process ', ' Subcellular Process ', ' Cells ', ' Cell Body ', ' Colon ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Ketosis-Resistant Diabetes Mellitus ', ' Maturity-Onset Diabetes Mellitus ', ' NIDDM ', ' Non-Insulin Dependent Diabetes ', ' Noninsulin Dependent Diabetes ', ' Noninsulin Dependent Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Stable Diabetes Mellitus ', ' T2 DM ', ' T2D ', ' T2DM ', ' Type 2 Diabetes Mellitus ', ' Type 2 diabetes ', ' Type II Diabetes Mellitus ', ' Type II diabetes ', ' adult onset diabetes ', ' ketosis resistant diabetes ', ' maturity onset diabetes ', ' type 2 DM ', ' type II DM ', ' type two diabetes ', ' Disease ', ' Disorder ', ' Foundations ', ' Gene Expression ', ' Patient Care ', ' Patient Care Delivery ', ' Genes ', ' Genome ', ' Goals ', ' Health ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Inflammation ', ' Inflammatory Bowel Diseases ', ' Inflammatory Bowel Disorder ', ' Inflammatory Intestinal Disease ', ' Inflammatory Intestinal Disorder ', ' Learning ', ' Methods ', ' Methodology ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Phenotype ', ' Physiology ', ' Research Proposals ', ' Resources ', ' Research Resources ', ' Schizophrenia ', ' Schizophrenic Disorders ', ' dementia praecox ', ' schizophrenic ', ' Signal Pathway ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Thinking ', ' thoughts ', ' Tissues ', ' Body Tissues ', ' Translating ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Measures ', ' falls ', ' Amaze ', ' Dataset ', ' Data Set ', ' Organ ', ' improved ', ' Area ', ' Variation ', ' Variant ', ' Biological ', ' Link ', ' Individual ', ' Therapeutic ', ' Genetic ', ' Complex ', ' cell type ', ' Pattern ', ' single cell analysis ', ' cohort ', ' trait ', ' Disease Outcome ', ' Participant ', ' disease risk ', ' disorder risk ', ' disorder model ', ' Disease model ', ' Modality ', ' response ', ' Meta-Analysis ', ' Data ', ' Detection ', ' Molecular ', ' groupings ', ' Grouping ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' burden of disease ', ' disease burden ', ' years of life lost to disability ', ' years of life lost to disease ', ' burden of illness ', ' designing ', ' design ', ' Population ', ' transcriptomics ', ' therapeutic target ', ' biorepository ', ' biobank ', ' exomes ', ' exome ', ' ER stress ', ' endoplasmic reticulum stress ', ' exome-seq ', ' exome sequencing ', ' rare allele ', ' rare variant ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' phenotypic data ', ' SCmRNAseq ', ' single cell mRNA sequencing ', ' scRNA-seq ', ' single cell RNA-seq ', ' single cell RNAseq ', ' single-cell RNA sequencing ', ' unsupervised machine learning ', ' unsupervised learning ', ' causal allele ', ' causal gene ', ' causal mutation ', ' causative mutation ', ' causative variant ', ' causal variant ', ' data heterogeneity ', ' data set heterogeneity ', ' dataset heterogeneity ', ' heterogeneous data ', ' heterogeneous data sets ', ' heterogeneous datasets ', ' heterogenous data sets ', ' heterogenous datasets ', ' heterogenous data ', ' statistical and machine learning ', ' machine learning method ', ' gene locus ', ' genetic locus ', ' genomic locus ', ' ']",NHGRI,"BROAD INSTITUTE, INC.",F32,2020,64926,MA-07,0.06423067473261553
"Interpreting function of non-coding sequences with synthetic biology and machine learning PROJECT SUMMARY/ABSTRACT Most disease-associated variants lie in non-coding regions of the genome and exert their influence through effects on gene expression. However, we lack a predictive framework to interpret such non-coding variants, limiting how genomic data is used in precision medicine. We may be able to interpret non-coding variants with new machine learning algorithms, but so far the practical applications of machine learning in functional genomics have been limited because of two major challenges. First, the size and diversity of training data sets in functional genomics are orders of magnitude smaller than in applications where machine learning has been successful, such as image recognition and product recommendation. A second challenge is that if training data are not collected in an appropriate in vitro cellular model, then the resulting machine learning models may not generalize to relevant in vivo cell types. To improve the application of machine learning to non-coding variants, I propose to address both the limited size of training data sets and the efficacy of cell culture models. A core principle of machine learning is that model performance improves with more data. In Aim 1, I propose to increase the size and diversity of training data by performing iterative cycles of machine learning and experimental validation with Massively Parallel Reporter Assays (MPRAs). The key aspect of my approach is to algorithmically design each successive MPRA library to contain sequences that are most likely to improve the next round of modeling. I recently trained my first model on data that I collected from MPRA experiments of cis-regulatory sequences that function in mammalian photoreceptors. To avoid any issues with cell lines, I performed these experiments in ex vivo developing retinas, which retain the appropriate tissue architecture. However, unlike photoreceptors, most cell types are not experimentally tractable in their native physiological context. Thus, it will be important to determine how well in vitro cell lines recapitulate in vivo cis-regulation. In Aim 2, I propose to determine whether a tractable cell culture model can recapitulate results from ex vivo retinas. I will use existing MPRA data from ex vivo retinas as a standard to compare against data collected in cell lines engineered to express combinations of photoreceptor transcription factors. I aim to address whether engineering tractable cell lines to express tissue-specific transcription factors might be a general approach for collecting data to train machine learning models that generalize to in vivo systems. Successful completion of these aims will produce a general approach to increase the size and diversity of functional genomic training data, and may result in a general method for producing experimentally tractable systems for machine learning applications, ultimately helping us better apply genomic data to precision medicine. PROJECT NARRATIVE Many genetic variants that cause disease do not affect the structure of genes, but instead affect short DNA sequences that control when, where, or how much a gene is produced. Every individual human contains thousands of genetic variants in these control regions, but only a small number of these variants influence gene production. I propose a combined experimental and computational framework to predict which variants affect gene production and which variants are harmless.",Interpreting function of non-coding sequences with synthetic biology and machine learning,10065897,F31HG011431,"['Affect ', ' Architecture ', ' Engineering / Architecture ', ' Base Sequence ', ' Nucleotide Sequence ', ' nucleic acid sequence ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Cell Culture Techniques ', ' cell culture ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Cells ', ' Cell Body ', ' Disease ', ' Disorder ', ' Engineering ', ' Gene Expression ', ' Genes ', ' Genome ', ' Human ', ' Modern Man ', ' In Vitro ', ' Libraries ', ' Methods ', ' Biological Models ', ' Biologic Models ', ' Model System ', ' Photoreceptors ', ' Photoreceptor Cell ', ' Photosensitive Cell ', ' Visual Receptor ', ' Production ', ' Recommendation ', ' Retina ', ' Testing ', ' Tissues ', ' Body Tissues ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' improved ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Training ', ' Individual ', ' Reporter ', ' machine learned ', ' Machine Learning ', ' cell type ', ' System ', ' experience ', ' Performance ', ' Structure ', ' Regulation ', ' Modeling ', ' cell engineering ', ' cellular engineering ', ' High Throughput Assay ', ' high throughput screening ', ' functional genomics ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Address ', ' Data ', ' in vivo ', ' cell assay ', ' Cellular Assay ', ' Validation ', ' imaging ', ' Image ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' computational framework ', ' computer framework ', ' designing ', ' design ', ' synthetic biology ', ' Cellular model ', ' Cell model ', ' application in practice ', ' practical application ', ' Algorithmic Design ', ' Algorithmic Engineering ', ' algorithm engineering ', ' algorithmic composition ', ' Algorithm Design ', ' precision-based medicine ', ' precision medicine ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' experiment ', ' experimental research ', ' experimental study ', ' machine learned algorithm ', ' machine learning algorithm ', ' ']",NHGRI,WASHINGTON UNIVERSITY,F31,2020,31454,MO-01,0.11349948916261225
"Comprehensive Characterization of Adaptive Regulatory Variation Linked to Human Disease Project Summary/ Abstract  Over the past decade there has been a rapid expansion of genome-wide association studies (GWAS), as well as the development of large-scale consortia like the UKBioBank and the All of Us project. While the number of genetic associations to human traits and disease is soaring, tools to characterize and interpret these variants are lacking. One challenge to realizing the potential of genomics is that over 99% of human genetic variation is non-coding, regulatory sequences. However, regulatory grammar  the complex pattern of sequences that interact with transcription factors to control gene expression, is poorly understood. A repertoire of well-characterized causal variants is needed to build generalizable models with which to unlock insights into the genetic basis of human health and history.  Natural selection is a powerful driver of human genetic variation. As our species has encountered new climates, dramatic alterations in diet, and novel pathogens, these selective pressures have left hundreds of signatures of adaptation in our genomes, reflected in our species diversity of disease risk and morphology. For selection to have acted positively on them, these adaptive alleles must exhibit relatively strong phenotypic effects, and they continue to contribute to modern traits and disease (e.g. height or sickle cell anemia). Salient examples of human adaptation include immunity, metabolism, and morphology, all of which have extensive, unresolved GWAS signals. This renders the lens of recent evolution a powerful, but underutilized, tool for identifying alleles that contribute to phenotypic variation in modern association studies.  This proposal aims to expand the repertoire of well-characterized GWAS signals, by A) using evolution to prioritize adaptive variants, and B) applying novel, high-throughput experimental and computational tools to comprehensively decipher the functions of regulatory variants. These approaches will identify much needed causal variants, devise paradigms for their study, and inform future predictive models to characterize them. During the mentored phase of the K99, I will first develop methods to colocalize signals of selection and GWAS, and then use Variant Effect Predictions (VEP) to predict their function. I will then employ high-through methods such as a the massively parallel reporter assay and CRISPR non-coding screen to functionally characterize them directly. From the adaptive GWAS alleles our screens identify, we will make in-vivo system to more deeply characterize them during the Independent R00 phase. During this time I will deploy a variety of genomic tools such as ChIP, ChIA-PET, and RNA-seq to understand the adaptive variants molecular etiology. I will use the empirical data fro these studies, and the MPRA/HCR-FlowFISH screens to build more accurate VEP models. ! Project Narrative While thousands of genomic regions have been linked to human evolution and diseases, many of the genetic variants responsible are non-coding and thus difficult to interpret. I propose to identify adaptive human alleles underlying genome wide association studies and comprehensively characterize them using novel computational and experimental tools. I will then make in-vivo models of these to test their function and effects on fitness, improving future predictions of how genetic variants impact human evolution and health.",Comprehensive Characterization of Adaptive Regulatory Variation Linked to Human Disease,10005404,K99HG010669,"['Alleles ', ' Allelomorphs ', ' Sickle Cell Anemia ', ' Hb SS disease ', ' HbSS disease ', ' Hemoglobin S Disease ', ' Hemoglobin sickle cell disease ', ' Hemoglobin sickle cell disorder ', ' sickle cell disease ', ' sickle disease ', ' sicklemia ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Cells ', ' Cell Body ', ' Climate ', ' Meteorological Climate ', ' climatic ', ' Deoxyribonucleases ', ' DNA Nucleases ', ' DNase ', ' Diet ', ' dietary ', ' Disease ', ' Disorder ', ' Evolution ', ' Exhibits ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Health ', ' Histones ', ' Recording of previous events ', ' History ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Immunity ', ' Lassa Fever ', ' Lassa disease ', ' Linkage Disequilibrium ', ' Mentors ', ' Metabolism ', ' Intermediary Metabolism ', ' Metabolic Processes ', ' Methods ', ' Modernization ', ' Phenotype ', ' pressure ', ' Research ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Testing ', ' Time ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' Natural Selections ', ' improved ', ' Left ', ' Phase ', ' Variation ', ' Variant ', ' Link ', ' Training ', ' insight ', ' African ', ' Data Bases ', ' data base ', ' Databases ', ' Gene Targeting ', ' Genetic ', ' Morphology ', ' Reporter ', ' tool ', ' machine learned ', ' Machine Learning ', ' Complex ', ' Scanning ', ' cell type ', ' Pattern ', ' Techniques ', ' System ', ' Height ', ' trait ', ' novel ', ' disease risk ', ' disorder risk ', ' Reporting ', ' Modeling ', ' Connectionist Models ', ' Neural Network Models ', ' Perceptrons ', ' Neural Network Simulation ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' genetic association ', ' CCRL2 ', ' CKRX ', ' CRAM-A ', ' CRAM-B ', ' Chemokine (C-C Motif) Receptor-Like 2 Gene ', ' HCR ', ' CCRL2 gene ', ' fitness ', ' Data ', ' Regulatory Element ', ' in vivo ', ' in vivo Model ', ' Epigenetic ', ' Epigenetic Change ', ' Epigenetic Mechanism ', ' Epigenetic Process ', ' genomic region ', ' Genomic Segment ', ' Preparation ', ' Molecular ', ' developmental ', ' Development ', ' NHGRI ', ' National Center for Human Genome Research ', ' National Human Genome Research Institute ', ' GWA study ', ' GWAS ', ' genome wide association ', ' genome wide association scan ', ' genome wide association studies ', ' genomewide association scan ', ' genomewide association studies ', ' genomewide association study ', ' whole genome association analysis ', ' whole genome association studies ', ' whole genome association study ', ' genome wide association study ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' computational tools ', ' computerized tools ', ' pathogen ', ' Population ', ' Cellular model ', ' Cell model ', ' human disease ', ' murine model ', ' mouse model ', ' lenses ', ' lens ', ' biorepository ', ' biobank ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' CRISPR ', ' CRISPR/Cas system ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' genomic editing ', ' genome editing ', ' genomic tools ', ' CRISPR method ', ' CRISPR methodology ', ' CRISPR technique ', ' CRISPR technology ', ' CRISPR-CAS-9 ', ' CRISPR-based method ', ' CRISPR-based technique ', ' CRISPR-based technology ', ' CRISPR-based tool ', ' CRISPR/Cas method ', ' CRISPR/Cas9 ', ' CRISPR/Cas9 technology ', ' Cas nuclease technology ', ' Clustered Regularly Interspaced Short Palindromic Repeats method ', ' Clustered Regularly Interspaced Short Palindromic Repeats methodology ', ' Clustered Regularly Interspaced Short Palindromic Repeats technique ', ' Clustered Regularly Interspaced Short Palindromic Repeats technology ', ' CRISPR/Cas technology ', ' CRISPRi ', ' Clustered Regularly Interspaced Short Palindromic Repeats interference ', ' CRISPR interference ', ' ChIA-PET ', ' Chromosome Interaction Analysis with Paired-End Tags ', ' Chromatin Interaction Analysis by Paired-End Tag Sequencing ', ' CRISPR editing screen ', ' CRISPR-based screen ', ' CRISPR/Cas9 screen ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR screen ', ' causal allele ', ' causal gene ', ' causal mutation ', ' causative mutation ', ' causative variant ', ' causal variant ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NHGRI,"BROAD INSTITUTE, INC.",K99,2020,125378,MA-07,0.10475877760314724
